


Program and Conference Information

25th

CROI

Conference on Retroviruses
and Opportunistic Infections



Boston
March 4-7, 2018

CONTENTS

CROI FOUNDATION	2
IAS–USA	2
CROI 2018 PROGRAM COMMITTEE	3
Scientific Program Committee	3
Community Liaison Subcommittee	5
EXTERNAL REVIEWERS	6
SCHOLARSHIP AWARDEES	8
New Investigator Awardees	8
International Investigator Awardees	12
Community Educator Awardees	12
CONTINUING MEDICAL EDUCATION	13
GENERAL INFORMATION	15
Overview	15
Conference Support	15
Americans With Disabilities Act	15
Emergency Services	15
Embargo Policies and Social Media	16
Welcome Reception	16
Meals	16
Overflow Accommodations for Oral Sessions	17
Mobile App	17
Website	17
Webcasts	17
Affiliated and Proximate Activities Policy	18
Wi-Fi Access at the Conference	18
Conference Badges	18
Child Care	18
Conference Etiquette	18
CROI HOTELS	19
CONFERENCE SERVICES	22
ABSTRACT PROCESS	24
PRECONFERENCE AND ORAL SESSIONS	26
POSTER SESSIONS, BY DAY	64
POSTER SESSIONS, BY CATEGORY	168
INDEX OF STUDIES RELATED TO WOMEN	172
INDEX OF PRESENTING AUTHORS	179
CONFERENCE SCHEDULE	INSIDE BACK COVER
CONVENTION CENTER FLOOR PLANS	BACK COVER

Printed in the United States of America.

© Copyright 2018 CROI Foundation/IAS–USA. All rights reserved.

ISBN #978-1-7320053-0-3

CROI FOUNDATION

The CROI Foundation is a 501(c)(3) not-for-profit professional organization that operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the annual Conference on Retroviruses and Opportunistic Infections (CROI).

Roles and Responsibilities of the CROI Foundation Volunteer Board of Directors

- Works closely with the CROI Scientific Program Committee (CROI PC) and the CROI Secretariat to accomplish the mission of CROI
- Approves nominations for members of the CROI PC and the CROI PC Chair and Vice Chairs
- Ensures that the CROI PC is responsible for the scientific program content of CROI
- Enters into and oversees the partner agreement with the CROI Secretariat
- Has the sole and absolute discretion to veto any policies, procedures, or actions taken or proposed to be taken by the CROI PC or the CROI Secretariat that would pose a substantial risk of preventing the Foundation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might cause the loss of such qualification
- Oversees the long-term financial and administrative integrity of CROI

CROI Foundation Board of Directors

Constance A. Benson, MD

President

University of California San Diego
San Diego, CA, United States

John M. Coffin, PhD

Secretary-Treasurer

Tufts University
Boston, MA, United States

Elaine J. Abrams, MD

ICAP at Columbia University
New York, NY, United States

Susan P. Buchbinder, MD

San Francisco Department
of Public Health
San Francisco, CA, United States

Judith S. Currier, MD, MSc

University of California Los Angeles
Los Angeles, CA, United States

Kevin M. De Cock, MD

Centers for Disease Control and Prevention
Nairobi, Kenya

Scott M. Hammer, MD

Columbia University
New York, NY, United States

Sharon L. Hillier, PhD

University of Pittsburgh
Pittsburgh, PA, United States

John W. Mellors, MD

University of Pittsburgh
Pittsburgh, PA, United States

Robert T. Schooley, MD

University of California San Diego
La Jolla, CA, United States

IAS–USA

The International Antiviral Society–USA is a 501(c)(3) not-for-profit professional education organization. The IAS–USA partners with the CROI PC and Foundation to organize CROI. The mission of the IAS–USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

Executive Director: Donna M. Jacobsen

Address: 425 California Street, Suite 1450

San Francisco, CA 94104-2120

Phone: 415-544-9400

Website: www.iasusa.org



CROI 2018 PROGRAM COMMITTEE

The Scientific Program Committee (PC) is a team of experts in their given field who volunteer to organize the scientific program for CROI. Members are selected based on their area of scientific expertise and their commitment to the mission of the conference. Initial terms are up to 3 years; subsequent terms are based on previous participation and interest level. Members are nominated by the PC and approved by the CROI Foundation Board of Directors. The PC members are responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; and organizing, conducting, or convening workshops, symposia, and special sessions.

Scientific Program Committee



Judith S. Currier, MD, MSc

CROI 2018 Chair

University of California
Los Angeles
Los Angeles, CA
United States



Sharon L. Hillier, PhD

CROI 2018 Vice Chair

University of Pittsburgh
Pittsburgh, PA
United States



Richard A. Koup, MD

CROI 2018 Vice Chair

Vaccine Research Center
National Institute of Allergy
and Infectious Diseases
National Institutes of Health
Bethesda, MD, United States



Elaine J. Abrams, MD

ICAP at Columbia University
New York, NY, United States



Susan P. Buchbinder, MD

San Francisco Department of
Public Health
San Francisco, CA, USA



Adaora Adimora, MD

University of North Carolina
at Chapel Hill
Chapel Hill, NC, United States



Connie L. Celum, MD, MPH

University of Washington
Seattle, WA, United States



Galit Alter, PhD

Ragon Institute of MGH, MIT
and Harvard
Cambridge, MA
United States



Richard E. Chaisson, MD

The Johns Hopkins University
Baltimore, MD, United States



Constance A. Benson, MD

University of California
San Diego
San Diego, CA, United States



Nicolas Chomont, PhD

Université de Montréal
Montreal, Canada



Paul Bieniasz, PhD

The Rockefeller University
New York, NY, United States



John M. Coffin, PhD

Tufts University
Boston, MA, United States



Kevin M. De Cock, MD
Centers for Disease Control
and Prevention
Nairobi, Kenya



Wafaa M. El-Sadr, MD, MPH
ICAP at Columbia University
New York, NY, United States



Joseph J. Eron, Jr, MD
University of North Carolina
at Chapel Hill
Chapel Hill, NC, United States



**Courtney V. Fletcher,
PharmD**
University of Nebraska
Medical Center
Omaha, NE, United States



Huldrych F. Günthard, MD
University Hospital Zurich
Zurich, Switzerland



Timothy Hallett, PhD
Imperial College London
London, United Kingdom



Scott M. Hammer, MD
Columbia University
New York, NY, United States



Diane V. Havlir, MD
University of California
San Francisco
San Francisco, CA
United States



James A. Hoxie, MD
University of Pennsylvania
Philadelphia, PA
United States



Peter W. Hunt, MD
University of California
San Francisco
San Francisco, CA
United States



Ilesh V. Jani, MD, PhD
Instituto Nacional de Saude
Maputo, Mozambique



Frank Kirchhoff, PhD
Ulm University
Medical Center
Ulm, Germany



Dennis L. Kolson, MD, PhD
University of Pennsylvania
Philadelphia, PA
United States



Hermione Lyall, MD
Imperial College Healthcare
National Health
Service Trust
London, United Kingdom



**James A. McIntyre,
MBChB, FRCOG**
Anova Health Institute
Johannesburg, South Africa



John W. Mellors, MD
University of Pittsburgh
Pittsburgh, PA, United States



**Nelly R. Mugo, MBChB,
MPH**
Kenya Medical
Research Institute
Nairobi, Kenya



Landon Myer, MD, PhD
University of Cape Town
Cape Town, South Africa



Andrew N. Phillips, PhD
University College London
London, United Kingdom



Peter Reiss, MD, PhD
Amsterdam Institute
for Global Health
and Development
Amsterdam, Netherlands



Douglas D. Richman, MD
University of California
San Diego; Veterans Affairs
San Diego Healthcare
System
San Diego, CA, United States



Serena S. Spudich, MD, MA
Yale University
New Haven, CT, United States



Jürgen K. Rockstroh, MD
University of Bonn
Bonn, Germany



Wesley I. Sundquist, PhD
University of Utah
Salt Lake City, UT,
United States



Robert T. Schooley, MD
University of California
San Diego
La Jolla, CA, United States



David L. Thomas, MD
The Johns Hopkins University
Baltimore, MD, United States



Guido Silvestri, MD
Emory University
Atlanta, GA, United States



Alexandra Trkola, PhD
University of Zurich
Zurich, Switzerland



Annette H. Sohn, MD
TREAT Asia
Bangkok, Thailand

Community Liaison Subcommittee

The Community Liaison Subcommittee is a group of community educators and advocates that provides feedback to the PC about the content and structure of the scientific program in general and specifically related to scientific topics of interest to the HIV/AIDS-affected community.



Mark Hubbard
Tennessee Association of
People With AIDS
Nashville, TN, United States



**Morenike Ukpong, FWACS,
MBA, BChD**
Obafemi Awolowo University
Ile-Ife, Nigeria



Jeff Taylor
AIDS Treatment
Activists Coalition
Palm Springs, CA
United States



Lisa Diane White, MPH
SisterLove, Inc.
Atlanta, GA, United States

The CROI Foundation wishes to thank for their service the following individuals who rotated off the Scientific Program Committee in 2017:

Harold W. Jaffe, MD

Ronald T. Mitsuyasu, MD

Julie M. Overbaugh, PhD

EXTERNAL REVIEWERS

We gratefully acknowledge the contributions of the following, who served as volunteer external reviewers of abstracts for CROI 2018.

Edward P. Acosta, PharmD

University of Alabama at Birmingham
Birmingham, AL, United States

Peter L. Anderson, PharmD

University of Colorado
Aurora, CO, United States

Till Bärnighausen, MD, PhD

Heidelberg University
Heidelberg, Germany

John M. Blandford, PhD

Centers for Disease Control and
Prevention
Atlanta, GA, United States

Marta Boffito, MD, PhD

Chelsea and Westminster NHS
Foundation Trust
London, United Kingdom

Jacob Bor, ScD

Boston University
Boston, MA, United States

William Borkowsky, MD

New York University
New York, NY, United States

Bruce J. Brew, MD, MBBS

University of New South Wales
Sydney, Australia

Todd T. Brown, MD, PhD

The Johns Hopkins University
Baltimore, MD, United States

Corey Casper, MD

Fred Hutchinson Cancer Research Center
Seattle, WA, United States

Ellen G. Chadwick, MD

Ann & Robert H. Lurie Children's
Hospital of Chicago
Chicago, IL, United States

David B. Clifford, MD

Washington University in St Louis,
St. Louis, MO, United States

Kelly Dooley, MD, PhD

The Johns Hopkins University
Baltimore, MD, United States

David Evans, PhD

University of Wisconsin-Madison
Madison, WI, United States

Charles W. Flexner, MD

The Johns Hopkins University
Baltimore, MD, United States

Patricia M. Flynn, MD

St. Jude Children's Research Hospital
Memphis, TN, United States

Jennifer Furin, MD, PhD

Case Western Reserve University
Cleveland, OH, United States

Dana H. Gabuzda, MD

Dana-Farber Cancer Institute,
Boston, MA, United States

Monica Gandhi, MD, MPH

University of California San Francisco
San Francisco, CA, United States

Gerardo Garcia-Lerma, PhD

Centers for Disease Control and
Prevention
Atlanta, GA, United States

Elvin Geng, MD, MPH

University of California San Francisco
San Francisco, CA, United States

Carlo Giaquinto, MD

University of Padova
Padova, Italy

Beatrice H. Hahn, MD

University of Pennsylvania
Philadelphia, PA, United States

James G. Hakim, MD

University of Zimbabwe
Harare, Zimbabwe

P. Richard Harrigan, PhD

British Columbia Centre for Excellence
in HIV/AIDS
Vancouver, Canada

Theodora Hatzioannou, PhD

The Rockefeller University
New York, NY, United States

Priscilla Hsue, MD

University of California San Francisco
San Francisco, CA, United States

Harold W. Jaffe, MD

Centers for Disease Control and
Prevention
Atlanta, GA, United States

Angela Kashuba, PharmD

University of North Carolina
at Chapel Hill
Chapel Hill, NC, United States

Susan E. Krown, MD

AIDS Malignancy Consortium
New York, NY, United States

Raphael J. Landovitz, MD

University of California Los Angeles
Los Angeles, CA, United States

Bruno Ledermann, PhD

University of Zurich
Zurich, Switzerland

Scott L. Letendre, MD
University of California San Diego
San Diego, CA, United States

Sharon R. Lewin, MD
University of Melbourne
Melbourne, Australia

Annie F. Luetkemeyer, MD
University of California San Francisco
San Francisco, CA, United States

Patrick W. G. Mallon, PhD, MBBS
University College Dublin
Dublin, Ireland

Natasha Martin, DPhil
University of California San Diego
San Diego, CA, United States

Grace A. McComsey, MD
Case Western Reserve University
Cleveland, OH, United States

Graeme Meintjes, PhD, MBChB
University of Cape Town
Cape Town, South Africa

Jonathan Mermin, MD, MPH
Centers for Disease Control and
Prevention
Atlanta, GA, United States

Gesine Meyer-Rath, MD, PhD
Boston University
Boston, MA, USA

Ronald T. Mitsuyasu, MD
University of California Los Angeles
Los Angeles, CA, USA

Jean-Michel Molina, MD, PhD
Hôpital St. Louis
Paris, France

Victor Musiime, PhD, MBChB
Makerere University
Kampala, Uganda

Susanna Naggie, MD, MHS
Duke University
Durham, NC, United States

Julie M. Overbaugh, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA, United States

Jean-Michel Pawlotsky, MD, PhD
Henri Mondor University Hospital
Creteil, France

Martina Penazzato, MD, PhD
World Health Organization
Geneva, Switzerland

Wendy Post, MD
The Johns Hopkins University
Baltimore, MD, United States

Paul Revill, MSc
University of York
York, United Kingdom

Lesley Scott, PhD
National Health Laboratory Service
Johannesburg, South Africa

Kenneth E. Sherman, MD, PhD
University of Cincinnati
Cincinnati, OH, United States

Marco Siccardi, PhD
University of Liverpool
Liverpool, United Kingdom

Viviana Simon, MD, PhD
Icahn School of Medicine at Mount Sinai
New York, NY, USA

Mario Stevenson, PhD
University of Miami
Miami, FL, United States

Timothy Wilkin, MD
Weill Cornell Medicine
New York, NY, United States

Alan Winston, MD
Imperial College London
London, United Kingdom

David L. Wyles, MD
Denver Health, University of Colorado
Denver, CO, United States

Robert Yarchoan, MD
National Cancer Institute
Bethesda, MD, United States

Clement Zeh, PhD, MPH
Centers for Disease Control and
Prevention
Atlanta, GA, United States

SCHOLARSHIP AWARDEES

CROI is committed to supporting new and early career investigators working in HIV research to help them further their education and to network with other researchers in the field. New Investigator Scholarship awardees are presenting authors on accepted abstracts and have been highly recommended by their mentors.

In addition, CROI offers scholarships to international researchers and community educators working in resource-limited countries who would otherwise be unable to attend CROI. Through their applications and letters of recommendation, these awardees have shown that they will greatly benefit from the opportunity to participate in CROI.

New Investigator Awardees

Hadega Aamer

Seattle Children's Research Institute

Julia A. Aepfelbacher

National Institutes of Health

Abhinav Ajaykumar

University of British Columbia

Raza M. Alvi

Massachusetts General Hospital

Patrizia Amelio

Lausanne University Hospital

Elizabeth M. Anderson

National Cancer Institute

Abigail Armstrong

University of Colorado

Tigran Avoumdjian

University of Washington

Nadine Bachmann

University Hospital Zurich

Roger Badia

IrsiCaixa Institute for AIDS Research

Omolara Baiyegunhi

University of KwaZulu-Natal

Kayode Balogun

University Health Network

Kiran Bandi

University of Pittsburgh

Anya Bauer

University of Pennsylvania

Eve-Marie A. Benson

The Johns Hopkins University

Lynn N. Bertagnoli

The Johns Hopkins University

Rachael Billock

University of North Carolina at Chapel Hill

Gilad Bismut

The Johns Hopkins University

Oscar Blanch-Lombarte

IrsiCaixa Institute for AIDS Research

Anne Boerekamps

Erasmus University Medical Center

David C. Boettiger

Kirby Institute

Denali Boon

The Johns Hopkins University

Julie Boucau

Massachusetts General Hospital

Carolyn Boudreau

Ragon Institute of MGH, MIT and Harvard

Kassem Bourgi

Vanderbilt University

Helen J. Box

University of Liverpool

Yann Breton

Laval University

Sarah Bridge

University of Minnesota

Egidio Brocca-Cofano

University of Pittsburgh

Manuela Bullo

University of North Carolina at Chapel Hill

Erin M. Burgunder

University of North Carolina at Chapel Hill

Haotian Cai

Association of Schools and Programs of Public Health

Yanhui Cai

Wistar Institute

Keri Calkins

The Johns Hopkins University

Eugenio N. Cavallari

Sapienza University of Rome

Emily Cedarbaum

University of California San Francisco

Luigi Celani

Sapienza University of Rome

Maddalena Cerrone

St. Stephen's AIDS Trust—Chelsea and Westminster Hospital

Antoine Chaillon

University of California San Diego

Chloe S. Chaudhury

National Institutes of Health

Sandra E. Chaudron

University of Zurich

Bonnie Chen

Case Western Reserve University

Liang Cheng

University of North Carolina at Chapel Hill

Sukrutha Chettimada

Dana-Farber Cancer Institute

Ryan Cheu

University of Washington

Fatema Z. Chowdhury

The Ragon Institute of MGH, MIT and Harvard

Aaron Christensen-Quick

University of California San Diego

Angelo A. Clementi-Allen

University of California San Francisco

Kalysha Closson

British Columbia Centre for Excellence in HIV/AIDS

Krystal Colon-Rivera

Wistar Institute

Julie Copelyn

University College London

Bjorn Corleis

Ragon Institute of MGH, MIT and Harvard

César N. Cortés-Rubio

National Institute of Respiratory Diseases

Daniela Angela Covino

Istituto Superiore di Sanità

Morgan L. Craig

Harvard University

Lize Cuypers

Katholieke Universiteit Leuven

Weiwei Dai

University of Massachusetts Medical School

Thibaut Davy-Mendez

University of North Carolina Chapel Hill

Davide De Francesco

University College London

Simon de Montigny

University of Montreal

Valentina De Zan

Ospedale San Raffaele

Christian Deo T. Deguit

University of the Philippines Manila

Heloise M. Delagrevierie

Hôpital Saint-Louis

Vincent Desrosiers

Laval University

Francisco Diez Fuentes

Institute de Salud Carlos III

Lourdes Domínguez-Domínguez

Hospital Universitario 12 de Octubre

Diako Ebrahimi

University of Minnesota

Ceri Evans

Queen Mary University of London

Emily Evans

Emory University

Mary Evans

Centers for Disease Control and Prevention

Claudia Fabrizio

University of Bari

Francisco Fanjul

Hospital Universitario de Son Espases

Shelli Farhadian

Yale University

Amanda Fernández-Rodríguez

Institute de Salud Carlos III

Bridget Fisher

Center for Infectious Disease Research

Jacob Flynn

National Institutes of Health

Lindsay T. Fourman

Massachusetts General Hospital

Chris Fujitnirun

Chulalongkorn University

Hirofumi Fukuda

Kyoto University

Roberta Gagliardini

Catholic University of the Sacred Heart

Pierre Gantner

Hôpitaux Universitaires de Strasbourg

Pilar Garcia Broncano

Ragon Institute of MGH, MIT and Harvard

Lucio Jesus Garcia-Fraile Fraile

Hospital Universitario de La Princesa

Rolando Garza

University of Pennsylvania

Marco Gelpi

University Hospital Rigshospitalet

Matthew Generoso

New York University

Jeffrey Gerold

Harvard University

Melissa Ghulam-Smith

Boston University

Ana Godinho-Santos

Universidade de Lisboa

Carmen M. González Domenech

Hospital Virgen de la Victoria

David Goodman-Meza

University of California Los Angeles

Bindu P. Gopalan

St. John's Research Institute

Ria Goswami

Duke University

Julien Gras

Hôpital Saint-Louis

Justin Greene

Oregon Health and Sciences University

Sharon A. Greene

University of Washington

David C. Griffith

The Johns Hopkins University

Ahmad Haeri Mazanderani

National Institute for Communicable Diseases

Megan Halkett

Northwestern University

Ryan C. Handoko

Yale University

Laurent Hany

CHU de Québec-Université Laval

Tiffany Hensley-McBain

University of Washington

Lucas E. Hermans

University Medical Center Utrecht

Akarin Hiransuthikul

HIV-NAT, Thai Red Cross AIDS Research Centre

Elske Hoornenborg

Public Health Service Amsterdam

Bethany A. Horsburgh

The Westmead Institute for Medical Research

Stephane Hua

Ragon Institute of MGH, MIT and Harvard

Seth C. Inzaule

Amsterdam Institute for Global Health and Development

Sergio Ita

University of California San Diego

Victoria Iyun

University of Cape Town

Madeleine Jennewein

Harvard University

Julie Jesson

INSERM

Steven W. Jin

Simon Fraser University

Ana Jordan-Paiz

IrsiCaixa Institute for AIDS Research

Claus Kadelka

University of Zurich

Gerrit Kann

University Hospital Frankfurt

Sanket Kant

McGill University

Christina B. Karsten

Ragon Institute of MGH, MIT and Harvard

Mark D. Kelley

University of Pittsburgh

Jéromine Klingler

INSERM

Andreas D. Knudsen

University of Copenhagen

Yik Lim Kok

University Hospital Zürich

Xiao Mei T. Kuang

Simon Fraser University

Hsiao-Hsuan Kuo

Ragon Institute of MGH, MIT and Harvard

Katharina Kusejko

University Hospital Zurich

Abena Kwaa

The Johns Hopkins University

Stephen Lai National Institutes of Health	Farah Mouhanna The George Washington University
Jennifer O. Lam Kaiser Permanente	Joseph Mudd National Institutes of Health
Camille Lange National Institutes of Health	Shibani S. Mukerji Dana-Farber Cancer Institute
Nontokozo Langwenya University of Cape Town	Larissa V. Mulka Brighton and Sussex Medical School
Catherine N. Le University of California Los Angeles	Alexandra J. Murray The Johns Hopkins University
Lorna Leal Hospital Clinic of Barcelona	Andrew Musick National Institutes of Health
Matthew E. Levy The George Washington University	Sarah Mutch University of Manitoba
Sam Li University of Colorado	Francis Mwimanzi Kumamoto University
Timothy Lin University of California San Diego	George Mwinnyaa The Johns Hopkins University
Kelsey B. Loeliger Yale University	Henry Nabeta University of Louisville
Giuseppe Lofano Massachusetts General Hospital	Florence Nabwire Cambridge University
Joanna Luczkowiak Universidad Autónoma de Madrid	Golnaz Namazi Brigham and Women's Hospital
Jesus M. Luevano Ragon Institute of MGH, MIT and Harvard	Manon Nayrac INSERM
Parag Mahale National Cancer Institute	Megan Neary University of Liverpool
Jaclyn Mallard Boston College	Charles P. Neff University of Colorado
Jennifer Manne-Goehler Beth Israel Deaconess Medical Center	Anne M. Neilan Massachusetts General Hospital
Alyssa R. Martin National Institutes of Health	Huyen Nguyen University Hospital Zurich
Ilaria Mastorosha Lazzaro Spallanzani National Institute for Infectious Diseases	Nadia Nguyen New York State Psychiatric Institute
Rodrigo Matus-Nicodemos Vaccine Research Center, NIAID	Thuy T.T. Nguyen Pitié-Salpêtrière Hospital
Robert T. Maughan University College Dublin	Julia Niessl University of Montreal
Mitchell R. McClean Indiana University	Bernadien Nijmeijer Academic Medical Center
Suzanne McCluskey Massachusetts General Hospital	Talia M. Nir University of Southern California
Wyatt J. McDonnell Vanderbilt University	Sarah B. Nodder Boston University
Allison M. McFall The Johns Hopkins University	Alessandra Noto Lausanne University Hospital
Angela McLaughlin St. Paul's Hospital	Jasantha Odayar University of Cape Town
Vikram Mehraj McGill University	Pamela M. Odorizzi University of California San Francisco
Kate G. Michel Georgetown University	Tess O'Meara Yale University
Brooks I. Mitchell University of Hawaii	Edmund Osei-Kuffour Heinrich Heine University Hospital
Julie Mitchell US Military HIV Research Program	Nandagopal Panneerselvam YR Gaitonde Center for AIDS Research and Education
Aaloke Mody University of California San Francisco	Anar S. Patel Emory University
Samantha A. Molsberry Harvard University	Tess Peterson University of Minnesota
Audrey Monnin INSERM	Hanh T. Pham McGill University
Jessica L. Montoya University of California San Diego	Phuong Pham National Institutes of Health
Ethan Morgan Northwestern University	Samuel Pierre GHESKIO
Sara Moron-Lopez IrsiCaixa Institute for AIDS Research	Carmela Pinnetti Lazzaro Spallanzani National Institute for Infectious Diseases
Elena Morocchi University of Rome Tor Vergata	

Maria Pino	Yerkes National Primate Research Center	Mariya V. Sivay	The Johns Hopkins University
Micah Piske	University of British Columbia	Shayla Smith	Columbia University
Alex Pollard	Brighton and Sussex Medical School	Matthew A. Spinelli	University of California San Francisco
Rosalie Ponte	McGill University	Nithya Srinivas	University of North Carolina at Chapel Hill
Joan T. Price	University of North Carolina at Chapel Hill	Carly Elizabeth C. Starke	National Institutes of Health
Alizé Proust	CHU de Québec-Université Laval	Melanie Stecher	University of Cologne
Joel Provost	Laval University	Natalia Stella-Ascariz	Hospital La Paz Institute for Health Research
Maria Pyra	University of Washington	Zachary Strongin	Brigham and Women's Hospital
Daniel Radwan	The Johns Hopkins University	Megan M. Stumpf	Fred Hutchinson Cancer Research Center
Mohammad A. Rahman	National Institutes of Health	Jing Sun	The Johns Hopkins University
Rajith Kumar Reddy Rajoli	University of Liverpool	Nicholas Tan	University of Washington
Cláudia Priscila Ramos Muniz	Instituto Nacional de Cancer	Shema Tariq	University College London
Erin Ready	University of British Columbia	Lee M. Tatham	University of Liverpool
Ludy Registre	Boston University	Bryn C. Taylor	University of California San Diego
Enrico Richter	University Hospital Essen	Kirk A. Taylor	Imperial College London
Kathryn A. Risher	London School of Hygiene & Tropical Medicine	Sushama Telwatte	San Francisco VA Medical Center
Muntsa Rocafort	IrsiCaixa Institute for AIDS Research	Richard A. Teran	Columbia University
Marta Rodriguez-Garcia	Dartmouth College	Rebekka F. Thudium	University of Copenhagen
Andreas Ronit	Copenhagen University Hospital	Phillip Tomezsko	Harvard University
Ofelia M. Rosales Del Real	Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán	Jessie Torgersen	University of Pennsylvania
Marina Rubio Garrido	Hospital Ramón y Cajal	Berta Torres	Hospital Clinic of Barcelona
Rachel L. Rutishauser	University of California San Francisco	Wim Trypsteen	HIV Cure Research Center, Ghent University
Sahar Saeed	McGill University	Jonathan Underwood	Imperial College London
Syim Salahuddin	McGill University	Ward P.H. van Bilsen	Public Health Service Amsterdam
Romina Salpini	University of Rome Tor Vergata	Rachel Van Duyne	National Cancer Institute
Vishal Samboju	University of California San Francisco	Clarissa Van Hecke	HIV Cure Research Center, Ghent University
Ryan Sanford	Montreal Neurological Institute	Benni S. Vargas	University of Pittsburgh
Montserrat Sanmartí	Hospital Universitari Mútua de Terrassa	Jennifer Velloza	University of Washington
Anamaria D. Sarca	Kyoto University	Beate Vestad	Oslo University Hospital
Mariane H. Schleimann	Aarhus University Hospital	Line K. Vibholm	Aarhus University
Carla Serra Peinado	Vall d'Hebron Research Institute	Alinda Vos	University Medical Center Utrecht
Paola Sette	University of Pittsburgh	Victoria E. Walker-Sperling	National Cancer Institute
Radwa Sharaf	Harvard University	Qi Wang	University of North Carolina at Chapel Hill
Katie Sharp	University of California Los Angeles	Zheng Wang	University of Pittsburgh
Emily Shava	Botswana Harvard AIDS Institute Partnership	Zheng Wang	The Johns Hopkins University
Chelsea L. Shover	University of California Los Angeles	Tomas Raul Wiche Salinas	Centre Hospitalier de l'Université de Montreal

Ingeborg Wijting

Erasmus University Medical Center

Nicole E. Winchester

National Institutes of Health

Helen Wu

Oregon Health and Sciences University

H. Manisha N. Yapa

University of New South Wales, Australia

Christine Youn

National Institute of Allergy and Infectious Diseases

Yinfeng Zhang

The Johns Hopkins University

International Investigator Awardees

Clement G. Adu-Gyamfi

University of the Witwatersrand

Gbolahan Ajibola

Botswana Harvard AIDS Institute Partnership

Motswedi Anderson

Botswana Harvard AIDS Institute Partnership

Marilia B. Antonio

Universidad de São Paulo

Daniel W. Atwine

Médecins Sans Frontières Epicentre

James Ayieko

Kenya Medical Research Institute

Barbara Castelnovo

Infectious Disease Institute

Unoda A. Chakalisa

Botswana Harvard AIDS Institute Partnership

Menard L. Chihana

Médecins Sans Frontières Epicentre

Sergio M. de Almeida

Universidade Federal do Paraná

Kostyantyn Dumchev

Ukrainian Institute on Public Health Policy

Eduard Grebe

Stellenbosch University

Etienne Kadima

Botswana Harvard AIDS Institute Partnership

Makobu Kimani

Kenya Medical Research Institute

Marina Kornilova

Alliance for Public Health

Anna Lawino

Makerere University

Wei Lu

Peking Union Medical College Hospital

Mompatti O. Mmalane

Botswana Harvard AIDS Institute Partnership

Keolebogile N. Mmasa

Botswana Harvard AIDS Institute Partnership

Sikhulile Moyo

Botswana Harvard AIDS Institute Partnership

Lydia Nakiyingi

Infectious Disease Institute

Sabin Nsanzimana

Rwanda Biomedical Centre

Ninutchka Paengsai

Chiang Mai University

Tamsin K. Phillips

University of Cape Town

Angsana Phuphuakrat

Mahidol University

Shanmugam Saravanan

YR Gaitonde Center for AIDS Research and Education

Kenneth Ssebambulidde

Infectious Disease Institute

Sarah Jane Steele

Médecins Sans Frontières

Birkneh T. Tadesse

Hawassa University

Vu P. Thao

Oxford University Clinical Research Unit in Vietnam

Thiago S. TorresInstituto Nacional de Infectologia Evandro Chagas (INI)/
Fiocruz)**Darlisha A. Williams**

University of Minnesota

Community Educator Awardees

Oluwatosin B. Alaka

New HIV Vaccine and Microbicide Advocacy Society

David W. Andrist

The Ohio State University

Giorgio Barbareschi

European AIDS Treatment Group

Tamás Bereczky

European AIDS Treatment Group

Charles Brown

Preventive Care International

Giulio M. Corbelli

European AIDS Treatment Group

Michael J. Dorosh

Treatment Education Network

Florita C. Durueke

New HIV Vaccine and Microbicide Advocacy Society

Daniel K. GondweMalawi College of Medicine-Johns Hopkins University
Research Project**Tian Johnson**

African Alliance for HIV Prevention

Tapiwanashe Kujinga

Pan-African Treatment Access Movement

Grace KumwendaPakachere Institute for Health and Development
Communication**Maureen Luba**

Centre for the Development of People

Michael Meulbroek

Asociación para el Trasplante de Órganos a Seropositivos

Peter A. Mogere

Kenya Medical Research Institute-CCR PHRD Thika

Steven S. Muchnick

Delaney AIDS Research Enterprise to Defeat HIV

Kennedy Mupeli

Centre for Youth of Hope

Robert E. Newells

AIDS Project of the East Bay

Joyce W. Ng'ang'a

WACI Health

Moses S. Nsubuga

People in Need Agency

Elias F. Phiri

Addington Afro-Ethnic Health Promotion Group

Ferran Pujol Roca

Projecte dels NOMS-Hispanosida

Jorge Saz Berges

Joves Positius

Pich Seekaew

Thai Red Cross AIDS Research Centre

Cissy Ssuuna

Baylor College of Medicine Children's Foundation-Uganda

Harry C. Tembo

Zambia Community Advisory Platform

CONTINUING MEDICAL EDUCATION

Accreditation Statement

The International Antiviral Society—USA (IAS—USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.



The IAS—USA designates this live activity for a maximum of **17 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives

After participating in CROI 2018, participants will be able to:

- Describe basic science research advances in HIV
- List the most recent findings from clinical trials in the field of HIV and the implications of these data for state-of-the-art treatment strategies
- Describe current epidemiologic data on the prevalence of HIV infection, transmission, treatment, and linkage to and retention in care in populations worldwide; the implications of these data for public-health program planning; and current advances in biobehavioral prevention

Statement of Need

Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care practitioners, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible. CROI was founded in 1993 by researchers working in the field of HIV/AIDS and its complications, as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research into different facets of HIV and its complications, as well as selected other emerging infections.

CME Credit Information

Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for participation in CROI. CME credits can be claimed for premeeting workshops, opening session lectures, plenary lectures, and symposia. CME credits cannot be claimed for oral abstract sessions, themed discussion sessions, or poster sessions. For physician attendees Board certified by the American Board of Internal Medicine (ABIM), Maintenance of Certification (MOC) points are available for participation in CROI. Other researchers, practitioners, and attendees can receive a Certificate of Participation verifying their attendance, as required by the American Medical Association (AMA).

ABIM MOC Points



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **17 MOC points** in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Claiming CME Credits, ABIM MOC Points, or a Certificate of Participation

During the conference, links to the daily and final evaluations will be available at a secure web page on the CROI website at www.croiconference.org/electronic-materials. You will need your e-mail address that you **used to register for this conference** and your registration ID to access this page. To obtain CME credits, ABIM MOC points, or a Certificate of Participation for CROI, all final evaluations must be completed by April 9, 2018. Once the final evaluation and posttest are submitted, your certificate will be uploaded to your CROI profile in the CROI website within 2 to 3 business days.

To determine the number of CME credits, ABIM MOC points, or hours of participation that can be claimed, calculate time spent attending the conference, including premeeting workshops, opening session lectures, plenary lectures, and symposia. For example, if you attended 2 plenary talks (8:30 AM to 9:30 AM), and a symposium (4:00 PM to 6:00 PM), you would have a total of 3 hours to apply toward CME credits or ABIM MOC points (if applicable) for that day. At the end of CROI, please add the total hours you attended for your certificate.

A CME/ABIM MOC hour worksheet can be found at <http://www.croiconference.org/sites/default/files/uploads/croi2018-cme-worksheet.pdf>.

Disclosure of Financial Relationships

It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty members (speakers, presenters, etc) participating in IAS–USA-sponsored activities are required to disclose to the program audience any financial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation. (The Accreditation Council for Continuing Medical Education (ACCME) defines a financial interest as an interest in any amount.) The information is intended to make the IAS–USA audience aware of speaker and contributor interests and commitments with commercial companies or other entities, enabling the audience members to form their own judgments about such associations.

Each author or contributor is required to complete this financial disclosure declaration. In accordance with IAS–USA policy, the IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Disclosure information is detailed in the Abstract eBook.

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

GENERAL INFORMATION

Overview

CROI was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI is the preeminent HIV research meeting in the world and includes up to 4000 HIV research and care leaders internationally. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research. In 2018, we mark the 25th CROI.

Conference Support

CROI is largely supported by participant registration fees. CROI registration fees cover all hosted attendee meals (including the welcome reception) and travel expenses for invited participants (eg, speakers, leaders, moderators, and CROI PC), as well as selected meeting materials and other conference expenses.

In addition, CROI seeks grants from commercial companies, particularly from companies with competing products. These companies have no input in or control over the selection of faculty or content of the presentations. Commercial support is used to cover some of the costs of the convention center, audiovisual services, and other conference services.

CROI 2018 received grant support commitments from the following commercial companies:

PLATINUM SUPPORTERS

Gilead Sciences

Merck & Co

ViiV Healthcare

GOLD SUPPORTER

Janssen Therapeutics

Additional support has been provided by

AbbVie

Americans With Disabilities Act

CROI endeavors to comply fully with the legal requirements of the Americans with Disabilities Act (ADA). If you require assistance on-site, please visit the Attendee Services booth on the Plaza level during the conference.

Emergency Services

In the event of an emergency please contact the convention center command center, open 24 hours daily, or notify CROI staff. The command center can be reached at (617) 954-2111 and is located by the Boylston Street entrance to the convention center. In addition, security offices are located throughout the building at each of the building's entrances. A nurse is available on-site and is accessible by contacting the command center, notifying CROI staff, or visiting the nurse's office in the registration area.

Embargo Policies and Social Media

The research presented at CROI 2018 is embargoed until the conclusion of the session in which it is presented. For example, if a study is presented from 10:15 AM to 10:30 AM as part of a session that ends at 12:00 PM, the embargo on that study lifts at 12:00 PM. Embargoes on poster presentations lift at the conclusion of the session in which the poster is presented. If a study to be presented at CROI 2018 is included in an official CROI press conference and that press conference takes place before the official presentation of the study at the conference, the embargo lifts at the conclusion of the press conference in which the study is featured.

CROI embargo policies apply to any public dissemination of research information presented at the conference, including electronic publications (eg, blogs) or social media (eg, Facebook, Twitter). No public dissemination of research information from the conference is permitted prior to the lifting of the conference embargo. Individuals or organizations that violate the conference embargo policy may have their conference credentials revoked and may forfeit the opportunity to participate in future conferences.

Welcome Reception

All registered CROI attendees are invited to the Welcome Reception immediately following the Opening Session on March 4, 2018. The reception will be held in Halls C and D and the corresponding prefunction areas.

The Welcome Reception will offer attendees the opportunity to network with colleagues.

Meals

Hosted group morning coffee and light snacks are available to conference registrants from 7:30 AM to 8:30 AM, Monday, Tuesday, and Wednesday, outside of the general session room. An afternoon snack break will be available at 2:30 PM in Poster Hall A. Attendees are on their own for all other meals, including lunch and dinner. Below is a list of food service options located in the Convention Center or within a short walking distance.

Food Service at the Convention Center

Towne Stove and Spirits

The Capital Grill

Food Service at the Prudential Center (adjacent to the Convention Center)

Ben & Jerry's	Pinkberry
Cold Stone Creamery	Star Market
Crazy Dough's Pizza	Sugarfina
DAVIDsTEA	5 Napkin Burger
Dunkin' Donuts	Anna's Taqueria
Eataly	Au Bon Pain
Godiva	California Pizza Kitchen
Num Pang Kitchen	Dig Inn
Earl's Kitchen & Bar	L'Espalier
Porto	sweetgreen
The Cheesecake Factory	Top of the Hub
Towne Stove & Spirits	Wagamama

Food Service Within 3 Blocks of the Convention Center

Bukowski	50 Dalton St	617-437-9999	bukowskitavern.net
Dillon's	955 Boylston St	617-421-1818	dillonsboston.com
Boloco	76 Boylston St	617-266-2200	boloco.com
Trader Joe's	899 Boylston St	617-262-6505	traderjoes.com
The Pour House	907 Boylston St	617-236-1767	pourhouseboston.com
Atlantic Fish Company	761 Boylston St	617-267-4000	atlanticfishco.com
Starbucks	755 Boylston St	617-450-0310	starbucks.com

Food Service Within 3 Blocks of the Convention Center (continued)

Dirty Water Dough Co.	222 Newbury St	617-262-0090	dirtywaterdough.com
Summer Shack	50 Dalton St	617-867-9955	summershackrestaurant.com
Whiskey's	885 Boylston St	617-262-5551	whiskeysboston.com
Lir	903 Boylston St	617-778-0089	lironboylston.com
McGreevy's Boston	911 Boylston St	617-262-0911	mcgreevysboston.com
Abe & Louie's	793 Boylston St	617-536-6300	abeandlouies.com
DeLuca's Market	11 Charles St	617-523-4343	delucasmarket.com
Chipotle	553 Boylston St	617-236-1749	chipotle.com
B. Good	655 Boylston St	617-927-8333	bgood.com
Bar 10	10 Huntington Ave	617-424-7488	bar10boston.com
The Huntington at the Westin	10 Huntington Ave	617-262-9600	westincopleyplaceboston.com
Legal Sea Foods	100 Huntington Ave	617-266-7775	legalseafoods.com
Champion's Sports Bar	110 Huntington Ave	617-927-5304	championsboston.com
Osushi	10 Huntington Ave	617-266-2788	osushiboston.com

Overflow Accommodations for Oral Sessions

If a session room fills to capacity, there will be overflow areas in rooms 302, 311, and 312. There will be signs to direct you to the respective overflow room for the session you would like to attend.

Mobile App

To access the CROI mobile App, use your registration ID number (on your name badge) and the email address you used to register for CROI.

The CROI 2018 mobile App has many features to enhance your conference experience, including to:

- View abstracts
- Find information about speakers and other CROI attendees
- Create a personal calendar of the sessions you plan to attend
- E-mail session notes
- Receive the latest changes to the CROI program
- View electronic posters



The mobile App is compatible with iOS and Android devices. Search "CROI 2018" in your mobile device App store. Access is restricted to registered attendees. Your log-in information and password are provided with the registration materials.

Website

For additional information about the conference and to access electronic materials please visit the website at www.CROIconference.org.

The final Abstract eBook (flip book and PDF versions) will be available for public download following the conference. Abstracts from CROI 2018 can be viewed and downloaded in the searchable database during the conference. Abstracts and electronic posters from CROI 2014, 2015, 2016, and 2017 are available at www.croiconference.org/abstracts/search-abstracts/

Webcasts

Plenaries, symposia, scientific overviews, oral abstract sessions, and themed discussions are available as webcasts. Webcasts are also available as streaming video for the Apple iPad and iPhone.

Visit www.CROIconference.org or www.CROIwebcasts.org to access the CROI webcasts. Webcasts will be available to registered attendees within 24 hours of the end of the relevant session, and publicly after the conference ends.

Affiliated and Proximate Activities Policies

The goal of CROI is to promote meaningful, high-level scientific interchange of ideas and debate in order to find better ways to prevent, treat, and cure HIV/AIDS. In keeping with this goal, organizations (commercial companies and their agents, not-for-profit groups, government agencies, etc) must be approved to host affiliated or proximate activities and meetings occurring outside CROI session times. Affiliated activities are not sponsored by, endorsed by, or supported by the IAS–USA, the CROI Foundation, or CROI 2018.

Affiliated or proximate activities are those that are scheduled during or around CROI that involve any CROI attendees. If an activity or meeting is found to have violated the policies for affiliated activities, the sponsoring organization, the supporting organization, and the organizer of the meeting may be prohibited from holding an affiliated activity at future CROI conferences and may have their current registration revoked. Noncompliance may be subject to fines and damages, and could negatively impact the registration status and attendance of those attending an unapproved affiliated activity.

If you have organized a meeting or activity that includes CROI attendees, as described in the affiliated activity guidelines, and have not completed the Affiliated Activity application, please see an IAS–USA staff member in the IAS–USA office (Room 203) for assistance.

In the spirit of CROI and the goal of promoting scientific collaboration among colleagues, if you are invited to or are attending a meeting or activity that you feel may not have been approved by CROI, please contact an IAS–USA staff member in the IAS–USA office.

WiFi Access at the Conference

Complimentary wireless internet is provided at the Hynes Convention Center. As a courtesy to your fellow attendees, please disable the WiFi function on your unused devices. For example, if you have a tablet, laptop, and a WiFi enabled phone, please use one device at a time to access WiFi and disable the others.

WiFi Log-in Information

Network: CROI2018 Password: CROI2018

Note: the password is case sensitive; you will need to log in each day as the building resets the network each night.

Conference Badges

You must wear your name badge to gain entry to all official meeting activities, including the poster sessions. **DO NOT LOSE YOUR BADGE. Payment of US \$850 will be required to replace a lost badge.**

Child Care

Children are not permitted entry into any meeting room, including the poster area. If you should require child care, please contact the concierge of your hotel.

Conference Etiquette

In consideration of the work of presenters at CROI, and the CROI copyright policy, attendees should not photograph posters, record parts of talks, or post other people's data. Please ensure all cell phones and pagers are off or are set on SILENT mode. No photography is permitted in session rooms.

CROI HOTELS

Conference attendees are required to stay in one of the official conference hotels. The few exceptions to this include registrants who live in the Boston area (ie, within a 50-mile radius of the Hynes Convention Center) and registrants who are sharing a room with an approved CROI attendee with accommodations booked via the CROI Hotel Reservation System. Please inform the Conference Organizers if you have inadvertently booked a hotel stay outside of the CROI Hotel Reservation System.

CROI 2018 hotels are listed below.

Boston Marriott Copley Plaza

110 Huntington Ave.
Boston, MA 02116
PH: 617-236-5800

Boston Park Plaza

50 Park Plaza at Arlington St.
Boston, MA 02116
PH: 617-426-2000

The Charlesmark at Copley

655 Boylston St.
Boston, MA 02116
PH: 617-247-1212

The Colonnade Hotel

120 Huntington Ave.
Boston, MA 02116
PH: 617-424-7000

Copley Square Hotel

47 Huntington Ave.
Boston, MA 02116
PH: 617-536-9000

Fairmont Copley Plaza

138 St. James Ave.
Boston, MA 02116
PH: 617-267-5300

Hilton Boston Back Bay

40 Dalton St.
Boston, MA 02115
PH: 617-236-1100

Mandarin Oriental

776 Boylston St.
Boston, MA 02119
PH: 617-535-8888

The MidTown Hotel

220 Huntington Ave.
Boston, MA 02115
PH: 617-262-1000

Sheraton Boston

39 Dalton St.
Boston, MA 02199
PH: 617-236-2000

Taj Boston

15 Arlington St.
Boston, MA 02116
PH: 617-536-5700

Westin Copley Place

10 Huntington Ave.
Boston, MA 02116
PH: 617-262-9600

CROI HOTELS

- ★ The John B. Hynes Memorial Convention Center
- 1 Boston Marriott Copley Place
- 2 Boston Park Plaza Hotel
- 3 The Charlesmark at Copley
- 4 The Colonnade Hotel
- 5 Copley Square Hotel
- 6 Fairmont Copley Plaza
- 7 Hilton Boston Back Bay
- 8 Mandarin Oriental
- 9 The MidTown Hotel
- 10 Sheraton Boston
- 11 Taj Boston
- 12 Westin Copley Place





CONFERENCE SERVICES

Services	Location	Hours	
Boston Information	Registration Area on the Plaza Level	Saturday: Sunday: Monday to Wednesday:	2:30 PM – 7:30 PM 8:30 AM – 7:00 PM 8:00 AM – 6:30 PM
Bag and Coat Check	Plaza Level Room 109	Sunday: Monday to Wednesday:	8:00 AM – 9:30 PM 7:30 AM – 6:30 PM
Cyber Cafe	Plaza Level: Outside Poster Hall A 2nd Floor: Outside the General Session Room	Saturday: Sunday: Monday to Wednesday:	3:00 PM – 6:00 PM 7:00 AM – 7:00 PM 7:30 AM – 6:00 PM
Media Center	Room 210	Sunday: Monday to Wednesday:	10:00 AM – 7:00 PM 8:00 AM – 6:30 PM
Badge Pickup	Registration	Saturday:	3:00 PM – 6:00 PM
Attendee Services	Area on the Plaza Level	Sunday: Monday:	7:00 AM – 7:00 PM 7:00 AM – 6:00 PM
Housing Information		Tuesday and Wednesday:	8:00 AM – 6:00 PM
Scholarship Badge Pickup			
Media Badge Pickup			
IAS–USA Office	Room 203	Saturday: Sunday to Wednesday:	3:00 PM – 6:00 PM 7:00 AM – 6:00 PM
Speaker Ready Room	Room 200	Saturday: Sunday to Wednesday:	3:00 PM – 6:00 PM 6:00 AM – 6:00 PM
Personal Considerations Room	Room 308	Saturday: Sunday: Monday to Wednesday:	3:00 PM – 6:00 PM 9:00 AM – 7:00 PM 8:00 AM – 6:00 PM
New Mother's Room	Room 307	Saturday: Sunday: Monday to Wednesday:	3:00 PM – 6:00 PM 9:00 AM – 7:00 PM 8:00 AM – 6:00 PM
Networking Areas	Cafeteria, Rooms 303, 305, 309, 310, and Poster Halls A, B, D	Saturday: Sunday: Monday to Wednesday:	3:00 PM – 6:00 PM 9:00 AM – 7:00 PM 8:00 AM – 6:00 PM

CONFERENCE SERVICES

Notes

Local Information and reservations assistance.

Bag and coat check are free of charge.

Computers with internet access are available for webcasts and abstract searches.

The Media Center is a work space with Wi-Fi and is the location of the daily press conferences open exclusively to registered, accredited media.

Badges and conference material can be picked up at this location.

The conference organizers are available to answer questions or concerns regarding the conference.

Oral abstract, invited, and themed discussion session speakers must drop off presentations here at least 24 hours before their presentation. Poster presenters should submit an electronic version of their poster through the abstract submission website before the start of the conference.

The Personal Considerations Room is set aside for those who require a short-term private space for personal health needs. Use of this room is available on a first-come, first-served basis.

The New Mothers' Room is set aside for nursing mothers who require a short-term private room. Use of this room is on a first-come, first-served basis.

These areas are set up with tables and chairs for attendees to gather and network with colleagues.

ABSTRACT PROCESS

Scientific Categories

- A. Virology
- B. Pathogenesis: Human Studies and Animal Models
- C. Host Immune Responses to Infection, Vaccines, and Immunotherapy
- D. HIV Reservoirs, Latency, and All Curative Strategies Including Therapeutic Vaccines and Gene Therapy
- E. Neuropathogenesis and Central Nervous System Complications
- F. Clinical Pharmacology
- G. Antiretroviral Therapy: Pre-Clinical and Randomized Trials
- H. Antiretroviral Therapy: Efficacy and Effectiveness Studies
- I. HIV Drug Resistance
- J. HIV Diagnostics
- K. Hepatitis Viruses and Liver Complications
- L. Malignancies
- M. Cardiovascular Complications of HIV Infection and Antiretroviral Therapy
- N. Other Complications of HIV Infection and Antiretroviral Therapy
- O. Tuberculosis and Other Opportunistic Infections
- P. Maternal and Fetal HIV
- Q. Pediatrics and Adolescents
- R. Epidemiology
- S. Testing
- T. Prevention Interventions
- U. Contraceptive and Reproductive Health in Women
- V. Implementation and Scale-Up of Treatment and Care
- W. Population and Cost Modeling

Abstract Content

Author names, institutions, titles, and abstracts in the Abstract eBook and other materials are presented as submitted by the corresponding author.

Abstract Review Process

The PC and a panel of volunteer external reviewers reviewed more than 2000 submitted abstracts. Each abstract was reviewed by 5 to 10 reviewers selected for each abstract category based upon their individual expertise.

PC members and external experts in the field reviewed the abstracts for the quality and originality of the work and scored them numerically. All reviewers were instructed to abstain from scoring any abstract on which they are an author or coauthor, have a financial or personal conflict of interest, or do not have the appropriate expertise to evaluate. Scores ranged from 1 (definite oral presentation) to 5 (rejected).

Scores for each abstract were averaged and the standard deviation was calculated to assess variability. If variability was high, outlier scores are identified and censored. Abstracts with high variability in scores were discussed individually during a series of conference calls. Abstracts were accepted for oral presentations, for poster presentations, or rejected. Late-breaking abstract reviews included an assessment of the late-breaking nature of the work (versus just being a late submission).

Common Reasons for Abstract Rejection


- Information is not new enough
- Methodology is inadequate or insufficient to support conclusions
- Background does not summarize the hypothesis
- Submission is poorly written
- Abstract is duplicative of other submissions
- Abstract is not appropriate for CROI
- Controls are absent or inadequate
- Statistical evaluation is inadequate or absent
- Summary of essential results is inadequate or absent
- Data are inadequate or insufficient to support conclusions
- Submission reports clinical trial and data from unplanned analysis or incomplete or ongoing studies
- Format does not follow guidelines (eg, section[s] missing, more than 1 graphic, table, or figure submitted)

Statistics for Abstracts

General abstract submitted	1960
General abstracts accepted.....	1061
General oral abstracts	95
General poster abstracts.....	966
Late-breaking abstracts submitted	203
Late-breaking abstracts accepted	44
Late-breaking oral abstracts	19
Late-breaking poster abstracts	25
Total abstracts submitted.....	2163
Total abstract accepted	1105

All Authors on Accepted Abstracts

Region	N	Percent
Africa	101	9.1
Asia	35	3.2
Australia	11	1
Europe	226	20.5
Latin and South America.....	12	1.1
North America	720	65.2



PRECONFERENCE SESSIONS

SUNDAY, MARCH 4, 2018

Workshop W-1 PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

CME

Ballroom BC

9:00 AM - 12:15 PM

Target Audience: This workshop is directed toward new trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators (both international and domestic). However, it is open to all CROI attendees.


Level of Knowledge: It is assumed that participants have been conducting research in the field for less than 3 years.

Objectives: At the completion of the session, participants will be able to:

- Describe the current state of the art of selected areas of HIV basic and clinical research
- List the leading research themes being presented at CROI 2018
- Navigate CROI 2018, maximize the knowledge gained, and interact with research colleagues
- Clarify their individual research interests in relation to the priorities discussed at the workshop and CROI 2018 overall

Conveners

Serena S. Spudich, *Yale University, New Haven, CT, USA*



John W. Mellors, *University of Pittsburgh, Pittsburgh, PA, USA*

1 PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES



SEEING HIV: THE VIRAL LIFECYCLE ANIMATED

Janet Iwasa, *University of Utah, Salt Lake City, UT, USA*



ADVANCES IN MOLECULAR VIROLOGY

Frank Kirchhoff, *Ulm University Medical Center, Ulm, Germany*



ADVANCES IN IMMUNOLOGY

Alexandra Trkola, *University of Zurich, Zurich, Switzerland*



ADVANCES IN TUBERCULOSIS TREATMENT AND PREVENTION

Richard E. Chaisson, *The Johns Hopkins University, Baltimore, MD, USA*



ADVANCES IN HIV PREVENTION

Wafa M. El-Sadr, *ICAP at Columbia University, New York, NY, USA*



ADVANCES IN HIV CURE

Huldrych F. Günthard, *University of Zurich, Zurich, Switzerland*

LUNCH AND MARTIN DELANEY PRESENTATION
WOMEN IN RESEARCH: SCIENCE IS BETTER
WHEN WOMEN ARE REPRESENTED

CME

Ballroom BC**12:30 PM – 1:30 PM**

Description: The Martin Delaney Presentation is held annually during the workshops for Young Investigators, International Scholars, and Community Educators in honor of pioneering HIV/AIDS activist Martin Delaney (1945-2009). It recognizes the important contributions of community advocacy and engagement in research.

Target Audience: This session is directed toward new trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators (both international and domestic.) Attendance is mandatory for all community educator scholarship recipients. It is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for less than 1 year.

Objectives: After attending this lecture, participants will be able to:

- Describe the importance of women as activists in research
- Explain the importance of women as researchers
- Describe the importance of mentorship in encouraging women to contribute as the next generation of HIV researchers

Introduction

Sharon L. Hillier, University of Pittsburgh, Pittsburgh, PA, USA



Moderator

Lisa Diane White, SisterLove, Inc, Atlanta, GA, USA

2 WOMEN IN RESEARCH: SCIENCE IS BETTER WHEN WOMEN ARE REPRESENTED



WOMEN AS ACTIVISTS IN RESEARCH

Dázon Dixon Diallo, SisterLove, Inc, Atlanta, GA, USA



WOMEN CONDUCTING RESEARCH

Tonia Poteat, The Johns Hopkins University, Baltimore, MD, USA



IMPORTANCE OF MENTORSHIP IN DEVELOPING THE NEXT GENERATION OF INVESTIGATORS

Monica Gandhi, University of California San Francisco, San Francisco, CA, USA



Workshop W-2 FRONTIERS IN LABORATORY SCIENCE

CME

Room 304-306

2:00 PM – 4:00 PM

Target Audience: This session is directed to students, researchers, and clinicians who are interested in learning about hot new technologies that are influencing HIV research or hold a substantial potential for research.

Level of Knowledge: It is assumed that the participants are familiar with the main technological and data analysis approaches used in HIV research.

Objectives: At the completion of the session, participants will be able to:

- Describe new approaches to designing synthetic nanocarrier systems for drug delivery based on principles of virus assembly and entry
- Describe state of the art imaging technologies enabling the visualization of single HIV particle dissemination through tissues and cells
- Describe emerging opportunities to exploit single cell transcriptomic and sequencing technologies to probe opportunities to interfere with the cellular viral reservoir

Conveners

Galit Alter, *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA*



Frank Kirchhoff, *Ulm University Medical Center, Ulm, Germany*

3 VIRUS-LIKE NANOCARRIER FOR DELIVERY OF BIOMOLECULES BETWEEN CELLS

Joerg Votteler, *University of Utah, Salt Lake City, UT, USA*



4 3D AND MULTI-SCALE IMAGING OF HIV-1 SPREAD IN TISSUES

Pamela J. Bjorkman, *California Institute of Technology, Pasadena, CA, USA*



5 SINGLE CELL VIRAL AND RECEPTOR BAR CODES: BEYOND THE SINGLE CELL TRANSCRIPTOME

Eli A. Boritz, *NIAID, Bethesda, MD, USA*



Workshop W-3 CLINICAL TRIAL DESIGN AND ANALYSIS

CME

Ballroom A

2:00 PM – 4:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical and epidemiologic studies.

Level of Knowledge: It is assumed that participants are familiar with the basic design of randomized and observational clinical trials and with basic HIV epidemiology.

Objectives: At completion of the session, participants will be able to:

- Describe how phylogenetic studies can inform interventions at a population level
- Assess strategies for measuring the population-level impact of interventions
- Distinguish pragmatic trials from controlled trials and describe the methodological challenges of each

Conveners

Susan P. Buchbinder, *San Francisco Department of Public Health, San Francisco, CA, USA*



Richard E. Chaisson, *The Johns Hopkins University, Baltimore, MD, USA*

6 SEEING THE FOREST THROUGH THE TREES: USING PHYLOGENETICS TO IMPACT THE EPIDEMIC

Susan J. Little, *University of California San Diego, San Diego, CA, USA*



7 MEASURING THE POPULATION-LEVEL IMPACT OF INTERVENTIONS

Jessica E. Justman, ICAP at Columbia University, New York, NY, USA



8 PRAGMATIC TRIALS

Alison Grant, London School of Hygiene & Tropical Medicine, London, UK



Workshop W-4 INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS C

CME

Ballroom BC

2:00 PM – 4:00 PM

Target Audience: This session is directed to persons interested in the management of hepatitis C virus (HCV) infection.


Level of Knowledge: It is assumed that participants are familiar with the general principles of HCV treatment and the medications used.

Objectives: At completion of the session, participants will be able to:

- Describe the management of HCV infection in pregnancy, childhood, and adolescence
- Distinguish between HCV reinfection and relapse and describe the management strategies for acute HCV infection
- Identify when HCV resistance testing is necessary and describe approaches to HCV retreatment after treatment failure
- Describe the diagnostic modalities of and treatment for steatosis in the context of HCV, including post-HCV treatment

Conveners

Debika Bhattacharya, University of California Los Angeles, Los Angeles, CA, USA



Arthur Kim, Harvard Medical School, Boston, MA, USA

9 INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS C



HCV PREVENTION AND TREATMENT IN CHILDREN

Ravi Jhaveri, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA



ACUTE HCV INFECTION WITH REINFECTION

Christoph Boesecke, University of Bonn, Bonn, Germany



HCV RESISTANCE AND RETREATMENT

Pablo Ryan, Hospital Universitario Infanta Leonor, Madrid, Spain



STEATOSIS: TESTING AND TREATMENT

Kathleen E. Corey, Massachusetts General Hospital, Boston, MA, USA

OPENING SESSION**Auditorium / Hall C / Auditorium Balcony****CME****5:00 PM – 7:00 PM****Session Hosts****Judith S. Currier****CROI 2018 Chair***University of California Los Angeles, Los Angeles, CA, USA***Richard A. Koup,****CROI 2018 Vice Chair***Vaccine Research Center; National Institute of Allergy and Infectious Diseases National Institutes of Health; Bethesda, MD, United States***Sharon L Hillier****CROI 2018 Vice Chair***University of Pittsburgh, Pittsburgh, PA, USA***Bernard Fields Lecture**

The Bernard Fields Lecture, named in tribute to the exemplary work of the esteemed microbiologist and virologist Bernard Fields, is given during the Opening Session, usually by a basic scientist recognized for his or her important and relevant contributions to the fields of virology and viral pathogenesis.

10 THE POTENTIAL OF INTERNATIONAL COLLABORATIONS FOR HIV PREVENTION: STUDIES OF MOTHER-TO CHILD-TRANSMISSION


Julie M. Overbaugh, *Fred Hutchinson Cancer Research Center, Seattle, WA, USA*

N'Galy-Mann Lecture

The N'Galy-Mann Lecture recognizes an HIV/AIDS researcher for his or her important and relevant work in the fields of epidemiology or clinical research. The lecture is named in honor of Drs Bosenge N'Galy and Jonathan Mann for their crucial, pioneering work in HIV science in Africa.


11 MICH MAR GENO - THE GIFT OF HOPE

Elizabeth A. Bukusi, *Kenya Medical Research Institute, Nairobi, Kenya*

**YOU SHALL LHiV 2:ZERO**

A performance of personal testimonies, dance, music, and song

MONDAY, MARCH 5, 2018

**Plenary PL-1 MONDAY PLENARY SESSION
Auditorium / Hall C / Auditorium Balcony****8:30 AM – 9:30 AM****CME**

- 12 THE EARLY DAYS OF AIDS: LOOKING BACK AND THINKING AHEAD**
8:30

Harold W. Jaffe, *Centers for Disease Control and Prevention, Atlanta, GA, USA*



- 13 PATHOGENESIS OF TUBERCULOSIS AND VACCINE PREVENTION**
9:00

JoAnne L. Flynn, *University of Pittsburgh, Pittsburgh, PA, USA*

**Oral Abstract 0-01 VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS****Ballroom A****10:00 AM – 12:00 PM****Oral Abstract Moderators**

Jacob D. Estes, *Oregon Health and Sciences University, Beaverton, OR, USA*

Sandhya Vasan, *Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand*

- 14 IDENTIFICATION OF A NOVEL LOCUS OF HIV REGULATION IN POPULATIONS OF AFRICAN DESCENT**
10:00

Paul J. McLaren, Deepti Gurdassani, Manj Sandhu, Jacques Fellay

- 15 HOST FACTORS ASSOCIATED WITH BNAB DEVELOPMENT IN HIV-1 CONTROLLERS**
10:15

Enrique Martin-Gayo, Hsiao Rong Chen, Ce Gao, Zhengyu Ouyang, Dhoohyung Kim, Kellie E. Kolb, Alex K. Shalek, Bruce D. Walker, Mathias Lichtenfeld, Xu G. Yu

- 16LB INTERDOMAIN STABILIZATION IMPAIRS CD4 BINDING AND IMPROVES IMMUNOGENICITY OF SOSIPS**
10:30

Peng Zhang, Jason Gorman, Hui Geng, Yin LIN, Yaroslavl Tsibovskiy, Huiyi Miao, Qingbo Liu, Tsion Andine, Alice Kwon, Ferzan Uddin, Mit Patel, Christina Guzzo, John R. Mascola, Peter D. Kwong, Paolo Lusso

- 17 EQUAL DISTRIBUTION OF SIV DNA IN MEMORY T HELPER CELL SUBSETS OF RHESUS MACAQUES**
10:45

Stephen Lai, Joseph Mudd, Jason Brenchley

- 18 KINETICS OF GASTROINTESTINAL DYSFUNCTION IN ACUTE SIV INFECTION OF MACAQUES**
11:00

Tiffany Hensley-McBain, Alicia Berard, Charlene J. Miller, Jennifer A. Manuzak, Alexander S. Zevin, Patricia Polacino, Brian Agricola, Mark Cameron, R. Keith Reeves, Jeremy Smedley, Shiu-Lok Hu, Brandon Keele, Adam Burgener, Nichole Klatt

- 19 PROGRESSIVE LYMPH NODE DYSFUNCTION DURING SIV INFECTION IS NOT REVERSED WITH ART**
11:15

Claire Deleage, Ismail B. Turkbey, Peter L. Choyke, Yanling Liu, Gregory Q. Del Prete, Brandon Keele, Jeffrey D. Lifson, Jacob D. Estes

- 20 P38 MAPK IN VIVO INHIBITION IMPACTS SIV-MEDIATED IMMUNE ACTIVATION & CD4 T-CELL LOSS**
11:30 Omkar Chaudhary, Felipe Lelis, Ronald Veazey, Anna Aldovini
- 21 INTRON—CONTAINING HIV-1 RNA ACTIVATES TYPE I INTERFERON AND INFLAMMATORY CYTOKINES**
11:45 Sean McCauley, Kyusik Kim, Anetta Nowosielska, Ann Dauphin, William E. Diehl, Jeremy Luban

Oral Abstract 0-02 ART: NEW DATA AND NEW INSIGHTS**Auditorium****10:00 AM – 12:00 PM****Oral Abstract Moderators****Giovanni Di Perri, University of Torino, Torino, Italy****Michelle S. Cespedes, Icahn School of Medicine at Mt Sinai, New York, NY, USA**

- 22 SWITCH TO BICTEGRAVIR/F/TAF FROM DTG AND ABC/3TC**
10:00 Jean-Michel Molina, Douglas Ward, Indira Brar, Anthony Mills, Hans-Jurgen Stellbrink, Luis López-Cortés, Peter Ruane, Daniel Podzamczer, Cynthia Brinson, Joseph M. Custodio, Hui Liu, Kristen Andreatta, Hal Martin, Andrew Cheng, Erin Quirk
- 23 IMPACT OF RALTEGRAVIR INTENSIFICATION OF FIRST-LINE ART ON IRIS IN THE REALITY TRIAL**
10:15 Diana Gibb, Alexander J. Szubert, Ennie Chidziva, Abbas Lugemwa, Shalton Mwaringa, Abraham Siika, Jane E. Mallewa, Mutsa Bwakura-Dangarembizi, Sheila Kabahenda, Andrew Reid, Keith Baleeta, Sarah Walker, Sarah Pett, for the REALITY trial team
- 24 HAIR ANTIRETROVIRAL LEVELS STRONGLY PREDICT VIROLOGIC OUTCOMES IN ACTG'S A5257 TRIAL**
10:30 Monica Gandhi, Igbo Ofotokun, Peter Bacchetti, Chengshi Jin, Heather Ribaudo, David Haas, Anandi N. Sheth, Howard Horng, Nhi Phung, Karen Kuncze, Alexander Louie, Hideaki Okochi, Raphael J. Landovitz, Jeffrey J. Lennox, Judith S. Currier, for the A5257 Study Team
- 25 TENOFOVIR DIPHOSPHATE IN DRIED BLOOD SPOTS IS A STRONG PREDICTOR OF VIRAL SUPPRESSION**
10:45 Jose R. Castillo-Mancilla, Mary Morrow, Ryan P. Coyle, Stacey Coleman, Edward M. Gardner, Jia-Hua Zheng, Lucas Ellison, Lane R. Bushman, Jennifer J. Kiser, Samantha MaWhinney, Peter L. Anderson
- 26 MULTIPLE DAILY DOSES OF MK-8591 AS LOW AS 0.25 MG ARE EXPECTED TO SUPPRESS HIV**
11:00 Randolph P. Matthews, Deanne J. Rudd, Vanessa Levine, Sandra Zhang, Laura Sterling, Jay Grobler, Ryan Vargo, S. Aubrey Stoch, Marian Iwamoto
- 27 COMPARATIVE LYMPHOID TISSUE PHARMACOKINETICS (PK) OF INTEGRASE INHIBITORS (INSTI)**
11:15 Courtney V. Fletcher, Ann Thorkelson, Lee Winchester, Timothy Mykris, Jon Weinhold, Kayla Campbell, Jodi Anderson, Jacob Zulk, Puleng Moshele, Timothy Schacker
- 28LB RIFAMPIN EFFECT ON TENOFOVIR ALAFENAMIDE (TAF) PLASMA/INTRACELLULAR PHARMACOKINETICS**
11:30 Maddalena Cerrone, Omamah Alfarisi, Megan Neary, Mark A. Marzinke, Teresa Parsons, Andrew Owen, Gary Maartens, Anton Pozniak, Charles W. Flexner, Marta Boffito

29LB SYSTEMATIC VS TEST-GUIDED TUBERCULOSIS TREATMENT: DATA OF THE STATIS RANDOMIZED TRIAL

François-Xavier Blanc, Anani D. Badje, Maryline Bonnet, Delphine Gabillard, Eugène Messou, Conrad Muzoora, Sovannarith Samreth, Duc Bang Nguyen, Laurence Borand, Anaïs Domergue, Naome Natukunda, Serge Eholie, Serge Domoua, Xavier Anglaret, Didier Laureillard

30LB RESULTS OF ACTG A5288: A STRATEGY STUDY IN RLS FOR 3RD-LINE ART CANDIDATES

Beatriz Grinsztejn, Michael D. Hughes, Justin Ritz, Robert Salata, Peter Mugyenyi, Evelyn Hogg, Linda Wieclaw, Robert Gross, Catherine Godfrey, Nagalingeswaran Kumarasamy, Cecilia Kanyama, John W. Mellors, Carole Wallis, Ann Collier, for the A5288 Study Team

Questions for the final 3 presentations will be held until the conclusion of the sessions.

Oral Abstract 0-03 ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION**Ballroom C****10:00 AM – 12:00 PM****Oral Abstract Moderators**

Vidya Mave, Byramjee Jeejeebhoy Government Medical College, Pune, India

Thomas Harrison, St. George's University of London, London, United Kingdom

31 10:00 EFFECT OF TB SCREENING AND RETENTION INTERVENTIONS ON EARLY ART MORTALITY IN BOTSWANA

Andrew F. Auld, Tefera Agizew, Anikie Mathoma, Rosanna Boyd, Anand Date, Sherri Pals, Christopher Serumola, Unami Mathebula, Heather Alexander, Tedd V. Ellerbrock, Goabaone Rankgoane-Pono, Pontsho Pono, Katherine Fielding, Alison Grant, Alyssa Finlay

32 10:15 A CLUSTER-RANDOMIZED TRIAL OF SYMPTOM VS TST SCREENING TO IMPROVE CHILD IPT UPTAKE

Nicole Salazar-Austin, Silvia Cohn, Grace Barnes, Molefi Tladi, Katlego Matlhaoleng, Catharina Swanepoel, Zarina Motala, Ebrahim Variava, Neil A. Martinson, Richard E. Chaisson

33 10:30 SAFETY AND EFFICACY OF DOLUTEGRAVIR-BASED ART IN TB/HIV COINFECTED ADULTS AT WEEK 24

Kelly Dooley, Richard Kaplan, Noluthando Mwelase, Beatriz Grinsztejn, Eduardo Ticona, Marcus Lacerda, Pedro Cahn, Elena Belonosova, Mounir Ait-Khaled, Kostas Angelis, Dannah Brown, Rajendra P. Singh, Christine Talarico, Allan-Raymond Tenorio, Michael Aboud

34 10:45 PHARMACOKINETICS OF BICTEGRAVIR ADMINISTERED TWICE DAILY IN COMBINATION WITH RIFAMPIN

Joseph M. Custodio, Steve K. West, Sean Collins, Amanda Vu, Deqing Xiao, Hal Martin, Erin Quirk, Brian P. Kearney, Anita Mathias

35 11:00 HIGHER HIGH DOSE FLUCONAZOLE FOR THE TREATMENT OF CRYPTOCOCCAL MENINGITIS

Umesh G. Laloo, Richard Larsen, Judith Aberg, Evelyn Hogg, Lauren Komarow, David B. Clifford, Sandy Pillay, Deborah Langat, Agrey Bukuru, Vidya Mave, Khuanchai Supparatpinyo, **Wadzanai Samaneka**

36 11:15 ADJUNCTIVE SERTRALINE IN HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS

Joshua Rhein, Kathy Huppler Hullsieck, Lillian Tugume, Edwin Nuwagira, Edward Mpoza, Reuben Kiggundu, Kenneth Ssebambulidde, Darlisha A. Williams, Ananta Bangdiwala, Mahsa Abassi, Abdu Musubire, Conrad Muzoora, David Meya, David R. Boulware, for the ASTRO-CM Study Team

**37LB ONE MONTH OF RIFAPENTINE/ISONIAZID TO PREVENT TB IN
11:30 PEOPLE WITH HIV: BRIEF-TB/A5279**

Susan Swindells, Ritesh Ramchandani, Amita Gupta, Constance A. Benson, Jorge T. Leon-Cruz, Ayotunde Omoz-Oarhe, Marc Antoine Jean Juste, Javier R. Lama, Javier A. Valencia, Sharlaa Badal-Faesen, Laura E. Moran, Courtney V. Fletcher, Eric Nuermberger, **Richard E. Chaisson**, for the ACTG 5279/BRIEF TB Study Team (Brief Rifapentine/Isoniazid Efficacy for TB Prevention)

**38LB URINE-BASED SCREENING FOR TUBERCULOSIS: A RANDOMIZED
11:40 TRIAL IN HIV-POSITIVE INPATIENTS**

Ankur Gupta-Wright, Elizabeth L. Corbett, Joep J. van Oosterhout, Doug K. Wilson, Daniel Grint, Melanie Alufandika-Moyo, Jurgens A. Peters, Lingstone Chiume, Stephen D. Lawn, Katherine Fielding

**39LB A RANDOMIZED CONTROLLED TRIAL OF HIGH-DOSE RIFAMPIN
11:50 FOR PULMONARY TUBERCULOSIS**

Gustavo E. Velásquez, Meredith B. Brooks, Julia M. Coit, Dante Vargas Vásquez, Epifanio Sánchez Garavito, Roger I. Calderón, Judith Jiménez, Karen Tintaya, Charles A. Peloquin, Elna Osso, Dylan B. Tierney, Kwonjune J. Seung, Leonid Lecca, Geraint R. Davies, Carole D. Mitnick

Questions for the final 3 presentations will be held until the conclusion of the session.

**Oral Abstract 0-04 SURVEILLANCE AND EPIDEMIOLOGY:
NEW APPROACHES**

Ballroom B

10:00 AM – 12:00 PM

Oral Abstract Moderators

Alexandra M. Oster, *CDC, Atlanta, GA, USA*

Robin Wood, *Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa*

**40 RAPIDLY GROWING HIV TRANSMISSION CLUSTERS IN THE
10:00 UNITED STATES, 2013–2016**

Anne Marie France, Nivedha Panneer, Cheryl B. Ocfemia, Neeraja Saduvala, Ellsworth Campbell, William M. Switzer, Joel O. Wertheim, Alexandra M. Oster

**41 CLUSTER ANALYSIS REVEALS IMPORTANT SHIFT OF DRIVERS OF
10:15 THE HIV EPIDEMIC IN SWISS MSM**

Nadine Bachmann, Claus Kadelka, Teja Turk, Katharina Kusejko, Jürg Böni, Vincent Aubert, Sabine Yerly, Thomas Klimkait, Huldrych F. Günthard, Roger Kouyos, for the Swiss HIV Cohort Study

**42 PHYLOGENETIC PATTERNS OF HIV TRANSMISSION AMONG
10:30 TRANSGENDER WOMEN IN LOS ANGELES**

Manon Ragonnet-Cronin, Yunjin W. Hu, Sheldon Morris, Zhijuan Sheng, Kathleen Poortinga, Joel O. Wertheim

**43 ASSESSING THE ROLE OF GEOGRAPHICAL HIV HOT-SPOTS IN THE
10:45 SPREAD OF THE EPIDEMIC**

Diego F. Cuadros, Tiago Graf, Tulio de Oliveira, Till Bärnighausen, Frank Tanser

**44 USING SUCCESSIVE SURVEYS TO CALCULATE INCIDENCE AMONG
11:00 AT-RISK POPULATIONS IN THE US**

Janet C. Burnett, Qian An, Dita Broz, Cyprian Wejnert, for the NHBS Study Group

- 45 11:15 FEMALE HIV ACQUISITION PER SEX ACT IS ELEVATED IN LATE PREGNANCY AND POSTPARTUM**
 Kerry A. Thomson, James P. Hughes, Jared Baeten, Grace John-Stewart, Connie L. Celum, Craig R. Cohen, Nelly R. Mugo, James Kiarie, **Renee Heffron**
- 46 11:30 SHARP DECLINE IN MALE HIV INCIDENCE IN A RURAL SOUTH AFRICAN POPULATION (2004–2015)**
Alain Vandormael, Adam N. Akullian, Adrian Dobra, Tului de Oliveira, Frank Tanser
- 47LB 11:45 ONGOING HIV MICROEPIDEMICS IN RURAL SOUTH AFRICA: THE NEED FOR FLEXIBLE INTERVENTIONS**
Cordelia Coltart, Maryam Shahmanesh, Stephane Hue, Janet Seeley, Till Bärnighausen, Benn Sartorius, Tului de Oliveira, Thembelihle Zuma, Natsayi Chimbindi, Anne Johnson, Deenan Pillay, Frank Tanser

Themed Discussion TD-01 EARLY EVENTS: METHODS AND MECHANISMS

Ballroom A

1:30 PM – 2:30 PM

Themed Discussion Leader

Viviana A. Simon, Icahn School of Medicine at Mt Sinai, New York, NY, USA

- 186 NEF UPREGULATES FASL EARLY WHILE MHCS ARE DOWNREGULATED LATE IN HIV-INFECTED CELLS**
Rodrigo Matus-Nicodemos, Daniel Douek, Richard A. Koup
- 185 HIV-1 CORE MORPHOLOGY ASSESSMENT USING SINGLE VIRION IMAGING BASED ON FRET**
Anamarie D. Sarca, Hirofumi Fukuda, Luca Sardo, Jessica Smith, Kotaro Shirakawa, Kazuki Horikawa, Taisuke Izumi, Akifumi Takaori-Kondo
- 187 VISUALISATION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 cDNA BY CLICK CHEMISTRY**
 Flore De Wit, **Frauke Christ**, Sambasivarao Pillalamarri, Akkaledevi Venkatesham, Arthur Van Aerschot, Zeger Debyser
- 189 UBP43 (USP18) ABROGATES INTERFERON AND SAMHD1-MEDIATED RESTRICTION OF HIV-1**
Edmund Osei-Kuffour, Kerstin Schott, Philipp A. Lang, Karl S. Lang, Renate König, Dieter Häussinger, Carsten Münk
- 190 VPR ENHANCES VIRAL GENE EXPRESSION FROM UNINTEGRATED DNA IN A DCAF1-DEPENDENT MANNER**
Sarah B. Nodder, Caitlin Miller, Hisashi Akiyama, Chelsea R. Ettinger, Rahm Gummuluru

Themed Discussion TD-02 CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION

Room 304-306

1:30 PM – 2:30 PM

Themed Discussion Leader

Gary Maartens, University of Cape Town, Cape Town, South Africa

- 455 EFAVIRENZ PHARMACOKINETICS IN HIV/TB COINFECTED PERSONS RECEIVING RIFAPENTINE**
Anthony Podany, Erin Sizemore, Michael Chen, Neil A. Martinson, Rodney Dawson, Sharlaa Badal-Faesen, Sachiko Miyahara, Ekaterina Kurbatova, William C. Whitworth, Richard E. Chaisson, Susan E. Dorman, Payam Nahid, Kelly Dooley, Susan Swindells, for the AIDS Clinical Trials Group & Tuberculosis Trials Consortium A5349 / Study 31 Team

456 EFAVIRENZ PHARMACOKINETICS WITH RIFAMPIN DOUBLE DOSE IN TB-HIV INFECTED PATIENTS

Daniel W. Atwine, Elisabeth Baudin, Thibaut Gelé, Winnie R. Muyindike, Mworozi Kenneth, Racheal Kyohairwe, Kenneth Kananura, Dan Nyehangane, Patrick Orikiriza, Valérie Furlan, Anne-Marie Taburet, Aurélie Barrail-Tran, Maryline Bonnet, for the ANRS12292 Rifaviren study group

457 PHARMACOKINETICS OF EFAVIRENZ 400MG WITH ISONIAZID/RIFAMPICIN IN PEOPLE WITH HIV

Maddalena Cerrone, Xinzhu Wang, Megan Neary, Christine Weaver, Serge Fedele, Isaac Day-Weber, Andrew Owen, Andrew Hill, Myra McClure, Marta Boffito

458 IN SILICO DRUG INTERACTION OF LONG-ACTING RILPIVIRINE AND CABOTEGRAVIR WITH RIFAMPIN

Rajith Kumar Reddy Rajoli, Paul Curley, David Back, Charles W. Flexner, Andrew Owen, Marco Siccardi

Themed Discussion TD-03 THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA

Auditorium

1:30 PM – 2:30 PM

Themed Discussion Leader

Satish Gopal, University of North Carolina Project–Malawi, Lilongwe, Malawi

649 HIV AND CANCER RISK IN CONTEXT OF HIGH ART COVERAGE IN BOTSWANA

Scott Dryden-Peterson, Neo Tapela, Isaac Nkele, Oaitse John, Gita Suneja, Surbhi Grover, Memory Bvochora-Nsingi, Malebogo Pusoentsi, Joseph Makhemba, Mompati O. Mmalane, Mukendi Kayembe, Shahin Lockman

650 SOUTH AFRICAN HIV CANCER MATCH STUDY: A PILOT STUDY TOWARDS PRECISION PUBLIC HEALTH

Mazvita Sengayi, Wenlong C. Chen, Adrian Spoerri, Elvira Singh, Matthias Egger, Julia Bohlius

658 LEEP TREATMENT OF EXTENSIVE CERVICAL INTRAEPITHELIAL NEOPLASIA IN HIV-INFECTED WOMEN

Sharon A. Greene, Hillary M. Topazian, Hugo De Vuyst, Christine J. McGrath, Barbra A. Richardson, Grace John-Stewart, Anthony Cagle, Evans Nyongesa-Malava, Nelly Yatich, Catherine Kiptinness, Sameh Sakr, Nelly R. Mugo, Michael H. Chung

659 GENE PROFILE INFORMS HPV GRADE BUT NOT RELAPSE AFTER LEEP IN ART-SUPPRESSED HIV+HPV+

Emmanouil Papasavvas, Andrew V. Kossenkov, Livio Azzoni, Nicola M. Zetola, Agnieszka Mackiewicz, Brian Ross, Matthew Fair, Surya Vadrevu, Doreen Ramogola-Masire, Cindy Firnhaber, Luis Montaner

655 KNOWLEDGE OF KAPOSI SARCOMA (KS) AND HIV AMONG TRADITIONAL HEALERS IN ZIMBABWE

Suzanne P. Fiorillo, Francis Jaji, Maxwell Matimba, Thomas Campbell, Margaret Borok

Themed Discussion TD-04 HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?

Ballroom C

1:30 PM – 2:30 PM

Themed Discussion Leader**Jennifer Jao, Icahn School of Medicine at Mt Sinai, New York, NY, USA****878 LOPINAVIR/RITONAVIR INDUCES MITOCHONDRIAL TOXICITY IN HIV-EXPOSED UNINFECTED CHILDREN**

Audrey Monnin, Nicolas Nagot, Marianne Periès, Roselyne Vallo, Nicolas Meda, Mandisa Singata, James Tumwine, Pascal Reynier, Thorkild Tylleskär, Philippe Van de Perre, Jean-Pierre Moles, for the PROMISE PEP consortium ANRS 12174

879 HEV BLOOD MTDNA CONTENT REMAINS ELEVATED FROM BIRTH INTO EARLY LIFE (0-3 YEARS)

Abhinav Ajaykumar, Mayanne Zhu, Hugo Soudeyns, Fatima Kakkar, Jason Brophy, Ari Bitnun, Ariane Alimenti, Deborah M. Money, Helene C. Cote, for the CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children (CARMA)

880 INCREASED INFLAMMATION AND MONOCYTE ACTIVATION IN HIV-EXPOSED UNINFECTED INFANTS

Marisa M. Mussi-Pinhata, Adriana Weinberg, Qilu Yu, Rachel A. Cohen, Sahera Dirajjal-Fargo, Nicholas Funderburg, Emily Bowman, Nahida Chakhtoura, Grace A. McComsey

881 INNATE IMMUNE ACTIVATION AMONG HIV-1 EXPOSED UNINFECTED INFANTS FROM BOTSWANA

Pilar Garcia Broncano, Samuel W. Kgole, Gosego Masasa, Terence Mohammed, Sikhulile Moyo, Joseph Makhema, Xu G. Yu, Jennifer Jao, Roger L. Shapiro, Mathias Lichterfeld, Kathleen M. Powis

882 MICROBIAL TRANSLOCATION, IMMUNE ACTIVATION, AND GUT DYSBIOSIS IN HIV-EXPOSED INFANTS

Charles D. Mitchell, Sady Dominguez, Varghese George, Eddy Perez-Then, Carlos V. Castillo, Juan L. Santana-Guerrero, Jeannette Baez, Margaret Roach, William Walters, Qiaojuan Shi, Shao-Pei Chou, Ruth Ley, Savita Pahwa

Themed Discussion TD-05 HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE

Ballroom B

1:30 PM – 2:30 PM

Themed Discussion Leader**Adeeba Kamarulzaman, University of Malaya Medical Centre, Kuala Lumpur, Malaysia****970 HIV DIAGNOSES AMONG PEOPLE WHO INJECT DRUGS — UNITED STATES, 2010-2015**

Sheryl Lyss, Tianchi Zhang, Alexandra M. Oster

971 CHARACTERISTICS OF HIV INCIDENT INFECTIONS AMONG PERSONS WHO INJECT DRUGS IN THE US

Johanna Chapin-Bardales, Silvina Masciotra, Amanda Smith, Brooke Hoots, William M. Switzer, Wei Luo, S. Michele Owen, Gabriela Paz-Bailey

973 NEW DIAGNOSES OF HIV AMONG INJECTING DRUG USERS, NEW YORK CITY 2006-2016

Lucia V. Torian, Jasmine Abdelnabi, Lisa A. Forgione, Joel O. Wertheim

974 DRUG OVERDOSE DEATHS AMONG PERSONS WITH HIV IN NEW YORK CITY, 2007-2015**Sarah L. Braunstein, Rebekkah S. Robbins, Demetre C. Daskalakis****975 3-YEAR OUTCOMES OF PATIENT NAVIGATION+FINANCIAL INCENTIVES FOR HIV+ SUBSTANCE USERS****Daniel Feaster, Carlos del Rio, Abigail Matthews, Lauren Gooden, Tim Matheson, Maxine Stitzer, Mamta K. Jain, Allan Rodriguez, Wendy S. Armstrong, Gregory M. Lucas, Mari-Lynn Drainoni, Carmen L. Masson, David C. Perlman, Petra Jacobs, Lisa Metsch****Symposium S-1 STOP IT NOW: TARGETING EARLY INFECTION EVENTS**
Ballroom A**CME 4:00 PM – 6:00 PM**

Target Audience: This session is directed to clinicians and scientists who are interested in understanding emerging themes in HIV-1 pathogenesis and recent models showing how targeted interventions during primary HIV-1 infection have led to virological control.

Level of Knowledge: It is assumed that the participants are familiar with the basic concepts of HIV pathogenesis and have some familiarity with B cell and T cell immunology.

Objectives: At the completion of the session, participants will be able to:

- Describe how CD8 T cells can inhibit HIV-1 replication during acute infection and appreciate new models showing how this can lead to immunologic control of viral replication
- Describe how neutralizing antibodies to HIV-1 and antibodies to host proteins (alpha-4 beta-7) can directly and indirectly limit HIV dissemination during acute infection and lead to viral control
- Outline different clinical strategies now under investigation that are aimed at modulating early events in HIV infection in humans and appreciate how they may lead to HIV-1 control without a need for antiretroviral drug therapy

Conveners

Brandon Keele, National Cancer Institute, Frederick, MD, USA



Michaela Müller-Trutwin, Institute Pasteur, Paris, France

48 MECHANISMS OF EARLY CD8+ T CELL CONTROL


4:00 Jonah Sacha, Oregon Health and Sciences University, Portland, OR, USA

**49 EARLY BROADLY NEUTRALIZING ANTIBODY TREATMENT LEADING TO T-CELL CONTROL**

Malcolm Martin, NIAID, Bethesda, MD, USA

**50 ANTI-ALPHA-4/BETA-7 ANTIBODY-MEDIATED CONTROL: UNDERSTANDING THE MECHANISM**

James Arthos, NIH, Bethesda, MD, USA

**51 EARLY INTERVENTION THERAPIES IN HUMANS: ART, ANTIBODIES, AND VACCINES**

Eugène Kroon, Thai Red Cross AIDS Research Center, Bangkok, Thailand



Symposium S-2 BREAST IS BEST, BUT IT'S A VIRAL MILKSHAKE! CME
Room 304-306 **4:00 PM – 6:00 PM**

Target Audience: This session is directed to students, researchers, and clinicians who are interested in learning more about transmission of retroviruses through breast feeding.

Level of Knowledge: It is assumed that the participants are familiar with the basic epidemiology of breast milk transmission of HIV and HTLV-1.

Objectives: At the completion of the session, participants will be able to:

- Describe infant gut immunology and its ontogeny, microbiome, and host susceptibility to viral infection through breast milk
- Describe the epidemiology, virology, pathophysiology and risk to the infant of breast milk exposure to HIV and HTLV-1
- Explain the efficacy of prevention of transmission of breast milk viruses
- Explain the pharmacology of breast milk excretion of antiretrovirals, optimal antiretroviral therapy (ART) combinations for breast feeding, and risk of ART toxicity to the infant

Conveners

Ruth Nduati, University of Nairobi, Nairobi, Kenya



Philippe Van de Perre, CHU de Montpellier, Montpellier, France

52 THE INFANT GUT: A GREAT DEFENSE SYSTEM?

4:00 Andrew Prendergast, Queen Mary University of London, London, UK



53 MOTHER-TO-CHILD TRANSMISSION OF HTLV-1

4:30 Antoine Gessain, Institut Pasteur, Paris, France



54 CAN WE ELIMINATE BREASTMILK TRANSMISSION OF HIV?

5:00 Ameena Goga, South African Medical Research Council, Cape Town, South Africa



55 ART IN BREASTMILK: DEFINING THE RISK-BENEFIT RATIO

5:30 Catriona Waitt, University of Liverpool, Liverpool, UK



Symposium S-3 OBSTACLES TO THE GLOBAL CONTROL OF TUBERCULOSIS

CME

Ballroom C**4:00 PM – 6:00 PM**

Target Audience: This session is directed to clinicians and researchers interested in the pathogenesis, clinical manifestations, diagnosis, treatment and prevention of tuberculosis (TB) and its complications, including HIV and TB co-infection.

Level of Knowledge: It is assumed that participants are familiar with basic TB biology, epidemiology, clinical features and treatment.

Objectives: At the completion of the session, participants will be able to:

- Describe the changing epidemiology of TB and the global burden of TB disease
- Describe new approaches for identifying and tracking TB transmission
- Identify new regimens and strategies for treatment of drug-resistant TB

Conveners

David Alland, Rutgers New Jersey Medical School,
Newark, NJ, USA



Mina C. Hosseinpour, University of North Carolina
Project—Malawi, Lilongwe, Malawi

**56 THE GLOBAL BURDEN OF TUBERCULOSIS AND
4:00 MODELING CONTROL STRATEGIES**

Nimalan Arinaminpathy, Imperial College London,
London, UK



**57 USING WHOLE GENOME SEQUENCING TO BETTER
4:30 UNDERSTAND TB TRANSMISSION DYNAMICS**

Neel R. Gandhi, Emory University, Atlanta, GA, USA



**58 UNDIAGNOSED TUBERCULOSIS: PROMISE FOR
5:00 PREVENTION**

Neil A. Martinson, Perinatal HIV Research Unit, Soweto,
South Africa



**59 NEW DEVELOPMENTS IN THE MANAGEMENT OF
5:30 DRUG-RESISTANT TUBERCULOSIS**

Serena Koenig, Brigham and Women's Hospital, Boston,
MA, USA



Symposium S-4 STRATEGIES FOR IMPROVING THE US CARE CASCADE: CONFRONTING A FRAGMENTED HEALTH SYSTEM

CME

Ballroom B**4:00 PM – 6:00 PM**

Target Audience: This session is directed to students, researchers, and clinicians who are interested in learning about the current status of the US HIV epidemic, challenges to delivering comprehensive care, and strategies for improving care delivery and addressing disparities.

Level of Knowledge: It is assumed that the participants are familiar with basic HIV epidemiology.

Objectives: At the completion of the session, participants will be able to:

- Describe the epidemiology of the US epidemic with a focus on most heavily affected populations
- Review challenges in HIV testing and strategies to improve HIV testing uptake
- Describe challenges to retention in care and strategies for improving it
- Discuss how the fragmented health system in the US negatively affects provision of comprehensive continuity care and list ways to promote solutions for reaching and retaining vulnerable populations

Conveners

Ank E. Nijhawan, *University of Texas Southwestern, Dallas, TX, USA*



Darrell Wheeler, *University at Albany, New York, NY, USA*

60 THE EVOLVING HIV EPIDEMIC IN THE UNITED STATES

4:00 **Carlos del Rio**, *Emory University, Atlanta, GA, USA*



61 HIV TESTING AND LINKAGE: THE GATEWAY TO TREATMENT AND PREVENTION

4:30 **Hyman Scott**, *San Francisco Department of Public Health, San Francisco, CA, USA*



62 HIV CARE ENGAGEMENT: MAXIMIZING INDIVIDUAL AND POPULATION HEALTH

5:00 **Michael J. Mugavero**, *University of Alabama at Birmingham, Birmingham, AL, USA*



63 SYSTEMS OF CARE FOR VULNERABLE POPULATIONS IN THE UNITED STATES

5:30 **Julia C. Dombrowski**, *University of Washington, Seattle, WA, USA*



TUESDAY, MARCH 6, 2018

Plenary PL-2 TUESDAY PLENARY SESSION
Auditorium / Hall C / Auditorium Balcony
CME**8:30 AM – 9:30 AM**

- 64 THE VAGINAL MICROBIOME AND ACQUISITION OF HIV INFECTION**
 8:30 **Nichole Klatt, University of Washington, Seattle, WA, USA**



- 65 ADDRESSING MENTAL HEALTH: A CRUCIAL COMPONENT TO ENDING THE HIV EPIDEMIC**
 9:00 **Robert H. Remien, New York State Psychiatric Institute and Columbia University, New York, NY, USA**


Oral Abstract O-05 THE HIV RESERVOIR AND VIRAL REPLICATION
Auditorium
10:00 AM – 12:00 PM**Oral Abstract Moderators****Zandrea Ambrose, University of Pittsburgh, Pittsburgh, PA, USA****Sarah Palmer, The Westmead Institute for Medical Research, Westmead, NSW, Australia**

- 66 PERSISTENT DETECTION OF HIV RNA+ CELLS WITH ART STARTED IN FIEBIG 1&2 VS FIEBIG 3-5**
 10:00 **Eugène Kroon, Mark de Souza, Suthat Chottanapund, Jodi Anderson, Sopark Manasnayakorn, Siri Jorstad, Caitlin David, Adam Conner, Erika Helgeson, Cavan Reilly, Merlin L. Robb, Daniel Douek, Jintanat Ananworanich, Timothy Schacker, for the RV254/SEAECO10 Study Group**

- 67 CD8+ T CELL RESPONSES IN TREATED HYPERACUTE HIV INFECTION LIMIT HIV RESERVOIR SIZE**
 10:15 **Zaza Ndhlovu, Samuel W. Kazer, Thandeka Nkosi, Funsho Ogunshola, Amber D. Moodley, Krista Dong, Alex K. Shalek, Thumbi Ndungú, Bruce D. Walker**

- 68 EXPANDED CLONES HARBORING REPLICATION-COMPETENT VIRUS WAX AND WANE OVER TIME**
 10:30 **Zheng Wang, Mithra R. Kumar, Janet Siliciano, Robert Siliciano, for the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA**

- 69LB DETERMINANTS OF HIV-1 RESERVOIR SIZE AND LONG-TERM DYNAMICS UNDER SUPPRESSIVE ART**
 10:45 **Nadine Bachmann, Chantal von Siebenthal, Valentina Vongrad, Kathrin Neumann, Teja Turk, Niko Beerewinkel, Jasmina Bogojeska, Jacques Fellay, Volker Roth, Roger Kouyos, Karin Metzner, Huldrych F. Günthard, for the Swiss HIV Cohort Study**

- 70 NO EVIDENCE FOR ONGOING HIV REPLICATION IN LYMPH NODES DURING SUPPRESSIVE ART**
 11:00 **William R. McManus, Michael J. Bale, Jonathan Spindler, Ann Wiegand, Andrew Musick, Xiaolin Wu, David Wells, Stephen H. Hughes, Brandon Keele, Rebecca Hoh, Jeffery Milush, John M. Coffin, John W. Mellors, Steven G. Deeks, Mary F. Kearney**

71	NO RESIDUAL VIRUS REPLICATION IN A RANDOMISED TRIAL OF DOLUTEGRAVIR INTENSIFICATION
11:15	Thomas A. Rasmussen , James McMahon, J. Judy Chang, Jennifer Audsley, Ajantha Solomon, Surekha Tennakoon, Ashanti Dantanarayana, Tim Spelman, Tina Schmidt, Stephen J. Kent, Vincent Morcilla, Sarah Palmer, Julian Elliott, Sharon R. Lewin
72	SINGLE ROMIDEPSIN INFUSIONS DO NOT INCREASE HIV EXPRESSION IN PERSONS ON ART (A5315)
11:30	Deborah McMahon , Lu Zheng, Joshua C. Cyktor, Evgenia Aga, Bernard J. Macatangay, Catherine Godfrey, Michael Para, Ronald T. Mitsuyasu, Evelyn Hogg, Joseph Hesselgesser, Edward P. Acosta, Rajesh T. Gandhi, John W. Mellors, for the A5315 Team
73LB	PGT121 COMBINED WITH GS-9620 DELAYS VIRAL REBOUND IN SHIV-INFECTED RHESUS MONKEYS
11:45	Erica Borducchi, Peter Abbink, Joseph Nkolola, Mark G. Lewis, Romas Gelezunas, Dan Barouch
Oral Abstract 0-06 NON-AIDS COMPLICATIONS	
Ballroom A	
10:00 AM – 12:00 PM	
Oral Abstract Moderators	
Mosepele Mosepele , University of Botswana, Gaborone, Botswana	
Helen Kovari , University Hospital Zurich, Zürich, Switzerland	
74	IL-6, D-DIMER OR T-CELLS: WHICH BEST PREDICT EVENTS OR EXPLAIN BENEFITS OF EARLY ART?
10:00	Jason V. Baker , Birgit Grund, Shweta Sharma, Abdel Babiker, for the INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group
75	SERIOUS CLINICAL OUTCOMES IN HIV-POSITIVE PERSONS WITH CHRONIC KIDNEY DISEASE (CKD)
10:15	Lene Ryom , Jens D. Lundgren, Matthew Law, Ole Kirk, Wafaa M. El-Sadr, Fabrice Bonnet, Rainer Weber, Eric Fontas, Antonella D'Arminio Monforte, Andrew N. Phillips, Colette Smit, Camilla Ingrid Hatleberg, Caroline Sabin, Amanda Mocroft, for the D:A:D Study Group
76	INCREASED RISK OF PERIPHERAL ARTERY DISEASE IN PERSONS WITH HIV COMPARED TO CONTROLS
10:30	Andreas D. Knudsen , Jens D. Lundgren, Marco Gelpi, Ashley Roen, Amanda Mocroft, Shoaib Afzal, Børge Nordestgaard, Henrik Sillesen, Andreas Ronit, Anne-Mette Lebech, Lars Køber, Klaus F. Kofoed, Susanne D. Nielsen
77	HIV INFECTION IS ASSOCIATED WITH PROGRESSION OF HIGH RISK CORONARY PLAQUE IN THE MACS
10:45	Wendy Post , Sabina Haberlen, Long Zhang, Mallory Witt, Lisa Jacobson, Todd T. Brown, Frank J. Palella, Lawrence Kingsley, Matthew Budoff
78	CAROTID ARTERY ATHEROSCLEROSIS IS ASSOCIATED WITH MORTALITY IN HIV+ WOMEN AND MEN
11:00	David B. Hanna , Jee-Young Moon, Kathryn Anastos, Sabina Haberlen, Audrey French, Frank J. Palella, Stephen J. Gange, Mallory Witt, Seble Kassaye, Jason Lazar, Phyllis Tien, Lawrence Kingsley, Wendy Post, Robert C. Kaplan, Howard Hodis
79	IMPACT OF LDMTX ON IMMUNE ACTIVATION AND ENDOTHELIAL FUNCTION IN TREATED HIV
11:15	Priscilla Hsue , Heather Ribaudo, Steven G. Deeks, Michael M. Lederman, Carl Fichtenbaum, Annie F. Luetkemeyer, Eric Daar, Benigno Rodriguez, Babafemi Taiwo, David Haas, Victoria Johnson, James H. Stein, Judith S. Currier

80 PLATELET FUNCTION UPON SWITCHING TO TAF VS CONTINUING ABC: A RANDOMIZED SUBSTUDY

Patrick W. Mallon, Alan Winston, Frank Post, Dermot Kenny, Colm Bergin, Robert T. Maughan, Elena Alvarez-Barco, Willard Tinago, Eimear Dunne, Mingjin Yan, Moupali Das, Martin Rhee, for the GS-US-311-1717 Platelet Sub Study Team

81LB A TREATMENT AS PREVENTION TRIAL TO ELIMINATE HCV IN HIV+ MSM: THE SWISS HCVREE TRIAL

Dominique L. Braun, Benjamin H. Hampel, Huyen Nguyen, Markus Flepp, Marcel Stoeckle, Charles Béguelin, Patrick Schmid, Julie Delaloye, Mathieu Rougemont, Enos Bernasconi, Dunja Nicca, Roger Kouyos, Jürg Böni, Huldrych F. Günthard, Jan S. Fehr, for the Swiss HIV Cohort Study

Oral Abstract 0-07 OF MICE, MONKEYS, AND MEN: PrEP FROM PRECLINICAL TO POPULATION LEVEL IMPACT

Ballroom B

10:00 AM – 12:00 PM

Oral Abstract Moderators

Craig W. Hendrix, Johns Hopkins University, Baltimore, MD, USA

Elske Hoornenborg, Public Health Service Amsterdam, Amsterdam, Netherlands

82 PROTECTION AGAINST REPEATED VAGINAL SHIV CHALLENGES

10:00 BY BNAB 3BNC117 AND 10-1074

David A. Garber, Debra Adams, James Mitchell, Shanon Ellis, Till Schoofs, Michael S. Seaman, Janet McNicholl, Michel Nussenzweig, Walid Heneine

83 LONG-ACTING CABOTEGRAVIR PROTECTS MACAQUES AGAINST REPEATED PENILE SHIV EXPOSURES

10:15 Charles Dobard, Natalia Makarova, Kenji Nishiura, Mara Sterling, Chuong Dinh, James Mitchell, David A. Garber, William Spreen, Walid Heneine, Gerardo Garcia-Lerma

84 GRIFFITHSIN/CARRAGEENAN INSERTS PREVENT SHIV, HSV-2, AND HPV INFECTIONS IN VIVO

10:30 Nina Derby, Manjari Lal, Meropi Aravantinou, Larisa Kizima, Patrick Barnable, Aixa Rodriguez, Manshun Lai, Asa Wesenberg, Shweta Ugaonkar, Brooke Grasperge, James Blanchard, Agegnehu Gettie, Natalia Teleshova, Jose A. Fernandez-Romero, Thomas M. Zydowsky

85 ORAL FTC/TAF COMBINATION PREVENTS VAGINAL SHIV INFECTION IN PIGTAIL MACAQUES

10:45 Ivana Massud, Mian-er Cong, Susan Ruone, James Mitchell, Frank Deyounks, Angela Holder, Chuong Dinh, James F. Rooney, Darius Babusis, Yeojin Park, Scott McCallister, Christian Callebaut, Walid Heneine, Gerardo Garcia-Lerma

86 BY RACE/ETHNICITY, BLACKS HAVE HIGHEST NUMBER NEEDING PrEP IN THE UNITED STATES, 2015

11:00 Dawn K. Smith, Michelle Van Handel, Jeremy A. Grey

87 GETTING TO ZERO NEW HIV DIAGNOSES IN SAN FRANCISCO: WHAT WILL IT TAKE?

11:15 Susan P. Buchbinder, Stephanie E. Cohen, Jen Hecht, Ling Hsu, Robert P. Kohn, Henry F. Raymond, Albert Y. Liu, Hyman Scott, Oliver Bacon, Tracey Packer, Susan Philip, Diane V. Havlir, Susan Scheer

88 RAPID REDUCTION IN HIV DIAGNOSES AFTER TARGETED PrEP IMPLEMENTATION IN NSW, AUSTRALIA

11:30 Andrew Grulich, Rebecca J. Guy, Janaki Amin, Heather-Marie Schmidt, Christine Selvey, Jo Holden, Karen Price, Robert Finlayson, Mark Bloch, Iryna Zablotska, Fengyi Jin, David Smith, Anna McNulty, David A. Cooper, for the EPIC-NSW research team

**89LB LOW DOSE MK-8591 PROTECTS RHESUS MACAQUES AGAINST
RECTAL SHIV INFECTION**

Martin Markowitz, Agegnehu Gettie, Leslie St. Bernard, Hiroshi Mohri, Brooke Grasperge, James Blanchard, Li Sun, Kerry Fillgrove, Daria Hazuda, Jay Grobler

**Oral Abstract 0-08 90:90:90: PROGRESS, CHALLENGES, AND
NEW TOOLS**

Ballroom C

10:00 AM – 12:00 PM

Oral Abstract Moderators

Mauro Schechter, Projeto Praça Onze, Rio de Janeiro, Brazil

Glenda E. Gray, Perinatal HIV Research Unit, Soweto, South Africa

**90 HIV TREATMENT, PREVENTION, AND INCIDENCE IN A
10:00 HYPERENDEMIC UGANDAN FISHING COMMUNITY**

Joseph Kagaayi, Gertrude Nakigozi, Godfrey Kigozi, Mary K. Grabowski, Victor Ssempijja, Fred Nalugoda, Ronald H. Gray, Robert Ssekubugu, Caitlin E. Kennedy, Thomas C. Quinn, David Serwadda, Maria Wawer, Steven J. Reynolds, Larry W. Chang

**91 PROGRESS TOWARD 90-90-90: 2016 LESOTHO POPULATION-
10:15 BASED HIV IMPACT ASSESSMENT RESULTS**

Kyaw Thin, Koen Frederix, Stephen McCracken, Andrea Low, Hetal Patel, Nahima Ahmed, Bharat S. Parekh, Jessica E. Justman, Amee M. Schwitters

**92 CLINICAL PRESENTATION OF HIV DIFFERS BY AGE IN VACS
10:30 (2010-2015)**

Amy C. Justice, Kirsha S. Gordon, Shelli Feder, Neel R. Gandhi, Lydia A. Barakat, Maria Rodriguez-Barradas, Vincent C. Marconi, Sheldon T. Brown, Julie A. Womack, Janet Tate, for the VACS Project

**93 THE RAPID ART PROGRAM INITIATIVE FOR HIV DIAGNOSES
10:45 (RAPID) IN SAN FRANCISCO**

Oliver Bacon, Jennie C. Chin, Ling Hsu, Stephanie E. Cohen, Darpan Sachdev, Diane Jones, Jonathan Fuchs, Susan Scheer, Susan P. Buchbinder, Diane V. Havlir

**94 SAME-DAY ART INITIATION AFTER HOME-BASED HIV TESTING:
11:00 A RANDOMIZED CONTROLLED TRIAL**

Niklaus D. Labhardt, Isaac Ringera, Thabo I. Lejone, Thomas Klimkait, Josephine Muhairwe, Alain Amstutz, Tracy R. Glass

**95 RANDOMIZED CONTROLLED TRIAL OF FINANCIAL INCENTIVES
11:15 FOR ACHIEVING VIRAL SUPPRESSION**

Harsha Thirumurthy, Devy Emperador, Alex Ndyabakira, Dalsone Kwarisiima, Carol S. Camlin, Moses R. Kamya, Diane V. Havlir, Gabriel Chamie

**96 EXTENDED-RELEASE NALTREXONE IMPROVES VIRAL
11:30 SUPPRESSION IN HIV+ PRISONERS**

Sandra Springer, Marwan Azar, Angela DiPaola, Russell Barbour, Breanne Biondi, Maua Herme, Frederick Altice

**97 HIGHER MORTALITY IN HIV - INFECTED VS.- UNINFECTED
11:45 ADULTS DESPITE ART, BOTSWANA**

Tendani Gaolathe, Kathleen Wirth, Molly Pretorius Holme, Etienne Kadima, Unoda A. Chakalisa, Kutlo Manyake, Joseph Makhema, Mompatti O. Mmalane, Jean Leidner, Scott Dryden-Peterson, Kathleen M. Powis, Mosepele Mosepele, Refeletswe Lebelonyane, Lisa A. Mills, Shahin Lockman

Themed Discussion TD-06 ROLE OF THE MICROBIOME IN HIV INFECTION (AND VICE-VERSA)

Room 304-306

1:30 PM – 2:30 PM

Themed Discussion Leader

Roger Paredes, IrsiCaixa Institute for AIDS Research, Badalona, Spain

271 MICROBIOME-ASSOCIATED EPITHELIAL DISRUPTION MODIFIES HIV ACQUISITION RISK IN WOMEN

Laura Noël-Romas, Michelle Perner, Alicia Berard, Ann M. Carias, Kenzie Birse, John Schellenberg, Melissa Lemke, Annelie Tjernlund, Garrett Westmacott, Douglas Lauffenburger, Kristina Brolden, Lyle McKinnon, Kelly Arnold, Thomas Hope, Adam Burgener

272 IMPAIRED GUT TIGHT JUNCTION BUT PRESERVED ΓΔ AND MICROBIAL TRANSLOCATION IN ACUTE HIV

Elvira S. Cannizzo, Giuseppe Ancona, Delfina Tosi, Federica Savi, Camilla Tincati, Antonella D'Arminio Monforte, Giulia Marchetti

273 MICROBIAL DYSBIOSIS DOES NOT ALTER DISEASE PROGRESSION IN SIV-INFECTED ASIAN MACAQUES

Alexandra Ortiz, Sarah DiNapoli, Jacob Flynn, Carly Elizabeth C. Starke, Stephen Lai, Mackenzie Long, Ornella Sortino, Carol Vinton, Joseph Mudd, Jacob D. Estes, Jason Brenchley

274 EFFECTS OF PROBIOTIC VISBIOME ES ON COLONIC MUCOSAL CD4 CELLS: RESULTS FROM A5352S

Rachel Presti, Douglas W. Kitch, Adriana Andrade, Alan Landay, Jeffrey Jacobson, Cara Wilson, Eunice Yeh, Jacob D. Estes, Claire Deleage, Karin L. Klingman, Netanya S. Utay, Edgar T. Overton, Jason Brenchley, Brett Williams, for the A5352S Clinical Trial Team

275 THE IMPACT OF SYNBIOTICS IN ADVANCED HIV DISEASE: A RANDOMIZED CLINICAL TRIAL

Sergio Serrano-Villar, María Lagarde, Nadia Madrid, José I. Bernardino, Alejandro Vallejo, Carolina Gutiérrez, Alfonso Cabello, Mariano Matarranz, Judit Villar, Alberto Díaz de Santiago, Jose-Ramón Blanco, Talía Sainz, Federico Pulido, Santiago Moreno, Vicente Estrada

Themed Discussion TD-07 AGING BRAIN AND HIV: BEFORE AND AFTER

Room 302

1:30 PM – 2:30 PM

Themed Discussion Leader

Linda Chang, University of Maryland, Baltimore, MD, USA

437 CEREBRAL GLUTATHIONE METABOLISM IN ACUTE HIV INFECTION AND RESPONSE TO ART

Napapon Sailasuta, Jennifer Daniels, Phillip Chan, Carlo Sacdalan, Merlin L. Robb, Somporn Tipsuk, Jintanat Ananworanich, Duanghathai Suttichom, Robert Paul, Nisakorn Ratnaratorn, Mantana Pothisri, Netsiri Dumrongpisutikul, Serena S. Spudich, Victor Valcour, for the SEARCH 010/RV254 and RV304 Study Team

438 AMYLOID UPTAKE BY PET IMAGING SUGGEST PREMATURE AGING IN OLDER HIV+ INDIVIDUALS

Ned Sacktor, Richard Skolasky, Heidi Roosa, Cornelia Demsky, Yun Zhou, Weiguo Ye, Noble George, Peter B. Barker, Dean Wong, Mona Mohamed

439 NEUROIMAGING CORRELATES OF FRAILTY, COGNITION, AND HIV

Jeremy Strain, Robert S. Smith, Sarah Cooley, Beau M. Ances

440 SUBCLINICAL GLOBAL AND THALAMIC HYPOMETABOLISM ON FDG-PET IN TREATED HIV+ SUBJECTS

Dima A. Hammoud, Sanhita Sinharay, Sally Steinbach, Paul Wakim, Katrina Geannopoulos, Katherine Traino, Amit Dey, Stanley Rapoport, Edmund C. Tramont, Joseph Snow, Nehal N. Mehta, Bryan Smith, Avindra Nath

425 BRAIN VOLUMES CHANGES AFTER ABC/3TC + EFV OR TDF/FTC + ATV/R AS FIRST-LINE ART

Ignacio Pérez-Valero, Lucia Bailon, Alicia Gonzalez, Belen Alejos, Helena Melero, Norberto Malpica, Jose I. Bernardino, Juan González-García, Jose R. Arribas, for the La Paz HIV Group

Themed Discussion TD-08 ARE INTEGRASE STRAND-TRANSFER INHIBITORS RESISTANCE PROOF?

Ballroom C

1:30 PM – 2:30 PM

Themed Discussion Leader

Gerardo Garcia-Lerma, *Centers for Disease Control and Prevention, Atlanta, GA, USA*

542 LOW PREVALENCE OF INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE ACROSS BOTSWANA

Simani Gaseitsiwe, Sikhulile Moyo, Melissa Zahralban-Steele, Dorcas Maruapula, Baitshepi Mokaleng, Terence Mohammed, Shenaaz El-Halabi, Elliot G. Raizes, Tendani Gaolathe, Shahin Lockman, Max Essex, Vlad Novitsky

543 HIGH LEVEL RESISTANCE TO DOLUTEGRAVIR (DTG) AFTER EMERGENCE OF T97A MUTATION

Safia S. Kuriakose, Jomy M. George, Nicola Dee, Pam Stoll, Brian K. Agan, Robin L. Dewar, Alice K. Pau, Frank Maldarelli

544 UNINTEGRATED VIRAL DNA INVOLVED IN DOLUTEGRAVIR RESISTANCE

Isabelle Malet, Frédéric Subra, Hervé Leh, Charlotte Charpentier, Gilles Collin, Diane Descamps, Eric Deprez, Vincent Calvez, Anne-Geneviève Marcellin, **Olivier Delelis**

545 PREVALENCE AND CLINICAL IMPACT OF MINORITY RESISTANT VARIANTS TO INTEGRASE INHIBITORS

Thuy T. Nguyen, Djeneba Bocar Fofana, Charlotte Charpentier, Sidonie Lambert, Laurence Morand-Joubert, Diane Descamps, Marc Wirden, Christine Katlama, Minh Le, Gilles Peytavin, Philippe Flandre, Vincent Calvez, Eve Todesco, Anne-Geneviève Marcellin, for the ANRS AC11 Resistance Study Group.

546 INTEGRASE INHIBITOR RESISTANCE SELECTIONS INITIATED WITH DRUG RESISTANT HIV-1

Kristen Andreatta, Silvia Chang, Ross Martin, Madeleine Willkom, Kirsten L. White

Themed Discussion TD-09 BONES OF CONTENTION**Auditorium****1:30 PM – 2:30 PM****Themed Discussion Leader****Eugènia Negredo, Fundació Lluita Contra la Sida, Badalona, Spain****720 TDF PROPHYLAXIS FOR PMTCT OF HBV: EFFECT ON MATERNAL AND INFANT BONE MINERAL DENSITY**

Nicolas Salvadori, Bo Fan, Waralee Teeyasoontranon, Nicole Ngo-Giang-Huong, Siriluk Phanomcheong, Anita Luvira, Achara Puangsombat, Arunrat Suwannarat, Ussanee Srirompotong, Chaiwat Putiyanun, Athena Kourtis, Marc Bulterys, George K. Siberry, **Gonzague Jourdain**, for the iTAP Study Group

721 OPTION B-PLUS ART, PREGNANCY, LACTATION AND BONE HEALTH IN UGANDAN WOMEN

Florence Nabwire, Ann Prentice, Matthew M. Hamill, Mary G. Fowler, Josaphat Byagumisha, Adeodata Kekitiinwa, Gail R. Goldberg

722 RATES OF BONE LOSS SLOW AFTER THE FIRST YEAR OF ART: START BMD SUBSTUDY FINAL RESULTS

Andrew Carr, Birgit Grund, Ann V. Schwartz, Anchalee Avihingsanon, Sharlaa Badal-Faesen, Jose I. Bernadino, Patrick W. Mallon, Vicente Estrada, Alberto M. La Rosa, Sanjay Pujari, David White, Nicole Wyman Engen, Kristine E. Ensrud, Jennifer Hoy, for the START Bone Mineral Density Substudy Group

723 GREATER BONE TURNOVER MARKER DECLINE WITH ZOLEDRONIC ACID THAN WITH TDF-SWITCHING

Andrew Carr, Robyn Richardson, Stephen J. Kerr, Peter R. Ebeling, Nicholas Pocock, Jhon Rojas, Esteban Martinez, Jennifer Hoy, for the ZeST Study Group

724 COMBINED EFFECTS OF BISPHOSPHONATES & TDF→TAF SWITCH IN HIV+ ADULTS WITH LOW BMD

Todd T. Brown, Michael T. Yin, Samir K. Gupta, William R. Short, Melanie Thompson, Daniel Podzamczer, Giovanni Di Perri, Cheryl McDonald, Matthias Cavassini, Pablo Tebas, Ya-Pei Liu, Scott McCallister, Andrew Cheng, Moupani Das

Themed Discussion TD-10 EXPANDING PrEP IN WOMEN**Ballroom A****1:30 PM – 2:30 PM****Themed Discussion Leader****Quarraisha Abdool Karim, CAPRISA, Durban, South Africa****1048 PREDICTORS OF PrEP ELIGIBILITY AMONG AT-RISK WOMEN IN THE SOUTHERN UNITED STATES**

Anar S. Patel, Lakshmi Goparaju, Jessica M. Sales, Cyra Christina Mehta, Oni J. Blackstock, Dominika Seidman, Igbo Oforotun, Mirjam-Colette Kempf, Margaret Fischl, Elizabeth T. Golub, Adaora Adimora, Audrey French, Gina Wingood, Seble Kassaye, Anandi N. Sheth

1045 PREDICTORS OF WILLINGNESS TO TAKE PrEP AMONG BLACK AND LATINA TRANSGENDER WOMEN

Tonia Poteat, Erin Cooney, Mannat Malik, Thespina Yamanis, Maren Lujan, Andrea L. Wirtz

1046 PrEP AND EARLY ART FOR FEMALE SEX WORKERS IN SOUTH AFRICA: THE TAPS PROJECT

Robyn Eakle, Gabriela Gomez, Niven Naicker, Rutendo Bothma, Judie Mbogua, Maria A. Cabrera Escobar, Elaine Saayman, Michelle A. Moorhouse, **Willem D. Venter**, Helen Rees

1049 RISK BEHAVIOR, PERCEPTION, AND REASONS FOR PrEP AMONG YOUNG AFRICAN WOMEN IN HPTN 082

Connie L. Celum, Sinead Delany-Moretlwe, Sybil Hosek, Bonnie J. Dye, Linda-Gail Bekker, Nyaradzo Mgodi, Wonderful Mabuza, Goodness Zoh Mvuyane, Shorai Mukaka, Deborah J. Donnell, Subash Pathak, Heather Noble, Denni Lennon, Jessica M. Fogel, Peter L. Anderson

1043 PATTERNS OF ORAL PrEP ADHERENCE AND HIV RISK AMONG EASTERN AFRICAN WOMEN

Maria Pyra, Elizabeth Brown, Jessica E. Haberer, Renee Heffron, Elizabeth A. Bukusi, Stephen Asiimwe, Connie L. Celum, Elly T. Katabira, Nelly R. Mugo, Jared Baeten, for the Partners Demonstration Project Team

1047 HIGH PrEP UPTAKE AMONG KENYAN PREGNANT WOMEN OFFERED PrEP DURING ANTENATAL CARE

John Kinuthia, Jillian Pintye, Kenneth K. Mugwanya, Marline Serede, Joseph Sila, Felix Abuna, Harrison Lagat, Julia Dettinger, Tina Schuh, Jared Baeten, Grace John-Stewart

Themed Discussion TD-11 THE PERSISTENT CHALLENGE OF LATE PRESENTATION AND MORTALITY**Ballroom B****1:30 PM – 2:30 PM****Themed Discussion Leader****Nathan Ford**, WHO, Geneva, Switzerland**903 LIFE EXPECTANCY IN KEY POPULATIONS OF ADULTS WITH HIV IN THE US AND CANADA**

Keri N. Althoff, Richard D. Moore, Michael John Gill, Michael A. Horberg, Amy C. Justice, Mari Kitahata, Marina Klein, Fidel A. Desir, W. C. Mathews, Angel Mayor, Peter F. Rebeiro, Michael J. Silverberg, Stephen J. Gange, Robert S. Hogg, for the North American AIDS Cohort Collaboration for Research and Design (NA-ACCORD) of IeDEA

901 LONG-TERM MEASURES OF HIV EXPOSURE AND MORTALITY IN THE HIV OUTPATIENT STUDY

Frank J. Palella, Carl Armon, Stephen R. Cole, Rachel Hart, Nabil Rayeed, Ellen Tedaldi, Bienvenido Yangco, Richard Novak, Linda Battalora, Stacey Purinton, Kate Buchacz

891 SHIFTING MORTALITY TRENDS AMONG PERSONS WITH HIV AND INJECTION DRUG USE OVER 30 YEARS

Jing Sun, Damani A. Piggott, Abimereki D. Muzaale, Jacquie Astemborski, Shruti H. Mehta, Gregory D. Kirk

902 POST-HOSPITAL MORTALITY AND READMISSION AMONG HIV-INFECTED ADULTS IN SOUTH AFRICA

Chris Hoffmann, Minja Milovanovic, Deanne Kerrigan, Neil A. Martinson, Ebrahim Variava

898 PERSONS LIVING WITH HIV (PLHIV) WITH ADVANCED HIV DISEASE: NEED FOR NOVEL CARE MODELS

Wafaa M. El-Sadr, **Chloe A. Teasdale**, Katharine Yuengling, Peter Preko, Maureen Syowai, Felix Ndagiye, Miriam Rabkin, Elaine J. Abrams

Symposium S-5 MOLECULAR MACHINES
Ballroom A

CME

4:00 PM – 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding key stages in the HIV replication cycle, both from a basic science perspective and to advance the development of new therapeutics and more effective vaccines.

Level of Knowledge: It is assumed that the participants are familiar with the different stages of the viral life cycle and have a basic understanding of molecular biology.

Objectives: At the conclusion of this session, learners will be able to describe:

- The structures and mechanisms of viral and cellular machines that perform or block key stages of HIV replication
- HIV envelope protein structure and transformations, inhibition by drugs and antibodies, and progress toward an envelope-based vaccine.
- The molecular architecture and regulation of the RT-RNA complex that initiates HIV reverse transcription
- The structure and mechanism of SAMHD1, a host restriction factor that inhibits retroviral replication by depleting cytoplasmic dNTP pools
- The structure and mechanism of the Vps4 ATPase, the host machine that powers HIV budding

Conveners

Zandrea Ambrose, *University of Pittsburgh, Pittsburgh, PA, USA*



Bing Chen, *Boston Children's Hospital/Harvard Medical School, Boston, MA, USA*

98 HIV ENV: STRUCTURE, FUNCTION, AND INHIBITION THEREOF

4:00

Peter D. Kwong, *National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA*



99 ARCHITECTURE OF THE HIV-1 REVERSE TRANSCRIPTASE INITIATION COMPLEX

4:30

Elisabetta Viani Puglisi, *Stanford University, Stanford, CA, USA*



100 STRUCTURE AND MECHANISM OF THE SAMHD1 HIV-1 RESTRICTION FACTOR

5:00

Ian A. Taylor, *The Francis Crick Institute, London, UK*



101 STRUCTURE AND MECHANISM OF VPS4, THE ENZYME THAT DRIVES HIV BUDDING

5:30

Christopher P. Hill, *University of Utah, Salt Lake City, UT, USA*



Symposium S-6 LIFE EXPECTANCY AT 25
Ballroom C
CME**4:00 PM – 6:00 PM**

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the degree to which HIV contributes to increased morbidity and mortality in the modern ART era and potential intervention strategies to improve health beyond ART alone.

Level of Knowledge: It is assumed that participants are familiar with the general epidemiology of HIV infection and basic concepts in HIV pathogenesis, including immune activation.

Objectives: At the completion of the session, participants will be able to:

- Explain the degree to which HIV is associated with excess morbidity and mortality in the modern ART era, and subgroups of HIV-infected individuals that are at particularly high risk
- Describe the potential contribution of health-related behaviors and treatable noncommunicable chronic disease to this excess morbidity and mortality
- Describe the potential contribution of persistent immune activation and inflammation to morbidity and mortality during treated HIV infection as well as possible intervention targets

Conveners

Peter W. Hunt, *University of California San Francisco, San Francisco, CA, USA*



Dominique Costagliola, *Pierre and Marie Curie University, Paris, France*

102 LIFE EXPECTANCY IN THE MODERN ART ERA

4:00 **Caroline Sabin,** *University College London, London, UK*


103 IMPACT OF PHYSICAL AND MENTAL COMORBIDITIES ON LIFE EXPECTANCY

4:30 **Keri N. Althoff,** *Johns Hopkins University, Baltimore, MD, USA*


104 INFLAMMATION AND DISEASE RISK AMONG HIV-SEROPOSITIVE INDIVIDUALS

5:00 **Jason V. Baker,** *Hennepin County Medical Center, Minneapolis, MN, USA*



5:30–6:00 **Moderated discussion with the speakers**

Symposium S-7 PrEP WORKS, NOW WHAT? Ballroom B

CME

4:00 PM – 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the challenges and opportunities of preexposure prophylaxis (PrEP) as a treatment strategy

Level of Knowledge: It is assumed that the participants are familiar with basic HIV epidemiology and prevention strategies.

Objectives: At the completion of the session, participants will be able to:

- Describe the correlation between the uptake of PrEP and high rates of STIs
- Explain how PrEP could impact HIV incidence globally
- Describe the current challenges in PrEP scale-up and the various strategies to guide PrEP scale up

Conveners

Elizabeth M. Irungu, Kenya Medical Research Institute, Nairobi, Kenya



Leandro A. Mena, University of Mississippi Medical Center, Jackson, MS, USA

105 THE INTERSECTION OF PrEP AND SEXUALLY TRANSMITTED INFECTIONS

4:00 **Julia A. Schillinger,** CDC, Atlanta, GA, USA



106 IMPACT OF PrEP ON HIV INCIDENCE

4:30 **Roel Coutinho,** University Medical Center Utrecht, Utrecht, Netherlands



107 FIVE CONTROVERSIES IN PrEP SCALE-UP

5:00 **Linda-Gail Bekker,** University of Cape Town, Cape Town, South Africa



108 TAKING THE LEAP IN PrEP SCALE-UP: A GOOD TYPE OF CHALLENGE

5:30 **Nelly R. Mugo,** Kenya Medical Research Institute, Nairobi, Kenya



WEDNESDAY, MARCH 7, 2018

Plenary PL-3 WEDNESDAY PLENARY SESSION**Auditorium / Hall C / Auditorium Balcony****CME****8:30 AM – 9:30 AM****109 GROWING UP WITH HIV**

8:30

Patricia M. Flynn, St. Jude Children's Research Hospital, Memphis, TN, USA**110 ARE WE ON THE FAST TRACK TO "BEND AND END" THE HIV EPIDEMICS?**

9:00

Helen A. Weiss, London School of Hygiene & Tropical Medicine, London, UK**Oral Abstract 0-09 HIV REPLICATION, INHIBITION, AND RESTRICTION****Ballroom A****10:00 AM – 12:00 PM****Oral Abstract Moderators****Rahm Gummuluru, Boston University, Boston, MA, USA****Brandon Keele, National Cancer Institute, Frederick, MD, USA****111 IDENTIFICATION OF HIV-1 ENV MUTATIONS THAT CONFER BROAD RESISTANCE TO ARVS IN VITRO**

10:00

Rachel Van Duyne, Phuong Pham, Eric O. Freed**112 STRAIN-DEPENDENT ACTIVATION AND INHIBITION OF HIV-1 ENTRY BY A PF-68742 DIASTEREOMER**

10:15

Connie A. Zhao, Amy Princiotto, Mark Farrell, Amos B. Smith, Navid Madani, Joseph G. Sodroski**113LB TRISPECIFIC ANTIBODIES FOR PREVENTION AND TREATMENT OF HIV-1 INFECTION**

10:30

Amarendra Pegu, Zhi-yong Yang, Ling Xu, Ercole Rao, Nicole Doria-Rose, Jochen Beninga, Krisha McKee, Dana M. Lord, Ronnie R. Wei, Gejing Deng, Stephen Schmidt, Wang Keyun, Mario Roederer, John R. Mascola, Gary Nabel**114 MOLECULAR DETERMINANTS OF HIV HYPERMUTATION**

10:45

Diako Ebrahimi, Christopher Richards, Michael A. Carpenter, Jennifer McCann, Adam Cheng, Terumasa Ikeda, Daniel Salamango, Reuben S. Harris**115 HIV-1 SPLICING SUPPRESSION AS A POSSIBLE THERAPEUTIC TARGET**

11:00

Ann Emery, Matthew Takata, Jeffery Levengood, John Collins, Alice Telesnitsky, Blanton Tolbert, Paul Bieniasz, Ronald Swanstrom**116 A LONG INTERNAL LOOP GOVERNS THE SENSITIVITY OF THE ANTI-HIV PROTEIN SERINC5 TO NEF**

11:15

Weiwei Dai, Yoshiko Usami, Yuanfei Wu, Heinrich Gottlinger**117 PROTECTIVE GENE EXPRESSION SIGNATURE IN RESPONSE TO RHCMV/SIV VACCINE VECTORS**

11:30

Connor Driscoll, Richard Green, Fredrik Barrenas, Jean Chang, Elise Smith, Lynn Law, Scott Hansen, Louis J. Picker, Michael Gale

118 CROSS-SPECIES CMV VACCINATION REVEALS DETERMINANTS OF NON-CLASSICAL T CELLS

Justin Greene, Daniel Malouli, Scott Hansen, Travis Whitmer, Abigail Ventura, Roxanne Gilbride, Luke Uebelhoer, Jennie Womack, Matthew McArdle, Junwei Gao, Alfred Legasse, Michael K. Axthelm, Louis J. Picker, Klaus Fruh, Jonah Sacha

Oral Abstract 0-10 THE CNS RESERVOIR(S), REBOUND, AND BRAIN INJURY

Ballroom B

10:00 AM – 12:00 PM

Oral Abstract Moderators

Lishomwa Ndhlovu, University of Hawaii, Honolulu, HI, USA

Christina Marra, University of Washington/Harborview Medical Center, Seattle, USA

119 HIV-1 PERSISTS IN CSF CELLS IN HALF OF INDIVIDUALS ON LONG-TERM ART

Serena S. Spudich, Rajesh T. Gandhi, Joshua C. Cytor, Christina Lalama, Ronald Bosch, Bernard J. Macatangay, Charles Rinaldo, Kevin Robertson, Ann Collier, Catherine Godfrey, Evelyn Hogg, Joseph J. Eron, Deborah McMahon, John W. Mellors, for the A5321 Study Team

120 LONGITUDINAL TRAJECTORY OF BRAIN VOLUME AND CORTICAL THICKNESS IN PRIMARY INFECTION

Ryan Sanford, Beau M. Ances, Richard W. Price, Dieter Meyerhoff, Serena S. Spudich, Louis Collins

121 HIV AND BRAIN ATROPHIC SIGNATURE IN ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT

Lucette A. Cysique, Madeline Nichols, Thomas Gates, James Soares, Kirsten Moffat, Caroline Rae, Bruce J. Brew

122 LONGITUDINAL COGNITIVE OUTCOMES AFTER TREATMENT IN ACUTE HIV INFECTION

Phillip Chan, Umit Tokac, Joanna Hellmuth, Eugène Kroon, Donn Colby, Carlo Sacdalan, James L. Fletcher, Somporn Tipsuk, Suteeraporn Pinyakorn, Merlin L. Robb, Jintanat Ananworanich, Victor Valcour, Serena S. Spudich, Robert Paul, for the RV254/SEARCH 010 Study Team

123 IMPACT OF ART REGIMENS ON CSF VIRAL ESCAPE IN HIV-1 INFECTED ADULTS

Shibani S. Mukerji, Vikas Misra, David Lorenz, Hajime Uno, Susan Morgello, Donald Franklin, Ronald J. Ellis, Scott L. Letendre, Dana H. Gabuzda

124 SIV REBOUND IN THE SPINAL CORD AFTER STOPPING ART: A NOVEL CNS RESERVOIR

Megan E. McCarron, Lisa Mangus, Samuel A. Brill, Sarah E. Beck, Kelly A. Metcalf Pate, Suzanne E. Queen, **Joseph Mankowski**

125 IDENTIFICATION OF BRAIN INJURY USING A NOVEL DEFINITION OF COGNITIVE IMPAIRMENT

Jonathan Underwood, James H. Cole, Davide De Francesco, Caroline Sabin, Alan Winston, for the CHARTER group

126 HEME OXYGENASE-1 POLYMORPHISM ASSOCIATES WITH NEUROIMMUNE ACTIVATION IN HIV SUBJECTS

Alexander J. Gill, Rolando Garza, Suren A. Ambegaokar, Patricia J. Vance, Benjamin B. Gelman, Dennis L. Kolson

Oral Abstract 0-11 HEPATITIS C VIRUS / HIV-ASSOCIATED MALIGNANCIES
Room 304-306
10:00 AM – 12:00 PM
Oral Abstract Moderators
Milosz Parczewski, Pomeranian Medical University, Szczecin, Poland
Meredith S. Shiels, National Cancer Institute, Rockville, MD, USA
127 RETREATMENT OF HEPATITIS C INFECTION IN PATIENTS WHO FAILED GLECAPREVIR/PIBRENTASVIR
10:00

David L. Wyles, Ola Weiland, Betty Yao, Robert Reindollar, Frank Weilert, Jean-Francois Dufour, Stuart Gordon, Fred Poordad, Albrecht Stoehr, Ashley Brown, Stefan Mauss, Suvajit Samanta, Tami Pilot-Matias, Lino Rodrigues, Roger Trinh

128 8 WEEKS OF GRAZOPREVIR/ELBASVIR FOR ACUTE HCV: A MULTICENTER CLINICAL TRIAL (DAHHS 2)
10:15

Anne Boerekamps, Anja De Wegheleire, Guido van den Berk, Fanny Lauw, Mark Claassen, Dirk Posthouwer, Wouter Bierman, Sebastiaan Hullegie, Eric Florence, Anton Dofferhoff, Joop E. Arends, Bart Rijnders

129 FUELING THE EPIDEMIC: LOW RATES OF SPONTANEOUS CLEARANCE OF ACUTE HCV COINFECTION
10:30

Christoph Boesecke, Elena Müller Martinez, Mark Nelson, Patrick Ingiliz, Thomas Lutz, Stefan H. Scholten, Christiane Cordes, Heribert Knechten, Maria Martínez-Rebollar, Christoph D. Spinner, Michael Rausch, Thomas Reiberger, Stefan Mauss, Jürgen K. Rockstroh, for the PROBE-C study group

130 INTERNATIONAL VERSUS DOMESTIC HCV TRANSMISSION IN MSM: A PERSPECTIVE FOR THE DAA ERA
10:45

Luisa Salazar-Vizcaya, Roger Kouyos, Karin Metzner, Kamila Caraballo, Cyril Shah, Jürg Böni, Manuel Battegay, Enos Bernasconi, Alexandra Calmy, Matthias Cavassini, Herbert A. Mbunkah, Olivia Keiser, Andri Rauch, for the Swiss HIV Cohort Study

131 ITAP TRIAL: MATERNAL AND INFANT EFFICACY AND SAFETY RESULTS 12 MONTHS AFTER DELIVERY
11:00

Gonzague Jourdain, Linda J. Harrison, Nicole Ngo-Giang-Huong, Tim R. Cressey, Luc Decker, Camlin Tierney, Jullapong Achalapong, Prateep Kanjanavikai, Anita Luvira, Ussanee Srirompotong, Trudy V. Murphy, Noele Nelson, George K. Siberry, Stanislas Pol, for the iTAP Study Group

132 STATIN EXPOSURE IS ASSOCIATED WITH DECREASED RISK OF CANCER
11:15

Roger Bedimo, Fatma Shebl, Keith M. Sigel, Sheldon T. Brown, Kristina Crothers, Matthew B. Goetz, Amy C. Justice, Janet Tate, for the VA Aging Cohort Study

133 PREDICTORS OF KS-IRIS IN MILD/MODERATE AIDS-KS DURING ART IN LOW-RESOURCE SETTINGS
11:30

Thomas Campbell, Minhee Kang, Trijn Umbleja, Susan E. Krown, Agrey Bukuru, Jeffrey N. Martin, Catherine Godfrey, Mulinda Nyirenda, Naftali Busakhala, Margaret Borok, Deborah Langat, Brenda Hoagland, Noluthando Mwelase, Mina C. Hosseinipour, for the ACTG A5264 Protocol Team

134 ACTG 5282: HPV TEST&TREAT VS CYTOLOGY-BASED CERVICAL CANCER PREVENTION IN HIV+ WOMEN
11:45

Timothy Wilkin, Roy Matining, Vikrant Sahasrabuddhe, Huichao Chen, Reena Masih, Rosie Mngqibisa, Mohammed Rassool, Yamikani Mbilizi, Tsitsi M. Magure, Cynthia Riviere, Aida Asmelash, Ramesh Bhosale, Pamela Michelow, Catherine Godfrey, Cindy Firnhaber

Oral Abstract 0-12 CRITICAL ISSUES IN WOMEN'S HEALTH AND EARLY TREATMENT OF PEDIATRIC HIV INFECTION

Ballroom C

10:00 AM – 12:00 PM

Oral Abstract Moderators

Catherine Orrell, Desmond Tutu HIV Foundation, Cape Town, South Africa

Linda Barlow-Mosha, Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda

135 ARV PROPHYLAXIS/ART INITIATION AT BIRTH LIMITS THE SIZE OF THE RESERVOIR IN CHILDREN

10:00 Marta Massanella, Jintanat Ananworanich, Louise Leyre, Thidarath Jupimai, Panadda Sawangsinth, Mark de Souza, Suteeraporn Pinyakorn, Piyarat Suntarattiwong, Pope Kosalaraksa, Thitiporn Borkird, Kulkanya Chokephaibulkit, Suparat Kanjanavanit, Thanyawee Puthanakit, Nicolas Chomont, for the HIVNAT209 and HIVNAT194 study groups

136 LOW HIV RESERVOIR AT 84 WEEKS IN VERY EARLY TREATED HIV-INFECTED CHILDREN IN BOTSWANA

10:15 Roger L. Shapiro, Mathias Lichterfeld, Michael D. Hughes, Kara Bennett, Kenneth Maswabi, Gbolahan Ajibola, Pilar Garcia-Broncano, Sikhulile Moyo, Terence Mohammed, Patrick Jean-Philippe, Maureen Sakoi, Oganne Batlang, Shahin Lockman, Joseph Makhema, Daniel R. Kuritzkes

137 TIME TO VIRAL REBOUND AFTER STOPPING ART IN CHILDREN TREATED FROM INFANCY IN CHER

10:30 Avy Violari, Man Chan, Kennedy N. Otwombe, Ravindre Panchia, Patrick Jean-Philippe, Diana Gibb, Mark Cotton, Abdel Babiker, for the CHER Study Team and EPIICAL Consortium

138 SIMILAR CLINICAL OUTCOMES BETWEEN FORMULA AND BREASTFEEDING WOMEN IN PROMISE

10:45 Risa M. Hoffman, Konstantia Angelidou, Sean Brummel, Friday Saidi, Dingase E. Dula, Vidya Mave, Lee Fairlie, Gerhard Theron, Moreen Kamateeka, Tsungai Chipato, Avy Violari, Nahida Chakhtoura, Judith S. Currier, Mary Glenn Fowler, for the IMPAACT PROMISE 1077BF/FF Team

139 PROMISE TRIAL: RESULTS OF CONTINUED VS DISCONTINUED ART AFTER END OF BREASTFEEDING

11:00 Taha E. Taha, Sean Brummel, Konstantia Angelidou, Mary Glenn Fowler, Patricia M. Flynn, Cornelius Mukuzunga, Dingase E. Dula, Maxensia Owor, Dhayendre Moodley, Tsungai Chipato, Amy J. Loftis, Nahida Chakhtoura, Katie McCarthy, Judith S. Currier, for the IMPACT PROMISE Study Team15

140 ART DETECTION AND RESISTANCE DURING VIRAEMIC EPISODES IN PREGNANCY AND BREASTFEEDING

11:15 Landon Myer, Andrew D. Redd, Elton Mukonda, Briana Lynch, Tamsin K. Phillips, Anna Eisenberg, Allison Zerbe, Autumn Braud, Nei-Yuan M. Hsiao, Craig Martens, Maia Lesosky, James A. McIntyre, William Clarke, Elaine J. Abrams, Steven J. Reynolds

141 VAGINAL CONTRACEPTIVE HORMONE EXPOSURE PROFOUNDLY ALTERED BY EFV- AND ATV/R-BASED ART

11:30 Kimberly K. Scarsi, Yoninah S. Cramer, David Gingrich, Susan L. Rosenkranz, Francesca Aweka, Robert Coombs, Carmen D. Zorrilla, Kristine Coughlin, Laura E. Moran, Baiba Berzins, Catherine Godfrey, Susan E. Cohn, for the AIDS Clinical Trials Group A5316 Study Team

142LB RANDOMIZED TRIAL OF SAFETY OF ISONIAZID PREVENTIVE THERAPY DURING OR AFTER PREGNANCY

11:45

Amita Gupta, Grace Montepiedra, Lisa Aaron, Gerhard Theron, Katie McCarthy, Carolyne Onyango-Makumbi, Tsungai Chipato, Gaerolwe Masheto, Katherine Shin, Bonnie Zimmer, Timothy R. Sterling, Nahida Chakhtoura, Patrick Jean-Philippe, Adriana Weinberg, for the the IMPAACT P1078/TB APPRISE Study Team

**Oral Abstract 0-13 IMPROVING USE OF THE TOOLS WE HAVE:
HIV TESTING AND VAGINAL RINGS**

Auditorium**10:00 AM – 12:00 PM****Oral Abstract Moderators**

Euphemia Sibanda, Centre for Sexual Health and HIV AIDS Research, Harare, Zimbabwe

Rachel Baggaley, World Health Organization, Geneva, Switzerland

143LB HIGH UPTAKE AND REDUCED HIV-1 INCIDENCE IN AN OPEN-LABEL TRIAL OF THE DAPIVIRINE RING

10:00

Jared Baeten, Thesla Palanee-Phillips, Nyaradzo Mgodi, Ashley Mayo, Annalene Nel, Zeda Rosenberg, Sharon L. Hillier, Elizabeth Brown, for the MTN-025/HOPE Study Team

144LB HIV INCIDENCE AND ADHERENCE IN DREAM: AN OPEN-LABEL TRIAL OF DAPIVIRINE VAGINAL RING

10:15

Annalene Nel, Neliette Van Niekerk, Ben Van Baelen, Zeda Rosenberg, for the The IPM 032/DREAM Study Team

145 WHO REMAINS UNTESTED FOLLOWING NEAR-UNIVERSAL (>95%) POPULATION HIV TESTING?

10:30

Dalsone Kwarisiima, Jane Kabami, Norton Sang, Kevin Kadebe, Atukunda Mucunguzi, Katherine Snyman, Tamara D. Clark, Elizabeth A. Bukusi, Teri Liegler, Edwin D. Charlebois, Laura B. Balzer, Maya L. Petersen, Moses R. Kamya, Diane V. Havlir, Gabriel Chamie

146 EXPANDED HIV TESTING ELIGIBILITY INCREASES DETECTION OF HIV INFECTIONS, WESTERN KENYA

10:45

Rachael Joseph, Paul K. Musingila, Fredrick Miruka, Lucy Ng'ang'a, Hellen Mutai, Kevin M. De Cock, Felix M. Mulama, Caroline O. Dande, Polycarp Musee, Stella Wanjohi

147 OPTIMAL HIV TESTING STRATEGIES TO INCREASE HIV DIAGNOSIS IN SOUTH AFRICA

11:00

Leigh F. Johnson, Gesine Meyer-Rath, Craig Van Rensburg, Caroline Govathson

148 EFFECT OF HIV SELF-TESTING ON SEXUAL PARTNER NUMBERS FOR ZAMBIAN FEMALE SEX WORKERS

11:15

Catherine E. Oldenburg, Michael M. Chanda, Katrina F. Ortblad, Magdalene Mwale, Steven Chongo, Nyambe Kamungoma, Catherine Kanchele, Andrew Fullem, Guy Harling, Till Bärnighausen

149 HIV SELF-TEST DISTRIBUTION INCREASES TEST FREQUENCY IN SOUTH AFRICAN MSM

11:30

Sheri A. Lippman, Tim Lane, Oscar Rabede, Hailey Gilmore, Yea-Hung Chen, Nkululeko Mlotshwa, Kabelo Maleke, Alexander Marr, James A. McIntyre

**150LB LINKAGE TO CARE AFTER HIV SELF-TESTING IN ZIMBABWE:
A CLUSTER-RANDOMISED TRIAL**

Euphemia Sibanda, Melissa Neuman, Mary Tumushime, Karin Hatzold, Constancia Watadzaushe, Miriam N. Mutseta, Jeffrey Dirawo, Sue Napierala, Getrude Ncube, Miriam Taegtmeyer, Cheryl Johnson, Katherine Fielding, Helen A. Weiss, Elizabeth L. Corbett, Frances Cowan

Themed Discussion TD-12 T AND B CELL INTERACTIONS IN LYMPH NODES**Ballroom A****1:30 PM – 2:30 PM****Themed Discussion Leader****Michael R. Betts**, *University of Pennsylvania, Philadelphia, PA, USA***284 FREQUENCIES AND DISTRIBUTION OF ENV-SPECIFIC B CELLS IN BLOOD VERSUS LYMPH NODES**

Alessandra Noto, Andrew McDavid, Phu Van, Madeleine Suffiotti, Agostino Riva, Jean-Marc Corpataux, Song Ding, Craig Fenwick, Raphael Gottardo, Giuseppe Pantaleo

285 T AND B CELL ALTERATIONS IN PERIPHERAL BLOOD AND LYMPH NODE IN ACUTE HIV INFECTION

Supranee Buranapraditkun, Hiroshi Takata, Carlo Sacdalan, Sopark Manasnayakorn, Suthat Chottanapund, Pattarawat Thantiworasit, Peerinya Prueksakaew, Khunthalee Benjapornpong, Bessara Nuntapinit, Timothy Schacker, Merlin L. Robb, Nelson L. Michael, Jintanat Ananworanich, Lydie Trautmann, for the RV254/SEARCH010

286 CYTOLYTIC CD4+ T CELLS WITH FOLLICULAR HOMING PROPERTIES IN CHRONIC HIV INFECTION

Enrico Richter, Johanna Eberhard, Marek Korencak, Bruce T. Schultz, Britta Flach, Stefan Esser, Julian Schulze zur Wiesch, Hendrik Streeck

287 TFC CELLS INTERACT WITH OTHER FOLLICULAR T CELLS TO CONTROL SIV VIREMIA

Mohammad Arif Rahman, Katherine M. McKinnon, Tatiana S. Karpova, David A. Ball, David Venzon, Wenjin Fan, Guobin Kang, Qingsheng Li, Marjorie Robert-Guroff

Themed Discussion TD-13 BIG APPLICATIONS OF LITTLE RNAs**Ballroom C****1:30 PM – 2:30 PM****Themed Discussion Leader****Raymond T. Chung**, *Massachusetts General Hospital, Boston, MA, USA***637 POTENTIAL FOR SERUM MICRO-RNAs TO PREDICT FIBROSIS REGRESSION DURING HBV TREATMENT**

Cody Orr, Rob Myers, David Gong, Biao Li, Zhaoshi Jiang, John Flaherty, Anuj Gaggar, G. Mani Subramanian, **Eric G. Meissner**

638 HEPATIC EXPRESSION OF HSA-MIR-125A-5P AND FIBROSIS IN OVERT AND OCCULT HBV INFECTION

Lorenzo Onorato, Aniello Russo, Giorgio de Stefano, Carmine Minichini, Mario Starace, Pietro Filippini, Loredana Alessio, Nunzia Farella, Nicoletta Potenza, Evangelista Sagnelli, Nicola Coppola

639 CIRCULATING MICRORRNAs IN HIV PATIENTS REVEAL SPECIFIC SIGNATURES FOR LIVER DAMAGE

Miguel Angel Martinez, Sandra Franco, Daniela Buccione, Beatriz Mothe, Lidia Ruiz, Maria Nevot, Ana Jordan-Paiz, Raquel Pluvinet, Susanna Aussó, Rosa M. Morillas, Lauro Sumoy, Cristina Tural

640 miRNA PROFILE OF HCV SPONTANEOUS CLEARANCE INDIVIDUALS SHOW PREVIOUS HCV INFECTION

Óscar Brochado Kith, Alicia Gómez Sanz, Luis M. Real, Javier Crespo, Pablo Ryan, Juan Macías, Joaquín Cabezas, Juan A. Pineda, María T. Arias-Loste, Isabel Cuesta, Sara Monzón-Fernández, Luz M. Medrano, María Á. Jimenez-Sousa, Salvador Resino, **Amanda Fernández-Rodríguez**

Themed Discussion TD-14 OUTCOMES OF PREVENTION STRATEGIES FOR CRYPTOCOCCAL MENINGITIS

Ballroom B

1:30 PM – 2:30 PM

Themed Discussion Leader

Graeme Meintjes, University of Cape Town, Cape Town, South Africa

784 CRAG STATUS AND EFFECT ON BENEFITS FROM ENHANCED PROPHYLAXIS IN THE REALITY TRIAL

Sarah Pett, Lewis Haddow, Ruth Nhema, Moira J. Spyer, Laura Benjamin, Grace Najjuka, Ibrahim Daud, Jay Berkley, Juliet Kitabala, James G. Hakim, Rob Heyderman, Sarah Walker, Diana Gibb, for the REALITY trial team

785 EVALUATION OF A CRYPTOCOCCAL SCREENING AND TREATMENT PROGRAM IN HIV CLINICS IN UGANDA

Elizabeth Nalintya, David Meya, Sarah Lofgren, Kathy Huppler Hullsieck, David R. Boulware, **Radha Rajasingham**

786 CLINIC-BASED LATERAL FLOW CRYPTOCOCCAL ANTIGEN TESTING AT HIV DIAGNOSIS, SOUTH AFRICA

Paul K. Drain, Ting Hong, Hilary Thulare, Mahomed-Yunus Moosa, Connie L. Celum

787 SYMPTOMATIC CRYPTOCOCCAL ANTIGENEMIA PRESENTING AS EARLY CRYPTOCOCCAL MENINGITIS

Kenneth Ssebambulidde, Mahsa Abassi, Joshua Rhein, Ananta Bangdiwala, Darlisha A. Williams, Edward Mpoza, Lillian Tugume, Richard Kzwizer, Abdu Musubire, Fiona Cresswell, Sarah Lofgren, Kathy Huppler Hullsieck, David R. Boulware, David Meya, for the ASTRO-CM

788 POSTMORTEM CRYPTOCOCCAL MENINGITIS FOLLOWING TREATMENT FOR CRYPTOCOCCAL ANTIGENAEMIA

Rachel M. Wake, Tanvier Omar, Aaron S. Karat, Joseph N. Jarvis, **Nelesh P. Govender**, Thomas S. Harrison

Themed Discussion TD-15 PHYLOGENETICS FOR PUBLIC HEALTH INTERVENTION

Room 302

1:30 PM – 2:30 PM

Themed Discussion Leader

Andrew Leigh Brown, University of Edinburgh, Edinburgh, United Kingdom

953 PHYLOGENETIC METHODS OF IDENTIFYING FOCI OF HIV-1 TRANSMISSION

Angela McLaughlin, P. Richard Harrigan, Jean A. Shoveller, Jeffrey Joy

957 HIV TRANSMISSION CLUSTER DYNAMICS THAT INFORM PUBLIC HEALTH INTERVENTION IN ILLINOIS

Manon Ragonnet-Cronin, Joel O. Wertheim, Christina S. Hayford, Richard D'Aquila, Fangchao Ma, Cheryl Ward, **Nanette Benbow**

959 PREDICTIVE MODEL FOR HIV TRANSMISSION CLUSTER GROWTH IN NORTH CAROLINA

Rachael Billock, Kimberly A. Powers, Erika Samoff, Victoria L. Mobley, William C. Miller, Joseph J. Eron, Ann M. Dennis

955 ASSOCIATION BETWEEN VIRAL SUPPRESSION AND MOLECULAR CLUSTER GROWTH, UNITED STATES

Nivedha Panneer, Alexandra M. Oster, Cheryl B. Ocfemia, Sheryl Lyss, Joel O. Wertheim, Anne Marie France

956 HIGH VIRAL LOAD ACROSS STAGE OF INFECTION ASSOCIATED WITH CLUSTERING IN US NETWORK

Joel O. Wertheim, Alexandra M. Oster, Nivedha Panneer, Chenhua Zhang, Neeraja Saduvala, Ellsworth Campbell, Jeffrey A. Johnson, William M. Switzer, Walid Heneine

960 AGE DISPARITIES IN EUROPEAN HIV TRANSMISSION PAIRS UNCOVERED WITH VIRAL SEQUENCE DATA

Matthew D. Hall, Chris Wymant, Oliver Ratmann, Jan Albert, Norbert Bannert, Anne-Marte Bakken Kren, Marion Cornelissen, Kate Grabowski, Huldrych F. Günthard, Laurence Meyer, Kholoud Porter, Matti Ristola, Guido Vanham, Christophe Fraser, for the BEEHIVE Collaboration

Themed Discussion TD-16 CLOSING THE GAP: INTEGRATION OF FAMILY PLANNING INTO HIV PREVENTION AND CARE

Room 304-306

1:30 PM – 2:30 PM

Themed Discussion Leader

Renee Heffron, University of Washington, Seattle, WA, USA

1068 INTEGRATION OF FAMILY PLANNING INTO HIV CARE AND TREATMENT PROGRAM IN KENYA

Wangui Muthigani, Emily R. Begnel, **Dunstan Achwoka**, Tai Ho Chen, John Kinuthia, Christine J. McGrath, Alison L. Drake, for the FP Working Group

1069 MISSED OPPORTUNITY FOR FAMILY PLANNING IN HIV-INFECTED WOMEN ON ART IN TOGO

Shino Arikawa, Cécile Cazes, Anne Thomas, Thierry Tiendrebeogo, Benjamin G. Kariyiare, Vincent Pitche, Didier K. Ekouevi, Renaud Bequet

1070 CONTRACEPTION AND PrEP IN SOUTH AFRICAN HAIR SALONS: OWNER, STYLIST, AND CLIENT VIEWS

Ingrid V. Bassett, Ai Xu, Sabina Govere, Hilary Thulare, Simone C. Frank, Christina Psaros, Robert A. Parker

1071 PREGNANCY INTENTION AND CONTRACEPTIVE USE IN MALAWI'S PMTCT PROGRAM

Deus Thindwa, Megan Landes, Monique van Lettow, Annie Kanyemba, Ernest Nkhoma, Thokozani Kalua, Happy Phiri, Joep J. van Oosterhout, for the NEMAPP consortium

Oral Abstract 0-14 DEFINING THE HIV RESERVOIR**Ballroom A****4:00 PM – 6:00 PM****Oral Abstract Moderators****Sara Gianella, University of California San Diego, La Jolla, CA, USA****Eli A. Boritz, NIH, Bethesda, MD, USA****151 NOVEL PARADIGM FOR MEASURING HIV-1 RESERVOIR ALLOWS QUANTITATION OF INTACT PROVIRUSES**
4:00**Katherine Bruner, Alexandra J. Murray, Ya-Chi Ho, Gregory Laird, Zheng Wang, Kyungyoon J. Kwon, Subul A. Beg, Andrew Timmons, Sarah B. Laskey, Janice E. Clements, Janet Siliciano, Robert Siliciano****152LB CLONES OF CD4 T CELLS WITH UNIQUE GENE SIGNATURE CONTRIBUTE TO HIV-1 PERSISTENCE**
4:15**Lillian B. Cohn, Israel T. da Silva, Renan Valieris, Amy Huang, Julio C. Lorenzi, Yehuda Z. Cohen, Joy A. Pai, Allison Butler, Marina Caskey, Mila Jankovic, Michel Nussenzweig****153 IDENTIFICATION OF INTEGRATION SITES OF INDUCIBLE HIV-1 USING HIV-1 RNA SORTSEQ**
4:30**Ales Varabyou, C. Conover Talbot, Hao Zhang, Subul A. Beg, Ross Pollack, Haiping Hao, Joseph B. Margolick, Robert Siliciano, Mihaela Pertea, Ya-Chi Ho****154LB HERITABLE CLONE-SPECIFIC DIFFERENCES IN HIV-1 GENE EXPRESSION**
4:45**Edmond A. Atindaana, David Read, Kalyani Pyaram, Sarah Emery, Cheong-Hee Chang, Jeffrey Kidd, Alice Telesnitsky****155 CD32+PD-1+ TFH CELLS ARE THE MAJOR HIV RESERVOIR IN LONG-TERM ART-TREATED INDIVIDUALS**
5:00**Alessandra Noto, Francesco Procopio, Jean-Marc Corpataux, Giuseppe Pantaleo****156 MAJORITY OF THE LATENT RESERVOIR RESIDES IN CD32A NEGATIVE CD4 T CELLS**
5:15**Lynn N. Bertagnolli, Jennifer White, Subul A. Beg, Gregory Laird, Francesco R. Simonetti, Jun Lai, Costin Tomescu, Alexandra J. Murray, Annukka Antar, Hao Zhang, Joseph B. Margolick, Luis Montaner, Robert Siliciano, Janet Siliciano****157 CD32 DOES NOT MARK THE HIV-1/SIV LATENT RESERVOIR**
5:30**Christa E. Osuna, Richard Apps, So-Yon Lim, Jessica L. Kublin, Rasmie Thomas, Yanqin Ren, Nathaniel D. Bachtel, Margaret Ackerman, Jintanat Ananworanich, Dan Barouch, Nelson L. Michael, R. Brad Jones, Douglas Nixon, James Whitney, for the BELIEVE study****158 CD32+ CD4+ T CELLS ARE HIV TRANSCRIPTIONALLY ACTIVE RATHER THAN A RESTING RESERVOIR**
5:45**Mohamed Abdel-Mohsen, Costin Tomescu, Surya Vadrevu, Adam M. Spivak, Leticia Kuri-Cervantes, Guoxin Wu, Kara Cox, María J. Buzón, Michael R. Betts, Vicente Planelles, Karam Mounzer, Bonnie J. Howell, Daria Hazuda, Pablo Tebas, Luis Montaner**

Symposium S-8 ART: THE NEXT 25 YEARS
Ballroom B

CME

4:00 PM – 6:00 PM

This session is dedicated to the memory of Dr. Mark Wainberg

Target Audience: This session is directed to clinicians and scientists who are interested in understanding advances in antiretroviral therapy.

Level of Knowledge: It is assumed that the participants are familiar with the basic principles of antiretroviral therapy in clinical practice.

Objectives: At the completion of the session, participants will be able to:

- Integrate new antiretroviral therapy into clinical practice
- Identify challenges and opportunities for new antiretroviral therapy in children
- Describe new generic antiretrovirals that are entering care in Sub-Saharan Africa

Conveners

Eric Arts, Western University, London, Ontario, Canada



Marta Boffito, Chelsea and Westminster NHS Foundation Trust, London, United Kingdom

159 INTEGRATING NEW ANTIRETROVIRAL THERAPIES

4:00

Chloe Orkin, Barts Health NHS Trust, London, UK


160 BROADLY NEUTRALIZING ANTIBODIES FOR HIV PREVENTION AND TREATMENT: DREAM OR PIPE DREAM?

4:30

Daniel R. Kuritzkes, Brigham and Women's Hospital, Boston, MA, USA


161 ANTIRETROVIRAL THERAPY IN CHILDREN: PRESENT CHALLENGES, FUTURE OPPORTUNITIES

5:00

Helena Rabie, Stellenbosch University, Cape Town, South Africa


162 TRANSITIONING TO NEW GENERIC ANTIRETROVIRALS IN SUB-SAHARAN AFRICA

5:30

Tendani Gaolathe, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana



**Symposium S-9 EMERGING PRIORITIES IN LIVER DISEASE
Ballroom C**
CME**4:00 PM – 6:00 PM**

Target Audience: This session is directed to clinicians and scientists interested in the management of hepatitis C virus (HCV) and hepatitis C virus (HBV) infections.

Level of Knowledge: It is assumed that participants are familiar with the general principles of HCV and HBV prevention and management.

Objectives: At the completion of the session, participants will be able to:

- Recognize the impact of the opioid epidemic on the spread of infectious diseases
- Compare the opportunities and challenges in the plans to eliminate HCV by 2030
- Recognize the rising epidemic of liver cancer and compare the impacts of HBV and HCV
- Describe the benefits and risks of transplanting organs infected with HIV or HCV

Conveners

Benjamin Linas, *Boston University Medical Center,
Boston, MA, USA*



Gail Matthews, *Kirby Institute, Sydney, Australia*

**163 THE OPIOID EPIDEMIC AND INFECTIOUS DISEASES:
A PUBLIC HEALTH CRISIS**

4:00

Sally Hodder, *West Virginia Clinical and Translational Science Institute, Morgantown, WV, USA*



164 GLOBAL ELIMINATION OF HEPATITIS C

4:30

Jordan Feld, *Toronto General Hospital, Toronto, ON, Canada*



165 THE RISING CHALLENGE OF LIVER CANCER

5:00

Massimo Colombo, *University of Milan, Milan, Italy*



**166 EXPANDING HOPE: ORGAN TRANSPLANTS FROM
DONORS WITH HIV OR HCV INFECTION**

5:30

Christine Durand, *Johns Hopkins Hospital, Baltimore, MD, USA*



POSTER SESSIONS BY DAY

MONDAY, MARCH 5, 2018

Poster P-A1 MOLECULAR VIROLOGY

Poster Hall A

2:30 PM – 4:00 PM

167 RHESUS PRIMARY CELL IN VITRO SHIV INFECTION ASSAY CORRELATES WITH IN VIVO REPLICATION

Adrienne E. Swanstrom, Sean O'Brien, Paul Bieniasz, Theodora Hatzioannou, Mario Roederer, Brandon Keele, Gregory Q. Del Prete, Jeffrey D. Lifson

168 FIRST REPORT OF A SUBTYPE B CONTAINING HIV-1 RECOMBINANT OF SUB-SAHARAN AFRICA ORIGIN

Gustavo Kijak, **Erik Billings**, Eric Sanders-Buell, Anne Marie O'Sullivan, Nicaise Ndembu, Sylvia Adebajo, Afoke Kokogho, Mark Milazzo, Merlin L. Robb, Nelson L. Michael, Sodsai Tovanabutra, Man Charurat, Trevor Crowell, Julie Ake, for the MHRP Viral Sequencing Core and the TRUST/RV368 Study Group

169 PHYLOGENETIC CLUSTERS OF HIV-1 REVEAL POTENTIAL VIRAL GENETIC IMPACT ON COMORBIDITIES

Katharina Kusejko, Dominique L. Braun, Manuel Battegay, Enos Bernasconi, Alexandra Calmy, Matthias Cavassini, Matthias Hoffmann, Jürg Böni, Sabine Yerly, Thomas Klimkait, Matthieu Perreau, Andri Rauch, Roger Kouyos, Huldrych F. Günthard, for the Swiss HIV Cohort Study

170 IS FITNESS RESPONSIBLE FOR POORER ART RESPONSE IN HIV-1 SUBTYPE F INFECTED PATIENTS?

Eva Poveda, Dane Winner, Samira Jousset, Berta Pernas, Marta Grandal, Antonio Aguilera, Angeles Castro, Alvaro Mena, Miguel E. Quinones-Nateu

171 DETECTION OF ANTI-ASP ANTIBODIES IN SERA OF HIV+ INDIVIDUALS

Antonio Mancarella, Elisa De Crignis, Giampietro Corradin, Craig Fenwick, Matthieu Perreau, Giuseppe Pantaleo, Cecilia Graziosi

172 STO-609 INHIBITS P24 RELEASE FROM GAG-EXPRESSING CELLS

Antonio Valentin, **Sue Crawford**

173 PROGRESS IN DEVELOPING HIGHLY POTENT SECOND-GENERATION MATURATION INHIBITORS

Phuong Pham, Emiko Urano, Sherimay Ablan, Justin A. Kaplan, T.J. Nitz, David E. Martin, Carl Wild, Ritu Gaur, Eric O. Freed

174 THE VIROME OF A NEW WORLD PRIMATE UNVEils A RETROVIRUS THAT CAUSES IMMUNOSUPPRESSION

Cláudia Priscila Ramos Muniz, Dawn M. Dudley, Liliane T. Cavalcante, Gislaine Curty, Stefanie V. Santos, Alcides Pissinatti, David H. O'Connor, Marcelo Alves Soares, André Felipe Andrade dos Santos

175LB PRIMER ID SEQUENCING TO STUDY THE DEVELOPMENT OF CXCR4-USING HIV-1 VARIANTS

Shuntai Zhou, Ean Spielvogel, Sabrina Clark, Adaora Adimora, Catalina Ramirez, Andrew Edmonds, Igbo Ofoetokun, Seble Kassaye, Margaret Fischl, Stephen J. Gange, Alan Landay, Maria Villacres, Jack DeHovitz, Kathryn Anastos, Ronald Swanstrom

Poster P-B1 HIV TRANSMISSION AND DISEASE PROGRESSION**Poster Hall A****2:30 PM – 4:00 PM****203 HSV-1/HSV-2 INFECTION IN MACAQUES AND REACTIVATION AFTER EXPOSURE TO HETEROLOGOUS HSV**

Priya Srinivasan, Jining Zhang, Clare Burn, Tyana Singletary, Dawn Little, Lara Pereira, Pedro Mesquita, Betsy Herold, **James M. Smith**

204 ASSESSING BIOLOGIC RISK FOR HIV TRANSMISSION IN TRANSGENDER WOMEN

Alexandra Schuetz, Carlo Sacdalan, Nisakorn Ratnaratorn, Yuwadee Phuang-Ngern, Eugène Kroon, Rungsun Rerknimitr, Suthat Chottanapund, Denise C. Hsu, Tanyaporn Wansom, Nelson L. Michael, Merlin L. Robb, Robert J. O'Connell, Jintanat Ananworanich, **Sandhya Vasan**, for the RV304 Study Group

205 RACIAL DIFFERENCES IN A4B7 EXPRESSION OF THE CCR6+ SUBSET OF CD4+ T CELLS

Alyssa R. Martin, Aida Sivro, Zoe Packman, Livia R. Goes, Lyle McKinnon, Jacquie Astemborski, Gregory D. Kirk, Shruti H. Mehta, Claudia Cicala, James Arthos, Andrew D. Redd, Anthony S. Fauci, Thomas C. Quinn

206 5'UTR SNP RS111686073 MODIFIES EXPRESSION OF TAPASIN IN BLACKS

Victoria E. Walker-Sperling, Veron Ramsuran, Vivek Naranbhai, Maureen Martin, Hongchuan Li, Stephen K. Anderson, Louis-Marie Yindom, Sarah Rowland-Jones, Krista Dong, Thumbi Ndungú, Bruce D. Walker, Mary Carrington

207 CELL RECRUITMENT EVENTS DURING THE MENSTRUAL CYCLE ASSOCIATE WITH SHIV SUSCEPTIBILITY

Alison S. Kohlmeier, Ivana Massud, Susan Ruone, Mian-er Cong, James Mitchell, Frank Deyoungs, Gerardo Garcia-Lerma

208 DETERMINANTS OF SUBOPTIMAL IMMUNOLOGICAL RESPONSE AFTER ART INITIATION IN ACUTE HIV

Ryan C. Handoko, Donn Colby, Eugène Kroon, Mark de Souza, Suteeraporn Pinyakorn, Peeriya Prueksakaew, Jennifer Chiarella, Shelly J. Krebs, Irini Sereti, Victor Valcour, Nelson L. Michael, Nittaya Phanuphak, Jintanat Ananworanich, Serena S. Spudich, for the SEARCH 010/RV254 Study Team

209 CD4 INCREASE <100 CELLS/MM³ DURING 2 YEARS OF ART IS ASSOCIATED WITH WORSE OUTCOMES

Sol Aldrete, Kirk A. Easley, Jeong H. Jang, Tian Dai, Yi No Chen, Jason Okulicz, Brian K. Agan, Mirko Paiardini, Vincent C. Marconi

210 EFFECTS OF LONG-TERM ART ON SIVAGMSAB-INFECTED PIGTAILED MACAQUES

Benjamin Pollicchio, **Paola Sette**, Ranjit Sivanandham, Cui Ling Xu, Tianyu He, Egidio Brocca-Cofano, Kevin D. Raehtz, Ellen P. Penn, Tammy Dunsmore, George S. Haret-Richter, Russell Tracy, Cara Wilson, Alan Landay, Cristian Apetrei, Ivona Pandrea

211 EFFECTS OF SUBCLINICAL CMV REPLICATION ON T-CELL ACTIVATION DURING EARLY ART

Aaron Christensen-Quick, Marta Massanella, Andrew Frick, Celsa A. Spina, Milenka Vargas, Masato Nakazawa, Christy M. Anderson, Sara Gianella

- 212 SPECT/CT IMAGING OF CD4-POOL SUGGESTS A NOVEL CORRELATE OF BENIGN DISEASE PROGRESSION**
 Sharat Srinivasula, Jorge Carrasquillo, Insook Kim, Chang Paik, H. Clifford Lane, **Michele Di Mascio**
- 213 INFLAMMATORY MONOCYTES CONTRIBUTE TO IMPAIRED INFLUENZA VACCINE RESPONSES IN AGING**
 Varghese George, Suresh Pallikkuth, Rajendra Pahwa, Lesley R. de Armas, Stefano Rinaldi, Margaret Roach, Li Pan, Maria F. Pallin, Celeste Sanchez, Margaret Fischl, Gordon Dickinson, Allan Rodriguez, Maria L. Alcaide, **Savita Pahwa**
- 214 TRANSCRIPTOME PROFILING AND DATA MINING: PREDICTIVE GENES OF HIV DISEASE PROGRESSION**
Francisco Diez Fuertes, Esther Calonge, Maria Pernas, Humberto Erick De La Torre Tarazona, Isabelle Casademont, Anavaj Sakuntabhai, José Alcamí Pertejo
- 215 CD4 T CELL DEPLETION IN PRIMATES IS ASSOCIATED WITH LOSS OF INNATE LYMPHOID CELLS**
Joseph Mudd, Kathleen Busman-Sahay, Sarah DiNapoli, Stephen Lai, Virginia Sheikh, Andrea Lisco, Claire Deleage, Brian Richardson, David J. Palesch, Mirko Paiardini, Mark Cameron, Irini Sereti, R. Keith Reeves, Jacob D. Estes, Jason Brenchley

Poster P-C3 NEUTRALIZING ANTIBODIES**Poster Hall A****2:30 PM – 4:00 PM**

- 288 CHARACTERIZATION OF THE NEUTRALIZING ANTIBODY RESPONSE IN A LINKED HIV SUPERINFECTION**
 Deogratius Ssemwanga, Nicole Doria-Rose, **Andrew D. Redd**, Andrea R. Shiakolas, Andrew Longosz, Rebecca N. Nsubuga, Gershim Asiki, Janet Seeley, Amy Ransier, Sam Darko, Daniel Douek, Stephen Porcella, Thomas C. Quinn, John R. Mascola, Pontiano Kaleebu
- 289 BROAD SPECTRUM OF NEUTRALIZATION-ENHANCEMENT BY NOVEL CD4MIMIC COMPOUND YIR-821**
 Shokichi Takahama, Kazuki Tanaka, Hasan Zahid, Alam Muntasir, Takeo Kuwata, Ami Masuda, Kohei Takahashi, Takuya Kobayakawa, Takuya Yamamoto, Tomoyuki Miura, Liye He, Hirokazu Tamamura, Shilei Ding, Andrés Finzi, **Shuzo Matsushita**
- 290 A 2-DIMENSIONAL APPROACH TO ANALYZING BROADLY NEUTRALIZING ANTIBODY COMBINATIONS**
Nicholas E. Webb, Colin M. Sevaried, Nicole Tobin, Grace M. Aldrovandi
- 291 OPTIMIZING HIV-1 VIRUS TEST PANELS FOR EFFECTIVE DETECTION OF NEUTRALIZATION BREADTH**
 Claus Kadelka, Peter Rusert, Roger Kouyos, Huldrych F. Günthard, Alexandra Trkola, for the Swiss HIV Cohort Study
- 292 HIV RECEPTOR USAGE IMPACTS SENSITIVITY TO V1-V3 LOOP BROADLY NEUTRALIZING ANTIBODIES**
Ludy Registre, Yvetane Moreau, Sila Ataca, Manish Sagar
- 293 USE OF PROMISCUOUS GLYCAN AT V3 REGION CORRELATES WITH ELITE NEUTRALIZATION RESPONSE**
Nandagopal Paneerselvam, Jayantha Bhattacharya, Aylur K. Srikrishnan, Rajat Goyal, Chinnambedu Ravichandran Swathirajan, Shilpa Patil, Shanmugam Saravanan, Suprit Deshpande, R Vignesh, Sunil S. Solomon, Nikhil Singla, Joyeeta Mukherjee, Kailapuri G. Murugavel

- 294 ENV STRUCTURE IS EVOLVING AT DIFFERENT RATES IN DIVERSE CLADES OF HIV-1**
Raghavendranath Kandula, Hagit Hodis, Yunxia O'Malley, Kallin Khan, Hillel Haim
- 295 OPENPRIMER, A PRIMER DESIGN TOOL FOR AMPLIFYING B CELL CDNA ENCODING HUMAN ANTIBODIES**
Matthias Döring, Christoph Kreer, Nathalie Lehnert, Nico Pfeifer, Florian Klein
- 296LB STRUCTURE-GUIDED IMPROVEMENT OF HIV-1 BROADLY NEUTRALIZING ANTIBODIES**
Qingbo Liu, Yen-Ting Lai, Peng Zhang, Peter D. Kwong, Paolo Lusso

Poster P-C4 NON-NEUTRALIZING ANTIBODIES**Poster Hall A****2:30 PM – 4:00 PM**

- 297 THE CODEVELOPMENT OF ANTIBODY GLYCOSYLATION AND FUNCTIONALITY IN HIV INFECTION**
Madeleine Jennewein, Jennifer Mabuka, Bruce D. Walker, Thumbi Ndungú, Galit Alter
- 298 GP41–SPECIFIC ANTIBODIES MEDIATE POTENT ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY**
Megan M. Stumpf, Katherine L. Williams, Nicole Naiman, Meghan Garrett, Nitya Ramadoss, Peter Kim, Julie Overbaugh
- 299 DISSECTING THE PHENOTYPE AND TRANSCRIPTOME OF IGG3+ B CELLS**
Saheli Sadanand, Wen-Han Yu, Dario Garcia-Dominguez, Galit Alter
- 300 DEFINING CORRELATES OF ANTIBODY-POLYFUNCTIONALITY IN RV144 VACCINEES**
Stephanie Fischinger, Todd J. Suscovich, Hendrik Streeck, Galit Alter
- 301 DEFINING CORRELATES OF HUMORAL IMMUNE PROTECTION AGAINST EBV**
Christina B. Karsten, Sally A. Shin, Howard M. Heller, Kumaran Kolandaivelu, Jaap M. Middeldorp, Bruce D. Walker, Boris Julg, Galit Alter
- 302 LEVERAGING NEUTROPHILS TO CONTROL HIV VIA IGA**
Nickita Mehta, Magdalena Sips, Jishnu Das, Marina Krykbaeva, Anne-Sophie Dugast, Fernanda Cerqueira, Galit Alter

Poster P-D01 MECHANISMS OF HIV LATENCY AND ITS REVERSAL**Poster Hall A****2:30 PM – 4:00 PM**

- 320 TRANSCRIPTIONAL BLOCKS UNDERLYING HIV LATENCY DIFFER BETWEEN GUT AND BLOOD IN VIVO**
Sushama Telwatte, Sulgi Lee, Ma Somsouk, Hiroyu Hatano, Christopher Baker, Peggy Kim, Tsui-Hua Chen, Jeffery Milush, Peter W. Hunt, Steven G. Deeks, Joseph K. Wong, Steven A. Yerubin
- 321 PATTERN RECOGNITION RECEPTOR AGONISTS INDUCE HIV IN ART SUPPRESSED HIV+ DONOR CELLS**
Jasmine Kaur, Angela Tsai, George Kukolj, Tomas Cihlar, Jeffrey Murry
- 322 TRANSCRIPTIONAL REPROGRAMMING IN CCR5+ MEMORY CD4+ T CELLS PROMOTES HIV-1 LATENCY**
Liang Shan, Kai Deng, Adam Capoferra, Robert Siliciano

- 323 LTR METHYLATION AND RESIDUAL VIREMIA IN INDIVIDUALS ON SUPPRESSIVE ART**
César N. Cortés-Rubio, Santiago Avila-Rios, Gonzalo Salgado-Montes de Oca, Margarita Matías-Florentino, Christopher E. Ormsby, Ana P. Carranco-Arenas, Gustavo Reyes-Terán
- 324 SYNTHETIC INGENOLS MAXIMIZE PROTEIN KINASE C-INDUCED HIV-1 LATENCY REVERSAL**
Adam M. Spivak, Racheal Nell, Paul Sebahar, Mark Petersen, Ryan Looper, Vicente Planelles
- 325 EXOSOMAL TAT REACTIVATES LATENT HIV-1**
Xiaoli Tang, Huafei Lu, Stacey Chapman, Bharat Ramratnam
- 326 SINGLE-CELL TRANSCRIPTOMICS TO EVALUATE HIV LATENCY ESTABLISHMENT IN CD4 T CELLS**
Lesley R. de Armas, Kyle Russell, Sion Williams, Robert K. Suter, Stefano Rinaldi, Li Pan, Suresh Pallikkuth, Rajendra Pahwa, Ramzi T. Younis, Savita Pahwa
- 327 BCL6 INHIBITION REPRESSES THF/NON-TFH HIV INFECTION AND T-CELL/MYELOID ACTIVATION**
Yanhui Cai, Mohamed Abdel-Mohsen, Costin Tomescu, Matthew Fair, Livio Azzoni, Emmanouil Papasavvas, Fengtian Xue, Jie Sun, Neil D. Romberg, Carole Le Coz, Luis Montaner
- 328 IDENTIFICATION OF SMALL MOLECULES THAT INHIBIT REACTIVATION OF LATENT HIV-1**
Benni S. Vargas, Feng Han, Nicholas S. Giacobbi, Phalguni Gupta, Nicolas Sluis-Cremer
- 329 CONTRIBUTION OF lncRNAs IN ESTABLISHMENT OF HIV LATENCY IN CENTRAL MEMORY CD4 T CELLS**
Wim Trypsteen, Cory White, Alberto Bosque, Pieter Mestdagh, Steve Lefever, Celsa A. Spina, Linos Vandekerckhove, Nadejda Beliakova-Bethell
- 330 TRANSLATION EFFICIENCY LIMITS HIV-1 LATENCY REVERSAL**
Phillip Tomezsko, Daniel R. Kuritzkes, Silvi Rouskin, Athé Tsibris
- 331 LRA TREATMENT ALTERS ANTIGEN PROCESSING AND PEPTIDE PRESENTATION IN CD4 T CELLS**
Julie Boucau, Alvaro Sanchez Bernabeu, Sylvie Le Gall
- 332 SPONTANEOUS REACTIVATION OF LATENT HIV-1 PROMOTERS IS LINKED TO THE CELL CYCLE**
Yik Lim Kok, Stefan Schmutz, Anne Inderbitzin, Kathrin Neumann, Audrey Kelley, Lisa Jörimann, Mohamed Shilaih, Valentina Vongrad, Roger Kouyos, Huldrych F. Günthard, Christian Berens, Karin Metzner
- 333 CYTOSINE METHYLATION OF THE HIV LTR WHEN STARTING ART IN ACUTE VS CHRONIC INFECTION**
Sarah LaMere, Sara Gianella, Antoine Chaillon, Christina Huynh, Susan J. Little, Davey M. Smith

Poster P-D02 INSIGHTS FROM HIV REBOUND**Poster Hall A****2:30 PM – 4:00 PM**

- 334 IMPACT OF TREATMENT INTERRUPTION ON HIV RESERVOIRS AND IMMUNOLOGIC PARAMETERS**
Katherine Clarridge, Jana Blazkova, Kevin Einkauf, Marissa Hand, Mary Petrone, Eric Refsland, Jesse Justement, Victoria Shi, Erin Huiting, Catherine Seamon, Susan Moir, Michael Sneller, Mathias Lichterfeld, Tae-Wook Chun

335 SHORT-TERM ART INTERRUPTION HAS LITTLE EFFECT ON LEVELS OF INTEGRATED PROVIRAL DNA

Zachary Strongin, Radwa Sharaf, Jake VanBelzen, Jeffrey Jacobson, Elizabeth Connick, Paul Volberding, Daniel Skiest, Rajesh T. Gandhi, Daniel R. Kuritzkes, Una O'Doherty, Jonathan Z. Li

336 HIV REBOUND DRIVEN BY RARE SUPERSPREADING CD4+ T CELL LINEAGES

Jason M. Hataye, Joseph P. Casazza, David R. Ambrozak, Katharine Best, C.J. Liang, Sam Darko, Amy R. Henry, Farida Laboune, Taina T. Immonen, Frank Maldarelli, Takuya Yamamoto, Daniel Douek, Brandon Keele, Alan S. Perelson, Richard A. Koup

337 HIV-1 VIRAL REBOUND AND SAFETY OUTCOMES OF POSTPARTUM TREATMENT INTERRUPTION IN WOMEN

Catherine N. Le, Paula Britto, Sean Brummel, Risa M. Hoffman, Patricia M. Flynn, Taha E. Taha, Anne Coletti, Mary Glenn Fowler, Karin L. Klingman, James A. McIntyre, Jonathan Z. Li, Judith S. Currier

338 A5340: BRIEF ATI DOES NOT ALTER THE SIZE OR COMPOSITION OF THE LATENT HIV-1 RESERVOIR

Katharine J. Bar, D. B. Salantes, Yu Zheng, Felicity Mampe, Subul A. Beg, Jun Lai, Randall Tressler, Richard A. Koup, James A. Hoxie, Mohamed Abdel-Mohsen, Edgar T. Overton, Robert Siliciano, Janet Siliciano, Pablo Tebas, for the ACTG A5340 Clinical Trial Team

Poster P-D03 HIV RESERVOIRS IN ACUTE INFECTION**Poster Hall A**

2:30 PM – 4:00 PM

339 HIV RESERVOIR ESTABLISHMENT DURING HYPERACUTE CLADE C INFECTION

Guinevere Q. Lee, Kavidha Reddy, Kevin Einkauf, Kamini Gounder, Krista Dong, Bruce D. Walker, Xu G. Yu, Thumbi Ndungú, Mathias Lichtenfeld

340 MOLECULAR PROFILE OF HIV-1 RESERVOIRS IN EARLY-TREATED INFANTS FROM BOTSWANA

Pilar Garcia Broncano, Kevin Einkauf, Ce Gao, Guinevere Q. Lee, Kenneth Maswabi, Gbolahan Ajibola, Sikhulile Moyo, Terence Mohammed, Thabani Ncube, Joseph Makhema, Kathleen M. Powis, Xu G. Yu, Daniel R. Kuritzkes, Roger L. Shapiro, Mathias Lichtenfeld

341 HIV RNA PERSISTS LONG-TERM IN LYMPH NODES OF INDIVIDUALS INITIATED ON ART IN FIEBIG I

Omolara Baiyegunhi, Funsho Ogunshola, Nasreen Ismail, Krista Dong, Bruce D. Walker, Thumbi Ndungú, Zaza Ndhlovu

342 THE HIV RESERVOIR DURING EARLY ANTIRETROVIRAL THERAPY AND MARAVIROC INTENSIFICATION

Antoine Chaillon, Sara Gianella, Steven Lada, Maile Karris, Douglas D. Richman, Sanjay R. Mehta, Susan J. Little, Joel O. Wertheim, Davey M. Smith

343 HIV SEROLOGY FOLLOWING TREATMENT INTERRUPTION IN VERY EARLY TREATED PEOPLE

Rapee Trichavaroj, Supanit Pattanachaiwit, Sasiwimol Ubolyam, Panadda Sawangsint, Jintana Intasan, Eugène Kroon, Donn Colby, Robert J. O'Connell, Sandhya Vasan, Praphan Phanuphak, Nittaya Phanuphak, Jintanat Ananworanich, Mark de Souza, Siriwat Akapirat, for the SEARCH019/RV409 & SEARCH022/RV411 Study Groups

Poster P-D04 IMPACT OF ANTIRETROVIRAL THERAPY ON HIV/SIV RESERVOIRS**Poster Hall A****2:30 PM – 4:00 PM**

- 344 REEVALUATING SIGNALS OF VIRAL REPLICATION & EVOLUTION IN LYMPHOID TISSUE DURING ART**
Daniel S. Rosenbloom, Alison L. Hill, Sarah B. Laskey, Robert Siliciano
- 345 MONITORING THE IMPACT OF ART MODIFICATION WITH LONGITUDINAL FDG-PET IN SIV-MODEL**
Sanhita Sinharay, Sharat Srinivasula, William T. Schreiber-Stainthorp, Swati Shah, Paula DeGrange, Andrew Bonvillain, Jing Wang, Lori E. Dodd, H. Clifford Lane, Dima A. Hammoud, Michele Di Mascio
- 346 SPREAD OF HIV-DNA IN CD4+ T-CELL SUBSETS DEPENDS ON ART INITIATION TIMING**
Pierre Gantner, Cindy Barnig, Marialuisa Partisani, Geneviève Beck-Wirth, Jean-Pierre Faller, Martin Martinot, Mahsa Mohseni-Zadeh, Christine Cheneau, Marie-Laure Batard, Patricia Fischer, Béatrice Uring-Lambert, Siamak Bahram, David Rey, Samira Fafi-Kremer
- 347 RAPID DECAY OF HIV PERSISTENCE MARKERS IN ACUTELY ART-TREATED INDIVIDUALS IN PERU**
Marta Massanella, Rachel A. Bender Ignacio, Javier R. Lama, Amelie Pagliuzza, Ricardo Alfaro, Jessica Rios, Carmela Ganoza, Delia Pinto-Santini, Trupti I. Gilada, Ann Duerr, Nicolas Chomont, for the MERLIN study group

Poster P-E1 NEUROCOGNITIVE CORRELATES, INCLUDING ANTIRETROVIRAL THERAPY AND VASCULAR DISEASE**Poster Hall A****2:30 PM – 4:00 PM**

- 400 CLASSIFYING COGNITIVE STATUS IN HIV-INFECTED MEN BY MULTIVARIATE NORMATIVE COMPARISON**
Zheng Wang, Yu Cheng, Samantha A. Molsberry, Lawrence Kingsley, Andrew Levine, Eileen Martin, Eric N. Miller, Cynthia Munro, Ann B. Ragin, Ned Sacktor, Eric C. Seaberg, James T. Becker, for the Neuropsychology Working Group of the Multicenter AIDS Cohort Study
- 401 USE OF NON-ANTIRETROVIRAL MEDICATIONS THAT MAY IMPACT NEUROCOGNITION**
Kendra K. Radtke, Peter Bacchetti, Leah H. Rubin, Kathryn Anastos, Howard Crystal, Daniel Merenstein, Roksana Karim, Kathleen M. Weber, Andrew Edmonds, Anandi N. Sheth, Margaret Fischl, David Vance, Ruth Greenblatt
- 402 BRAIN NEUROTRANSMITTER GENOMICS AND EFAVIRENZ CENTRAL NERVOUS SYSTEM (CNS) EFFECTS**
David Haas, Yuki Bradford, Anurag Verma, Shefali S. Verma, Sarah A. Pendergrass, Joseph J. Eron, Roy M. Gulick, Sharon Riddler, Paul E. Sax, Thomas Campbell, Eric Daar, Gene D. Morse, Edward P. Acosta, Marylyn D. Ritchie, for the AIDS Clinical Trials Group
- 403LB POORER NEUROCOGNITIVE PERFORMANCE ASSOCIATED WITH CSF HIV DNA DESPITE LONG-TERM ART**
Kevin Robertson, Ronald Bosch, Serena S. Spudich, Rajesh T. Gandhi, Joshua C. Cyktor, Hanna Mar, Bernard J. Macatangay, Christina Lalama, Charles Rinaldo, Ann Collier, Catherine Godfrey, Joseph J. Eron, Deborah McMahon, John W. Mellors, for the ACTG A5321 team

- 404 DETERMINANTS OF COGNITIVE FUNCTION DIFFER IN A EUROPEAN AND A KOREAN COHORT**
Davide De Francesco, Alan Winston, Jun Yong Choi, Rosan van Zoest, Jonathan Underwood, Judith Schouten, Nam Su Ku, Woo Joo Kim, Peter Reiss, Caroline Sabin, for the Comorbidity in Relation to AIDS (COBRA) Collaboration and the Korean NeuroAIDS Project
- 405 HIV SUBTYPE AND RISK OF HIV-ASSOCIATED NEUROCOGNITIVE DISORDER IN RAKAI, UGANDA**
Ned Sacktor, Deanna Saylor, Gertrude Nakigozi, Kate Grabowski, Noeline Nakasujja, Xiangrong Kong, Kevin Robertson, Ronald H. Gray, Maria Wawer
- 406 VITAMIN D IS NOT ASSOCIATED WITH HIV-ASSOCIATED NEUROCOGNITIVE DISORDER IN UGANDA**
Deanna Saylor, Gertrude Nakigozi, Noeline Nakasujja, Kevin Robertson, Ronald H. Gray, Maria Wawer, **Ned Sacktor**
- 407 VACS INDEX PREDICTS SYMPTOMATIC HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS IN UGANDA**
Deanna Saylor, Gertrude Nakigozi, Noeline Nakasujja, Kevin Robertson, Ronald H. Gray, Maria Wawer, **Ned Sacktor**
- 408 NEUROPSYCHOLOGICAL PHENOTYPES IN THE MACS**
Samantha A. Molsberry, Yu Cheng, Lawrence Kingsley, Lisa Jacobson, Andrew Levine, Eileen Martin, Eric N. Miller, Cynthia Munro, Ann B. Ragin, Ned Sacktor, James T. Becker, for the Neuropsychology Working Group of the Multicenter AIDS Cohort Study
- 409 PREVALENCE OF HIV NEUROCOGNITIVE IMPAIRMENT IN A RURAL TANZANIAN COHORT**
Montserrat Sanmartí, Ana-Claire Meyer, Angels Jaen, Kevin Robertson, Nora Tan, Leila Samson, Regina Ndaki, Marcel Tanner, Manuel Battegay, David Dalmau, Emilio Letang
- 410 PREDICTORS OF HIV-RELATED COGNITIVE IMPAIRMENT IN EAST AFRICA**
Benedetta Milanini, Isabel E. Allen, Emmanuel Bahemana, Yakubu Adamu, Francis Kiweewa, Jonah Jonah Maswai, John Owuoth, Christina Polyak, Julie Ake, Victor Valcour, for the AFRICOS study Team
- 411 PLASMA D-DIMER RELATES TO PHYSICAL HEALTH AND MOTOR SKILLS ACROSS THE AGE SPAN IN HIV**
Jessica L. Montoya, Scott L. Letendre, Ronald J. Ellis, Dilip V. Jeste, David J. Moore
- 412 CARDIOVASCULAR RISK FACTORS ASSOCIATED WITH NEUROCOGNITIVE IMPAIRMENT DIFFER BY SEX**
Felicia C. Chow, Kunling Wu, Katherine Tassiopoulos, Baiba Berzins, Kevin Robertson, Babafemi Taiwo
- 413 IMPACT OF DETERMINANTS OF INCREASED VASCULAR RISK ON NEUROCOGNITION IN HIV+ PATIENTS**
Ilaria Mastrorosa, Patrizia Lorenzini, Carmela Pinnelli, Alessandra Vergori, Gabriele Fabbri, Raffaella Libertone, Maria Maddalena Plazzi, Pietro Balestra, Martina Ricottini, Rita Bellagamba, Mauro Zaccarelli, Adriana Ammassari, Stefania Cicalini, Andrea Antinori
- 414 BIOMARKERS OF ENDOTHELIAL ACTIVATION IN HIV-ASSOCIATED ISCHEMIC STROKE**
Susan M. Graham, Susanna Harju-Baker, Junmei Chen, Jennie Le, Dominic W. Chung, Mark M. Wurfel, Yu Ni, Robin M. Nance, Peter W. Hunt, David Tirschwell, Alice S. Ryan, Jeffrey N. Martin, Heidi M. Crane, Jose A. Lopez, W. C. Liles

415 HAND IMPROVEMENT IS ASSOCIATED WITH INCREASED CPE SCORE AFTER ARV INTENSIFICATION

Gilles Force, Idir Ghout, Elodie Bouaziz-Amar, Karim Dorgham, Dhiba Marigot-Outtandy, Didier Troisvallets, Valerie Hahn, Helene Defferriere, Natacha Darchy, Jacques Ropers, Jean-Louis Laplanche, Constance Delaugerre, Gilles Peytavin, Guislaine Carcelain, Pierre de Truchis

416 CROSS-SECTIONAL AND CUMULATIVE LONGITUDINAL CPE SCORES ARE NOT ASSOCIATED WITH HAND

Galia Santos, **Katharine Darling**, Isabella Locatelli, Melanie Metral, Alexandra Calmy, Thanh Doco-Lecompte, Christoph Hauser, Helen Kovari, Philip E. Tarr, Marcel Stoeckle, Caroline Di Benedetto, Patrick Schmid, Renaud Du Pasquier, Matthias Cavassini, for the NAMACO study group

417 EXOSOMAL MICRO-RNA EXPRESSION ASSOCIATES WITH NEUROPSYCHOLOGICAL FUNCTION DURING ART

Tess O'Meara, Yong Kong, Brinda Emu, Kevin Robertson, Richard W. Price, Sarah Yosief, Xinran N. Liu, Rabib Chaudhury, Serena S. Spudich, Lingeng Lu

418 NO CHANGE IN NEUROCOGNITIVE FUNCTION AFTER SWITCHING FROM EFAVIRENZ TO RILPIVIRINE

Giuseppe Lapadula, Davide P. Bernasconi, Francesca Bai, Antonio Di Biagio, Emanuele Focà, Stefano Bonora, Francesco Castelli, Claudio Viscoli, Alessandra Bandera, Antonella D'Arminio Monforte, Andrea Gori, for the The SWEAR Study Group

Poster P-E2 NEUROPSYCHOLOGIC COMPLICATIONS OF HIV INFECTION
Poster Hall A 2:30 PM – 4:00 PM

419 BENEFICIAL EFFECT OF 6 MONTHS OF PROBIOTICS ON ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT

Luigi Celani, Eugenio Nelson Cavallari, Mariangela Fratino, Claudia Pinacchio, Giuseppe Corano Scheri, Gabriella De Girolamo, Giancarlo Ceccarelli, Claudio M. Mastroianni, Carolina Scagnolari, Vincenzo Vullo, Gabriella d'Ettorre

420 LOW DOSE HYDROCORTISONE ENHANCES COGNITIVE FUNCTIONING IN HIV-INFECTED WOMEN

Leah H. Rubin, Luan Phan, Pauline M. Maki

421 ORAL MGBG WITH cART BLOCKS AIDS AND SIVE, AND REDUCES CNS INFECTION AND CAROTID IMT

Jaclyn Mallard, Jamie Schafer, Kevin White, Arianna Noggle, Joseph Enders, Cecily Midkiff, Xavier Alvarez, Tricia H. Burdo, Kenneth C. Williams

Poster P-E3 NEUROCOGNITIVE CORRELATES: TREATMENT STRATEGIES AND ADJUNCTIVE TREATMENT
Poster Hall A 2:30 PM – 4:00 PM

422 DEPRESSION IS COMMON AND ASSOCIATED WITH COGNITIVE FUNCTION IN WELL-TREATED HIV

Åsa Mellgren, Maria Jivegård, Magnus Gisslén

423 DEPRESSION SYMPTOM CHANGES OF HIV-POSITIVE INDIVIDUALS IN THE RAKAI COHORT

Noeline Nakasujja, Gertrude Nakigozi, Deanna Saylor, Kevin Robertson, Ronald H. Gray, Maria Wawer, Ned Sacktor

424 CNS TOXICITY OF DTG IS NOT ASSOCIATED WITH PSYCHIATRIC CONDITIONS OR PLASMA EXPOSURE

Christian Hoffmann, Eva Wolf, Knud Schewe, Michael Sabranski, Hans-Jurgen Stellbrink, Axel Adam, Thomas Buhk, Stefan Hansen, Stefan Fenske, Thomas Brinkmann, Harald Ertl, Jürgen Hartleb, Gerrit Mohrmann, Christian Noah

Poster P-F1 ANTIRETROVIRAL, ANTITUBERCULAR, AND ANTIMALARIAL PHARMACOKINETICS

Poster Hall D

2:30 PM – 4:00 PM

455 EFAVIRENZ PHARMACOKINETICS IN HIV/TB COINFECTED PERSONS RECEIVING RIFAPENTINE

Anthony Podany, Erin Sizemore, Michael Chen, Neil A. Martinson, Rodney Dawson, Sharlaa Badal-Faesen, Sachiko Miyahara, Ekaterina Kurbatova, William C. Whitworth, Richard E. Chaisson, Susan E. Dorman, Payam Nahid, Kelly Dooley, Susan Swindells, for the AIDS Clinical Trials Group & Tuberculosis Trials Consortium A5349 / Study 31 Team

456 EFAVIRENZ PHARMACOKINETICS WITH RIFAMPIN DOUBLE DOSE IN TB-HIV INFECTED PATIENTS

Daniel W. Atwine, Elisabeth Baudin, Thibaut Gelé, Winnie R. Muyindike, Mworozi Kenneth, Racheal Kyohairwe, Kenneth Kananura, Dan Nyehangane, Patrick Orikiriza, Valérie Furlan, Anne-Marie Taburet, Aurélie Barrail-Tran, Maryline Bonnet, for the ANRS12292 Rifaviren study group

457 PHARMACOKINETICS OF EFAVIRENZ 400MG WITH ISONIAZID/RIFAMPICIN IN PEOPLE WITH HIV

Maddalena Cerrone, Xinzhu Wang, Megan Neary, Christine Weaver, Serge Fedele, Isaac Day-Weber, Andrew Owen, Andrew Hill, Myra McClure, Marta Boffito

458 IN SILICO DRUG INTERACTION OF LONG-ACTING RILPIVIRINE AND CABOTEGRAVIR WITH RIFAMPIN

Rajith Kumar Reddy Rajoli, Paul Curley, David Back, Charles W. Flexner, Andrew Owen, Marco Siccardi

459 DOLUTEGRAVIR INTERACTIONS WITH ARTEMETHER-LUMEFANTRINE AND AMODIAQUINE-ARTESUNATE

Stephen I. Walimbwa, Mohammed Lamorde, Catriona Waitt, Julian P. Kaboggoza, Laura Else, Pauline Byakika-Kibwika, Alieu Amara, Joshua Gini, Markus Winterberg, Joel Tarning, Saye Khoo, for the DolACT Research Group

Poster P-F2 PHARMACOLOGIC ASSESSMENT OF ADHERENCE

Poster Hall D

2:30 PM – 4:00 PM

460 TENOFOVIR HIV-1 PLASMA PROPHYLACTIC CONCENTRATION: iPREX, VOICE, PARTNERS META-ANALYSIS

Katarina Vucicevic, Craig W. Hendrix, Robert M. Grant, Connie L. Celum, Jared Baeten, Jeanne Marrazzo, Peter L. Anderson, David Glidden, Radojka M. Savic

461 PERSISTENT LOW-LEVEL VIREMIA IS ASSOCIATED WITH LOW PROTEASE INHIBITOR LEVELS IN HAIR

Alfredo Aguirre, Cyra Christina Mehta, Sophia A. Hussen, Igbo Ofotokun, Ruth Greenblatt, Daniel Merenstein, Angela Kashuba, Kathryn Anastos, Mirjam-Colette Kempf, Elizabeth T. Golub, Jack DeHovitz, Mardge H. Cohen, Sheri Weiser, Anandi N. Sheth

462 EFAVIRENZ LEVEL IN HAIR PREDICTS VIROLOGIC RESPONSE BETTER THAN LEVEL IN BLOOD

Laura Dickinson, Marco Siccardi, Kathryn Anastos, Mardge H. Cohen, Deborah Gustafson, Gerald Sharp, Stephen J. Gange, Seble Kassaye, Peter Bacchetti, **Ruth Greenblatt**, for the Women's Interagency HIV Study

463 PHARMACOLOGIC MEASURES OF PrEP ADHERENCE AMONG HIGH-RISK MSM IN HPTN 067

Jennifer Velloza, Monica Gandhi, Craig W. Hendrix, Peter Bacchetti, Pamela Murnane, James P. Hughes, Maoji Li, Marcel Curlin, Timothy H. Holtz, Sharon Mannheimer, Mark A. Marzinke, K. Rivet Amico, Estelle Piwowar-Manning, Susan H. Eshleman, Robert M. Grant

Poster P-H1 ANTIRETROVIRAL TREATMENT-NAIVE STUDIES

Poster Hall D

2:30 PM – 4:00 PM

489 DRV/R/3TC FDC FOR HIV-1 TREATMENT-NAIVE PATIENTS: WEEK 48 RESULTS OF THE ANDES STUDY

Maria I. Figueroa, Omar G. Sued, Ana M. Gun, Waldo Beloso, Diego M. Cecchini, Gustavo Lopardo, Daniel Pryluka, Maria J. Rolon, Valeria I. Fink, Santiago Perez Lloret, **Pedro Cahn**

490 MORTALITY/MORBIDITY AFTER INITIATING ART WITH CD4 <100 CELLS/UL IN THE REALITY TRIAL

Frank Post, Alexander J. Szubert, Andrew Prendergast, Victoria Johnston, Hermione Lyall, Felicity Fitzgerald, Peter Mugenyi, James G. Hakim, Priscilla Chepkorir, Clara Agutu, Symon Kaunda, Sarah Walker, Diana Gibb, Sarah Pett, for the REALITY trial team

491 SIMILAR EFFICACY & SAFETY BY SUBGROUP IN DRIVE-AHEAD: DOR/3TC/TDF VERSUS EFV/FTC/TDF

Chloe Orkin, Kathleen E. Squires, Jean-Michel Molina, Paul E. Sax, Wing-Wai Wong, Otto Sussmann, Richard Kaplan, Anthony Rodgers, Xia Xu, Gina Lin, Sushma Kumar, George G. Hanna, Carey Hwang, Elizabeth Martin, for the DRIVE-AHEAD Study Group

492 AGE, GENDER, AND RACE ANALYSES OF D/C/F/TAF IN HIV-1 TREATMENT NAÏVE PATIENTS

Bruce Rashbaum, Cheryl McDonald, Cristina Mussini, Christoph D. Spinner, John Jezorowski, Eric Y. Wong, Kimberley Brown

493 DURABILITY OF INITIAL REGIMENS WHEN STARTING ART WITH -200 CD4 AND +5HLOG HIV-RNA

Nicola Gianotti, Patrizia Lorenzini, Alessandro Cozzi-Lepri, Andrea De Luca, Giordano Madeddu, Laura Sighinolfi, Carmela Pinnetti, Carmen Santoro, Paola Meraviglia, Cristina Mussini, Andrea Antinori, Antonella D'Arminio Monforte, for the ICONA Foundation Study Group

Poster P-H2 INTEGRASE STRAND-TRANSFER INHIBITORS: SAFETY, EFFICACY, AND IRIS

Poster Hall D

2:30 PM – 4:00 PM

494 SAFETY PROFILE OF DOLUTEGRAVIR:REAL-LIFE DATA OF LARGE SCALE IMPLEMENTATION IN BRAZIL

Cynthia Julia B. Batista, Mariana V. Meireles, Fernanda F. Fonseca, Ana R. Pati Pascom, Fernanda Rick, Filipe d. Perini, Robério A. Júnior Carneiro, Karim Sakita, Alexsana S. Tresse, Adele Benzaken

495 ARE INTEGRASE INHIBITORS A RISK FACTOR FOR IRIS IN THE ANRS 146 OPTIMAL TRIAL?

Jean-Daniel Lelievre, Lambert Assoumou, Esther Aznar, Federico Pulido, Giuseppe Tambussi, Manuel Crespo, Agnes Meybeck, Jean-Michel Molina, Fanny Cardon, Constance Delaugerre, Rémi Lancar, Lydie Béniguel, Yves Levy, **Dominique Costagliola**, for the the ANRS 146 - GeSIDA 7211 study group

496 Raltegravir-based ART IS EFFECTIVE AND SAFE IN HIV+ LIVER TRANSPLANT RECIPIENTS

Christian Manzardo, Lucia Serrano, Jesús Fortún, Marino Blanes, Montserrat Tuset, Miguel Montejo, Miguel Jiménez, Elisa Cordero, Raquel Lastras, Esteban Ribera, María Luisa Gonzalez-Dieguez, Asunción Moreno, Antoni Rimola, Jose M. Miro, for the FIPSE Cohort Investigators

497 INSTI-BASED INITIAL ART IN A US COHORT OF HIV-INFECTED ADULTS

Stockton Mayer, Nabil Rayeed, Rachel Hart, Richard Novak, Bienvenido Yangco, Frank J. Palella, Benjamin Young, Kate Buchacz

Poster P-H3 ANTIRETROVIRAL SWITCH STUDIES**Poster Hall D****2:30 PM – 4:00 PM****498 IMPACT OF PREVIOUS M184V ON VIROLOGICAL OUTCOME OF SWITCH TO 3TC-BASED DUAL THERAPIES**

Roberta Gagliardini, Arturo Ciccullo, Alberto Borghetti, Franco Maggioli, Dario Bartolozzi, Vanni Borghi, Monica Pecorari, Antonio Di Biagio, Anna Paola Callegaro, Bianca Bruzzone, Francesco Saladini, Stefania Paolucci, Lara Bellazzi, Simona Di Giambenedetto, Andrea De Luca

499 HIV TREATMENT EXPERIENCED PATIENTS SWITCHED TO D/C/F/TAF: AGE, GENDER, RACE ANALYSES

Gregory D. Huhn, Edwin DeJesus, Pierre-Marie Girard, Romana Petrovic, Eric Y. Wong, Kimberley Brown

500 SWITCHING TO BICTEGRAVIR/EMTRACITABINE/TENOFOVIR ALAFENIMIDE (B/F/TAF) IN WOMEN

Cissy Kityo, Debbie Hagins, Ellen Koenig, Anchalee Avihingsanon, Ploenchai Chetchotisakd, Khuanchai Supparatpinyo, Natalya Gankina, Vadim Pokrovsky, Evgeny Voronin, Jeffrey L. Stephens, Edwin DeJesus, Hui Wang, Erin Quirk, Hal Martin, Tariro Makadzange

501 EFFECT OF SWITCHING TO INTEGRASE INHIBITOR ON THE HIV RESERVOIR IN ILEUM BIOPSIES

Sara Moron-Lopez, Victor Urrea, Jordi Navarro, Maria C. Puertas, Ariadna Torrella, Maria Salgado, Cristina Galvez, Bibiana Planas, Linos Vandekerckhove, Julià Blanco, Manuel Crespo, Javier Martinez-Picado

502 ANALYSIS OF HIV PATIENTS SWITCHING TO D/C/F/TAF BY PRIOR ARV TREATMENT EXPERIENCE

Joseph J. Eron, Chloe Orkin, Jean-Michel Molina, Erika Van Landuyt, Erkki Lathouwers, Romana Petrovic, Richard E. Nettles, Kimberley Brown

503 WHO WANTS TO SWITCH? GAUGING INTEREST IN POTENTIAL NEW ANTIRETROVIRAL THERAPIES

Jan Ostermann, Caroline Derrick, Amy Hobbie, Andrew Weinhold, Noor Al-Shareef, Valerie Yelverton, Sharon Weissman, Helmut Albrecht, **Nathan Thielman**

504 SWITCHING TO RPV/FTC/TAF FROM RPV/FTC/TDF OR EFV/FTC/TDF: WEEK 96 RESULTS

Anthony Mills, Cynthia Brinson, Claudia Martorell, Gordon Crofoot, Eric Daar, Olayemi Osiyemi, Bruce Rashbaum, David Shamblaw, Hans-Jurgen Stellbrink, Daniel Podzamczer, Hui Liu, Ya-Pei Liu, Danielle Porter, Sean Collins, Devi SenGupta

505 FACTORS PREDICTING VIROLOGICAL FAILURE DURING DOLUTEGRAVIR MAINTENANCE MONOTHERAPY

Ingeborg Wijting, Sofie L. Rutsaert, Casper Rokx, David M. Burger, Elrozy Andrinopoulou, Linos Vandekerckhove, Bart Rijnders

506 RESISTANCE ANALYSES OF BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE SWITCH STUDIES

Kristen Andreatta, Madeleine Willkom, Ross Martin, Silvia Chang, Hal Martin, Hiba Graham, Erin Quirk, Kirsten L. White

507 IN SILICO CLINICAL TRIALS FOR EVALUATION OF HIV SHORT-CYCLE STRATEGIES

Melanie Prague, Chloé Pasin, Linda Wittkop, Pierre Duffau, Estibaliz Lazaro, Charles Cazanave, Marc Vareil, Fabrice Bonnet, **Rodolphe Thiébaut**

Poster P-K01 HCV DIAGNOSIS AND TESTING

Poster Hall D

2:30 PM – 4:00 PM

576 EFFECTIVENESS OF BEST PRACTICE ALERT AND PROVIDER EDUCATION FOR HEP C SCREENING

Mamta K. Jain, Joanne Sanders, Lisa Quirk, Brian Adamson, Barbara J. Turner, Amit G. Singal

577 CHANGES IN HEPATITIS C VIRUS (HCV) TESTING AWARENESS IN MASSACHUSETTS, 2015-2016

Monina Klevens, Monica Morrison, Liisa Randall, H D. Fukuda, Daniel Church, Shauna Onofrey, Kevin Cranston, Alfred DeMaria

578 LINKAGE TO CARE FOR PREVIOUSLY DIAGNOSED HCV-INFECTED EMERGENCY DEPARTMENT PATIENTS

Yu-Hsiang Hsieh, Anuj Patel, Danielle Signer, Erica Shelton, Jacob Cohen, Mustapha Saheed, David L. Thomas, Richard Rothman

579 VERY LOW HEPATITIS C VIRAL LOADS IN ABSENCE OF THERAPY: IMPACT ON HCV ANTIGEN TESTING

Barbara Bertisch, Matteo Brezzi, Francesco Negro, Beat Muellhaupt, Patrizia Kuenzler-Heule, Patrick Schmid, Olivier Clerc, Alberto Moriggia, Darius Moradpour, **Olivia Keiser**, for the Swiss Hepatitis C Cohort Study

580 EVALUATION OF DBS HCV RNA QUANTIFICATION AND GENOTYPING IN RESOURCE LIMITED SETTINGS

Jayaseelan Boobalan, Thongadi R. Dinesha, Sathasivam Sivamalar, Selvamurthi Gomathi, Rajendran Revathi, Aylur K. Srikrishnan, Amrose Pradeep, Shruti H. Mehta, Sunil S. Solomon, Pachamuthu Balakrishnan, **Shanmugam Saravanan**

Poster P-K02 MOLECULAR EPIDEMIOLOGY OF HCV NETWORKS

Poster Hall D

2:30 PM – 4:00 PM

581 CLUSTERING OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS IN BALTIMORE

Oluwaseun Falade-Nwulia, Shruti H. Mehta, Mark Sulkowski, Carl A. Latkin, David L. Thomas, Zach Downing, Rachel Latanich, Gregory D. Kirk, Rebecca Rose, Stuart C. Ray, Oliver Laeyendecker

- 582 UNRAVELLING HCV1A WHEREABOUTS IDENTIFIES A NEED FOR A PAN-EUROPEAN PREVENTION PROGRAM**
Lize Cuypers, Bram Vrancken, Lavinia Fabeni, Velia C. Di Maio, Milosz Parczewski, Vladimir Chulanov, Perpetua Gomes, Anna Maria Geretti, Christoph Sarrazin, Cillian De Gascun, Saleta Sierra, Federico García, Anne-Mieke Vandamme, Francesca Ceccherini Silberstein
- 583 NS5A RESISTANCE ASSOCIATES WITH ADVANCED LIVER FIBROSIS BUT NOT TRANSMISSION CLUSTERS**
Milosz Parczewski, Ewa Janczewska, Justyna Kordek, Iwona Cielniak, Arkadiusz Pisula, Monika Bociąga-Jasik, Władysław Łojewski, Aleksandra Szymczak, Łukasz Socha, Magdalena Leszczyszyn-Pynka, Anna Urbańska, Ewa Siwak, Nadine Lübke
- 584 GENETIC CORROBORATION OF HCV TRANSMISSION AMONG YOUNG ADULT INJECTING PARTNERSHIPS**
Damien C. Tully, Judith Hahn, David J. Bean, Jennifer Evans, Kimberly Page, Todd M. Allen

Poster P-K03 NEW HCV INFECTIONS**Poster Hall D****2:30 PM – 4:00 PM**

- 585 HCV RNA AND ANTIGEN DETECTION FOR DIAGNOSIS OF ACUTE HEPATITIS C AMONG MSM ON PrEP**
Julien Gras, Nadia Mahjoub, Isabelle Charreau, Laurent Cotte, Cécile Tremblay, Julie Chas, François Raffi, Eric Cua, Brigitte Guillou, Nicolas Guigue, Marie-Laure Chaix Baudier, Laurence Meyer, Jean-Michel Molina, Constance Delaugerre, for the ANRS IPERGAY study group
- 586 ESTIMATING HIV, HCV AND HSV-2 INCIDENCE FROM EMERGENCY DEPARTMENT SEROSURVEYS**
Oliver Laeyendecker, Simon E. Spencer, Louise Dyson, Yu-Hsiang Hsieh, Eshan U. Patel, Richard Rothman, Gabor Kelen, Thomas C. Quinn, T. Deirdre Hollingsworth
- 587 ESTIMATING HIV AND HCV INCIDENCE AMONG PERSONS WHO INJECT DRUGS IN INDIA**
Denali Boon, Sunil S. Solomon, Aylur K. Srikrishnan, Allison M. McFall, Pachamuthu Balakrishnan, Syed Iqbal, Gregory M. Lucas, Oliver Laeyendecker, Thomas C. Quinn, Shruti H. Mehta
- 588 HIV-1 ENHANCES SEXUAL TRANSMISSION OF HEPATITIS C VIRUS BY HUMAN LANGERHANS CELLS**
Bernadien Nijmeijer, Ramin Sarrami Forooshani, Gaby Steba, Richard Molenkamp, Renee Schreurs, Matthijs Siegenbeek van Heukelom, Marc van der Valk, Carla Ribeiro, Teunis Geijtenbeek
- 589 CHANGE IN HIV RISK BEHAVIOR IN PWID ON HCV TREATMENT WITH OR WITHOUT OAT AND PREP**
Sarah Kattakuzhy, Laura Nussdorf, Kristi Hill, Rachel Silk, Chloe Gross, Elizabeth Akoth, Poonam Mathur, Benjamin Emmanuel, Nadeera Sidique, Chloe S. Chaudhury, David Sternberg, Henry Masur, Shyam Kottilil, Elana S. Rosenthal
- 590 HCV INCIDENCE IN HIV-INFECTED AND IN PrEP-USING MSM**
Laurent Cotte, Eric Cua, Jacques Reynes, François Raffi, David Rey, Pierre Delobel, Amandine Gagneux-Brunon, Christine Jacomet, Romain Palich, Hélène Laroche, André Cabié, Bruno Hoen, Christian Chidiac, Pierre Pradat, for the DatAIDS Study Group

- 591 HCV INCIDENCE IS STILL INCREASING IN FRENCH HIV-INFECTED MSM**
Laurent Cotte, Thomas Huleux, François Raffi, Pierre Delobel, Jacques Reynes, Pascal Puglièse, David Rey, Firouze Bani-Sadr, Isabelle Poizot-Martin, André Cabié, Antoine Chéret, Claudine Duvivier, Marc-Antoine Valantin, Pierre Pradat, for the DatAIDS Study Group
- 592 LOW PREVALENCE OF HEPATITIS C VIRUS AMONG NYC MSM INITIATING PrEP AND PEP, 2016-2017**
Tarek Mikati, Kelly Jamison, Christine M. Borges, Demetre C. Daskalakis
- 593 ASSESSING DIFFERENCES IN HISTORIC AND RECENT HIV/HCV COINFECTION IN PHILADELPHIA**
Dana Higgins, Danica Kuncio, Kathleen Brady, Coleman Terrell

Poster P-L1 HIV-ASSOCIATED CANCER: EPIDEMIOLOGY AND OUTCOMES
Poster Hall D **2:30 PM – 4:00 PM**

- 649 HIV AND CANCER RISK IN CONTEXT OF HIGH ART COVERAGE IN BOTSWANA**
Scott Dryden-Peterson, Neo Tapela, Isaac Nkele, Oaitse John, Gita Suneja, Surbhi Grover, Memory Bvochora-Nsingi, Malebogo Pusoentsi, Joseph Makhema, Mompati O. Mmalane, Mukendi Kayembe, Shahin Lockman
- 650 SOUTH AFRICAN HIV CANCER MATCH STUDY: A PILOT STUDY TOWARDS PRECISION PUBLIC HEALTH**
Mazvita Sengayi, Wenlong C. Chen, Adrian Spoerri, Elvira Singh, Matthias Egger, Julia Bohlius
- 651 STILL HIGH RISK OF VIRUS-RELATED CANCER DESPITE 20 YEARS OF cART IN ICONA COHORT**
Pierluca Piselli, Diego Serraino, Alessandra Bandera, Andrea Antinori, Enrico Girardi, Claudia Cimiglia, Alessandro Tavelli, Francesca Bai, Gianmaria Baldin, Andrea Calcagno, Antonella D'Arminio Monforte, Antonella Cingolani, for the Icona Foundation Study Group
- 652 CANCER STAGE, TREATMENT, AND SURVIVAL COMPARING HIV CLINIC ENROLLEES AND SEER**
Keri Calkins, Geetanjali Chander, Corinne Joshu, Anthony T. Fojo, Richard D. Moore, Bryan Lau
- 653 RISK OF NON-AIDS-DEFINING CANCERS AMONG VETERANS WITH WELL-CONTROLLED HIV INFECTION**
Aaron P. Thrift, Kathryn E. Royse, Peter A. Richardson, Suchismita Raychaudhury, Roxanne Desiderio, Donna L. White, Jennifer R. Kramer, Elizabeth Chiao
- 654 TRENDS IN INCIDENCE OF KAPOSI SARCOMA AMONG MALES IN ALL 50 UNITED STATES, 2000-2013**
Aaron P. Thrift, Donna L. White, Harrison Nguyen, Kathryn E. Royse, Jennifer R. Kramer, Elizabeth Chiao
- 655 KNOWLEDGE OF KAPOSI SARCOMA (KS) AND HIV AMONG TRADITIONAL HEALERS IN ZIMBABWE**
Suzanne P. Fiorillo, Francis Jaji, Maxwell Matimba, Thomas Campbell, Margaret Borok

656LB INTERIM SAFETY ANALYSIS OF CITN-12: PEMBROLIZUMAB IN PATIENTS WITH HIV AND CANCER

Thomas S. Uldrick, Priscila H. Gonçalves, Steven Fling, Brinda Emu, Marc S. Ernstooff, Judith Kaiser, Matthew Lindsley, Lisa Lundgren, Kathryn Lurain, Rob Gorelick, Frank Maldarelli, Elad Sharon, Robert Yarchoan, Martin "Mac" A. Cheever

Poster P-M7 DISLIPIDEMIA: MECHANISMS AND INTERVENTIONS

Poster Hall D

2:30 PM – 4:00 PM

703 THE MEDITERRANEAN PORTFOLIO DIET IN HIV DYSLIPIDAEMIA: A RANDOMIZED CONTROLLED TRIAL

Clare Stradling, G N. Thomas, Karla Hemming, Shahrad Taheri, Stephen Taylor, Jonathan Ross, Satyajit Das

704 BIOMARKERS AND GENETICS OF CELL CHOLESTEROL DYSREGULATION IN HIV NONPROGRESSORS

Giovanna Rappocciolo, Diana Campbell DeLucia, Jeremy J. Martinson, Stacy Wendell, Charles Rinaldo, for the Multicenter AIDS Cohort Study (MACS)

705 STATIN USE AND CARDIOVASCULAR DISEASE MITIGATION AMONG PERSONS LIVING WITH HIV

Derek T. Larson, Seung Hyun Won, Anuradha Ganesan, Ryan Maves, Jason Okulicz, Karl Kronmann, Xiuping Chu, Christina Schofield, Thomas O'Bryan, Brian K. Agan, Robert Deiss

706 INCREASED RISK OF LOW ADIPONECTIN AND ATHEROGENIC DYSLIPIDEMIA IN HIV INFECTION

Marco Gelpi, Shoaib Afzal, Ashley Roen, Amanda Mocroft, Anne-Mette Lebech, Birgitte Lindegaard, Klaus F. Kofoed, Børge Nordestgaard, Jens D. Lundgren, Susanne D. Nielsen

707 NON-CLASSICAL MONOCYTE AND CD4/CD8 RATIO PREDICTS ANKLE BRACHIAL INDEX IN TREATED HIV

Dominic Chow, Nattawat Klomjit, Louie M. Gangcuangco, Scott A. Souza, Sean Terada, Lindsay Kohorn, Lishomwa C. Ndhlovu, Cecilia Shikuma

708 MICROBIAL-RELATED METABOLITE TMAO AND CAROTID ARTERY ATHEROSCLEROSIS IN HIV INFECTION

Zhilei Shan, David B. Hanna, Clary Clish, Justin M. Scott, Robert Burk, Sabina Haberlen, Sanjiv J. Shah, Joseph B. Margolick, Wendy Post, Howard Hodis, Alan Landay, Kathryn Anastos, Robert C. Kaplan, Qibin Qi

709 IL-32 ISOFORMS AS NOVEL BIOMARKERS FOR CVD IN HIV-INFECTED INDIVIDUALS

Mohamed El-Far, Sarah M. Zaidan, Carl Chartrand-Lefebvre, Petronela Ancuta, Nicolas Chomont, Etienne Larouche-Anctil, Jean-Pierre Routy, Benoit Trottier, Jean-Guy Baril, Paul MacPherson, Sylvie Trottier, Robert C. Kaplan, Alan Landay, Madeleine Durand, Cécile Tremblay, for the Canadian HIV and Aging Cohort Study

Poster P-M8 CARDIAC AND PULMONARY COMPLICATIONS IN LOW- AND MIDDLE-INCOME SETTINGS

Poster Hall D

2:30 PM – 4:00 PM

710 INTEGRATED VS REFERRED MANAGEMENT OF CVD RISK FACTORS FOR HIV+ PATIENTS IN SWAZILAND

Miriam Rabkin, Anton M. Palma, Margaret McNairy, Samkelo Simelane, Averie B. Gachuhi, Raymond A. Bitchong, Harriet Nuwagaba-Biribonwoha, Pido Bongomin, Velephi Okello, Wafaa M. El-Sadr

711 HIGH PREVALENCE OF HYPERTENSION IN HIV-INFECTED AND HIV-UNINFECTED ADULTS IN BOTSWANA

Mosepele Mosepele, Kara Bennett, Tendani Gaolathe, Joseph Makhema, Mompati O. Mmalane, Molly Pretorius Holme, Refeletswe Lebelonyane, Kathleen M. Powis, Jean Leidner, Joseph N. Jarvis, Neo Tapela, Tiny Masupe, Lucky Mokgatlhe, Kathleen Wirth, Shahin Lockman

712 HYPERTENSION AND DIABETES CONTROL ALONG THE HIV CARE CASCADE IN SOUTH AFRICA

Jennifer Manne-Goehler, Mark J. Siedner, Livia Montana, Guy Harling, Pascal Geldsetzer, Julia K. Rohr, Xavier Gomez-Olive, Alisha Wade, Thomas Gaziano, Kathleen Kahn, Stephen Tollman, Till Bärnighausen

713 PREVALENCE OF NON-COMMUNICABLE DISEASES IN LONG-TERM AIDS SURVIVORS IN HAITI

Samuel Pierre, Vanessa Rivera, Grace Seo, Benedict Charles, Gaetane Julmiste, Alexandra Apollon, Emelyne Dumont, Molene Cadet, Myung Hee Lee, Katey Walsh, Adias Marcelin, Patrice Severe, Daniel Fitzgerald, Jean W. Pape, Margaret McNairy

714 PAN AFRICAN PULMONARY HYPERTENSION COHORT COMPARING RISK AND SURVIVAL OF HIV+/HIV-

Friedrich Thienemann, Vitaris Kodogo, Feriel Azibani, Karen Sliwa, for the Pan African Pulmonary Hypertension Cohort (PAPUCO) Study Group

715 INTEGRATING HYPERTENSION SCREENING AT VOLUNTARY HIV TESTING IN SOUTH AFRICA

Paul K. Drain, Ting Hong, Hilary Thulare, Mahomed-Yunus Moosa, Connie L. Celum

716 SIGNS OF CARDIOVASCULAR DISEASE IN A RURAL AFRICAN POPULATION; DOES HIV PLAY A ROLE?

Alinda Vos, Kerstin Klipstein-Grobusch, Hugo Tempelman, Diederick Grobbee, Roel Coutinho, Walter Devillé, Roos Barth, for the Ndlovu Research Consortium

717 HYPERTENSION AND HIV AS COMORBIDITES IN SOUTH AFRICA: MODELING THE DUAL BURDEN

Brianna Osetinsky, Omar Galarraga, Mark Lurie, Stephen McGarvey, Till Bärnighausen, Sake de Vlas, Jan A. Hontelez

718 CORONARY ARTERY CALCIFICATION IN VIROLOGICALLY SUPPRESSED AGING HIV-INFECTED THAIS

Pairoj Chatranukulchai, Monravee Tumkosit, Sarawut Siwamogsatham, Tanakorn Apornpong, Sivaporn Gatechompol, Akarin Hiransuthikul, Win M. Han, Stephen J. Kerr, Opass Putcharoen, Smonporn Boonyaratavej, Kiat Ruxrungham, Praphan Phanuphak, **Anchalee Avihingsanon**, for the HIV-NAT 006 and HIV-NAT 207 study groups

Poster P-N01 BONE DISEASE**Poster Hall D****2:30 PM – 4:00 PM****719 ARV-NAIVE HIV-INFECTED ADULTS HAD LOWER BONE FORMATION MARKERS THAN HIV-UNINFECTED**

Lalita Wattanachanya, Jureeporn Jantarapakde, **Anchalee Avihingsanon**, Reshmie Ramautarsing, Stephen J. Kerr, Deondara Trachunthong, Thanaporn Mansawat, Kanitta Pussadee, Nipat Teeratakulpisarn, Tanate Jadwattanakul, Tawatchai Chaiwatanarat, Nittaya Phanuphak, Sarat Sunthornyothisin, Praphan Phanuphak, for the TNT 003 and TNT 003.1 study team

720 TDF PROPHYLAXIS FOR PMTCT OF HBV: EFFECT ON MATERNAL AND INFANT BONE MINERAL DENSITY

Nicolas Salvadori, Bo Fan, Waralee Teeyasoontranon, Nicole Ngo-Giang-Huong, Siriluk Phanomcheong, Anita Luvira, Achara Puangsombat, Arunrat Suwannarat, Ussanee Srirompotong, Chaiwat Putiyanun, Athena Kourtis, Marc Bulterys, George K. Siberry, **Gonzague Jourdain**, for the iTAP Study Group

721 OPTION B-PLUS ART, PREGNANCY, LACTATION AND BONE HEALTH IN UGANDAN WOMEN

Florence Nabwire, Ann Prentice, Matthew M. Hamill, Mary G. Fowler, Josaphat Byagumisha, Adeodata Kekitiinwa, Gail R. Goldberg

722 RATES OF BONE LOSS SLOW AFTER THE FIRST YEAR OF ART: START BMD SUBSTUDY FINAL RESULTS

Andrew Carr, Birgit Grund, Ann V. Schwartz, Anchalee Avihingsanon, Sharlaa Badal-Faesen, Jose I. Bernadino, Patrick W. Mallon, Vicente Estrada, Alberto M. La Rosa, Sanjay Pujari, David White, Nicole Wyman Engen, Kristine E. Ensrud, Jennifer Hoy, for the START Bone Mineral Density Substudy Group

723 GREATER BONE TURNOVER MARKER DECLINE WITH ZOLEDRONIC ACID THAN WITH TDF-SWITCHING

Andrew Carr, Robyn Richardson, Stephen J. Kerr, Peter R. Ebeling, Nicholas Pocock, Jhon Rojas, Esteban Martinez, Jennifer Hoy, for the ZeST Study Group

724 COMBINED EFFECTS OF BISPHOSPHONATES & TDF→TAF SWITCH IN HIV+ ADULTS WITH LOW BMD

Todd T. Brown, Michael T. Yin, Samir K. Gupta, William R. Short, Melanie Thompson, Daniel Podzamczer, Giovanni Di Perri, Cheryl McDonald, Matthias Cavassini, Pablo Tebas, Ya-Pei Liu, Scott McCallister, Andrew Cheng, Moupal Das

725 BONE, RENAL, AND INFLAMMATION MARKERS IN THE DOLUTEGRAVIR MONOTHERAPY (DOMONO) STUDY

Ingeborg Wijting, Casper Rokx, Sandra A. Smits, M. C. Zillikens, Theodora de Vries-Sluijs, Karin Schurink, Hannelore Bax, Maarten Derkzen, Elozy Andrinopoulou, Ineke van der Ende, Eric van Gorp, Jan Nouwen, Annelies Verbon, Wouter Bierman, Bart Rijnders

726 OMEGA-3 FATTY ACID SUPPLEMENTATION IN HIV PATIENTS: A RANDOMIZED CLINICAL TRIAL

Juan M. Tiraboschi, Antonio Navarro-Alcaraz, Elena Ferrer, Carmen Gomez-Vaquero, Dolors Giralt, Arkaitz Imaz, Maria Saumoy, Daniel Podzamczer

727 HYPERKYPHOSIS AND AGING IN THE WOMEN'S INTERAGENCY HIV STUDY

Anne M. Ritchie, Wendy B. Katzman, Yifei Ma, Rebecca Scherzer, Mardge H. Cohen, Michael T. Yin, Phyllis Tien

Poster P-N07 FRAILTY AND FUNCTIONAL STATUS

Poster Hall D

2:30 PM – 4:00 PM

755 EFFECTS OF HIV STATUS ON FUNCTIONAL BENEFITS OF EXERCISE IN OLDER SEDENTARY ADULTS

Kristine M. Erlandson, Samantha MaWhinney, Melissa P. Wilson, Lilyana Gross, Sean A. McCandless, Wendy M. Kohrt, Robert Schwartz, Todd T. Brown, Thomas Campbell, Catherine M. Jankowski

756 THE ASSOCIATION OF PAIN AND LONG-TERM OPIOID THERAPY WITH HIV TREATMENT OUTCOMES

Jessica Merlin, Dustin M. Long, William Becker, Edward R. Cachay, Katerina A. Christopoulos, Heidi M. Crane, E. J. Edelman, Richard Harding, Jane Liebschutz, W. C. Mathews, Michael J. Mugavero, Sonia Napravnik, Michael Saag, Joanna Starrels, **Robert Gross**

**Poster P-01 TUBERCULOSIS INCIDENCE, SCREENING, AND DIAGNOSIS
Poster Hall D 2:30 PM – 4:00 PM****766 MOBILITY PREDICTS INCIDENT TB INFECTION IN CHILDREN & ADULTS IN RURAL UGANDA**

Carina Marquez, Atukunda Mucunguzi, Gabriel Chamie, Laura B. Balzer, Joel Kironde, Theodore Ruel, Bridget Nzurubara, Dalsone Kwarisima, Edwin D. Charlebois, Maya L. Petersen, Diane V. Havlir, for the SEARCH Collaboration

767 IMPROVED SENSITIVITY OF A NOVEL RECOMBINANT PROTEIN SKIN TEST FOR THE DIAGNOSIS OF TB

Roberto Badaro, Corey Casper, Rhea Coler, C A. Araujo-Neto, Diana B. Pedral-Sampaio, Maria Nakatani, Antonio Campos Neto, Steven Reed

768 HIV-ASSOCIATED TB IN A LOW BURDEN COUNTRY: IS SCREENING FOR LATENT TB STILL NEEDED?

Enrico Girardi, Alessandro Cozzi-Lepri, Andrea Gori, Annalisa Saracino, Antonio Di Biagio, Giuseppe Lapadula, Giancarlo Orofino, Miriam Lichtner, Sergio Lo Caputo, Andrea Antinori, Antonella D'Arminio Monforte, Cristina Mussini, for the Icona Foundation Study Group

769 A PILOT RCT OF GENEXPERT MTB/RIF ON A MOBILE HIV TESTING UNIT IN SOUTH AFRICA

Ingrid V. Bassett, Leah S. Forman, Sabina Govere, Hilary Thulare, Simone C. Frank, Bright Mhlongo, Elena Losina

770 TRENDS IN HIV- AND SEX-STRATIFIED TUBERCULOSIS CASE NOTIFICATIONS IN BLANTYRE, MALAWI

Marriott Nliwasa, Augustine Choko, Mphatso Mwapasa, Daniel Grint, Peter MacPherson, Elizabeth L. Corbett

771 ROLE OF CHEST X-RAY IN DIAGNOSIS OF HIV-ASSOCIATED SMEAR-NEGATIVE TB IN UGANDA

Lydia Nakiyingi, John Mark Bwanika, Willy Ssengooba, Frank Mubiru, Harriet Mayanja-Kizza, Jerrold Ellner, Susan E. Dorman, Yukari C. Manabe

**Poster P-02 TUBERCULOSIS BIOMARKERS AND INFLAMMATION
Poster Hall D 2:30 PM – 4:00 PM****772 C-REACTIVE PROTEIN TO SCREEN FOR HIV-ASSOCIATED TUBERCULOSIS IN SOUTH AFRICA**

Adrienne E. Shapiro, Ting Hong, Sabina Govere, Dumezweni Ntshangase, Hilary Thulare, Mahomed-Yunus Moosa, Afton Dorasamy, Connie L. Celum, Jacques H. Grosset, Paul K. Drain

773 PLASMA INDOLEAMINE 2,3-DIOXYGENASE, A BIOMARKER FOR TUBERCULOSIS IN HIV INFECTION

Clement G. Adu-Gyamfi, Tracy Snyman, Chris Hoffmann, Neil A. Martinson, Richard E. Chaisson, Jaya A. George, Melinda S. Suchard

774 HIV INFECTION IMPAIRS MYCOBACTERIUM TUBERCULOSIS-SPECIFIC CD4 T-CELL RESPONSES

Patrizia Amelio, Jerry Hella, Klaus Reither, Lujeko Kamwela, Omar Lweno, Anneth Tumbo, Linda Geoffrey, Song Ding, Giuseppe Pantaleo, Claudia Daubenberger, Matthieu Perreau

775 VARIATION IN THE NLRP3 GENE IS ASSOCIATED WITH INFLAMMATION AND MORTALITY IN HIV/TB

Shruthi Ravimohan, Kebatshabile Ngoni, Neo Tamuhla, Caroline Tiemessen, Drew Weissman, Gregory Bisson

776 DECAY OF INFLAMMATION MARKERS IN HIV-1/TB COINFECTED INDIVIDUALS INITIATING ART

Heloise M. Delagreverie, Claire Bauduin, Nathalie De Castro, Beatriz Grinsztejn, Marc Chevrier, Samia Mourah, Issa Kalidi, Jose H. Pilotto, Carlos Brites, Nemora T. Barcellos, Genevieve Chene, Linda Wittkop, Jean-Michel Molina, Constance Delaugerre, for the ANRS study group REFLATE-TB ANRS 12-180

777 ANALYSIS OF PHAGOCYTE FUNCTION IN HIV/TB CO-INFECTION USING A NOVEL WHOLE BLOOD ASSAY

Ankur Gupta-Wright, Dumizulu Tembo, Kondwani C. Jambo, Elizabeth Chimbayo, David G. Russell, Henry Mwandumba

Poster P-03 TUBERCULOSIS TRANSMISSION DYNAMICS, DRUG RESISTANCE, AND TREATMENT ISSUES

Poster Hall D

2:30 PM – 4:00 PM

778 SPATIAL OVERLAP LINKS SEEMINGLY UNCONNECTED GENOTYPE-MATCHED TB CASES IN RURAL UGANDA

Gabriel Chamie, Midori Kato-Maeda, Devy Emperador, Bonnie Wandera, John Crandall, Michael Janes, Carina Marquez, Moses R. Kamya, Edwin D. Charlebois, Diane V. Havlir

779 SPATIAL DISTRIBUTION OF RIFAMPICIN-RESISTANT TB IN WESTERN CAPE, SOUTH AFRICA

Avery McIntosh, Helen E. Jenkins, Laura F. White, Elizabeth J. Ragan, Tania Dolby, John Simpson, Megan B. Murray, Rob Warren, **Karen R. Jacobson**

780 TREATING RIFAMPICIN-RESISTANT TB WITH DELAMANID IN A HIGH HIV PREVALENCE SETTING

Erika K. Mohr, Anja Reuter, Jennifer Hughes, Justine Fargher, Johnny Daniels, Bongani Chabalala, Gabriella Ferlazzo, Virginia de Azevedo, Amir Shroufi, Laura Trivino Duran, Petros Isaakidis

781 PHARMACOKINETICS OF RIFABUTIN 150 MG QD VS 300 MG TIW WITH LPV/R IN HIV/TB PATIENTS

Chris Fujitnirun, Weerawat Manosuthi, Sivaporn Gatechompol, Phornchai Pingsusaen, Narukjaporn Thammajaruk, Angela Colbers, Rob Aarnoutse, Kiat Ruxrungham, David M. Burger, Anchalee Avihingsanon, Opas Putcharoen

782 WIRELESSLY OBSERVED THERAPY VS DIRECTLY OBSERVED THERAPY FOR TB MEDICATION ADHERENCE

Sara H. Browne, Charles A. Peloquin, Amanda J. Tucker, Kathleen Moser, Julie Low, Anya Umlauf, Florin Vaida, Constance A. Benson

Poster P-P1 ANTIRETROVIRAL PHARMACOKINETICS, SAFETY, AND STRATEGIES DURING PREGNANCY**Poster Hall D****2:30 PM – 4:00 PM****803 INCREASED RISK OF HYPERTENSION IN PREGNANCY AMONG WOMEN ON NEVIRAPINE-BASED REGIMENS**

Rebecca Zash, Paige L. Williams, Denise Jacobson, Modiegi Diseko, Gloria Mayondi, Judith Mabuta, Katherine Johnson, Mompati O. Mmalane, Max Essex, Shahin Lockman, Joseph Makhema, Chipo Petlo, Roger L. Shapiro

804 DOES CHANGING ART IN EARLY PREGNANCY FOR FETAL RISKS DESTABILIZE VIRAL SUPPRESSION?

Violaine Peyronnet, Josiane Warszawski, **Jeanne Sibiude**, Catherine Dollfus, Christine Rouzioux, Jérôme Le Chenadec, Albert Faye, Roland Tubiana, Laurent Mandelbrot, for the ANRS Inserm EPF C001 cohort study group

805 COMPARISON OF FOUR CLASSICAL PI- AND Raltegravir-BASED REGIMENS DURING PREGNANCY

Jeanne Sibiude, Olivia Dialla, Roland Tubiana, Stephane Blanche, Catherine Dollfus, Pierre Frange, Jérôme Le Chenadec, Laurent Mandelbrot, Josiane Warszawski, for the ANRS-EPF-C01 Research Group

806 Raltegravir in pregnancy: patterns of use and birth outcomes in the UK and Ireland

Rebecca Sconza, Virginia Rasi, Helen Peters, Mario Cortina-Borja, Claire Thorne

807 DolPHIN-1: Dolutegravir vs Efavirenz when initiating treatment in late pregnancy

Catriona Waitt, Stephen I. Walimbwa, Catherine Orrell, Mohammed Lamorde, Christie Heiberg, Ushma Mehta, Julian P. Kaboggoza, Julie Anne Coombs, Josaphat Byagumisha, Alieu Amara, Thoko Malaba, Laura Else, Landon Myer, **Saye Khoo**, for the DolPHIN-1 Study Group

808 Dipsticks proteinuria to predict renal dysfunction in HIV-infected pregnant women

Mwangelwa Mubiana-Mbewe, Bridget Mugisa, Bernadette Ngeno, Paul R. Young, Jillian L. Kadota, Benjamin H. Chi, **Charles B. Holmes**, Michael Vinikoor

809 Concentrations of TVF-DP during pregnancy among women using PrEP

Maria Pyra, Peter L. Anderson, Kenneth K. Mugwanya, Jessica E. Haberer, Renee Heffron, Stephen Asimwe, Elly T. Katabira, Nelly R. Mugo, Elizabeth A. Bukusi, Connie L. Celum, Jared Baeten, for the Partners Demonstration Project Team

810 Ex vivo cotyledon perfusion fairly predicts in vivo ARV human placental transfer

Vincent Madelain, Minh Le, Agnes Bourgeois Moine, Sophie Matheron, Diane Descamps, Laurent Mandelbrot, **Gilles Peytavin**

Poster P-P2 ADHERENCE, VIRAL SUPPRESSION, AND RETENTION IN PREGNANT AND POSTPARTUM WOMEN**Poster Hall D****2:30 PM – 4:00 PM****811 Cabergoline for lactation suppression among HIV+ and HIV-women**

Sarah Humphrey, Maeve Baechler, Melissa Schiff, **Jane Hitti**

- 812 PREDICTORS OF VIROLOGIC FAILURE IN POSTPARTUM WOMEN ON ART IN PROMISE 1077HS**
Risa M. Hoffman, Meredith G. Warshaw, K. Rivet Amico, Jose H. Pilotto, Gaerolwe Masheto, Jullapong Achalapong, Elizabeth S. Machado, Kulkanya Chokephaibulkit, Geraldo Duarte, Anne Coletti, Renee Browning, Nahida Chakhtoura, Karin L. Klingman, Judith S. Currier, for the IMPAACT PROMISE 1077HS Team
- 813 DISPARITIES IN ANTENATAL VIROLOGIC FAILURE AMONG WOMEN RECEIVING OPTION B+ IN KENYA**
Keshet Ronen, Brian Khasimwa, Bhavna Chohan, Daniel Matemo, Jennifer Unger, Alison L. Drake, **John Kinuthia**, Grace John-Stewart
- 814 ART ADHERENCE AMONG PREGNANT AND NON-PREGNANT WOMEN IN SOUTH AFRICA AND UGANDA**
Lynn T. Matthews, Catherine Orrell, Bosco M. Bwana, Stephen Asiimwe, Gideon Amanyire, Nicholas Musinguzi, Anna Cross, Kathleen Bell, Alexander C. Tsai, Christina Psaros, David R. Bangsberg, Jessica E. Haberer, for the META Study Team
- 815 EARLY CLINICAL EVENTS AFTER ART INITIATION IN PREGNANCY INFLUENCE VIRAL LOAD OUTCOMES**
Jasantha Odayar, Elaine J. Abrams, Allison Zerbe, Tamsin K. Phillips, Landon Myer
- 816 WITHDRAWN**
- 817 QUANTIFYING VISIT ADHERENCE IN PREGNANT WOMEN INITIATING ART IN SWAZILAND**
Nontokozo Langwenya, Harriet Nuwagaba-Biribonwoha, William J. Reidy, Averie B. Gachuhi, Simangele Mthethwa, Velephi Okello, Landon Myer, Elaine J. Abrams
- 818 TEXT MESSAGING FOR RETENTION IN PMTCT: A STEPPED-WEDGE CLUSTER-RANDOMIZED TRIAL**
Thomas A. Odeny, James P. Hughes, Elizabeth A. Bukusi, Eliud Akama, Elvin Geng, King Holmes, R. Scott McClelland
- 819 DOES QI IMPROVE PMTCT PROCESSES IN RURAL SOUTH AFRICA? A STEPPED-WEDGE CLUSTER RCT**
H. Manisha N. Yapa, Jan-Walter De Neve, Terusha Chetty, Carina Herbst, Frank Post, David A. Cooper, Awachana Jiamsakul, Pascal Geldsetzer, Guy Harling, Philippa Matthews, Frank Tanser, Kobus Herbst, Dickman Gareta, Deenan Pillay, Till Bärnighausen
- 820 IMPROVED POSTPARTUM HIV OUTCOMES AFTER CARE COORDINATION TEAM INTERVENTION**
Anandi N. Sheth, Stephanie Hackett, Christina M. Meade, Jennifer M. Davis, Joy Ford, Jeronia Blue, Lisa Curtin, Andres Camacho-Gonzalez, Ann Chahroudi, Rana Chakraborty, Melody P. Palmore, Martina L. Badell

Poster P-Q1 PHARMACOKINETICS, SAFETY, AND UPTAKE OF HIV CO-TREATMENTS IN CHILDREN**Poster Hall D****2:30 PM – 4:00 PM**

- 837 EFFECT OF ANTITUBERCULOSIS THERAPY ON THE PHARMACOKINETICS OF EFAVIRENZ IN CHILDREN**
Azewura Kwara, Hongmei Yang, Sampson Antwi, Anthony Enimil, Fizza S. Gillani, Anima M. Sarfo, Antoinette Ortsin, Albert Dompreh, Lubbe Wiesner, Charles A. Peloquin
- 838 PHARMACOKINETICS OF 8-HOURLY LOPINAVIR/RITONAVIR IN CHILDREN ON RIFAMPICIN**
Helena Rabie, Holly Rawizza, Peter Zuidewind, Jana L. Winckler, Heather Zar, Annelies Van Rie, Jennifer Norman, Helen Mcilleron
- 839 TUBERCULOSIS DISEASE AND ISONIAZID USE IN SOUTH AFRICAN CHILDREN LIVING WITH HIV**
Gloria E. Anyalechi, Chloe A. Teasdale, Emilia M. Rivadeneira, Rommel Bain, Gurpreet Kindra, Mary Mogashoa, Stephen M. Arpadi, Elaine J. Abrams
- 840 TEMPORAL TRENDS IN GLOBAL PEDIATRIC COTRIMOXAZOLE USE AND IMPACT ON MORTALITY**
David C. Boettiger, Matthew Law, Annette H. Sohn, Mary-Ann Davies, Kara K. Wools-Kaloustian, Valérianne Leroy, Marcel Yotebieng, Michael J. Vinikoor, Rachel Vreeman, Andrew Edmonds, Azar Kariminia, for the IeDEA global consortium

Poster P-Q2 SOMETHING OLD, SOMETHING NEW: PHARMACOKINETICS AND SAFETY OF ARVs FOR INFANTS, CHILDREN, AND ADOLESCENTS**Poster Hall D****2:30 PM – 4:00 PM**

- 841 PHARMACOKINETICS AND SAFETY OF LOPINAVIR/RITONAVIR SOLUTION IN HIV-INFECTED NEWBORNS**
Adrie Bekker, Nathan Hanan, Mae Cababasay, Jiajia Wang, Firdose Nakwa, Elizabeth Smith, Jack Moye, Avy Violari, Mark Cotton, Lubbe Wiesner, Jennifer Norman, Barend Fourie, Edmund V. Capparelli, Mark Mirochnick, for the IMPAACT P1106 team
- 842 EFFECTIVENESS AND SAFETY OF LPV/R PELLETS-BASED ART IN CHILDREN: 48-WEEK ANALYSIS**
Isabelle Andrieux-Meyer, Olawale Salami, Raymond Omollo, **Dalton Wamalwa**, Elizabeth Maleche Obimbo, Adeodata Kekitiinwa, Juliet Mwanga-Amumpaire, Patrick Oyaro, Elizabeth A. Bukusi, Moses Waweru, Monique Wasunna, Janice Lee, François Simon, Marc Lallement, for the LIVING STUDY GROUP
- 843 SAFETY, PK, & EFFICACY OF FTC/TAF IN HIV-INFECTED ADOLESCENTS (12-18 YRS)**
Janet Chen, Xavier Saez-Llorens, Elizabeth Castaño, Faeezah Patel, Ann Melvin, Elizabeth J. McFarland, Jaime G. Deville, Mark Cotton, Chrisna Andersen, Heather Maxwell, Mingjin Yan, Sophia R. Majeed, Erin Quirk, Hiba Graham, Cheryl Pikora
- 844 BICTEGRAVIR/FTC/TAF SINGLE-TABLET-REGIMEN IN ADOLESCENTS: WEEK 24 RESULTS**
Aditya Gaur, Carina Rodriguez, Eric J. McGrath, Elizabeth Hellstrom, Afaaf Liberty, Eva Natukunda, Pope Kosalaraksa, Kulkanya Chokephaibulkit, Amy Coluci, Sophia R. Majeed, Danielle Porter, Pamela Wong, Erin Quirk, Hiba Graham, Cheryl Pikora

845 P1101: PHASEI/II STUDY OF Raltegravir CONTAINING REGIMEN IN HIV-TB COTREATED CHILDREN

Tammy Meyers, **Paul Krogstad**, Pearl Samson, Edward P. Acosta, Jack Moye, Ellen Townley, Sarah Bradford, Linda Marillo, Laura Hovind, Thucuma Sise, Hedy Teppler, Sylvia Dittmer, Lee Fairlie, Anneke Hesselink, Mark Cotton

Poster P-Q3 AGING UP WITH HIV INFECTION: HEALTH OUTCOMES OF ADOLESCENTS AND YOUNG ADULTS

Poster Hall D

2:30 PM – 4:00 PM

846 MILESTONES AND OUTCOMES OF YOUNG ADULTS WITH PERINATAL HIV INFECTION OR EXPOSURE

Elaine J. Abrams, Claude A. Mellins, Amelia Bucek, Curtis Dolezal, Jeannette Raymond, Andrew Wiznia, Cheng-Shiun Leu

847 SELF-HARM IN ADOLESCENTS WITH PERINATAL HIV AND HIV-AFFECTED ADOLESCENTS IN ENGLAND

Julie Copelyn, Lindsay Thompson, Marthe Le Prevost, Kate Sturgeon, Katie Rowson, Susie Brice, Ali Judd

848 MONITORING THE 3rd 90: ARE WE ON TRACK WITH ADOLESCENTS AND YOUTH?

Evelyne Ngugi, Agnes Natukunda, Tai Ho Chen, Kenneth Masamaro, Lucy Ng'ang'a, Jonathan Mwangi, Immaculate Mutisya, Abraham Katana, Peter W. Young

849 STUNTING AND GROWTH OF HIV-INFECTED ADOLESCENTS: HOW TO INTERPRET PROGRAMMATIC DATA?

Julie Jesson, Michael Schomaker, Karen Malatesta, Dewi K. Wati, Azar Kariminia, Mariam Sylla, Kouakou Kouadio, Shobna Sawry, Michael J. Vinikoor, Samuel Ayaya, Rachel Vreeman, Mary-Ann Davies, Valérianne Leroy, for the leDEA global cohort consortium

850 PREVALENCE OF GLOMERULAR DYSFUNCTION AMONG PERINATALLY HIV-INFECTED THAI ADOLESCENTS

Tavitiya Sudjaritruk, Suparat Kanjanavanit, Linda Aurpibul, Tawalchaya Chotecharoentanan, Saowalak Sarachai, Kamolrawee Sintupat, Ratchaneekorn Khampan, for the NEPHRO study team

Poster P-R1 LATE PRESENTATION AND MORTALITY

Poster Hall B

2:30 PM – 4:00 PM

886 TRENDS IN CAUSE-SPECIFIC MORTALITY ON THE HIV CARE CASCADE, SOUTHERN & EASTERN AFRICA

Kathryn A. Risher, Clara Calvert, Basia Zaba, Emma Slaymaker, Kobus Herbst, Jessica Nakiyingi-Miiro, Amelia C. Crampin, Mark Urassa, Baltazar Mtenga, Georges Reniers

887 ADVANCED HIV AND THE CARE CASCADE IN THE BOTSWANA COMBINATION PREVENTION PROJECT

Refeletswe Lebelonyane, Lisa A. Mills, Chipo Mogorosi, Shenaaz El-Halabi, Janet Moore, Lisa Block, Huisheng Wang, Joe Theu, Joseph Makhema, Stembile Matambo, Tafireyi Marukutira, Etienne Kadima, Max Kapanda, Pamela J. Bachanas, **Joseph N. Jarvis**

888 IMPROVED VIRAL SUPPRESSION BUT STABLE MORTALITY IN PEOPLE WHO INJECT DRUGS, 1997-2015

Becky L. Genberg, Gregory D. Kirk, Jacquie Astemborski, Hana Lee, Shruti H. Mehta

- 889 FACTORS ASSOCIATED WITH DELAYED HIV DIAGNOSES IN WASHINGTON, DC, 2006-2015**
Rupali K. Doshi, Jessica Li, Kerri Dorsey, Auntre D. Hamp
- 890 LOWER MITOCHONDRIAL DNA COPY NUMBER IS ASSOCIATED WITH HIV & PREDICTIVE OF MORTALITY**
Jing Sun, Ryan Longchamps, Damani A. Piggott, Jason A. Sumpter, Shruti H. Mehta, Dan Arking, Gregory D. Kirk, for the the ALIVE study
- 891 SHIFTING MORTALITY TRENDS AMONG PERSONS WITH HIV AND INJECTION DRUG USE OVER 30 YEARS**
Jing Sun, Damani A. Piggott, Abimereki D. Muzaale, Jacquie Astemborski, Shruti H. Mehta, Gregory D. Kirk
- 892 INDIVIDUAL AND SITE-LEVEL FACTORS ASSOCIATED WITH RISK OF DEATH AMONG PEOPLE WITH HIV**
Amanda D. Castel, Lindsey Powers Happ, Anne K. Monroe, Maria Jaurretche, Arpi Terzian, Alan Greenberg, for the DC Cohort Executive Committee
- 893 MORTALITY IS HIGHER AMONG SUCCESSFULLY TREATED PWH COMPARED TO MATCHED CONTROLS**
Veronica Svedhem-Johansson, Zaake de Coninck, Laith Hussain-Alkhateeb, Anna Mia Ekström, Göran Bratt, Magnus Gisslén, Max Petzold
- 894 RATES OF MORTALITY AMONG SCHIZOPHRENIC PEOPLE LIVING WITH AND WITHOUT HIV**
Kalysha Closson, Kate Salters, Thomas L. Patterson, Oghenowede Eyawo, William Chau, Monica Ye, Mark Hull, Viviane D. Lima, Julio S. Montaner, Robert S. Hogg, for the Comparative Outcomes Service Utilization Trends (COAST) Cohort Study
- 895 CAUSES OF DEATH AND EARLY MORTALITY IN PEOPLE WITH HIV IN MEXICO (2004-2015)**
Yanink Caro-Vega, Pablo F. Belaunzarán-Zamudio, Jesús Alegre-Díaz, Brenda Crabtree-Ramírez, Raúl Ramírez-Reyes, Pablo Kuri-Morales, Malaquías López-Cervantes, Juan Sierra-Madero
- 896 LATE PRESENTATION WITH HIV IN AFRICA: PHENOTYPES, RISK AND RISK STRATIFICATION**
Abraham Siika, Leanne McCabe, Mutua Bwakura-Dangarembizi, Cissy Kityo, Jane E. Mallewa, Kath Maitland, Anna Griffiths, Keith Baleeta, Shepherd Mudzingwa, James Abach, Kusum Nathoo, Andrew Prendergast, Sarah Walker, Diana Gibb, for the REALITY trial team
- 897 SMOKING, CHRONIC DISEASES, AND MORTALITY OF PEOPLE RECEIVING ART IN BRITISH COLUMBIA**
Erin Ready, Monica Ye, William Chau, Viviane D. Lima, Paul Sereda, Katherine Lepik, Robert S. Hogg, Rolando Barrios, Julio S. Montaner, David Moore
- 898 PERSONS LIVING WITH HIV (PLHIV) WITH ADVANCED HIV DISEASE: NEED FOR NOVEL CARE MODELS**
Wafaa M. El-Sadr, Chloe A. Teasdale, Katharine Yuengling, Peter Preko, Maureen Syowai, Felix Ndagije, Miriam Rabkin, Elaine J. Abrams
- 899 HIGH MORTALITY AMONG PLHIV WITH TB IN LESOTHO DESPITE HIGH ART UPTAKE**
Andrea Howard, Kieran Hartsough, Kathryn Curran, Koen Frederix, Fred Asiimwe, Llang Maama-Maime, Simon G. Marealle, Eric Pevzner

900 SUBSTANTIAL MORTALITY AND LOSS PRIOR TO TREATMENT IN ART-ELIGIBLE PATIENTS IN ZAMBIA

Aaloke Mody, Izukanji Sikazwe, Theodora Savory, Kombatende Sikombe, Paul Somwe, Mwanza wa Mwanza, Carolyn Bolton Moore, Nancy Padian, Charles B. Holmes, Elvin Geng

901 LONG-TERM MEASURES OF HIV EXPOSURE AND MORTALITY IN THE HIV OUTPATIENT STUDY

Frank J. Palella, Carl Armon, Stephen R. Cole, Rachel Hart, Nabil Rayeed, Ellen Tedaldi, Bienvenido Yangco, Richard Novak, Linda Battalora, Stacey Purinton, Kate Buchacz

902 POST-HOSPITAL MORTALITY AND READMISSION AMONG HIV-INFECTED ADULTS IN SOUTH AFRICA

Chris Hoffmann, Minja Milovanovic, Deanne Kerrigan, Neil A. Martinson, Ebrahim Variava

903 LIFE EXPECTANCY IN KEY POPULATIONS OF ADULTS WITH HIV IN THE US AND CANADA

Keri N. Althoff, Richard D. Moore, Michael John Gill, Michael A. Horberg, Amy C. Justice, Mari Kitahata, Marina Klein, Fidel A. Desir, W. C. Mathews, Angel Mayor, Peter F. Rebeiro, Michael J. Silverberg, Stephen J. Gange, Robert S. Hogg, for the North American AIDS Cohort Collaboration for Research and Design (NA-ACCORD) of IeDEA

Poster P-R2 EPIDEMIOLOGY AND RISK FACTORS

Poster Hall B

2:30 PM – 4:00 PM

904 RATE AND RISK OF TRANSMISSIBLE HIV RNA (>1500 COPIES/ML) AMONG ADULTS ON ART

Keri N. Althoff, Kate Buchacz, Richard D. Moore, Stephen J. Gange, Mari Kitahata, Michael A. Horberg, Ronald Bosch, Jennifer S. Lee, Jeffrey N. Martin, Kenneth H. Mayer, Pragna Patel, Charles Rabkin, Jennifer E. Thorne, John T. Brooks, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

905 INFECTION PRESSURE IN MEN WHO HAVE SEX WITH MEN AND THEIR SUITABILITY TO DONATE BLOOD

Ward P. van Bilsen, Hans L. Zaaijer, Amy Matser, Katja van den Hurk, Maarten F. Schim van der Loeff, Ed Slot, Maria Prins, Thijs J. Van de Laar

906 INDIVIDUAL AND NETWORK DRIVERS OF RACIAL DISPARITIES AMONG YMSM

Brian Mustanski, Ethan Morgan, Richard D'Aquila, Michelle Birkett, Patrick Janulis, Gregory Phillips, Michael E. Newcomb

907 HIV DIAGNOSES AND TRENDS IN THE SOUTHERN UNITED STATES, 2010-2015

Meg Watson, Andre Dailey, Alexandra M. Oster

908 DEGREE OF HOUSING INSTABILITY SHOWS INDEPENDENT "DOSE-RESPONSE" WITH HIV SUPPRESSION

Angelo A. Clemenzi-Allen, Elvin Geng, Katerina A. Christopoulos, Hali Hammer, Susan P. Buchbinder, Diane V. Havlir, Monica Gandhi

909 ONGOING NEED FOR BEHAVIORAL HIV PREVENTION INTERVENTIONS FOR HIV-POSITIVE MSM OVER 50

Mary Ann Chiasson, Martin J. Downing, Irene Yoon, Steven Houang, Sabina Hirshfield

910 UNDISCLOSED HIV INFECTION AMONG MSM IN NATIONAL HIV BEHAVIORAL SURVEILLANCE

Brooke Hoots, Cyprian Wejnert, Amy Martin, Richard Haaland, Silvina Masciotra, Catlaiann Sionean, Amanda Smith, William M. Switzer, Gabriela Paz-Bailey, for the NHBS Study Group

911 HIV TRANSMISSION BETWEEN MEN WHO HAVE SEX WITH MEN AND HETEROSEXUAL WOMEN

Alexandra M. Oster, Nivedha Panneer, Sonia Singh

912 RELIABILITY OF SELF-REPORTED HIV STATUS AMONG AFRICAN MSM SCREENED FOR HPTN 075

Jessica M. Fogel, Yinfeng Zhang, Xu Guo, William Clarke, Autumn Bread, Vanessa Cummings, Erica Hamilton, Arthur Ogendo, Noel Kayange, Ravindre Panchia, Karen Dominguez, Ying Q. Chen, Theodorus Sandfort, Susan H. Eshleman, for the HPTN 075 Study Team

913 FACTORS ASSOCIATED WITH VIRAL SUPPRESSION AMONG MSM IN WASHINGTON, DC

Auntre D. Hamp, **Jenevieve Opoku**, Adam Allston

914 RACIAL DIFFERENCES IN EGOCENTRIC NETWORK PROPERTIES AMONG GAY, BISEXUAL AND OTHER MSM

Meagan Zarwell, William T. Robinson

915 ECONOMIC DEPENDENCE AND HIV RISK AMONG YOUNG, BLACK MEN WHO HAVE SEX WITH MEN

Kalysha Closson, Gbolahan Olarewaju, Richard Crosby

916 WITHDRAWN**917 HIV DIAGNOSES AMONG WOMEN IN RURAL VS NON-RURAL AREAS, UNITED STATES, 2010-2016**

Ndidi Nwangwu-Ike, Neeraja Saduvala, Meg Watson, Alexandra M. Oster

918 FACTORS ASSOCIATED WITH HIV INFECTION AMONG FEMALES AGED 15-24 IN ZAMBIA

Haotian Cai, Danielle T. Barradas, Sundeep Gupta, Kathy Hageman, Andrea Low, Nzali Kancheya, Katrina Sleeman, Dan B. Williams, Karampreet Sachathee, Hetal Patel, Omega Chituwo, Lloyd Mulenga, for the ZAMPHIA Project Team

919 WITHDRAWN**920 HIV PREVALENCE AMONG WOMEN WHO EXCHANGE SEX RECRUITED IN 4 US CITIES, 2016**

Senad Handanagic, Brooke Hoots, Kristen Leigh Hess, Emily Higgins, Paige Padgett, Sarah L. Braunstein, Sara N. Glick, Dita Broz, Gabriela Paz-Bailey, Cyprian Wejnert, Lina Nerlander, for the NHBS High Risk Women Study Group

921 TRANSACTIONAL SEX MEASUREMENT AND ASSOCIATION WITH HIV INCIDENCE AMONG WOMEN

Mary K. Grabowski, Virginia Burke, Gertrude Nakigozi, Fred Nalugoda, Robert Ssekubugu, Larry W. Chang, Godfrey Kigozi, Deanne Kerrigan, David Serwadda, Betty Nantume, Darix K. Ssebagala, Ronald H. Gray, Joseph Kagaayi, Maria Wawer, Caitlin E. Kennedy

922 VIOLENCE AND HIV RISK FACTORS AMONG WOMEN WHO EXCHANGE SEX FOR MONEY OR DRUGS

Christine Agnew-Brune, Lina Nerlander, Dita Broz, Zaida Lopez, Stephanie Schuette, Vivian Griffin, Alexis Rivera, Sara N. Glick, Gabriela Paz-Bailey

- 923 SEXUAL PARTNER TYPE AND INCIDENT HIV-INFECTION AMONG ADOLESCENT GIRLS IN HPTN 068**
Nadia Nguyen, Kimberly A. Powers, Annie Green Howard, William C. Miller, Carolyn T. Halpern, Yaw Agyei, Catherine MacPhail, Kathleen Kahn, Audrey Pettifor
- 924 AN AGE-STRATIFIED RISK SCORE TO PREDICT HIV ACQUISITION IN YOUNG SOUTH AFRICAN WOMEN**
 Emma K. Burgess, **Nonhlanhla Yende-Zuma**, Delivette Castor, Quarraisha Abdool Karim
- 925 SEROSORTING FOR CONJUGAL RELATIONSHIP FORMATION IN HETEROSEXUAL COUPLES, SOUTH AFRICA**
Hae-Young Kim, Alain Vandormael, Andrew Tomita, Till Bärnighausen, Frank Tanser
- 926 SELF-REPORTED RISKY SEXUAL PRACTICES AMONG ADOLESCENTS AND YOUNG ADULTS IN BOTSWANA**
Unoda A. Chakalisa, Kathleen Wirth, Kara Bennett, Etienne Kadima, Kutlo Manyake, Tendani Gaolathe, Pamela J. Bachanas, Tafireyi Marukutira, Scott Dryden-Peterson, Mompati O. Mmalane, Joseph Makhemba, Molly Pretorius Holme, Max Essex, Shahin Lockman, Kathleen M. Powis
- 927 HIGH PREVALENCE OF CONCURRENT SEXUAL PARTNERSHIPS IN A LARGE POPULATION SURVEY**
Etienne Kadima, Kathleen Wirth, Kara Bennett, Tendani Gaolathe, Jean Leidner, Unoda A. Chakalisa, Erik VanWidenfelt, Pamela J. Bachanas, Refeletswe Lebelonyane, Mompati O. Mmalane, Joseph Makhemba, Molly Pretorius Holme, Shahin Lockman, Max Essex, Sikhulile Moyo
- 928 ARE FISHERFOLK AT HIGHER RISK THAN THEIR NEIGHBORS: FINDINGS FROM WESTERN KENYA, 2015**
Emily Zielinski-Gutierrez, Sifunjo F. Odongo, Daniel Kwaro, Kennedy Mutai
- 929 NATIONAL TRENDS IN HIV PREVALENCE IN 3 KEY POPULATIONS IN UKRAINE**
Kostyantyn Dumchev, Yana Sazonova, Tetiana Salyuk, Olga Varetska
- 930 TRENDS IN HIV INFECTION AMONG AMERICAN INDIANS/ALASKA NATIVES, US 2010–2014**
Andrew J. Mitsch, Xiao Wang, Dean Seneca, Sonia Singh, Donald Warne
- 931 COMPLEX HIV EPIDEMIC DYNAMICS IN MIGRANTS IN EUROPEAN UNION/ECONOMIC AREA (EU/EEA)**
Julia Del Amo, Inma Jarrin, Victoria Hernando, Cristina Moreno, Belen Alejos, Anastasia Pharris, Teymur Noori
- 932 HIV TESTING AND US ACQUISITION AMONG AFRICAN IMMIGRANTS LIVING WITH HIV IN THE US**
Roxanne P. Kerani, Amanda Lugg, Baiba Berzins, Oumar Gaye, Lauren Lipira, Camille Bundy, Helena Kwakwa, King Holmes, Matthew R. Golden
- 933 NO CHANGE IN THE FREQUENCY OF AGE DISPARATE RELATIONSHIPS OR IMPACT ON HIV STATUS**
George Mwinnyaa, Oliver Laeyendecker, Kate Grabowski, Joseph Ssekasanvu, Anthony Ndyanabo, Robert Ssekubugu, Joseph Kagaayi, Godfrey Kigozi, Gertrude Nakigozi, David Serwadda, Ronald H. Gray, for the Rakai Health Sciences Program

934 HIGH INCIDENCE AND BURDEN OF HIV INFECTION IN EAST LONDON, SOUTH AFRICA

Bhakti Hansoti, Anna Eisenberg, David Stead, Nomzamo Mvandaba, Eshan U. Patel, Andy Parrish, Madeleine Whalen, Reinaldo Fernandez, George Mwinnnyaa, Steven J. Reynolds, Andrew D. Redd, Stewart Dendorf, Richard Rothman, Oliver Laeyendecker, Thomas C. Quinn

935 ARE HIV PREVALENCE ESTIMATES FOR WESTERN KENYA TOO HIGH?

Peter W. Young, Emily C. Zielinski-Gutierrez, Daniel Kwaro, Martien W. Borgdorff, Joshua Gitonga, Joyce Wamicwe, Samuel M. Mwalili, Rachel Joseph, **Kevin M. De Cock**

936 ASSOCIATION OF MOBILITY WITH HIV RECENT INFECTIONS AND VIREMIA IN BOTSWANA

Mompati O. Mmalane, Sikhulile Moyo, Baraedi W. Sento, Jean Leidner, Kara Bennett, Thandie Phindela, Kutlo Manyake, Ernest Moseki, Tendani Gaolathe, Joseph Makhema, Molly Pretorius Holme, Janet Moore, Max Essex, Shahin Lockman, Kathleen Wirth

937 NEW METHOD FOR RAPID DETECTION OF HIV TIME-SPACE CLUSTERS FOR PUBLIC HEALTH ACTION

Laurie Linley, Arthur Fitzmaurice, Meg Watson, Chenhua Zhang, Riuguang Song, **Anne Marie France**, Alexandra M. Oster

938 EPIDEMIOLOGICAL STUDY OF TRANSMISSION CLUSTERS IN A LOCAL HIV-1 COHORT

Carmen M. González Domenech, Isabel Viciana-Ramos, Gabriel Sena-Corrales, Laura Mora Navas, Guillermo Ojeda, Enrique Nuño, Encarnación Clavijo, Rosario Palacios, Jesus Santos

939 AGE-DEPENDENT RACIAL/ETHNIC DISPARITIES IN LONGITUDINAL HIV CARE INDICATORS

Fidel A. Desir, Catherine R. Lesko, Richard D. Moore, Michael J. Silverberg, Peter F. Rebeiro, Michael A. Horberg, Mari Kitahata, Stephen Crystal, Angel Mayor, Marina Klein, Amy C. Justice, Michael John Gill, Keri N. Althoff, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of iDeA

940 HIV VIRAL SUPPRESSION ASSESSED BY TWO METRICS IN NORTH CAROLINA DURING 2016

Manuela Bullo, Erika Samoff, Nicole Dzialowy Adams, Brad Wheeler, Kimberly A. Powers, Anna Cope

941 UNDISCLOSED ANTIRETROVIRAL DRUG USE IN BOTSWANA – IMPLICATIONS FOR NATIONAL ESTIMATES

Sikhulile Moyo, Simani Gaseitsiwe, Kathleen M. Powis, Terence Mohammed, Comfort Maphorisa, William Abrams, Liziwe Chebani, Kutlo Manyake, Molly Pretorius Holme, Tendani Gaolathe, Joseph Makhema, Shahin Lockman, William Clarke, Max Essex, Vlad Novitsky

942 CONCOMITANTLY SUPPRESSED SYSTEMIC AND IMBALANCED MUCOSAL IMMUNITY INCREASE HIV RISK

Charles S. Morrison, **Raina Fichorova**, Pai-Lien Chen, Sophie Gao, Cynthia Kwok, Hidemi Yamamoto, Sharon Anderson, Christopher Bukowsky, Robert Barbieri, Anna Wald, Tsungai Chipato, Robert Salata, Gustavo Doncel

943 RELATIONSHIP BETWEEN DEPRESSION AND RISK BEHAVIORS IN A US MILITARY HIV COHORT

Brandon W. Carney, James White, Xiaohe Xu, Thankam Sunil, Colton Daniels, Morgan Byrne, Anuradha Ganesan, Robert Deiss, Grace E. Macalino, Brian K. Agan, Jason Okulicz

Poster P-T01 BARRIERS AND FACILITATORS OF PrEP**Poster Hall B****2:30 PM – 4:00 PM****1005 DISTANCE TO CLINIC IS A BARRIER TO PrEP UPTAKE & RETENTION IN UGANDA SEARCH COMMUNITY**

Christopher Mayer, Asiphas Owaraganise, Jane Kabami, Dalsone Kwarisiima, Catherine A. Koss, Edwin D. Charlebois, Moses R. Kamya, Maya L. Petersen, Diane V. Havlir, **Britta Jewell**

1006 GEOGRAPHIC ACCESS TO PrEP CLINICS AMONG US MSM: DOCUMENTING PrEP DESERTS

Kevin Weiss, Anna Bratcher, Patrick S. Sullivan, Aaron J. Siegler

1007 THE PrEP CASCADE AT NYC SEXUAL HEALTH CLINICS: NAVIGATION IS THE KEY TO UPTAKE

Preeti Pathela, Kelly Jamison, Susan Blank, Tarek Mikati, Trevor Hedberg, Sarit A. Golub, Lena Saleh, Christine M. Borges

1008 OUT-OF-POCKET COSTS IMPEDE PrEP USE AMONG YOUNG MSM IN THE PRIVATE HEALTHCARE SYSTEM

Rupa R. Patel, Sunidhi Singh, Christian Farag, Kenneth H. Mayer, Philip A. Chan, Amber Salter, Leandro A. Mena, Zachary Feinstein, John Crane, Timothy McBride

1009 HIGH DISCONTINUATION OF PRE-EXPOSURE PROPHYLAXIS WITHIN SIX MONTHS OF INITIATION

Chelsea L. Shover, Marjan Javanbakht, Steven Shoptaw, Robert Bolan, Pamina Gorbach

1010 PrEP IMPLEMENTATION AND PERSISTENCE IN A COUNTY HEALTH DEPARTMENT IN ATLANTA, GA

Charlotte-Paige M. Rolle, Udodirim Onwubiko, Jennifer Jo, Anandi N. Sheth, Colleen F. Kelley, **David P. Holland**

1011 HIV PREEXPOSURE PROPHYLAXIS AS A GATEWAY TO PRIMARY CARE

Julia L. Marcus, Kenneth Levine, Chris Grasso, Douglas Krakower, Victoria Powell, Kyle T. Bernstein, Stephen L. Boswell, Kenneth H. Mayer

1012 TRENDS IN PrEP UPTAKE, ADHERENCE, AND DISCONTINUATION AMONG YMSM IN CHICAGO

Ethan Morgan, Daniel T. Ryan, Kevin Morgan, Richard D'Aquila, Michael E. Newcomb, Brian Mustanski

1013 PATTERNS AND CORRELATES OF PARTICIPANT RETENTION IN THE US PrEP DEMO PROJECT

Susanne Doblecki-Lewis, Daniel Feaster, Albert Y. Liu, Stephanie E. Cohen, Richard A. Elion, Oliver Bacon, Gabriel Cardenas, Michael Kolber, Megan Coleman

1014 INCREASING PrEP UPTAKE, PERSISTENT DISPARITIES IN AT-RISK PATIENTS IN A BOSTON CENTER

Kenneth H. Mayer, Chris Grasso, Kenneth Levine, Douglas Krakower, Victoria Powell, Stephen L. Boswell, Julia L. Marcus

1015 DISPARITIES IN PrEP UPTAKE AMONG PRIMARY CARE PATIENTS SCREENED FOR HIV/STIs IN SF

Hyman Scott, Anne Hirozawa, Miranda Nordell, Monica Gandhi, Catherine James, Hali Hammer, Susan Scheer, Susan P. Buchbinder

- 1016 EARLY ADOPTERS OF PrEP AMONG MSM IN INDIA AND DETERMINANTS OF EMERGING DISPARITIES**
Viraj V. Patel, Alpana Dange, Sarit A. Golub, Shruta Neytra, Yashesh Parekh, Christopher Pina, Julia H. Arnsten, Jack Harrison-Quintana, Kenneth H. Mayer
- 1017 ACCEPTABILITY OF PrEP AMONG A LARGE COHORT OF YOUNG TRANSGENDER WOMEN IN 2 US CITIES**
Arjee J. Restar, Lisa Kuhns, Sari Reisner, Robert Garofalo, Matthew J. Mimiaga
- 1018 AUTOMATED IDENTIFICATION OF POTENTIAL PrEP CANDIDATES USING ELECTRONIC HEALTH DATA**
Douglas Krakower, Susan Gruber, John T. Menchaca, Sharon Ulery, Ira B. Wilson, Kenneth H. Mayer, Michael Klompass
- 1019 MONITORING PrEP USE AMONG WASHINGTON STATE MSM: RESULTS OF AN INTERNET SURVEY**
Darcy W. Rao, Jason Carr, Kelly Naismith, Julia Hood, James P. Hughes, **Matthew R. Golden**
- 1020 COMPARING THE CHARACTERISTICS OF BRAZILIAN MSM USING APP FOR SEXUAL ENCOUNTERS**
Thiago S. Torres, Raquel B. De Boni, Mauricio Vasconcelos, Paula M. Luz, Brenda Hoagland, Ronaldo I. Moreira, Alex Garner, Valdilea Veloso, Beatriz Grinsztejn
- 1021 HIV RISK PERCEPTION AMONG MEN WHO HAVE SEX WITH MEN: A RANDOMIZED CONTROLLED TRIAL**
Jill Blumenthal, Donald E. Mulvihill, Sonia Jain, Sara Graber, Marvin Hanashiro, Eric Ellorin, Xiaoying Sun, Richard Haubrich, Sheldon Morris
- 1022LB DISTRIBUTION OF ACTIVE PrEP PRESCRIPTIONS AND THE PrEP-TO-NEED RATIO, US, Q2 2017**
Aaron J. Siegler, Farah Mouhanna, Robertino Mera Giler, Scott McCallister, Howa Yeung, Jeb Jones, Jodie L. Guest, Michael Kramer, Cory Woodyatt, Elizabeth Pembleton, Patrick S. Sullivan

Poster P-T08 MUCOSAL SAFETY STUDIES OF VAGINAL, RECTAL RING, AND ORAL PrEP

Poster Hall B

2:30 PM – 4:00 PM

- 1055 TDF/FTC PrEP, LUBRICANT USE, AND THE RECTAL MUCOSAL MICROBIOTA AMONG HIV-NEGATIVE MSM**
Colleen F. Kelley, Jeffrey Fountain, Angela Holder, Chuong Dinh, LaShonda Hall, Sheila Heeke, Yingtian Hu, Colleen S. Kraft, Nicole A. Pescatore, Yijuan Hu, Clyde Hart, Richard Haaland
- 1056 GENDER-SPECIFIC RECTAL PROTEOME CHANGES WITH ORAL AND TOPICAL MARAVIROC USE AS PrEP**
Sarah Mutch, Laura Noël-Romas, Jarret C. Engstrom, Rhonda M. Brand, Aaron Siegel, Ross Cranston, Ian McGowan, Adam Burgener
- 1057 MICROBIOME AND PROTEOME ALTERATIONS WITH DAPIVIRINE RING USE IN ADOLESCENT GIRLS**
Christina Farr Zuend, **Laura Noël-Romas**, Jeanne Marrazzo, Sharon L. Hillier, Charlene S. Dezzutti, Kathleen E. Squires, Katherine Bunge, Adam Burgener

1058 ACTIVITY OF GRIFFITHSIN-M78Q-AN HIV ENTRY INHIBITOR-IN THE RECTAL ENVIRONMENT

Henry Nabeta, Sanet Steyn, Amanda Lasnik, Ian McGowan, Joshua Fuqua, Joseph C. Kouokam, Kenneth E. Palmer

1059LB EARLY TERMINATION OF A PHASE 1 TRIAL OF TENOFOVIR DISOPROXIL FUMARATE VAGINAL RING

Marla J. Keller, Laurie Ray, Jessica M. Atrio, Lilia Espinoza, Shada Sinclair, Jessica Goymer, Mark A. Marzinke, Bruce Frank, Peter L. Anderson, Jeanne Marrazzo, Nelly R. Mugo, Craig W. Hendrix, Betsy Herold

1060LB HYPO-OSMOLAR RECTAL ENEMA TVF FORMULATION PREVENTS SHIV ACQUISITION

Peng Xiao, Sanjeev Gumber, Mark A. Marzinke, Abhijit Date, Thuy Hoang, Justin Hanes, Laura Ensign, Lin Wang, Lisa C. Rohan, Richard Cone, Edward J. Fuchs, Craig W. Hendrix, **Francois Villinger**

Poster P-U2 CARING FOR WOMEN LIVING WITH HIV: MENOPAUSE AND CONTRACEPTION

Poster Hall B

2:30 PM – 4:00 PM

1072 HIV-1 RESERVOIR DYNAMICS IN MENOPAUSAL WOMEN DURING HORMONE THERAPY

Stephanie Banning, Olivia Roberts-Sano, Emanuele Mazzola, Qianjing He, Stacey Chapman, Rebecca Gelman, Susan Cu-Uvin, **Athe Tsibris**

1073 ASSOCIATION OF HIV STATUS WITH SEXUAL FUNCTION IN WOMEN AGED 45-60

Nasreen Toorabally, Cath Mercer, Kirstin Mitchell, Fiona Burns, Caroline Sabin, Richard Gilson, **Shema Tariq**

1074 MENOPAUSAL SYMPTOMS ARE ASSOCIATED WITH PSYCHOLOGICAL DISTRESS IN HIV+ WOMEN

Shema Tariq, Fiona Burns, Lorraine Sherr, Richard Gilson, Alexandra Rolland, Caroline Sabin

1075 REPRODUCTIVE TRACT INFECTION RISK-BASED SCREENING FOR IUD INSERTION IN HIV+ WOMEN

Nontokozo Langwenya, Catherine Todd, Heidi Jones, Donald R. Hoover, Agnes Ronan, Landon Myer

Poster P-W2 MODELING ANTIRETROVIRAL THERAPY INTERVENTIONS AND OUTCOMES

Poster Hall B

2:30 PM – 4:00 PM

1155 ASSESSING THE UTILITY OF THE TIPPING POINT RATIO FOR MONITORING ART PROGRAM SUCCESS

Simon de Montigny, Marie-Claude Boily, Benoît R. Mâsse, Kate M. Mitchell, Dobromir Dimitrov

1156 PREDICTING THE PROBABILITY AND TREATMENT COSTS OF ELIMINATING HIV IN BOTSWANA

Katie Sharp, Sally Blower

1157 COST-EFFECTIVENESS OF MEDICAL CARE COORDINATION FOR HIGH-RISK PWH IN LA COUNTY

Moses J. Flash, Wendy H. Garland, Bruce R. Schackman, Sona Oksuzyan, Justine A. Scott, Philip J. Jeng, Emily B. Martey, Marisol Mejia, Elena Losina, Emily P. Hyle, Sonali P. Kulkarni, Kenneth Freedberg

1158 220 VULNERABLE COUNTIES: ONE YEAR LATER

Alana Sharp, Brian Honermann, Austin Jones, Gregorio A. Millett

TUESDAY, MARCH 6, 2018

Poster P-A2 HOST CELL PATHWAYS AND VIRAL REPLICATION
Poster Hall A 2:30 PM – 4:00 PM

- 176 IDENTIFICATION OF FASNALL, A NOVEL FASN INHIBITOR THAT ATTENUATES HIV-1 REPLICATION**
 Manjusha Kulkarni, Annette Burkhouse, Menakshi Bhat, Yazan Alwarawrah, Phillip Hughes, Jesus Arcos, David Loiselle, Jordi Torrelles, Nicholas Funderburg, Timothy Haystead, **Jesse Kwiek**
- 177 EXPRESSION OF MDM2 IN MACROPHAGES FAVORS HIV-1 INTEGRATION THROUGH INHIBITION OF P53**
 Yann Breton, Vincent Desrosiers, Michel Ouellet, Michel J. Tremblay
- 178 INTERPLAY BETWEEN FOLATE CYCLE AND HIV-1 INFECTION IN MONOCYTE-DERIVED MACROPHAGES**
 Vincent Desrosiers, Yann Breton, Michel Ouellet, Michel J. Tremblay
- 179 LOXL3 REGULATES HIV-1 INFECTION IN HUMAN PRIMARY MACROPHAGES**
 Laurent Hany
- 180 SYNONYMOUS RECODED ENV GENE INDUCE LETHALITY AND LOSS OF PROTEIN EXPRESSION IN HIV-1**
 Ana Jordan-Paiz, Maria Nevot, Sandra Franco, Miguel Angel Martinez
- 181 ENHANCEMENT OF HIV-1 INFECTION BY BUPRENORPHINE**
 German G. Gornalusse, Lucia Vojtech, Claire Levy, Rogelio M. Valdez, Urvashi Pandey, Julie McElrath, Florian Hladik
- 182LB EBV BORF2 INHIBITS AND SEQUESTERS HUMAN APOBEC3B TO PROTECT VIRAL GENOME INTEGRITY**
 Adam Cheng, Jaime Yockteng Melgar, Lori Frappier, Reuben S. Harris

Poster P-A3 EARLY EVENTS: METHODS AND MECHANISM
Poster Hall A 2:30 PM – 4:00 PM

- 183 R5X4 EVOLVE DISTINCT GP41 ACTIVATION PATHWAYS TO SENSE ALTERNATE CORECEPTOR BINDING**
 Annemarie Laumaea, Benjamin K. Dickerman, Jacqueline K. Flynn, Paul R. Gorry, Jason M. Mackenzie, Heidi E. Drummer, Pantelis Poumbourios
- 184 VARIABILITY OF HIV-1 V2 ENV DOMAIN FOR INTEGRIN BINDING: CLINICAL CORRELATES**
 Claudia Fabrizio, Davide F. Bavaro, Luciana Lepore, Antonella Lagioia, Gioacchino Angarano, Laura Monno, Annalisa Saracino
- 185 HIV-1 CORE MORPHOLOGY ASSESSMENT USING SINGLE VIRION IMAGING BASED ON FRET**
 Anamaria D. Sarca, Hirofumi Fukuda, Luca Sardo, Jessica Smith, Kotaro Shirakawa, Kazuki Horikawa, Taisuke Izumi, Akifumi Takaori-Kondo
- 186 NEF UPREGULATES FASL EARLY WHILE MHCS ARE DOWNREGULATED LATE IN HIV-INFECTED CELLS**
 Rodrigo Matus-Nicodemos, Daniel Douek, Richard A. Koup
- 187 VISUALISATION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 CDNA BY CLICK CHEMISTRY**
 Flore De Wit, Frauke Christ, Sambasivarao Pillalamarri, Akkaledevi Venkatesham, Arthur Van Aerschot, Zeger Debyser

- 188 HIV RT STRAND TRANSFER AND NONTEMPLATED BASE ADDITION ARE MECHANISTICALLY INDEPENDENT**
Joanna Luczkowiak, Tania Matamoros, Luis Menéndez-Arias
- 189 UBP43 (USP18) ABROGATES INTERFERON AND SAMHD1-MEDIATED RESTRICTION OF HIV-1**
Edmund Osei-Kuffour, Kerstin Schott, Philipp A. Lang, Karl S. Lang, Renate König, Dieter Häussinger, Carsten Münk
- 190 VPR ENHANCES VIRAL GENE EXPRESSION FROM UNINTEGRATED DNA IN A DCAF1-DEPENDENT MANNER**
Sarah B. Nodder, Caitlin Miller, Hisashi Akiyama, Chelsea R. Ettinger, Rahm Gummuluru
- 191LB A NOVEL MODE OF RNA BINDING ASSISTS APOBEC3H IN THE MOLECULAR ARMS RACE AGAINST HIV**
Jennifer Bohn, Keyur Thummar, Ashley York, Alice Raymond, William C. Brown, Paul Bieniasz, Theodora Hatzioannou, Janet L. Smith

Poster P-B2 IMMUNE ACTIVATION AND SUPPRESSION IN HIV INFECTION

Poster Hall A

2:30 PM – 4:00 PM

Poster Sessions • Tuesday

- 216 HIV UNSPLICED RNA EXPRESSION INDUCES INNATE IMMUNE ACTIVATION AND T CELL DYSFUNCTION**
Hisashi Akiyama, Caitlin Miller, Chelsea R. Ettinger, Anna C. Belkina, Jennifer Snyder-Cappione, Rahm Gummuluru
- 217 INSULIN-LIKE GROWTH FACTOR 1 INVERSELY RELATES TO MONOCYTE ACTIVATION MARKERS IN HIV**
Lindsay T. Fourman, Natalia Czerwonka, Sofia D. Shaikh, Takara L. Stanley, Kathleen V. Fitch, Janet Lo, Steven K. Grinspoon
- 218 EXOSOMES ARE ASSOCIATED WITH IMMUNE ACTIVATION AND OXIDATIVE STRESS IN HIV PATIENTS**
Sukrutha Chettimada, David Lorenz, Vikas Misra, Dana H. Gabuzda
- 219 CONTROLLED STUDY TO EVALUATE IMMUNOLOGIC EFFECT OF ISOTRETINOIN ON HIV-1 INFECTION**
Nina Lin, Bernard J. Macatangay, Ellen S. Chan, Heather Ribaudo, Karin L. Klingman, Linda Boone, Jonathan Z. Li, Maureen A. Kane, Francesca Aweeka, Charles Rinaldo, Ian McGowan, Daniel R. Kuritzkes, Douglas Kwon, for the ACTG A5325/A5330s team
- 220 HIV-1 UNMASKS THE PLASTICITY OF INNATE LYMPHOID CELLS**
Yetao Wang, Kyle Gellatly, Alan Derr, Smita Jaiswal, Alper Kucukural, Patrick McDonel, Thomas Greenough, Jean Marie Houghton, Manuel Garber, Jeremy Luban
- 221 SYSTEMIC ACTIVATION OF NOVEL IGA+ NATURAL KILLER-LIKE B CELLS IN HIV/SIV INFECTIONS**
Chiadika Nwanze, Cordelia Manickam, R. Keith Reeves
- 222 IL-15 DRIVES THE GENERATION AND SURVIVAL OF SENESCENT CD8 T CELLS IN HIV INFECTION**
Stephen R. Morris, Bonnie Chen, Soumya Panigrahi, Scott F Sieg, Souheil A Younes, Sara Gianella, Michael M. Lederman, Michael L. Freeman
- 223 REGULATION OF B CELLS BY IgG3 IN HIV-INFECTED INDIVIDUALS**
Christine Youn, Lela Kardava, Haewon Sohn, James W. Austin, Wei Wang, Clarisa M. Buckner, Marissa Hand, Kathleen Gittens, Richard Kwan, Michael Sneller, Tae-Wook Chun, Susan K. Pierce, Susan Moir

224LB RESISTANCE OF HIV-INFECTED MACROPHAGES TO CTL KILLING DRIVES IMMUNE ACTIVATION

Kiera L. Clayton, David R. Collins, Joshua Lengieza, Farokh Dotiwala, Judy Lieberman, Bruce D. Walker

Poster P-B3 NATURAL AND UNNATURAL CONTROL OF HIV INFECTION
Poster Hall A 2:30 PM – 4:00 PM

225 SPECIFIC CTFH FREQUENCY CORRELATES WITH MEMORY B CELL RESPONSES IN HIV CONTROLLERS

Lisa A. Chakrabarti, Mathieu Claireaux, Moran Galperin, Daniela Benati, Alexandre Nouel, Madhura Mukhopadhyay, Pierre de Truchis, David Zucman, Samia Hendou, Faroudy Boufassa, Olivier Lambotte

226 INTERACTION OF HOST AND VIRAL GENOMICS ON HIV DISEASE PROGRESSION IN RAKAI UGANDA

Genevieve L. Wojcik, **Michael A. Eller**, David Serwadda, Kate Grabowski, Fred Wabwire-Mangen, Anthony Ndyanabo, Merlin L. Robb, Nelson L. Michael, Leigh Anne Eller, Ronald H. Gray, Thomas C. Quinn, Oliver Laeyendecker, for the Rakai Health Sciences Program

227 FC DEPENDENT ANTI-HIV-SPECIFIC ANTIBODY FUNCTIONALITY DISTINGUISHES HIV CONTROLLERS

Sanket Kant, Franck P. Dupuy, Chris Leeks, Alexandre Barbe, Ningyu Zhang, Cindy X. Zhang, Jean-Pierre Routy, Petronela Ancuta, Cécile Tremblay, Nicole Bernard

228 TEMPORAL VARIATION OF IGG SUBCLASSES DIFFERENTIATES HIV CONTROLLERS AND PROGRESSORS

Jishnu Das, Saheli Sadanand, Amy Chung, Todd J. Suscovich, Hendrik Streeck, Davey M. Smith, Susan J. Little, Douglas Lauffenburger, Douglas D. Richman, Galit Alter

229 ART REDUCES T CELL ACTIVATION AND IMMUNE EXHAUSTION MARKERS IN HIV CONTROLLERS

Jonathan Z. Li, Florencia P. Segal, Ronald Bosch, Christina Lalama, Randall Tressler, Cornelius N. Van Dam, Michael Keefer, Mary Carrington, Mathias Lichterfeld, Daniel R. Kuritzkes, Xu G. Yu, Alan Landay, Paul E. Sax, for the AIDS Clinical Trials Group A5308 Study Team

230 EFFICIENT ANTIBODY PROFILE IN HLA-B*57+ HIV CONTROLLERS

Jérémie Klingler, Angeline Rouers, Géraldine Laumond, Sylvie Schmidt, Camille Ducloy, Luzia Mayr, Thomas Decoville, Nathalie Salomé, Assia Samri, Veronique Avettand-Fenoel, Faroudy Boufassa, Christine Rouzioux, Olivier Lambotte, Arnaud Moris, Christiane Moog, for the ANRS CO21 Cohort

231 THE CHAMP COHORT: POST-TREATMENT CONTROLLERS IDENTIFIED FROM 9 CLINICAL STUDIES

Golnaz Namazi, Jesse Fajnzyber, Evgenia Aga, Ronald Bosch, Edward P. Acosta, Jeffrey Jacobson, Paul Volberding, Daniel Skiest, Ronald T. Mitsuyasu, Robert T. Schooley, Ann Collier, Jean-Pierre Routy, Bruce D. Walker, Jonathan Z. Li, for the CHAMP Study Team

232LB TARGETING HIGHLY NETWORKED CTL EPITOPES AS A MECHANISM OF ELITE HIV-1 CONTROL

Gaurav D. Gaiha, Elizabeth Rossin, Christian Landeros, Itai Muzhingi, Chioma A. Nwonu, Bruce D. Walker

233LB WOUND HEALING MECHANISMS REQUIRED IN PATHOGENESIS CONTROL OF SIV IN NATURAL HOST

Fredrik Barrenas, Kevin D. Raehtz, Lynn Law, Richard Green, Guido Silvestri, Steven E. Bosingher, Qingsheng Li, Matthew Thomas, Jean Chang, Elise Smith, Reem A. Dawoud, Cristian Apetrei, Ivona Pandrea, Michael Gale

Poster P-B4 CELL AND TISSUE DISREGULATION IN HIV INFECTION

Poster Hall A

2:30 PM – 4:00 PM

Poster Sessions • Tuesday

234 PERSISTENT DYSREGULATION OF HIV-SPECIFIC FOLLICULAR HELPER CELLS DURING ART

Julia Niessl, Amy E. Baxter, Antigoni Morou, Elsa Brunet-Ratnasingham, Madelene Lindqvist, Parsia A. Vagefi, Eileen P. Scully, Jean-Pierre Routy, Daniel E. Kaufmann

235 NEUTROPHIL DYNAMICS IN SIV-INFECTED PIGTAILED MACAQUES BEFORE AND AFTER ART

Egidio Brocca-Cofano, Tianyu He, Ranjit Sivanandham, Benjamin Pollicchio, Paola Sette, Tammy Dunsmore, George S. Haret-Richter, Alan Landay, Cristian Apetrei, Ivona Pandrea

236 CHARACTERIZATION OF FDC-BOUND VIRAL PRODUCTS DURING HIV/SIV INFECTION

Matthew Bronnimann, **Joy M. Folkvord**, Pamela Skinner, Eva Rakasz, Elizabeth Connick

237 HIV-2 IMPACT ON LYMPHOID ORGANS: EVIDENCE OF VIRAL REPLICATION AND TISSUE DISRUPTION

Ana Antão, Ana Pires, Cristina Ferreira, Helena Nunes-Cabaço, Sandra Mauricio, Cheila Rocha, Paula Matoso, Rui M. Victorino, Susana M. Fernandes, **Ana E. Sousa**

238 CD163+ LYMPH NODE MACROPHAGES ARE CORRELATED WITH LYMPH NODE FIBROSIS IN CHRONIC HIV

Brooks I. Mitchell, Fredrick Yost, Glen M. Chew, Michelle L. D'Antoni, Ashley Marumoto, Jodi Anderson, Caitlin David, Nancy Hanks, Dominic Chow, Timothy Schacker, Lishomwa C. Ndhlovu, Cecilia Shikuma

239 GUT HOMING DEFECTS AND EXHAUSTION OF BLOOD TH17 AND TH1 CELLS IN HIV INFECTION

Stephanie Dillon, Allison J. Christians, Kejun Guo, Gregory Austin, Alan Landay, Mario Santiago, Cara Wilson

240 VARIOUS SUBSETS OF CCR6+ CD4+ T CELLS ARE DIFFERENTIALLY TARGETED BY HIV-1 IN THE GUT

Manon Nayrac, Mary Requena, Claire Loiseau, Fatima L'Faqih, Michelle Cazabat, Nicolas Carrere, Bertrand Suc, Jacques Izopet, Pierre Delobel

241 SHIV/SIV INFECTION PROMOTES CD8 T CELL VASCULAR INFILTRATION BY CX3CL1 AND IL-15

Bonnie Chen, Soumya Panigrahi, Jonathan Wyrick, Stephen R. Morris, Scott F Sieg, Nicholas Funderburg, David A. Zidar, Mirko Paiardini, Francois Villinger, Souheil A Younes, Michael M. Lederman, Michael L. Freeman

242 SMOKING INHIBITS HIV-1 INDUCED CD8+ T CELL INFILTRATION INTO THE ALVEOLAR SPACE

Bjorn Corleis, Josalyn Cho, Samantha J. Gates, Antonella C. Lisanti, Puja Kohli, Amy K. Dickey, Abigail Schiff, Scott R. Harris, Benjamin Medoff, Douglas Kwon

- 243 INCREASES IN TH17 CELL DENSITY AT MUCOSAL SURFACES IN STATES OF ELEVATED PROGESTINS**
Megan Halkett, Ann M. Carias, Thomas Hope
- 244 IDENTIFICATION OF NK CELL SUBSETS CORRELATING WITH HIV DNA IN HIV-INFECTED SUBJECTS**
Christopher Pohlmeier, Veronica Gonzalez, Alivelu Irrinki, Ricardo Ramirez, Li Li, Andrew Mulato, Jeffrey Murry, Aaron Arvey, Rebecca Hoh, Steven G. Deeks, Garry Nolan, George Kukolj, Tomas Cihlar, Stefan Pflanz, Gundula Min-Oo
- 245 CHARACTERIZATION OF NKG2C+ MEMORY NK CELLS IN SIV INFECTION BY FISH-FLOW CYTOMETRY**
Daniel Ram, R. Keith Reeves

- Poster P-B5 COMPARTMENTS FOR HIV REPLICATION**
Poster Hall A **2:30 PM – 4:00 PM**
- 246 INNATE LYMPHOID CELLS IN ENDOCERVICAL MUCOSA OF HIV INFECTED WOMEN**
Natasa Strbo, Maria L. Alcaide, Laura Romero, Denisse Garcia, Margaret Fischl
- 247 HIV-1 VPR SUSTAINS IL-6 PRODUCTION TO PROMOTE HIV-1 REPLICATION IN MACROPHAGES**
Qi Wang, Lishan Su
- 248 T FOLLICULAR HELPER CELLS ARE MAJOR HIV-2 RESERVOIRS AND SUPPORT PRODUCTIVE INFECTION**
Ana Godinho-Santos, Ana Antão, Bárbara Tavares, Tiago Ferreira, Ana Serra-Caetano, Paula Matoso, Cheila Rocha, Russell B. Foxall, Ana E. Sousa
- 249 NEUTROPHIL EXTRACELLULAR TRAPS PREVENT HIV INFECTION IN THE GENITAL TRACT**
Fiona D. Barr, Christina Ochsenbauer, Charles Wira, Marta Rodriguez-Garcia
- 250 COMPARTMENTALIZED HIV-1 IS FOUND IN THE SEMEN OF MEN WITH AND WITHOUT URETHRITIS**
Olivia Council, Lihua Ping, Chase McCann, Gerald Tegha, Irving Hoffman, Debbie Kamwendo, Mitch Matoga, Myron S. Cohen, Ronald Swanstrom
- 251B WITHDRAWN**

- Poster P-C5 VACCINE DESIGN AND TESTING**
Poster Hall A **2:30 PM – 4:00 PM**
- 303 THE DEVELOPMENT OF A NOVEL MACHINE-LEARNING-GUIDED HIV IMMUNOGEN DESIGN**
Wen-Han Yu, Galit Alter, Christina B. Karsten, Douglas Lauffenburger, Daniel Lingwood, Dan Barouch
- 304 DEFINING THE COMMON CORRELATES OF HIV VACCINE TRIALS CROSS-PREDICTS VACCINE EFFICACY**
Wen-Han Yu, Dan Barouch, Douglas Lauffenburger, Margaret Ackerman, Caitlyn Linde, Thomas Broge, Galit Alter

- 305 VACCINATION WITH MF59 INDUCES DISTINCT VACCINE-SPECIFIC ANTIBODY FUNCTIONALITY**
Carolyn Boudreau, Todd J. Suscovich, Galit Alter
- 306 ADDITIONAL BOOST OF AIDSVAZ B/E FURTHER INCREASED RV305 IGG BUT NOT IGA ANTIBODIES**
Siriwat Akapirat, Sandhya Vasan, Supachai Rerks-Ngarm, Punnee Pitisutthithum, Kirsten S. Smith, Surawach Rittiroongrad, Jiraporn Puangkaew, Sanjay Phogat, Faruk Sinangil, Nelson L. Michael, Jean-Louis Excler, Jerome H. Kim, Nicos Karasavvas, Robert J. O'Connell, for the RV305 Study Group
- 307 INCREASE IN B CELL RESPONSES UPON LATE BOOST STRATEGIES OF ALVAC-HIV/AIDSVAZ B/E**
Alexandra Schuetz, Siriwat Akapirat, Weerawan Chuenarom, Punnee Pitisutthithum, Sorachai Nitayaphan, Suwat Chariyalertsak, Jaranit Kaewkungwal, Sanjay Phogat, Faruk Sinangil, Merlin L. Robb, Nelson L. Michael, Jerome H. Kim, Mark de Souza, Robert J. O'Connell, Sandhya Vasan
- 308 EPITOPEs ASSOCIATED WITH HIV-1 DYNAMICS AFTER DC-BASED THERAPEUTIC VACCINATION**
Mathieu Surenaud, Laura Richert, Monica Montes, Sandy Zurawski, Karolina Palucka, Jacques Banchereau, Rodolphe Thiébaut, Jean-Daniel Lelievre, Christine Lacabaratz, Yves Levy
- 309 SIV REBOUND KINETICS FOLLOWING TLR7-AGONIST & THERAPEUTIC VACCINE ADMINISTRATION**
Jeffrey Gerold, So-Yon Lim, Christa E. Osuna, Dan Barouch, James Whitney, Alison L. Hill
- 310 IPROTCT1: A VAC-3S VACCINE PHASE II STUDY IN HIV-INFECTED PATIENTS**
Christine Katlama, Gilles Pialoux, Laurent Cotte, Pierre-Marie Girard, Anne Simon, Jacques Reynes, Jürgen K. Rockstroh, Jose M. Gatell, Alain Devidas, Yazdan Yazdanpanah, Odile Launay, Laurence Weiss, Gerd Fätkenheuer, Béhazine Combadière, Vincent Vieillard
- 311 PHASE I CLINICAL TRIAL OF AN mRNA-BASED THERAPEUTIC VACCINE AGAINST HIV-1 INFECTION**
Lorna Leal, Alberto C. Guardo, Sara Moron-Lopez, Maria Salgado, Beatriz Mothe, Carlo Heirman, Kris Thielemans, Pieter Pannus, Christian Brander, Rob Gruters, Arno Andeweg, Javier Martinez-Picado, Montserrat Plana, Felipe Garcia, for the iHIVARNA consortium
- 312 HIV ANTIBODY GLYCOFORMS MODULATE IMMUNE COMPLEX-DRIVEN INNATE AND ADAPTIVE IMMUNITY**
Giuseppe Lofano, Wen-Han Yu, Margaret Ackerman, Todd J. Suscovich, Galit Alter

Poster P-C6 NOVEL INTERVENTIONAL STRATEGIES**Poster Hall A****2:30 PM – 4:00 PM**

- 313 RIFAXIMIN USE DOES NOT ALTER SCD14 LEVELS IN HIV-INFECTED PERSONS ON SUPPRESSIVE ART**
Anuradha Ganesan, Deborah McMahon, Netanya S. Utay, Jennifer Bell, Heather Burris, Timothy Whitman, Jing Qin, Jeffrey Laczek, Patrick Young, Brian K. Agan, Sheila Kumar, Dean Follmann, Stephen Wank, Frank Maldarelli, for the Gut – Check Rifaximin Team

314 EFFECT OF SWITCHING TO Raltegravir AND/OR ADDING LOSARTAN ON HIV IMMUNE ACTIVATION

Berta Torres, Alberto C. Guardo, Amanda Fabra, Lorna Leal, Cristina Rovira, Carmen Hurtado, Manel E. Bargalló, Constanza Lucero, Irene Fernandez, Flor Etcheverry, Jose M. Gatell, Montserrat Plana, Felipe Garcia

315 TLR9 AGONIST ENHANCES B CELL DIFFERENTIATION AND ANTIBODY PRODUCTION IN HIV+ ADULTS

Mariane H. Schleimann, Line K. Vibholm, Maria-Louise R. Kobberø, Manuel Schmidt, Burghardt Wittig, Tine Damsgaard, Peter Ahlborg, Michel Hellfritsch, Rikke Olesen, Lars Østergaard, Paul W. Denton, Martin Tolstrup, Ole S. Søgaard

316 A BISPECIFIC APPROACH FOR TARGETING NEGATIVE CHECKPOINT RECEPTORS IN HIV-1 LATENCY

Debbie S. Ruelas, Yanyan Zheng, Laura Garvin-Queen, Fahimeh Raoufi, Laurence Fayadat-Dilman, Yuan Li, Julie Strizki, Richard Barnard, Steven G. Deeks, Mohammad Tabrizifard, **Daniel Gorman**

317 HIV INFECTION OF TARGET CELLS IN PEDIATRIC TONSIL IS INHIBITED BY AN HSP90 INHIBITOR

Ria Goswami, Holly A. Heimsath, Riley J. Mangan, Joshua A. Eudailey, Guido Ferrari, Timothy Haystead, Barton F. Haynes, Sallie Permar

318 ALTERED AND INCOMPLETE IMMUNE RECONSTITUTION IN HIV+ STEM CELL TRANSPLANT RECIPIENTS

Daniel D. Murray, John Zaunders, Carole Ford, Kersten Koelsch, Samuel T. Milliken, Orla Morrissey, Sharon Avery, Joseph Sasadeusz, Matthew Law, Anthony Kelleher, Sharon R. Lewin, David A. Cooper, John Moore, Mark Polizzotto

319LB A4B7-BLOCKADE COMBINED WITH VRC01 MODULATES IMMUNE RESPONSES TO SHIV-AD8 INFECTION

Giulia Calenda, Ines Frank, Geraldine Arrode-Bruses, Amarendra Pegu, Wang Keyun, James Arthos, Claudia Cicala, Brooke Grasperge, James Blanchard, Olga Mizenina, Agegnehu Gettie, Anthony S. Fauci, John R. Mascola, **Elena Martinelli**

Poster P-D05 INTERVENTIONS IN SIV MODELS OF PERSISTENCE**Poster Hall A****2:30 PM – 4:00 PM****348 IL-21 PLUS IFNA LIMITS VIRAL PERSISTENCE AND REBOUND IN SIV-INFECTED RHESUS MACAQUES**

Maria Pino, Luca Micci, Justin L. Harper, Colin T. King, Guido Silvestri, Jeffrey D. Lifson, Mirko Paiardini

349 CD4 DEPLETION IN SIV-INFECTED MACAQUES ON EARLY ART HAS NO IMPACT ON VIRAL REBOUND

Adrienne E. Swanstrom, Taina T. Immonen, Claire Deleage, Kelli Oswald, William J. Bosche, Douglas K. Schneider, Sirish Khanal, James A. Thomas, Cathi Pyle, Charles M. Trubey, Jacob D. Estes, Jeffrey D. Lifson, Brandon Keele, **Gregory Q. Del Prete**

350 SIV PERSISTS IN LYMPHOID TISSUES DESPITE ALEMTUZUMAB-INDUCED CD4+ T CELL DEPLETION

Afam Okoye, Colleen Xu, Mukta Vaidya, Derick M. Duell, William B. Brantley, Alejandra Marenco, Yoshinori Fukazawa, Haesun M. Park, Thomas A. Rasmussen, Jeffrey D. Lifson, Michael K. Axthelm, Steven G. Deeks, Louis J. Picker, Sharon R. Lewin

351 ACCR5 ANTI-HIV CART CELLS ENGRAFT AND PERSIST IN SHIV-INFECTED PIGTAIL MACAQUES

Thor A. Wagner, Christopher Peterson, Brenda Seymour, Taylor Mesojednik, Jeb English, Bryan Sands, Courtnee Clough, Karsten Eichholz, Larry Corey, Hans-Peter Kiem, David J. Rawlings

352 FULLY MHC-MATCHED ALLOGENEIC HSCT IN SIV-INFECTED, ART-SUPPRESSED MACAQUES

Helen Wu, Benjamin Burwitz, Shaheed Abdulhaqq, Christine Shriver-Munsch, Tonya Swanson, Alfred Legasse, Katherine Hammond, Jason Reed, Mina Northrup, Stephanie Junell, Gabrielle Meyers, Richard Maziarz, Jeffrey Stanton, Jonah Sacha

353LB IL-15 TREATMENT INCREASES CYTOTOXIC LYMPHOCYTES IN LN FOLLICLES AND REDUCES SHIV RNA

George N. Pavlakis, Dionysios C. Watson, Eirini Moysi, Antonio Valentín, Cristina Bergamaschi, Santhi Devsundaram, Sotirios Fortis, Claire Deleage, Jacob D. Estes, Elena Chertova, Jeffrey D. Lifson, Constantinos Petrovas, Barbara K. Felber

Poster P-D06 NOVEL INTERVENTIONS TO TARGET HIV RESERVOIRS**Poster Hall A****2:30 PM – 4:00 PM**

Poster Sessions • Tuesday

354 GAMMA/DELTA CELLS TARGET THE HIV RESERVOIR: IMMUNOTHERAPEUTIC POTENTIAL FOR HIV CURE

Chloe Whitworth, Carolina Garrido, Katherine Sholtis, Matthew Clohosey, Nancie Archin, David M. Margolis, **Natalia Soriano-Sarabia**

355 BLOCKADE OF IFNAR RESCUES ANTI-HIV-1 CD8 T CELL FUNCTIONS TO REDUCE HIV-1 RESERVOIR

Liang Cheng, Jianping Ma, Guangming Li, Zhiyuan Hu, Liguang Zhang, Lishan Su

356 A PHASE 1 STUDY OF ALT-803 (IL-15 SUPERAGONIST) TO CLEAR LATENT HIV RESERVOIRS

Zachary Davis, Ann Thorkelson, Jodi Anderson, Hing C. Wong, Jonathan Karn, Curtis Dobrowski, Jeffrey S. Miller, Sarah Cooley, Daniel Douek, Timothy Schacker

357 EFFECT OF 24 WEEKS TLR9 AGONIST THERAPY ON CTL RESPONSES AND VIRAL REBOUND DURING ATI

Line K. Vibholm, Giacomo Frattari, Mariane H. Schleimann, Rikke Olesen, Mathias Licherfeld, Anni Winckelmann, Christina V. Konrad, Vibeke Klastrup, Thomas A. Rasmussen, Manuel Schmidt, Burghardt Wittig, Lars Østergaard, Paul W. Denton, Martin Tolstrup, Ole S. Søgaard

358 IFN-Α INDUCES NK-DEPENDENT HIV DNA DECLINE IN ART-TREATED HIV/HCV COINFECTED PATIENTS

Stephane Hua, Selena Vigano, Samantha Tse, Zhengyu Ouyang, Sean Harrington, Jordi Negron, Pilar Garcia-Broncano, Giulia Marchetti, Miguel Genebat, Manuel Leal, Salvador Resino, Ezequiel Ruiz-Mateos, Mathias Licherfeld, Xu G. Yu

359 THE THERAPEUTIC VACCINE VACC-4X TARGETS GAG CTL EPITOPIES WITH PREEXISTING MUTATIONS

Anni Winckelmann, Vincent Morcilla, Wei Shao, Lars Østergaard, Ole S. Søgaard, **Martin Tolstrup**, Sarah Palmer

360LB WITHDRAWN

Poster P-D07 CHARACTERIZING HIV RESERVOIRS**Poster Hall A****2:30 PM – 4:00 PM****361 SEX-BASED DIFFERENCES IN TRANSCRIPTOMIC PROFILES AND HIV RESERVOIR CORRELATES**

Eileen P. Scully, Khader Ghneim, Ashish Sharma, Ainsley Lockhart, Rowena Johnston, Monica Gandhi, Rebecca Hoh, Sharon R. Lewin, Nicolas Chomont, Steven G. Deeks, Rafick-Pierre Sekaly

362 THE IMPACT OF ART DURATION ON THE INFECTION OF T CELLS WITHIN ANATOMIC SITES

Eunok Lee, Susanne von Stockenstrom, Vincent Morcilla, Wei Shao, Wendy Hartogensis, Peter Bacchetti, Jeffery Milush, Rebecca Hoh, Ma Somsouk, Peter W. Hunt, Rémi Fromentin, Nicolas Chomont, Steven G. Deeks, Frederick M. Hecht, **Sarah Palmer**

363 PERSISTENCE OF CD4+PD-1HIGH T CELLS DESPITE LONG-TERM SUPPRESSIVE ART

Bernard J. Macatangay, Rajesh T. Gandhi, Deborah McMahon, Christina Lalama, Ronald Bosch, Joshua C. Cytor, Christopher Hensel, Evelyn Hogg, Luann Borowski, Joseph J. Eron, John W. Mellors, Charles Rinaldo, for the ACTG A5321

364 PROVIRAL LANDSCAPE IN HIV-1 POST-TREATMENT CONTROLLERS AND NON-CONTROLLERS

Radwa Sharaf, Guinevere Q. Lee, Xiaoming Sun, Evgenia Aga, Ronald Bosch, Rajesh T. Gandhi, Jeffrey Jacobson, Edward P. Acosta, Daniel R. Kuritzkes, Michael M. Lederman, Xu G. Yu, Mathias Lichtenfeld, Jonathan Z. Li, for the AIDS Clinical Trials Group (ACTG) NWCS 380 Study Team

365 HIV VIREMIA IS THE PRODUCT OF A SMALL FRACTION OF HIV INFECTED CELLS

Elizabeth M. Anderson, Shawn Hill, Jennifer Bell, Catherine A. Rehm, Sara Jones, Rob Gorelick, Mary F. Kearney, John M. Coffin, Frank Maldarelli

366 THE GENETIC TRAITS OF FULL-LENGTH HIV SEQUENCED FROM MEMORY T CELL SUBSETS

Bethany A. Horsburgh, Bonnie Hiener, Eunok Lee, John-Sebastian Eden, Timothy E. Schlub, Susanne von Stockenstrom, Jeffery Milush, Teri Liegler, Elizabeth Sinclair, Rebecca Hoh, Rémi Fromentin, Nicolas Chomont, Steven G. Deeks, Frederick M. Hecht, Sarah Palmer

367 PULMONARY MUCOSAL T CELLS AS POTENTIAL HIV RESERVOIRS DURING LONG-TERM ART

Syim Salahuddin, Omar Farnos, Ron Olivenstein, Aurelie Le Page, Amelie Pagliuzza, Christina de Castro, Jean Bourbeau, Petronela Ancuta, Bertrand Lebouché, Jean-Pierre Routy, Nicolas Chomont, Cecilia Costiniuk, Mohammad-Ali Jenabian

368 THE BIRC5/OX40 PATHWAY MAINTAINS SURVIVAL OF HIV-1-INFECTED CD4 T CELLS

Hsiao-Hsuan Kuo, Rushdy Ahmad, Guinevere Q. Lee, Hsiao-Rong Chen, Matthew J. Szucs, Athé Tsibris, Eric Rosenberg, Steven Carr, Xu G. Yu, Mathias Lichtenfeld

369 HIV-2 RESERVOIR DISTRIBUTION IN CD4 T CELLS RELATED TO CXCR6 AND TRIM-5 EXPRESSION

Assia Samri, Charlotte Charpentier, Mélanie Bertine, Mariama S. Diallo, Sophie Even, Veronique Morin, Anne Oudin, Gilles Collin, Sophie Matheron, Rodolphe Thiébaut, Rima Zoorob, Brigitte Autran, Francoise Brun-Vezinet, for the ANRS CO5 IMMUNOVIR-2 study group

370 EFFECTOR MEMORY T CELLS CONTRIBUTE TO X4 MONOTYPIC RESIDUAL PLASMA VIRUS PRODUCTION

Hadega Aamer, Sherry McLaughlin, Michael Dapp, Sheila Styrchak, Ana Gervassi, Janine Maenza, Ann Collier, James Mullins, Lisa Frenkel

371 TESTICULAR IMMUNE PRIVILEGE AND HIV-1 PERSISTENCE

Rosalie Ponte, Franck P. Dupuy, Zabrina Brumme, Natalie Kinloch, Art Poon, Pierre Brassard, Maud Bélanger, Vikram Mehraj, Reina Bendayan, Mohammad-Ali Jenabian, Jean-Pierre Routy

372 RECONSTRUCTING INTEGRATION DATES OF LATENT HIV SEQUENCES WITHIN-HOST

Bradley R. Jones, Natalie Kinloch, Joshua J. Horacsek, Bruce Ganase, Marianne Harris, P. Richard Harrigan, R. Brad Jones, Mark Brockman, Jeffrey Joy, Art Poon, Zabrina Brumme

373 IDENTIFICATION OF MACROPHAGE RESERVOIRS THROUGH TROPISM OF HIV-1 ENVELOPES

Viviane Machado, Thaisa Alvarado, Mario Stevenson, Labelle Barrios, Aubrey Morales, Mark Sharkey, Marco Salemi, Carla Mavian, Timothy J. Henrich

374LB HEMATOPOIETIC STEM AND PROGENITOR CELLS ARE A UNIQUE FUNCTIONAL HIV RESERVOIR

Thomas D. Zaikos, Valeri Terry, Nadia T. Sebastian Kettinger, Andrew J. Neevel, Ryan Yucha, Kathleen L. Collins

Poster P-E4 NEUROIMAGING AND ASSOCIATED BIOMARKERS**Poster Hall A****2:30 PM – 4:00 PM****425 BRAIN VOLUMES CHANGES AFTER ABC/3TC + EFV OR TDF/FTC + ATV/R AS FIRST-LINE ART**

Ignacio Pérez-Valero, Lucia Bailon, Alicia Gonzalez, Belen Alejos, Helena Melero, Norberto Malpica, Jose I. Bernardino, Juan González-García, Jose R. Arribas, for the La Paz HIV Group

426 LONGITUDINAL PET IMAGING OF THE SEROTONERGIC SYSTEM IN SIV-INFECTED NONHUMAN PRIMATES

Swati Shah, Sanhita Sinharay, Dianne Lee, William C. Reid, Paul Wakim, Kenta Matsuda, Avindra Nath, Vanessa Hirsch, Michele Di Mascio, Dima A. Hammoud

427 IMMUNOLOGICAL AND NEUROMETABOLITE CHANGES ASSOCIATED WITH SWITCH FROM EFV TO AN INSTI

Nina Lin, Yvonne Robles, Alan Landay, Tyler Starr, Jennifer Kinslow, Joshua Ladner, Rebeca M. Plank, Laura F. White, Kathy Melbourne, Alexander Lin, Daniel R. Kuritzkes

428 CHANGES IN BRAIN VOLUME AND COGNITION IN MICE EXPOSED IN UTERO TO ABC/3TC-ATV/ RTV

Kayode Balogun, Monica Guzman Lenis, Lindsay Cahill, Howard Mount, John Sled, Lena Serghides

429 BRAIN 18F-FDG PET OF SIV-INFECTED MACAQUES AFTER TREATMENT INTERRUPTION OR INITIATION

William T. Schreiber-Stainthorp, Sharat Srinivasula, Sanhita Sinharay, Swati Shah, Jing Wang, Lori E. Dodd, H. Clifford Lane, Michele Di Mascio, Dima A. Hammoud

430 INTACT STRUCTURAL AND FUNCTIONAL BRAIN IMAGING IN ACUTE HIV

Vishal Samboju, Carissa Philippi, Phillip Chan, Yann Cobigo, James L. Fletcher, Merlin L. Robb, Joanna Hellmuth, Khunthalee Benjapornpong, Netsiri Dumrongpisutkul, Mantana Pothisri, Robert Paul, Jintanat Ananworanich, Serena S. Spudich, Victor Valcour, for the SEARCH 010/RV254 and RV304 protocol team

431 HIV INFECTION AND AGE HAVE INDEPENDENT EFFECTS ON BRAIN GRAY MATTER VOLUME

Erin O'Connor, Thomas Zeffiro, Melissa F. Murray, Donna Martineck, James T. Becker

432 MULTIMODAL BRAIN IMAGING PREDICTS NEUROCOGNITIVE IMPAIRMENT IN CHRONIC HIV

Talia M. Nir, Hei Y. Lam, Chris R. Ching, Neda Jahanshad, Jaroslaw Harezlak, Kenia Martínez, Tong Zhu, Giovanni Schifitto, Ronald Cohen, Paul M. Thompson, Bradford A. Navia, for the HIV Neuroimaging Consortium

433 LESION LOAD IS ASSOCIATED WITH NEUROCOGNITIVE DEFICITS IN HIV-INFECTED INDIVIDUALS

Manori De Alwis, Matthew K. Schindler, Anuradha Ganesan, Seung Hyun Won, Robert Deiss, Xiuping Chu, Daniel B. Hawley, Brian K. Agan, Stanley Rapoport, Daniel S. Reich, Joseph Snow, Edmund C. Tramont, **Bryan Smith**, Govind Nair, Avindra Nath, for the Neuro-HIV Research Program

434 ANALYSIS OF THE EFFECTS OF HIV DISEASE ON FUNCTIONAL NEUROMAGNETIC CONNECTIVITY

Mark D. Kelley, Melissa F. Murray, Donna Martineck, Ricardo Bruna, Anto Bagic, James T. Becker

435 BRAIN WHITE MATTER HYPERINTENSITIES, HIV DISEASE, COGNITION AND DIABETES

Minjie Wu, Omalara Fatukasi, Shaolin Yang, Jeffry Alger, Peter B. Barker, Tae Kim, Andrew Levine, Eileen Martin, Cynthia Munro, Todd B. Parrish, Ann B. Ragin, Ned Sacktor, Eric C. Seaberg, **James T. Becker**, for the Neuropsychology Working Group of the Multicenter AIDS Cohort Study

436 MULTIVARIATE PATTERN ANALYSIS OF VOLUMETRIC NEUROIMAGING DATA IN TREATED HIV-DISEASE

Jonathan Underwood, James H. Cole, Robert Leech, Alan Winston, for the CHARTER group

437 CEREBRAL GLUTATHIONE METABOLISM IN ACUTE HIV INFECTION AND RESPONSE TO ART

Napapon Sailasuta, Jennifer Daniels, Phillip Chan, Carlo Sacdalan, Merlin L. Robb, Somporn Tipsuk, Jintanat Ananworanich, Duanghathai Suttichom, Robert Paul, Nisakorn Ratnaratorn, Mantana Pothisri, Netsiri Dumrongpisutkul, Serena S. Spudich, Victor Valcour, for the SEARCH 010/RV254 and RV304 Study Team

438 AMYLOID UPTAKE BY PET IMAGING SUGGEST PREMATURE AGING IN OLDER HIV+ INDIVIDUALS

Ned Sacktor, Richard Skolasky, Heidi Roosa, Cornelia Demsky, Yun Zhou, Weiguo Ye, Noble George, Peter B. Barker, Dean Wong, Mona Mohamed

439 NEUROIMAGING CORRELATES OF FRAILTY, COGNITION AND HIV

Jeremy Strain, Robert S. Smith, Sarah Cooley, Beau M. Ances

440 SUBCLINICAL GLOBAL AND THALAMIC HYPOMETABOLISM ON FDG-PET IN TREATED HIV+ SUBJECTS

Dima A. Hammoud, Sanhita Sinharay, Sally Steinbach, Paul Wakim, Katrina Geannopoulos, Katherine Traino, Amit Dey, Stanley Rapoport, Edmund C. Tramont, Joseph Snow, Nehal N. Mehta, Bryan Smith, Avindra Nath

441LB BRAIN PET IMAGING OF MICROGLIA IN MACAQUES WITH SIV ENCEPHALITIS

Dima A. Hammoud, Sanhita Sinharay, Kenta Matsuda, Dianne Lee, Swati Shah, William Reid, Paul Wakim, Vanessa Hirsch, Avindra Nath, Michele Di Mascio

Poster P-F3 ANTIRETROVIRAL PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTIONS**Poster Hall D****2:30 PM – 4:00 PM**

Poster Sessions • Tuesday

464 HIGHER NRTI METABOLITE:ENDOGENOUS NUCLEOTIDE RATIOS IN OLDER HIV+ WOMEN ON TDF/FTC

Julie B. Dumond, Camden Bay, Julie A. Nelson, Craig Sykes, Kathryn Anastos, Roopali Sharma, Seble Kassaye, Maria Villacres, Ruth Greenblatt, Audrey French, Stephen J. Gange, Igbo Ofoekun, Margaret Fischl, David Vance, Adaora Adimora

465 ETRAVIRINE PHARMACOKINETICS IN TREATMENT-EXPERIENCED CHILDREN AGES 1- <6 YEARS

Christine E. MacBrayne, Richard Rutstein, Ram Yoge, Andrew Wiznia, Lee Fairlie, Bobbie Graham, Carmelita Alvero, Jack Moye, Ellen Townley, Herta Crauwels, Xavier Woot de Trixhe, Lotke Tambuyzer, Simon Vanveggen, Magda Opsomer, **Jennifer J. Kiser**

466 CYP2B6 VARIANTS ALTER ETONOGESTREL PHARMACOKINETICS WHEN COMBINED WITH EFAVIRENZ

Megan Neary, Catherine Chappell, Kimberly K. Scarsi, Shadia Nakalema, Joshua Matovu, Sharon L. Achilles, Beatrice A. Chen, Marco Siccardi, Andrew Owen, Mohammed Lamorde

467 NR1I2 RS2472677 AND ABCG2 RS2231142 INFLUENCE DOLUTEGRAVIR CONCENTRATIONS IN PLASMA

Emilie R. Elliot, Megan Neary, Laura Else, Saye Khoo, Graeme Moyle, Daniel F. Carr, Xinzhu Wang, Myra McClure, Andrew Owen, Marta Boffito

468 PHARMACOKINETICS OF DOLUTEGRAVIR WITH AND WITHOUT DARUNAVIR/COBICISTAT

Emilie R. Elliot, Maddalena Cerrone, Laura Else, Alieu Amara, Elisa Bisdomini, Saye Khoo, Marta Boffito

469 PHARMACOKINETICS (PK) OF ETHINYLESTRADIOL/LEVONORGESTREL WITH ATAZANAVIR/COBICISTAT

Emilie R. Elliot, Elisa Bisdomini, Laura Else, Sujan Dilly Penchala, Saye Khoo, Graeme Moyle, Nneka Nwokolo, Marta Boffito

470 THE EFFECT OF ANTACIDS AND MULTIVITAMINS ON Raltegravir

Helen Reynolds, Joseph Lewis, Deidre Egan, Mas Chaponda, Laura Else, Justin Chiong, Darren M. Moss, David Back, Andrew Owen, Saye Khoo

**471 RAVIDASVIR PHARMACOKINETICS AND ARV DRUGS
INTERACTIONS IN HCV+/-HIV INFECTED ADULTS**

Tim R. Cressey, Soek-Siam Tan, Hajjah Rosaida Hj Mohd Said, Muhammad Radzi Abu Hassan, Haniza Omar, Tee Hoi Poh, Chan Wah Kheong, Suresh Kumar, Satawat Thongsawat, Kanawee Thetket, Suparat Khemnark, Anchalee Avihingsanon, François Simon, Isabelle Andrieux-Meyer, Marc Lallement

**Poster P-F4 ANTIRETROVIRAL PHARMACOLOGY IN COMPARTMENTS
AND RESERVOIRS**

Poster Hall D

2:30 PM – 4:00 PM

**472 MAPPING THE DISTRIBUTION OF EFAVIRENZ WITH BRAIN
TISSUE CELLS**

Nithya Srinivas, Elias Rosen, Gabriela D. Cruz, Craig Sykes, Amanda Schauer, Lourdes Adamson, Paul Luciw, Angela Kashuba

**473 SWITCHING TO TAF IN EVG-BASED REGIMENS: CSF
PHARMACOKINETICS AND ANTVIRAL ACTIVITY**

Qing Ma, Andrew Ocque, Gene D. Morse, Chelsea Sanders, Alina Burgi, Susan J. Little, Scott L. Letendre

**474 DIFFERENTIAL BRAIN TISSUE PENETRATION OF
ANTIRETROVIRALS AND FLUCONAZOLE**

Melanie Nicol, Jonee Taylor, Katelyn Pastick, James Fisher, Carol Karuganda, Joshua Rhein, Darlisha A. Williams, David Meya, David R. Boulware, Robert Lukande

**475 MASS SPEC IMAGING REVEALS ASSOCIATIONS BETWEEN ARVS,
VIRUS, AND CELLS IN LYMPH NODES**

Elias Rosen, Claire Deleage, Nicole White, Craig Sykes, Lourdes Adamson, Yuri Fedoriw, Jacob D. Estes, Paul Luciw, Angela Kashuba

**476 EFFECT OF SEX, SHIV, AND DRUG TRANSPORTERS ON LYMPH
NODE ANTIRETROVIRAL PENETRATION**

Erin M. Burgunder, John K. Fallon, Nicole White, Amanda Schauer, Craig Sykes, Lourdes Adamson, Jason R. Pirone, Paul Luciw, Philip C. Smith, Angela Kashuba

**477 HIV TARGET CELL DISTRIBUTION AND TFV PENETRATION IN
FORESKIN AND URETHRA**

Alison S. Kohlmeier, Kenji Nishiura, Natalia Makarova, Jessica Radzio-Basu, Gerardo Garcia-Lerma, Charles Dobard

**478 SEMINAL TENOFOVIR CONCENTRATIONS, VIRAL SUPPRESSION
AND SEMEN QUALITY WITH TAF VS TDF**

Arkaitz Imaz, Jordi Niubo, Mackenzie L. Cottrell, Emilia Perez, Angela Kashuba, Juan M. Tiraboschi, Sandra Morenilla, Benito Garcia, Daniel Podzamczer

Poster P-I1 TRANSMITTED DRUG RESISTANCE: A GLOBAL CONCERN

Poster Hall D

2:30 PM – 4:00 PM

**523 PRETREATMENT HIV DRUG RESISTANCE SPREAD WITHIN
TRANSMISSION CLUSTERS IN MEXICO CITY**

Margarita Matías-Florentino, Antoine Chaillon, **Santiago Avila-Rios**, Verónica Ruiz, Silvia del Arenal, Manuel A. Becerril-Rodríguez, Alicia Piñeirúa, Florentino Badial Hernandez, Andrea Gonzalez Rodriguez, Sanjay R. Mehta, Gustavo Reyes-Terán

524 SPREAD OF HIV-1 PRE-TREATMENT DRUG RESISTANCE IN THE COLOGNE-BONN REGION, GERMANY

Melanie Stecher, Martin Hoenigl, Anna-Maria Eis-Huebinger, Clara Lehmann, Gerd Fätkenheuer, Jan-Christian Wasmuth, Rolf Kaiser, Sanjay R. Mehta, Joerg Janne Vehreschild, Antoine Chaillon

525 IMPACT OF TRANSMITTED RESISTANCE ON CLINICAL OUTCOMES IN THE VMVN TRIAL IN VIETNAM

Vu P. Thao, Cuong D. Do Duy, Thanh Thuy Pham Thi, Duong T. Hao, Bui T. That, Donn Colby, Todd Pollack, Thuy Le

526 PREVALENCE OF HIV-1 ANTIRETROVIRAL DRUG RESISTANCE IN FLORIDA, 2015-2016

Karalee Poschman, Emma C. Spencer

527 PRETREATMENT HIV DRUG RESISTANCE IN THE START STUDY USING NEXT GENERATION SEQUENCING

John D. Baxter, David Dunn, Rasmus L. Marvig, Marc Bennedbaek, Alessandro Cozzi-Lepri, Shweta Sharma, Anna Tostevin, Michael Kozal, Mark Gompels, Angie N. Pinto, Jens D. Lundgren, for the INSIGHT START Study Group

528 DECLINE IN CLINICALLY RELEVANT RESISTANCE TO FIRST LINE ARV REGIMENS IN SPAIN

Marta Alvarez, José Ángel Fernández-Caballero, Ana B. Perez, Nuria Espinosa, Silvia García-Bujalance, María Jesus Pérez-Elias, Rafael Delgado, José A. Iribarren, Isabel Viciana, David Dalmau, Antonio Aguilera, Mar Masia, Victoria Hernando, **Federico García**, for the CoRIS Resistance Study Group

529 HIGH PREVALENCE OF NNRTI ANDINI-RESISTANT POLYMORPHIC VIRUS IN PRIMARY HIV INFECTION

Marie-Laure Chaix Baudier, Maxime Grudé, Heloise M. Delagreverie, Catherine Roussel, Hélène Pere, Hélène Le Guillou-Guillemette, Julia Dina, Anne Signori-Schmuck, Marie-Josée Carles, Laurence Morand-Joubert, Jacques Izopet, Laurence Meyer, Lambert Assoumou, Diane Descamps, for the AC11 ANRS Resistance Group

Poster P-12 ANTIRETROVIRAL RESISTANCE AND RESPONSE TO INITIAL THERAPY

Poster Hall D

2:30 PM – 4:00 PM

530 HIV DRUG RESISTANCE AS A SIGNIFICANT DRIVER OF FIRST-LINE TREATMENT FAILURE IN UGANDA

Suzanne McCluskey, Nicholas Musinguzi, Kimia Kamelian, Guinevere Q. Lee, Yap Boum, Bosco M. Bwana, Conrad Muzoora, Jeffrey N. Martin, Peter W. Hunt, Vincent C. Marconi, David R. Bangsberg, Jessica E. Haberer, P. Richard Harrigan, Mark J. Siedner

531 EFFECT OF 12-WEEK Raltegravir INTENSIFICATION OF FIRST-LINE ART ON HIV RESISTANCE

Cissy Kityo, Sarah Walker, Immaculate Nankya, Moira J. Spyer, Eva Nabulime, Mutua Bwakura-Dangarembizi, Linda Mipando, Simon Wachira, Anthony Etyang, Godfrey Musoro, Esther Nambi, Kusum Nathoo, Sarah Pett, Diana Gibb, for the REALITY trial team

532 POOLED WEEK 48 EFFICACY AND BASELINE RESISTANCE: B/F/TAF IN TREATMENT-NAIVE PATIENTS

Kirsten L. White, Rima Kulkarni, Madeleine Willkom, Ross Martin, Silvia Chang, Xuelian Wei, William Garner, Devi SenGupta, Hal Martin, Erin Quirk, Andrew Cheng

- 533 HIV DRUG RESISTANCE WITH EARLY VS DELAYED ANTIRETROVIRAL TREATMENT (HPTN 052)**
Philip J. Palumbo, Jessica M. Fogel, Ethan A. Wilson, Sarah E. Hudelson, Stephen Hart, Laura Hovind, Estelle Piwowar-Manning, Maria Papathanasopoulos, Mariza Morgado, Shanmugam Saravanan, Srikanth Tripathy, Ying Q. Chen, Myron S. Cohen, Susan H. Eshleman, for the HPTN 052 Study Team
- 534 DEFINING CLINICALLY RELEVANT THRESHOLD FOR ULTRASENSITIVE HIV RESISTANCE TESTING**
Seth C. Inzaule, Raph L. Hamers, Marc Noguera-Julian, Maria Casadella, Mariona Parera, Bonaventura Clotet, Tobias F. Rinke de Wit, Roger Paredes, for the PanAfrican Studies to Evaluate Resistance (PASER)
- 535 PROVIRAL DRUG RESISTANCE ACQUIRED DURING EARLY THERAPY PREDICTS VIROLOGICAL OUTCOME**
Bindu P. Gopalan, Reena Dsouza, Karthika Arumugam, Niharika Rajnala, Udaykumar Ranga, Anita Shet
- Poster P-13 RESISTANCE ON ANTIRETROVIRAL THERAPY: THE PROBLEM PERSISTS!**
- Poster Hall D** **2:30 PM – 4:00 PM**
- 536 RARE HIV VARIANTS WITH LINKED DUAL-CLASS RESISTANCE ARE ASSOCIATED WITH ART FAILURE**
Valerie F. Boltz, Wei Shao, Elias K. Halvas, James A. McIntyre, Robert T. Schooley, Shahin Lockman, Judith S. Currier, Fredrick Sawe, Evelyn Hogg, Michael D. Hughes, Mary F. Kearney, John M. Coffin, John W. Mellors
- 537 ACCUMULATION OF HIV DRUG RESISTANCE ON FAILING FIRST-LINE ART IN LUSAKA, ZAMBIA**
Parker Hudson, Lloyd Mulenga, Andrew Westfall, Ranjit Warrier, Aggrey Mweemba, Michael Saag, Jeffrey S. Stringer, Joseph J. Eron, Benjamin H. Chi
- 538 IMPACT OF FIRST-LINE ART CHOICE AND DURATION OF VIRAL FAILURE ON SECOND-LINE OPTIONS**
Seema T. Meloni, Chika K. Onwuamah, Oche Agbaji, Beth Chaplin, David O. Olaleye, Rosemary Audu, Ezechi C. Oliver, Godwin Imade, Adesola Z. Musa, Georgina N. Odaibo, Holly Rawizza, Prosper Okonkwo, Emmanuel O. Idigbe, Phyllis J. Kanki, for the Nigeria Drug Resistance Research Team
- 539 GENOTYPIC RESISTANCE PROFILES IN HIV-INFECTED CHILDREN WITH TREATMENT FAILURE**
Birkneh T. Tadesse, Byron A. Foster, Degu Jerene, Kyle Cobarrubias, Bemuluyigza Baraki, Natalie Kinloch, Mark Brockman, Eyasu Makonnen, Eleni Aklillu, Zabrina Brumme
- 540 FIRST-LINE HIV TREATMENT FAILURE IN NON-B SUBTYPES AND RECOMBINANTS IN UGANDA**
Art Poon, Emmanuel Ndashimye, **Mariano Avino**, Richard Gibson, Fred Kyeyune, Immaculate Nankya, Miguel E. Quinones-Nateu, Eric Arts, for the Ugandan Drug Resistance Study
- 541 HIGH LEVELS OF HIV DRUG RESISTANCE AMONG ADULTS FAILING SECOND-LINE ART IN NAMIBIA**
Michael R. Jordan, Ndapewa Hamunime, Souleymane Sawadogo, Simon Agolory, Andreas Shiningawamwe, Taffa Negussie, Christa L. Fischer Walker, Elliot G. Raizes, Nicholus Mutenda, Christian Hunter, Natalie Dean, Kim Steegen, Vibha Kana, Chunfu Yang, Steven Y. Hong

Poster P-14 ARE INTEGRASE STRAND-TRANSFER INHIBITORS RESISTANCE PROOF?**Poster Hall D****2:30 PM – 4:00 PM****542 LOW PREVALENCE OF INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE ACROSS BOTSWANA**

Simani Gaseitsiwe, Sikhulile Moyo, Melissa Zahralban-Steele, Dorcas Maruapula, Baitshepi Mokaleng, Terence Mohammed, Shenaaz El-Halabi, Elliot G. Raizes, Tendani Gaolathe, Shahin Lockman, Max Essex, Vlad Novitsky

543 HIGH LEVEL RESISTANCE TO DOLUTEGRAVIR (DTG) AFTER EMERGENCE OF T97A MUTATION

Safia S. Kuriakose, Jomy M. George, Nicola Dee, Pam Stoll, Brian K. Agan, Robin L. Dewar, Alice K. Pau, Frank Maldarelli

544 UNINTEGRATED VIRAL DNA INVOLVED IN DOLUTEGRAVIR RESISTANCE

Isabelle Malet, Frédéric Subra, Hervé Leh, Charlotte Charpentier, Gilles Collin, Diane Descamps, Eric Deprez, Vincent Calvez, Anne-Geneviève Marcellin, Olivier Delelis

545 PREVALENCE AND CLINICAL IMPACT OF MINORITY RESISTANT VARIANTS TO INTEGRASE INHIBITORS

Thuy T. Nguyen, Djeneba Bocar Fofana, Charlotte Charpentier, Sidonie Lambert, Laurence Morand-Joubert, Diane Descamps, Marc Wirden, Christine Katlama, Minh Le, Gilles Peytavin, Philippe Flandre, Vincent Calvez, Eve Todesco, Anne-Geneviève Marcellin, for the ANRS AC11 Resistance Study Group.

546 INTEGRASE INHIBITOR RESISTANCE SELECTIONS INITIATED WITH DRUG RESISTANT HIV-1

Kristen Andreatta, Silvia Chang, Ross Martin, Madeleine Willkom, Kirsten L. White

547 157Q INTEGRASE POLYMORPHISM: IN VITRO PHENOTYPIC IMPACT AND IN VIVO VIROLOGIC OUTCOME

Charlotte Charpentier, Isabelle Malet, Audrey Rodallec, Laurence Bocket, Corinne Amiel, Laurence Morand-Joubert, Pantxika Bellecave, Thuy T. Nguyen, Anne Maillard, Brigitte Montes, Marie Leoz, Constance Delaugerre, Vincent Calvez, Anne-Geneviève Marcellin, Diane Descamps

548 CHARACTERIZATION OF THE DOLUTEGRAVIR MONOTHERAPY-ACQUIRED S230R RESISTANCE MUTATION

Hanh T. Pham, Ingeborg Wijting, Lydia Labrie, Said Hassounah, Ineke van der Ende, Bluma G. Brenner, Bonnie Spira, Charles Boucher, Bart Rijnders, Jeroen J. van Kampen, Thibault Mesplede, Mark A. Wainberg

549 IN VITRO SELECTED RESISTANCE TO NEW INTEGRASE INHIBITORS BY B & NON-B SUBTYPE VIRUSES

Bluma G. Brenner, Maureen Oliveira, Ruxandra-Ilinca Ibanescu, Bonnie Spira, Thibault Mesplede, Jean-Pierre Routy

Poster P-J1 HIV DIAGNOSTICS**Poster Hall D****2:30 PM – 4:00 PM****563 FIELD EVALUATION OF A DUAL HIV/SYPHILIS TEST IN A COMMUNITY-BASED CLINIC, LOS ANGELES**

Chrysovalantis Stafylis, Lauren J. Natoli, Katheryn Salow, Emma Davidson, Yancy Granados, Mark R. McGrath, Jeffrey D. Klausner

- 564 FIELD EVALUATION OF A DUAL ANTIGEN RAPID TEST FOR HIV/SYPHILIS INFECTION, VIETNAM**
Keenan Withers, Minh D. Nguyen, Chrysovalantis Stafylis, Loc Pham, Le Minh Giang, Jeffrey D. Klausner
- 565 TIME FROM HIV INFECTION TO EARLIEST DETECTION FOR 4 FDA-APPROVED POINT-OF-CARE TESTS**
Kevin P. Delaney, Lauren Violette, George A. Ure, Andy M. Cornelius-Hudson, Lisa Niemann, Laura Wesolowski, Pollyanna Chavez, Steven Ethridge, Vanessa McMahan, Hollie Clark, David A. Katz, **Joanne Stekler**
- 566 UTILITY OF POC XPERT HIV-1 TESTS FOR DETECTION-QUANTIFICATION OF COMPLEX RECOMBINANTS**
Marina Rubio Garrido, Adolphe Ndarabu, Gabriel Reina, David Barquín, Silvia Carlos, Africa Holguin
- 567 RELATIVE SENSITIVITIES OF 4TH AND 5TH GEN COMBO HIV AG/AB, P24 AND VIRAL LOAD ASSAYS**
Mars Stone, John Bainbridge, Ana M. Sanchez, Andrea Pappas, Mark M. Manak, Robert Coombs, M Kathleen Shriver, Paul Contestable, Sangeetha Vijaysri Nair, David H. Wilson, Martin Stengelin, Gary Murphy, Indira Hewlett, Thomas M. Denny, Michael P. Busch
- 568 INCREASING POSITIVITY FOR NON-PLASMA SAMPLES USING THE ABBOTT REALTIME HIV-1 ASSAY**
Ming Chang, Junhui Wang, Jared Baeten, Andrew Mujugira, Robert Coombs
- 569 EVALUATION OF THE CDC/APHL HIV DIAGNOSTIC ALGORITHM WITH RECENTLY FDA-APPROVED ASSAYS**
Wei Luo, William Fowler, Krystin A. Price, Vickie Sullivan, Timothy Granade, Steven Ethridge, Laura Wesolowski, Kevin P. Delaney, William M. Switzer, S. Michele Owen, **Silvina Masciotra**
- 570 PERFORMANCE EVALUATION OF THE APTIMA HIV-1 QUANT ASSAY ON THE PANTHER SYSTEM**
Silvina Masciotra, Wei Luo, Tara Smith, Vickie Sullivan, William Fowler, Steven Ethridge, Laura Wesolowski, Kevin P. Delaney, William M. Switzer, S. Michele Owen
- 571 EVALUATION OF THE APTIMA HIV-1 QUANT DX ASSAY FOR MONITORING OF HIV-1 VIRAL LOAD**
Mónica García-Álvarez, Sagrario Zurita, Francisca Gutiérrez, Paula Aranguren, Samanta Aparicio, Rafael Delgado
- 572 CEPHEID XPERT HIV-1 VIRAL LOAD ASSAY PERFORMANCE EVALUATION**
Laura Wesolowski, William Fowler, Wei Luo, Silvina Masciotra, Kevin P. Delaney, Emeka Oraka, Pollyanna Chavez, Steven Ethridge, William M. Switzer, S. Michele Owen
- 573 CELLULAR HIV-1 NUCLEIC ACID DETECTION IN CASES WITH UNDETECTABLE PLASMA VIRAL LOAD**
Linda Jagodzinski, Holly R. Hack, Ying Liu, Jennifer Malia, Mark M. Manak, Nittaya Phanuphak, Mark de Souza, Eugène Kroon, Donn Colby, Nitiya Chomchey, Merlin L. Robb, Nelson L. Michael, Jintanat Ananworanich, Sheila A. Peel, for the RV254/SEARCH010
- 574 QUANTIFICATION OF UNDETECTABLE PLASMA HIV RNA (<20 COPIES/ML) WITH SINGLE-COPY ASSAY**
Nicolas A. Margot, Dianna L. Koontz, Scott McCallister, John W. Mellors, **Christian Callebaut**

575 REPLICATE APTIMA VL TESTING DETECTS RESIDUAL VIREMIA IN MOST ART-TREATED ADULTS

Sonia Bakkour, Sheila M. Keating, Xutao Deng, Mars Stone, Andrew Worlock, Steven G. Deeks, Peter Bacchetti, Melanie Dimapasoc, Joseph Lau, Leilani Montalvo, Scott Hauenstein, Douglas D. Richman, **Michael P. Busch**, for the Reservoir Assay Validation and Evaluation Network (RAVEN) Study Group

Poster P-K04 HCV CASCADE**Poster Hall D****2:30 PM – 4:00 PM****594 ACTIVE-C: A COMMUNITY-BASED PROGRAM TO TEST AND CURE HEPATITIS C IN ALABAMA**

Ricardo A. Franco, James W. Galbraith, Ashley Gilmore, Anthony Lee, Ashutosh Tamhane, Ronada Anderson, DeAnn Jones, Brendan McGuire, Ashwani K. Singal, E. Turner Overton, Omar Massoud, Michael Saag

595 MASSACHUSETTS HEPATITIS C CARE CASCADE, 2007-2015

Quynh Vo, Shauna Onofrey, Daniel Church, Kevin Cranston, Alfred DeMaria, Monina Klevens

596 THE HEPATITIS C CONTINUUM OF CARE AMONG HIV INFECTED INDIVIDUALS IN AUSTRIA

Michaela Rappold, Armin Rieger, Martin Gisinger, Mario Sarcletti, Brigitte Schmied, Maria Geit, Alexander Zoufaly, Bernhard Haas, Ninon Taylor, Manfred Kanatschnig, Laura Simula, Sara Krüger, Bruno Ledergerber, **Robert Zangerle**, for the AHVCOS Group

597 THE HCV DIAGNOSIS AND TREATMENT UPTAKE AMONG PATIENTS IN HIV CARE

Daniel Radwan, Oluwaseun Falade-Nwulia, Ryan Westergaard, W. C. Mathews, Edward R. Cachay, Judith Aberg, Richard D. Moore, Kelly Gebo, for the HIV Research Network

598 HEPATITIS C CARE CASCADE IN JAIL: IMPLICATIONS FOR HARD-TO-REACH POPULATIONS

Caroline Abe, Esmaeil Porsa, **Ank E. Nijhawan**

599 OPERATIONALIZING ELIMINATION: CURING HEPATITIS C IN THE PATIENT-CENTERED MEDICAL HOME

Sarah Rojas, Lisa Asmus, Christopher Cavanaugh, Maureen Khasira, Stephanie Constantino, Christian B. Ramers

Poster P-K05 HCV CASCADE: TREATMENT AND BEYOND**Poster Hall D****2:30 PM – 4:00 PM****600 INCREASING INCIDENCE OF DENIAL OF DAA THERAPY FOR CHRONIC HCV BY INSURANCE TYPE**

Charitha Gowda, Stephen Lott, Matthew Grigorian, Dena M. Carbonari, M. Elle Saine, Stacey Trooskin, Jason A. Roy, **Jay Kostman**, Paul N. Urick, Vincent Lo Re

601 HEPATITIS C TREATMENT UPTAKE AMONG INSURED HIV/HCV-COINFECTED PATIENTS

Jennifer O. Lam, Leo Hurley, Scott Chamberland, Jamila Champsí, Laura C. Gittleman, Daniel G. Korn, Jennifer B. Lai, Charles P. Quesenberry, Joanna Ready, Varun Saxena, Suk Seo, David J. Witt, Michael J. Silverberg, Julia L. Marcus

602 TREATMENT OF CHRONIC HEPATITIS C GT1,2,4 IN AFRICA: FINAL RESULTS OF ANRS TAC TRIAL

Karine Lacombe, Raoul Moh, Corine Chazallon, Babacar Sylla, Maud Lemoine, Charles Kouanfack, Eric Tchoumi Leuwat, Magloire Biwole Sida, Fatoumata Fadiga, Michèle Tagni-Sartre, Viviane Marie Pierre Cisse, Lawson-Ananissoh Laté Mawuli, Pierre-Marie Girard, Alain Attia, for the ANRS12311 TAC TRIAL

603 DAA IMPLEMENTATION RATE IN HIV/HCV PATIENTS IN SPAIN: 2 YEARS OF UNRESTRICTED ACCESS

Antonio Rivero-Juárez, Francisco Téllez, Manuel Castaño, Dolores Merino, Nuria Espinosa, Jesus Santos, Juan Macías, María Paniagua-García, Angel Zapata-López, Antonio Collado, Amparo Gomez-Vidal, Javier Perez Stachowski, Leopoldo Muñoz-Medina, Elisa Fernandez-Fuertes, Antonio Rivero

604 MULTICENTER REGISTRY IN HIV/HCV CO-INFECTED PATIENTS INITIATING LEDIPASVIR/SOFOSBUVIR

Kristen M. Marks, Nwora L. Okeke, Lawrence Park, Cody A. Chastain, Kimberly Workowski, Chris Woods, Kenneth E. Sherman, Gregory K. Robbins, Stefan Mauss, Jürgen K. Rockstroh, Susanna Naggie

605 UNREPORTED ALCOHOL USE WAS COMMON BUT DID NOT IMPACT HCV CURE IN HIV-INFECTED PWID

Risha Irvin, Geetanjali Chander, Kathleen Ward, Oluwaseun Falade-Nwulia, Juhi Moon, Catherine Sutcliffe, Sherilyn Brinkley, Taryn Haselhuhn, Stephanie Katz, Kayla Herne, Lilian Arteaga, David L. Thomas, Shruti H. Mehta, Mark Sulkowski

606 HIGH EFFICACY OF 8 WEEKS OF LEDIPASVIR/SOFOSBUVIR IN AFRICAN AMERICANS WITH HCV

Whitney Nichols, Alexander Geboy, Cathy Gurgol, Chinyere Ukaegbu, Nicole Brown, **Dawn Fishbein**

607 HIV PREDICTS FAILURE OF LDV/SOF IN HCV G1 TREATMENT-NAÏVE NON-CIRRHTIC PATIENTS

Juan Berenguer, José L. Calleja, Marisa Montes, Ángela Gil-Martín, Ana Moreno, Rafael Bañares, Teresa Aldámiz-Echevarría, Agustín Albillos, María J. Téllez, Antonio Olveira, Lourdes Domínguez-Domínguez, Javier García-Samaniego, Inma Jarrín, María J. Calvo, Juan González-García

608 PREDICTIVE FACTORS OF INTERFERON-FREE THERAPY FAILURE IN HIV/HCV COINFECTION

Lourdes Domínguez-Domínguez, María Lagarde, Otilia Bisbal, Mariano Matarranz, Carlos Lumbreras, Asunción Hernando, Rafael Rubio, Federico Pulido

609 PREDICTORS OF LACK OF HEPATITIS C ERADICATION USING DIRECT-ACTING ANTIVIRALS

Edward R. Cachay, Alvaro Mena, Laura Benitez, Ivana Maida, Carmen de Mendoza Fernández, Angeles Castro, Elena Dore, Craig Ballard, Vincent Soriano, W. C. Mathews, for the HCV-HIV Transatlantic Research Network (HCV-TREN)

610 DAA TREATMENT RESPONSE AMONG HIV/HCV-COINFECTED PATIENTS IN THE CNICS COHORT

H. Nina Kim, Robin M. Nance, Benigno Rodriguez, Kenneth H. Mayer, Richard D. Moore, Edward R. Cachay, W. C. Mathews, Elvin Geng, Joseph J. Eron, Ricardo A. Franco, Michael Saag, Mari Kitahata, for the Center for AIDS Research Network of Integrated Clinical Systems (CNICS)

611 REDUCTIONS IN HEALTHCARE SERVICE USAGE FOLLOWING DIRECT ACTING ANTIVIRAL THERAPY

Sahar Saeed, Erica E. Moodie, Mark Hull, Sharon Walmsley, Curtis Cooper, Alexander Wong, Michael John Gill, Valerie Martel-Laferriere, Erin C. Strumpf, Marina Klein, for the Canadian HIV-HCV Co-Infection Cohort Study

612 HIGH INCIDENCE OF HCV REINFECTION IN MSM IN THE DAA ERA

Patrick Ingiliz, Malte Wehmeyer, Stefan Christensen, Thomas Lutz, Knud Schewe, Axel Baumgarten, Dietrich Hueppe, Karl-Georg Simon, Jürgen K. Rockstroh, **Christoph Boesecke**, Stefan Mauss

Poster P-K06 HEPATITIS B AND DELTA

Poster Hall D

2:30 PM – 4:00 PM

Poster Sessions • Tuesday

613 PREVALENCE OF ACTIVE HEPATITIS B AMONG NEW YORK CITY MSM, PrEP AND PEP, 2016-2017

Tarek Mikati, Kelly Jamison, Christine M. Borges, Demetre C. Daskalakis

614 PREVALENCE AND PREDICTORS OF HEP B INFECTION AND HEP B/HIV CO-INFECTION, ZAMBIA 2016

Karampreet Sachathep, Kumbutso Dzekedzeke, Lloyd Mulenga, Nchimunya Nkombo, Webster Kasongo, Andrea Low, Suzue Saito, Stanley Kamocha, Kathy Hageman, Gina Mulundu, Eyasu Teshale

615 NEAR FULL LENGTH GENOMES OF CHRONIC AND OCCULT HBV FROM HIV PATIENTS IN BOTSWANA

Motswedi Anderson, Wonderful T. Choga, Sikhulile Moyo, Bonolo B. Phinius, Tshepiso Mbangiwa, Lynnette Bhebhe, Theresa K. Sebunya, Richard G. Marlink, Max Essex, Rosemary Musonda, Jason T. Blackard, Simani Gaseitsiwe

616 IN SILICO ANALYSIS OF OCCULT HBV ASSOCIATED MUTATIONS IN BOTSWANA

Motswedi Anderson, Wonderful T. Choga, Sikhulile Moyo, Tshepiso Mbangiwa, Bonolo B. Phinius, Theresa K. Sebunya, Joseph Makhema, Richard G. Marlink, Max Essex, Rosemary Musonda, Jason T. Blackard, Simani Gaseitsiwe

617 HIGHER RATES OF HBSAG CLEARANCE WITH TDF-CONTAINING THERAPY IN HBV/HIV COINFECTION

Pierre Gantner, Laurent Cotte, Clotilde Allavena, Firouze Bani-Sadr, Thomas Huleux, Claudine Duvivier, Marc-Antoine Valentin, Christine Jacomet, Veronique Joly, Antoine Chéret, Pascal Puglièse, Pierre Delobel, André Cabié, David Rey, for the dat'aids

618 HIGH HBV AND HIV SUPPRESSION WITH TREATMENT OF HIV/HBV COINFECTION IN B/F/TAF STUDIES

Jürgen K. Rockstroh, Paul E. Sax, Eric Daar, Sharon Walmsley, Kimberly Workowski, Chloe Orkin, Jose R. Arribas, Edwin DeJesus, David Wohl, Jean-Michel Molina, David Piontowsky, Xuelian Wei, Hal Martin, Andrew Cheng, Erin Quirk

619 PROGRESSIVE HBSAG LOSS IN HIV-HBV COINFECTED INDIVIDUALS ON TDF-INCLUSIVE CART

Jennifer Audsley, Anchalee Avihingsanon, Margaret Littlejohn, Scott Bowden, Gail Matthews, Christopher K. Fairley, Sharon R. Lewin, Joseph Sasadeusz

- 620 DETERMINANTS OF LIVER COMPLICATIONS AMONG HIV/HEPATITIS B-COINFECTED PATIENTS**
Vincent Lo Re, Craig W. Newcomb, Dena M. Carbonari, Jason A. Roy, Mari Kitahata, Joseph Lim, Michael J. Silverberg, Angel Mayor, Michael A. Horberg, Edward R. Cachay, Mark Hull, Richard D. Moore, Marina Klein, H. Nina Kim, for the North American AIDS Cohort Collaboration on Research and Design of leDEA
- 621 HIGH PREVALENCE OF ADVANCED LIVER DISEASE AMONG AN HIV/HBV REAL-WORLD COHORT**
Mamta K. Jain, Mandana Khalili, Raymond T. Chung, Kranthi Vysyaraju, David Wong, Mauricio Lisker-Melman, Mark Sulkowski, Marc Ghany, Richard K. Sterling
- 622 HEPATITIS DELTA INFECTION IN PATIENTS WITH HIV/HBV COINFECTION**
Giovanni B. Gaeta, Milensu Shanyinde, Giuseppina Brancaccio, Massimo Puoti, Antonella D'Arminio Monforte, Andrea De Luca, Alessandra Vergori, Stefano Rusconi, Antonio Mazzarelli, Antonella Castagna, Andrea Antinori, Alessandro Cozzi-Lepri
- 623 GAIN OF POSITIVE CHARGES IN HBSAG C-TERMINUS CORRELATES WITH HBV-INDUCED LIVER CANCER**
Romina Salpini, Luca Carioti, Marianna Aragri, Domenico Di Carlo, Luna Colagrossi, Giuseppina Cappiello, Pascale Trimoulet, Herve J. Fleury, Simona Franciosi, Loredana Sarmati, Massimo Andreoni, Mario Angelico, Francesca Ceccherini Silberstein, Carlo F. Perno, Valentina Svicher
- 624 SURVIVAL AFTER END-STAGE LIVER DISEASE IN ADULTS WITH HIV: DATA FROM THE NA-ACCORD**
Eve-Marie A. Benson, Marina Klein, Mari Kitahata, Richard D. Moore, Vincent Lo Re, Michael A. Horberg, Angel Mayor, Michael J. Silverberg, H. Nina Kim, Joseph J. Eron, Edward R. Cachay, Mark Hull, Stephen J. Gange, Keri N. Althoff, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of leDEA

Poster P-K10 STEATOSIS AND CIRRHOSIS**Poster Hall D****2:30 PM – 4:00 PM**

- 641 INCREASED RATES OF HEPATIC STEATOSIS IN YOUNG ADULTS WITH LIFE-LONG HIV INFECTION**
Julia A. Aepfelbacher, Julia Purdy, Aviva Mattingly, Kirsten Zambell, Chloe S. Chaudhury, Colleen Hadigan
- 642 CARDIOMETABOLIC RISK PROFILES IN HIV AND NONALCOHOLIC FATTY LIVER**
Alyson Kaplan, Donald Chute, Tracey G. Simon, Samson Okello, Hui Zheng, Raymond T. Chung, Kathleen E. Corey
- 643 UNANTICIPATED INCREASES IN FATTY LIVER IN HIV NAFLD PATIENTS WITH EPLERENONE**
Chloe S. Chaudhury, Julia Purdy, Chia-Ying Liu, Caryn G. Morse, Takara L. Stanley, David E. Kleiner, Colleen Hadigan
- 644 FAILURE RATE OF ULTRASOUND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA IN HIV+ PATIENTS**
Nicolás Merchante, Esperanza Merino, Francisco Rodríguez-Arrondo, Boris Revollo, Sofía Ibarra, María J. Galindo, Marta Montero, Miguel García-Deltoro, Antonio Rivero-Juárez, Marcial Delgado-Fernández, Francisco Téllez, María J. Ríos-Villegas, Jose J. Portu, Juan A. Pineda, for the GEHEP-002 Study Group

645 HIV+ PERSONS WITH CIRRHOSIS RECEIVE INADEQUATE SCREENING FOR ESOPHAGEAL VARICES

Chiara Saroli Palumbo, Amine Benmassaoud, Thomas Pembroke, Bertrand Lebouché, Philip Wong, Marc Deschenes, Marina Klein, Peter Ghali, Giada Sebastiani

646 MEDIUM-TERM EFFECTS OF DAA THERAPY ON HVPG IN PATIENTS WITH HCV-ASSOCIATED CIRRHOsis

Cristina Diez, **Juan Berenguer**, Luis Ibañez, Elba L. Herrera, Leire Pérez Latorre, María V. Catalina, Victor Hontanon, Diego Rincón, Teresa Aldámiz-Echevarría, Javier Martínez, José M. Bellón, José L. Calleja, Agustín Albillos, Juan González-García, Rafael Bañares

647 TRANSPLANT FREE SURVIVAL IN HIV ASSOCIATED NON-CIRRHOTIC PORTAL HYPERTENSION

Kathryn Childs, Lauren Hookham, Corinna Psomadakis, Rosa Miquel, Ruth Byrne, Mary Cannon, Kosh Agarwal, Mark Nelson, Chris Taylor, Abid Suddle

648 MR ELASTOGRAPHY DETECTS HIGHER LIVER FIBROSIS IN UNCONTROLLED HIV INFECTION

Marianna K. Baum, Sabrina S. Martinez, Richard L. Ehman, Kenneth E. Sherman, Pedro J. Greer, Jun Chen, Robert Laird, Angela Laird, Leslie Seminario, Angelique Johnson, Alhanooft Alohaly, Mukesh Mudgal, Alicia Sneij, Javier Tamargo, Adriana Campa

Poster P-L2 CERVICAL AND ANAL CANCER AND HPV**Poster Hall D**

2:30 PM – 4:00 PM

657 SUPPRESSIVE ART ASSOCIATED WITH EFFECTIVE TREATMENT OF CERVICAL PRECANCER

Christina Carlander, Philippe Wagner, Astrid van Beirs, Aylin Yilmaz, Kristina Elfgren, Joakim Dillner, Anders Sönnernborg, Pär Sparén

658 LEEP TREATMENT OF EXTENSIVE CERVICAL INTRAEPITHELIAL NEOPLASIA IN HIV-INFECTED WOMEN

Sharon A. Greene, Hillary M. Topazian, Hugo De Vuyst, Christine J. McGrath, Barbra A. Richardson, Grace John-Stewart, Anthony Cagle, Evans Nyongesa-Malava, Nelly Yatich, Catherine Kiptinness, Sameh Sakr, Nelly R. Mugo, Michael H. Chung

659 GENE PROFILE INFORMS HPV GRADE BUT NOT RELAPSE AFTER LEEP IN ART-SUPPRESSED HIV+HPV+

Emmanouil Papasavvas, Andrew V. Kossenkov, Livio Azzoni, Nicola M. Zetola, Agnieszka Mackiewicz, Brian Ross, Matthew Fair, Surya Vadrevu, Doreen Ramogola-Masire, Cindy Firnhaber, Luis Montaner

660 IMPACT OF SINGLE-DOSE NANOVALENT VACCINE FOR HIV-HPV COINFECTION IN SOUTH AFRICA

Nicholas Tan, Monisha Sharma, Ruanne V. Barnabas

661 COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING IN WOMEN WITH HIV IN SOUTH AFRICA

Nicole G. Campos, Naomi Lince-Deroche, Carla J. Chibwesha, Cindy Firnhaber, Pamela Michelow, Gesine Meyer-Rath, Lise Jamieson, Suzette Jordaan, Vivien Tsu, Jose Jeronimo, Jane Kim

662 CLEARANCE, PERSISTANCE, AND NEW HPV INFECTIONS IN A MEXICAN MSM - HIV COHORT

Ofelia M. Rosales Del Real, Rocío Méndez Martínez, Yanink Caro-Vega, Norma E. Rivera-Martínez, Alejandro M. García-Carrancá, Juan Sierra-Madero, Brenda Crabtree-Ramírez

663 AGE-SPECIFIC PREVALENCE OF VACCINE-PREVENTABLE ANAL HPV INFECTION IN HIV-INFECTED MSM

Alessandra Latini, Maria Gabriella Dona, Manuela Colafogli, Mauro Zaccarelli, Maria Benevolo, Francesca Rollo, Domenico Moretto, Amalia Giglio, Antonio Cristaudo, Massimo Giuliani

664 ABLATION OUTCOMES FOR HIV INFECTED AND UNINFECTED PATIENTS WITH ANAL DYSPLASIA

Keith M. Sigel, Yuxin Liu, Michael Gaisa

665 PATTERNS OF REPEATED ANAL CYTOLOGY TESTING AMONG HIV-POSITIVE AND HIV-NEGATIVE MSM

Hilary Robbins, Dorothy J. Wiley, Ken Ho, Michael Plankey, Susheel Reddy, Nancy Joste, Teresa Darragh, Elizabeth Breen, Stephen Young, **Gypsyamber D'Souza**

666 EFFECTIVENESS OF A SCREENING PROGRAM FOR ANAL CANCER PREVENTION IN HIV-INF. PATIENTS

Boris Revollo, Sebastia Videla, Arely Ornelas, Roger Paredes, Josep Coll, Marta Piñol, Francesc García-Cuyás, Antoni Tarrats, David Parés, Ross Cranston, Bonaventura Clotet, Guillem Sirera

Poster P-M4 PREDICTING CARDIOVASCULAR DISEASE RISK AND STATIN USE**Poster Hall D****2:30 PM – 4:00 PM****689 EFFECTS OF PITAVASTATIN ON ATHEROSCLEROTIC-ASSOCIATED BIOMARKERS IN PEOPLE WITH HIV**

Angsana Phuphuakrat, Artit Wongsa, Sirawat Srichatrapimuk, Boonrat Tassaneetrithip, Sasisopin Kiertiburanakul, Somnuek Sungkanuparph

690 STATIN COVERAGE IN AN HIV COHORT: COMPARISON OF ATP III, ACC/AHA, AND NLA GUIDELINES

Matthew E. Levy, Alan Greenberg, Manya Magnus, Naji Younes, Amanda D. Castel, for the DC Cohort Executive Committee

691 HIV+ MEN MATCHED BY AGE AND FRS WITH CONTROLS HAVE MORE CARDIOVASCULAR EVENTS

Stefan Esser, Marina Arendt, Christina Schulze, Volker Holzendorf, Norbert H. Brockmeyer, Karl-Heinz Joeckel, Raimund Erbel, Nico Reinsch, for the HIV HEART Study group and Heinz Nixdorf Recall Investigative group

Poster P-M5 REDUCING CARDIOVASCULAR DISEASE RISK**Poster Hall D****2:30 PM – 4:00 PM****692 COMPARING STRATEGIES FOR REDUCING MYOCARDIAL INFARCTION RATES IN HIV PATIENTS**

Priscilla Hsue, Grace A. McComsey, Calvin Cohen, Alejandro Sola, Anne C. Beaubrun

693 ZINC TO REDUCE MORTALITY AND CVD RISK AND HIV DISEASE PROGRESSION IN RUSSIAN DRINKERS

Matthew Freiberg, Natalia Gnatienko, Debbie Cheng, E Blokhina, Sharon Coleman, Margaret F. Doyle, Carly Bridden, Kaku So-Armah, Sally Bendiks, Russell Tracy, Kendall J. Bryant, Evgeny Krupitsky, Jeffrey H. Samet

Poster P-M6 HEART FAILURE, VENTRICULAR FUNCTION, AND PERIPHERAL ARTERY DISEASE
Poster Hall D
2:30 PM – 4:00 PM

- 694 MYOCARDIAL STEATOSIS IN RELATION TO CARDIAC DYSFUNCTION AMONG WOMEN LIVING WITH HIV**
Mabel Toribio, Tomas G. Neilan, Lauren Stone, Adam Rokicki, Corinne Rivard, Jacob C. Calkins, Mary O'Hara, Magid Awadalla, Virginia Triant, Lidia S. Szczepaniak, Markella V. Zanni
- 695 SUB-CLINICAL CARDIAC SYSTOLIC DYSFUNCTION AMONG WOMEN LIVING WITH HIV**
Magid Awadalla, Markella V. Zanni, Mabel Toribio, Lauren Stone, Adam Rokicki, Corinne Rivard, Virginia Triant, Tomas G. Neilan
- 696 SYSTOLIC HEART FAILURE AND HEART FAILURE OUTCOMES AMONG PERSONS LIVING WITH HIV**
Raza M. Alvi, Maryam Afshar, Noor Tariq, Jaime Gerber, Virginia Triant, Markella V. Zanni, Tomas G. Neilan
- 697 SLEEP APNEA AND HEART FAILURE WITH REDUCED EJECTION FRACTION AMONG HIV PATIENTS**
Raza M. Alvi, Magid Awadalla, Atul Malhotra, Noor Tariq, Adam Rokicki, Virginia Triant, Markella V. Zanni, Tomas G. Neilan
- 698 CARDIAC VENTRICULAR DISFUNCTION IN YOUNG VERTICALLY INFECTED HIV PATIENTS**
Lidia Capotosto, Eugenio Nelson Cavallari, Giuseppina Cusano, Ivano Mezzaroma, Giancarlo Ceccarelli, Luigi Celani, Camilla Ajassa, Gabriella d'Ettorre, Vincenzo Vullo, Antonio Vitarelli
- 699 ACUTE HIV INFECTION RESULTS IN SUBCLINICAL AND REVERSIBLE INFLAMMATORY CARDIOMYOPATHY**
Christopher Schuster, Florian Mayer, Corinna Wohlfahrt, Rodrig Marculescu, Michael Skoll, Robert Strassl, Maximilian Aichelburg, Noemi Pavo, Theresia Popow-Kraup, Martin Hülsmann, Armin Rieger, Georg Goliasch
- 700 CORONARY WALL THICKENING AND ASSOCIATION WITH MYOCARDIAL DIASTOLIC FUNCTION IN HIV**
Julia Purdy, Khaled Z. Abd-Elmoniem, Hwaida Hannoush, Vandana Sachdev, Colleen Hadigan, Ahmed M. Gharib
- 701 CONTRIBUTION OF HIV, HCV, AND VASCULAR RISK FACTORS TO PERIPHERAL ARTERIAL DISEASE**
Emily Cedarbaum, Yifei Ma, Rebecca Scherzer, Jennifer Price, Michael Plankey, Margaret Fischl, Eric C. Seaberg, Marge H. Cohen, Marcos Bamman, Jason Lazar, Adaora Adimora, Michael T. Yin, Phyllis Tien
- 702 CARDIAC ABNORMALITIES IN PERINATALLY INFECTED HIV+ SOUTH AFRICAN ADOLESCENTS ON ART**
Sana Mahtab, John Lawrenson, Norme J. Luff, Nana Akua Asafu-Agyei, Liesl Zülke, Landon Myer, Heather Zar

Poster P-N02 RENAL DISEASE**Poster Hall D****2:30 PM – 4:00 PM****728 PEOPLE LIVING WITH HIV IN FRANCE HAVE DELAYED ACCESS TO KIDNEY TRANSPLANTATION**

Jérôme Tourret, **Sophie Abgrall**, Mathilde Lassalle, Sophie Grabar, Corinne Isnard-Bagnis, Gilbert Deray, Benoit Barrou, Dominique Costagliola, Cécile Couchoud, Marguerite Guiguet, Sophie Tezenas du Moncel

729 CHRONIC KIDNEY DISEASE RISK FACTORS AND URINE KIDNEY INJURY MARKERS IN HIV+ PERSONS

Anthony Muiru, Michael Shlipak, Rebecca Scherzer, William Zhang, Simon Ascher, Chirag Parikh, Carl Grunfeld, Frank J. Palella, Ruibin Wang, Phyllis Tien, Qibin Qi, Michelle Estrella

730 VALIDATION OF A CHRONIC KIDNEY DISEASE RISK SCORE IN HIV+ PATIENTS IN THE US

Anthony Mills, Kathy L. Schulman, Jennifer Fusco, Ricky Hsu, Andrew Beyer, Girish Prajapati, Karam Mounzer, Gregory Fusco

731 CHRONIC KIDNEY DISEASE IN HIV POPULATIONS OF AFRICAN DESCENT IN THE UK

Sophie Jose, **Lisa Hamzah**, Rachael Jones, Deborah Williams, Alan Winston, Fiona Burns, Caroline Sabin, Frank Post, for the UK Collaborative HIV Cohort Study Steering Committee

732 SAFETY AND EFFICACY OF E/C/F/TAF IN HIV-INFECTED ADULTS ON CHRONIC HEMODIALYSIS

Joseph J. Eron, Jean-Daniel Lelievre, Robert Kalayjian, Jihad Slim, Anson K. Wurapa, Jeffrey L. Stephens, Cheryl McDonald, Eric Cua, Aimee Wilkin, Brigitte Schmied, Mehri McKellar, Joseph M. Custodio, Shuping Jiang, Devi SenGupta, Moupani Das

Poster P-N05 CHRONIC OBSTRUCTIVE PULMONARY DISEASE**Poster Hall D****2:30 PM – 4:00 PM****745 PROGRESSION OF QUANTITATIVE EMPHYSEMA IN A HIV-INFECTED SPANISH COHORT**

Francisco Fanjul, Gloria Samperiz, Helem Haydee Vilchez, María Leyes, Antoni Campins, María Angeles Ribas, María Peñaranda, Javier Murillas, Luisa Martín, Angel Ríos, Meritxell Lopez Zamora, Jose Luis Valera, Melchor Riera

746 SMOKING AND ACCELERATED LUNG FUNCTION DECLINE IN THE START PULMONARY SUBSTUDY

David MacDonald, Gary Collins, Nicholas Ingraham, Anne Melzer, Kristina Crothers, Anchalee Avihingsanon, Henry Mugerwa, Matti Ristola, Jonathan Shuter, Ken Kunisaki

747 MARIJUANA SMOKING IMPACTS PULMONARY DISEASE IN HIV-INFECTED MEN

David Lorenz, **Dana H. Gabuzda**

748 HIV INFECTION, SYSTEMIC INFLAMMATION AND LUNG FUNCTION IN RURAL UGANDA

Crystal North, Bernard Kakuhikire, Alexander C. Tsai, David C. Christiani, Douglas Kwon, Samson Okello, Mark J. Siedner, Russell Tracy

749 DIFFERENCES IN THE ADENOSINE SIGNALING PATHWAY AMONG HIV+ INDIVIDUALS WITH COPD

Kiran Bandi, Seyed M. Nouraei, Edwin Jackson, Peter Nam, Delbert Gillespie, Cynthia Klamar-Blain, Cathy Kessinger, Sharon Riddler, Alison Morris, Bernard J. Macatangay

750 PREDICTORS OF AIRFLOW OBSTRUCTION IN AN HIV TERTIARY CARE CLINIC

Cecilia Costiniuk, Roy Nitulescu, Christina de Castro, Natale Wasef, Syim Salahuddin, Jean-Pierre Routy, Bertrand Lebouché, Joseph Cox, Benjamin M. Smith, Jason Szabo, Alexandra de Pokomandy, Chris Tsoukas, Mohammad-Ali Jenabian, Jean Bourbeau, Marina Klein

751 HIV IS INDEPENDENTLY ASSOCIATED WITH HIGHER ALPHA-1 ANTITRYPsin

Rebekka F. Thudium, Jens D. Lundgren, Børge Nordestgaard, Jan Gerstoft, Susanne D. Nielsen, Andreas Ronit

Poster P-N06 DEPRESSION**Poster Hall D****2:30 PM – 4:00 PM****752 DEPRESSION IS INDEPENDENTLY ASSOCIATED WITH NEAR DOUBLING OF HIV VIRAL LOAD**

Susan M. Meffert, Thomas C. Neylan, Charles E. McCulloch, Jonah Jonah Maswai, John Owuoth, Francis Kiweewa, Lucas Maganga, Victor Valcour, Julie Ake

753 DEPRESSION IS ASSOCIATED WITH MISSED VISITS, EMERGENCY ROOM UTILIZATION, AND DRUG USE

Mamta K. Jain, Yordanos Tiruneh, Piper Duarte, Amneris Luque, Ank E. Nijhawan

754 DEPRESSIVE SYMPTOMS AND HIV INFECTION IN AN AGING UGANDAN COHORT

Jennifer Manne-Goehler, Bernard Kakuhikire, Alexander C. Tsai, Till Bärnighausen, Samson Okello, Mark J. Siedner

Poster P-N10 BIOMARKER PREDICTORS OF NON-AIDS EVENTS**Poster Hall D****2:30 PM – 4:00 PM****763 NOVEL BIOMARKERS PREDICTIVE OF NON-AIDS EVENTS DURING ART-MEDIATED VIRAL SUPPRESSION**

Martin Hoenigl, Carlee Moser, Nicholas Funderburg, Ronald Bosch, Amy Kantor, Yonglong Zhang, Jesper Eugen-Olsen, Malcolm Finkelman, Alan Landay, Michael M. Lederman, Sara Gianella, for the ACTG NWCS 329 study team

764 INFLAMMATION AND IMMUNE ACTIVATION MARKERS ASSOCIATED WITH NON-AIDS CANCERS IN HIV

Muhaimen Siddiqui, Elizabeth Breen, Jay Bream, Yue Chen, Dana H. Gabuzda, **Eric C. Seaberg**

765 SERUM ALBUMIN AS A LONG TERM PREDICTOR OF SERIOUS NON-AIDS EVENTS

Andreas Ronit, Camilla Ingrid Hatleberg, Lene Ryom, Fabrice Bonnet, Wafaa M. El-Sadr, Peter Reiss, Rainer Weber, Christian Pradier, Stephane de Wit, Matthew Law, Antonella D'Arminio Monforte, Jens D. Lundgren, Andrew N. Phillips, Caroline Sabin

Poster P-04 CRYPTOCOCCAL MENINGITIS AND OTHER FUNGAL INFECTIONS**Poster Hall D****2:30 PM – 4:00 PM****783 DIAGNOSTIC UTILITY OF MULTIPLEX PCR IN AN HIV-INFECTED POPULATION WITH MENINGITIS**

Sarah Bridge, Kathy Huppler Hullsieck, Richard Kwizera, Edwin Nuwagira, Anna Stadelman, Tadeo K. Kiiza, Liberica Ndyatunga, Kenneth Ssebambulidde, James Mwesigye, Edward Mpoza, Mahsa Abassi, David Meya, Conrad Muzoora, David R. Boulware, Joshua Rhein

784 CRAG STATUS AND EFFECT ON BENEFITS FROM ENHANCED PROPHYLAXIS IN THE REALITY TRIAL

Sarah Pett, Lewis Haddow, Ruth Nhema, Moira J. Spyer, Laura Benjamin, Grace Najjuka, Ibrahim Daud, Jay Berkley, Juliet Kitabala, James G. Hakim, Rob Heyderman, Sarah Walker, Diana Gibb, for the REALITY trial team

785 EVALUATION OF A CRYPTOCOCCAL SCREENING AND TREATMENT PROGRAM IN HIV CLINICS IN UGANDA

Elizabeth Nalintya, David Meya, Sarah Lofgren, Kathy Huppler Hullsieck, David R. Boulware, **Radha Rajasingham**

786 CLINIC-BASED LATERAL FLOW CRYPTOCOCCAL ANTIGEN TESTING AT HIV DIAGNOSIS, SOUTH AFRICA

Paul K. Drain, Ting Hong, Hilary Thulare, Mahomed-Yunus Moosa, Connie L. Celum

787 SYMPTOMATIC CRYPTOCOCCAL ANTIGENEMIA PRESENTING AS EARLY CRYPTOCOCCAL MENINGITIS

Kenneth Ssebambulidde, Mahsa Abassi, Joshua Rhein, Ananta Bangdiwala, Darlisha A. Williams, Edward Mpoza, Lillian Tugume, Richard Kwizera, Abdu Musubire, Fiona Cresswell, Sarah Lofgren, Kathy Huppler Hullsieck, David R. Boulware, David Meya, for the ASTRO-CM

788 POSTMORTEM CRYPTOCOCCAL MENINGITIS FOLLOWING TREATMENT FOR CRYPTOCOCCAL ANTIGENAEMIA

Rachel M. Wake, Tanvier Omar, Aaron S. Karat, Joseph N. Jarvis, **Nelesh P. Govender**, Thomas S. Harrison

789 DECLINING INCIDENCE OF HIV-ASSOCIATED CRYPTOCOCCOSIS IN SOUTH AFRICA, 2005-2015

Nelesh P. Govender, Cheryl Cohen, Phelly Matlapeng, Penny Crowther-Gibson, Susan Meiring, Alan Karstaedt, Halima Dawood, Kerrigan McCarthy, Graeme Meintjes, Vanessa Quan, for the GERMS-SA surveillance group

790 ETIOLOGIES OF SYMPTOMATIC RECURRENCE OF HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS

Emily Evans, Kathy Huppler Hullsieck, Edwin Nuwagira, Edward Mpoza, Kenneth Ssebambulidde, Lillian Tugume, Bozena M. Morawski, Sarah Lofgren, Mahsa Abassi, Darlisha A. Williams, Conrad Muzoora, David Meya, David R. Boulware, Joshua Rhein

791 HIGH MORTALITY ASSOCIATED WITH UNMASKING CRYPTOCOCCAL MENINGITIS

Joshua Rhein, **Kathy Huppler Hullsieck**, Nathan C. Bahr, Lillian Tugume, Edwin Nuwagira, Kenneth Ssebambulidde, Reuben Kiggundu, Emily Evans, Edward Mpoza, Darlisha A. Williams, Mahsa Abassi, Abdu Musubire, Conrad Muzoora, David Meya, David R. Boulware

792 CUSTOMIZED AMPHOTERICIN DURATION FOR CRYPTOCOCCAL MENINGITIS BASED ON FUNGAL BURDEN

Darlisha A. Williams, Kathy Huppner Hullsieck, Andrew Akampurira, Tonny Luggya, Edwin Nuwagira, Lillian Tugume, Edward Mpoza, Reuben Kiggundu, Kenneth Ssebambulidde, Mahsa Abassi, Conrad Muzoora, David Meya, David R. Boulware, Joshua Rhein, for the ASTRO-CM Trial

793 PCR AND URINE ANTIGEN FOR DIAGNOSIS OF DISSEMINATED HISTOPLASMOSIS IN AIDS PATIENTS

Maria D. Niembro-Ortega, Rosa A. Martínez-Gamboa, Brenda Crabtree-Ramírez, Pedro Martínez-Ayala, Andrea Rangel-Cordero, Nancy G. Velázquez-Zavala, Janet Santiago-Cruz, Paulette G. Díaz-Lomelí, Armando Gamboa-Domínguez, Edgardo F. Reyes-Gutiérrez, Pedro Torres-González, José Sifuentes-Osornio, Luis A. Ponce de Leon-Garduño, for the Mexican Consortium for the Study of Invasive Fungal Infections

794 ANTIFUNGAL DRUG SUSCEPTIBILITY OF TALAROMYCES MARNEFFEI CLINICAL ISOLATES, GUANGDONG

Linghua Li, Wanshan Chen, Fengyu Hu, Xiejie Chen, Weiping Cai, Xiaoping Tang

795 RISK FACTORS FOR IRIS IN HIV-ASSOCIATED PNEUMOCYSTIS PNEUMONIA AFTER ART INITIATION

Gerrit Kann, Hannah Bielke, Philipp De Leuw, Gundolf Schuettfort, Annette E. Haberl, Junaid Owasil, Claus P. Kuepper-Tetzl, Nils Wetzstein, Imke Wieters, Johanna Kessel, Markus Bickel, Pavel Khaykin, Christoph Stephan

Poster P-P3 INFANT HIV INFECTION AND DIAGNOSIS IN THE ERA OF OPTION B+**Poster Hall D****2:30 PM – 4:00 PM****821 MATERNAL VIRAL LOAD SUPPRESSION AND VERTICAL TRANSMISSION IN MALAWI'S PMTCT PROGRAM**

Ernest Nkhoma, Monique van Lettow, Beth A. Tippett Barr, Joep J. van Oosterhout, Eunice Mwandira, Lloyd Chilikutali, Annie Kanyemba, Zinenani T. Truwah, Andrew F. Auld, **Megan Landes**

822 INFANT HIV-FREE SURVIVAL IN THE ERA OF "OPTION B+" SERVICES IN RURAL ZAMBIA

Benjamin H. Chi, Wilbroad Mutale, Jennifer Winston, Winifreda Phiri, Joan T. Price, Charles Y. Msiska, Helen Ayles, Jeffrey S. Stringer

823 HIV-POSITIVITY AMONG HIV-EXPOSED INFANTS IN LESOTHO IN THE ERA OF OPTION B+

Tsigereda G. Belachew, Kieran Hartsough, Andrea Schaaf, Mahlompho Ntholeng, **Tiffany G. Harris**

824 HIGH HIV BURDEN AMONG CHILDREN IN LESOTHO: FINDINGS FROM A POPULATION BASED SURVEY

Koen Frederix, Stefania Davia, Keletso Ntene-Sealiete, Stephen M. Arpadi, Stephen McCracken, Kyaw Thin, Hetal Patel, Mosilinyane Letsie, Andrea Low

825 IMPACT OF BIRTH TESTING ON EARLY INFANT DIAGNOSIS IN KWAZULU-NATAL, SOUTH AFRICA

Shayla Smith, Louise Kuhn, Moherndran Archary, Pravi Moodley, Phillip LaRussa, Kerusha Govender

826 AGE AT HIV DIAGNOSIS WITHIN SOUTH AFRICA'S EARLY INFANT DIAGNOSIS PROGRAM, 2010-2015

Ahmad Haeri Mazanderani, William B. MacLeod, Jacob Bor, Gayle G. Sherman

827 MATERNAL ANTI-HIV-1 NAB RESPONSE ASSOCIATES WITH TRANSMISSION AND INFANT MORBIDITY

Melissa Ghulam-Smith, Alex Olson, Laura F. White, Charles Chasela, Sascha Ellington, Athena Kourtis, Denise Jamieson, Gerald Tegha, Charles van der Horst, Manish Sagar

828 ROLE OF REGULATORY T CELLS IN MOTHER TO CHILD TRANSMISSION OF HIV

Peter A. Kessler, Surinder P. Gill, Chris C. Ibegbu

Poster P-Q4 HIV AND ANTIRETROVIRAL THERAPY OUTCOMES IN CHILDREN AND ADOLESCENTS

Poster Hall D

2:30 PM – 4:00 PM

851 VIROLOGIC RESPONSE TO EFAVIRENZ-BASED FIRST-LINE IN CHILDREN BY PMTCT EXPOSURE STATUS

Lee Fairlie, Patience Nyakato, Mary-Ann Davies, Karl Technau, Geoffrey Fatti, Helena Rabie, Frank Tanser, Andrew Boulle, Robin Wood, Brian Eley, Shobna Sawry, Janet Giddy, Nosisha Sipambo, Andreas D. Haas, Louise Kuhn, for the leDEA-SA Collaboration

852 VIRAL SUPPRESSION IN HIV-INFECTED CHILD-CAREGIVER DYADS IN WESTERN KENYA

John M. Humphrey, Beverly Musick, **Edith Apondi**, Becky L. Gengenb, Adrian Gardner, Joseph Hogan, Kara K. Wools-Kaloustian

853 ARE HIV+ MIGRANT CHILDREN IN EUROPE AT INCREASED RISK OF POOR OUTCOMES ON ART?

Malte Kohns, Ruth Goodall, Luisa Galli, Ali Judd, Tessa Goetghebuer, Antoni Noguera-Julian, Laura Rodrigues, Henriëtte J. Scherbier, **Intira J. Collins**, for the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC)

854 BETTER TREATMENT OUTCOMES FOR RWANDAN CHILDREN AFTER "TREAT ALL"

Stephen M. Arpadi, Matthew R. Lamb, Isaie Nzeyimana, Greet Vandebriel, Gloria E. Anyalechi, Marcia Wong, Rebecca Smith, Emilia M. Rivadeneira, Eugenie Kayirangwa, Samuel S. Malamba, Canisious Musoni, Emilia Koumans, Sabin Nsanzimana

855 AFRICAN MULTI-SITE 2-YEAR STUDY OF NEUROCOGNITION IN HIV INFECTED/AFFECTED CHILDREN

Michael J. Boivin, **Miriam Chernoff**, Barbara Laughton, Bonnie Zimmer, Celeste Joyce, Linda Barlow-Mosha, Mutua Bwakura-Dangarembizi, Mmule Ratswana, Lee Fairlie, Portia Kamthunzi, Katie McCarthy, Patrick Jean-Philippe, Avy Violari, Mark Cotton, Paul Palumbo

856 CARDIO-ANKLE VASCULAR INDEX AMONG PERINATALLY HIV-INFECTED THAI ADOLESCENTS

Tavitiya Sudjaritruk, Linda Aurpibul, Suvaporn Anugulreungkit, Tawalchaya Chotecharoentanan, Siwanart Thamsala, Rattika Thummalangka, Kittipan Rerkasem, Thanyawee Puthanakit, for the PAD study team

857 SUBSTANTIAL GENDER DIFFERENCES IN LONGITUDINAL ARTERIAL STIFFNESS IN CHILDREN ON ART

Steve Innes, Mark Cotton, Kennedy N. Otwombe, Barbara Laughton, Philip Herbst, Innocent Karangwa, Sara H. Browne

858 MITOCHONDRIAL DYSFUNCTION IN WELL-SUPPRESSED PERINATALLY HIV-INFECTED CHILDREN ON ART

Jing Shen, Renate Strehlau, Afaaf Liberty, Stephanie Shiao, Faeezah Patel, Megan Burke, Avy Violari, Marc D. Foca, Stephen M. Arpadi, Louise Kuhn, for the Childhood HAART Alterations in Normal Growth, Genes, and aGing Evaluation Study (CHANGES) Team

859 VITAMIN D SUPPLEMENTATION ATTENUATES IMMUNE ACTIVATION IN HIV+ AVIREMIC YOUTH

Allison R. Eckard, Mary Ann O'Riordan, Vin Tangpricha, Danielle Labbato, Ann Chahroudi, Grace A. McComsey

860 SCD163, T CELL ACTIVATION AND HIV PROGRESSION IN PERINATALLY INFECTED HIV+ CHILDREN

Matthew Generoso, Patricia Alvarez, Adam Kravietz, Mussa Mwamzuka, Fatma Marshed, Aabid Ahmed, Alka Khaitan

Poster P-Q5 RESPONSE TO EARLY INFANT ANTIRETROVIRAL THERAPY
Poster Hall D

2:30 PM – 4:00 PM

861 VIROLOGIC RESPONSE TO ANTIRETROVIRAL THERAPY STARTED AT <12 WEEKS OF AGE

Victoria Iyun, Karl Technau, Brian Eley, Helena Rabie, Andrew Boule, Geoffrey Fatti, Frank Tanser, Robin Wood, Lee Fairlie, Mary-Ann Davies, for the International epidemiology Databases to Evaluate AIDS Southern Africa (IeDEA-SA) collaboration

862 MATERNAL ANTIRETROVIRAL THERAPY IN PREGNANCY AND NEONATE PRETREATMENT VIRAL LOAD

Faeezah Patel, **Stephanie Shiao**, Renate Strehlau, Megan Burke, Maria Paximadis, Sharon Shalekoff, Diana Schramm, Caroline Tiemessen, Elaine J. Abrams, Louise Kuhn, for the LEOPARD study team

863 T AND B CELL RESPONSES ASSOCIATE WITH SMALLER HIV RESERVOIR SIZE IN INFANTS AFTER ART

Julie Mitchell, Marta Massanella, Thanyawee Puthanakit, Pope Kosalaraksa, Piyarat Suntarattiwong, Suparat Kanjanavanit, Rawiwan Hansudewechakul, Thitiporn Borkird, Thidarat Jupimai, Panadda Sawangsinth, Mark de Souza, Nicolas Chomont, Jintanat Ananworanich, Lydie Trautmann, for the HIVNAT209 and RV254 study groups

864 FACTORS ASSOCIATED WITH HIV DNA LEVELS IN CHILDREN STARTING ART EARLY IN INFANCY

Man Chan, Alfredo Tagarro, Paola Zangari, Bridget Ferns, Caroline Foster, Anita De Rossi, Eleni Nastouli, M Ángeles Muñoz-Fernández, Diana Gibb, Paolo Rossi, Carlo Giaquinto, Abdel Babiker, Paolo Palma, Pablo Rojo Conejo, for the EPIICAL Consortium

865 EARLY CMV AND EBV ACQUISITION PREDICTS HIV DNA LEVELS IN INFANTS ON SUPPRESSIVE ART

Jennifer Slyker, Brandon Guthrie, Mark D. Pankau, Dalton Wamalwa, Sarah Benki-Nugent, Meei-Li Huang, Grace John-Stewart, Julie Overbaugh, Dara Lehman

866 HIV SPECIFIC IGM MEMORY B CELLS DOMINATE IN SERONEGATIVE EARLY-TREATED CHILDREN

Nicola Cotugno, **Elena Morocchi**, Ilaria Pepponi, Salvatore Rocca, Mark Cameron, Stefano Rinaldi, Silvia Di Cesare, Suresh Pallikkuth, Stefania Bernardi, Nigel Klein, Jintanat Ananworanich, Paolo Rossi, Savita Pahwa, Paolo Palma, for the EPIICAL Consortium

867 INTESTINAL DAMAGE AND INFLAMMATION IN PERINATALLY HIV-1-INFECTED AFRICAN INFANTS

Wei Li A. Koay, Jane Lindsey, Priyanka Uprety, Mutsa Bwakura-Dangarembizi, Adriana Weinberg, Myron Levin, Deborah Persaud

868 LASTING IMMUNE IMPACTS OF AGE AT START OF ART IN VERTICALLY HIV-INFECTED ADOLESCENTS

Mark Cameron, Stefano Rinaldi, Brian Richardson, Nicola Cotugno, Sion Williams, Suresh Pallikkuth, Lesley R. de Armas, Cheryl Cameron, Rajendra Pahwa, Paolo Palma, Savita Pahwa, for the EPIICAL Consortium

Poster P-R3 PHYLOGENETICS IN EPIDEMIOLOGY

Poster Hall B

2:30 PM – 4:00 PM

944 ARE REAL-TIME PHYLOGENY GUIDED INTERVENTIONS FEASIBLE? A LONGITUDINAL ANALYSIS

Larissa V. Mulka, Manon Ragonnet-Cronin, Jaime Vera-Rojas, Jackie Cassell, Anna Tostevin, David Dunn, Andrew Leigh Brown, for the UK HIV Drug Resistance Database

945 DYNAMICS OF THE CRF01AE EPIDEMICS IN THE CITIES OF SHANGHAI, SHENZHEN AND SHENYANG

Xiaoxu Han, Antoine Chaillon, Ping Zhong, Jin Zhao, Bin Zhao, Haibo Ding, Junjie Xu, Yi Lin, Yile Xue, Xuqin Wang, Min Zhang, Lin Wang, Davey M. Smith, Hong Shang

946 PHYLOGENETIC FEATURES OF ACTIVE LARGE CLUSTERS FUELING THE HIV EPIDEMIC IN QUEBEC MSM

Bluma G. Brenner, Ruxandra-Ilinca Ibanescu, Irene Vrbik, Michel Roger, Isabelle Hardy, David Stephens

947 HIV-1 SUPERINFECTION IN THE SWISS HIV COHORT STUDY: A LARGE SCALE SCREEN

Sandra E. Chaudron, Karin Metzner, Alex Marzel, Jürg Böni, Sabine Yerly, Thomas Klimkait, Matthieu Perreau, Roger Kouyos, Huldrych F. Günthard, for the Swiss HIV Cohort Study

948 GREATER THAN RANDOM HLA-B HOMOGENEITY IN HIV-1 TRANSMISSION CHAINS

Huyen Nguyen, Christian Thorball, Jacques Fellay, Jürg Böni, Sabine Yerly, Matthieu Perreau, Thomas Klimkait, Huldrych F. Günthard, Roger Kouyos, for the Swiss HIV Cohort Study

949 PREDICTING HIV CLUSTER GROWTH USING PHYLOGENETIC RECONSTRUCTION IN LOS ANGELES COUNTY

Manon Ragonnet-Cronin, Yunjin W. Hu, Joel O. Wertheim

950 ASSESSING HIV-1C TRANSMISSION NETWORK IN BOTSWANA AT LOW SAMPLING DENSITY

Vlad Novitsky, Melissa Zahralban-Steele, Sikhulile Moyo, Dorcas Maruapula, Baitshepi Mokaleng, Tapiwa Nkhisang, Mary F. McLane, Sally Madiba, Erik van Widenfelt, Tendani Gaolathe, Etienne Kadima, Shahin Lockman, Joseph Makhema, Simani Gaseitsiwe, Max Essex

- 951 HIV-1 GENETIC DIVERSITY AND TRANSMISSION DYNAMICS IN FISHING COMMUNITIES OF UGANDA**
 Nicholas Bbosa, Deogratius Ssemwanga, Jesus F. Salazar-Gonzalez, Rebecca N. Nsubuga, Maria Nannyonjo, Janet Seeley, Noah Kiwanuka, Bernard Bagaya, Gonzalo Yebra, **Andrew Leigh Brown**, Pontiano Kaleebu
- 952 PHYLOGENETIC AND GEOGRAPHIC SEPARATION IN HIV-INFECTED PEOPLE IN BRITISH COLUMBIA**
David McVea, Richard Liang, Jeffrey Joy, P. Richard Harrigan, Art Poon
- 953 PHYLDYNAMIC METHODS OF IDENTIFYING FOCI OF HIV-1 TRANSMISSION**
Angela McLaughlin, P. Richard Harrigan, Jean A. Shoveller, Jeffrey Joy
- 954 PHYLOGEOGRAPHIC ANALYSIS SUGGESTS GRAVITY MODEL OF HIV TRANSMISSION IN MEXICO**
 Antoine Chaillon, **Santiago Avila-Rios**, Ann M. Dennis, Joel O. Wertheim, Claudia García-Morales, Daniela Tapia-Trejo, Sanjay R. Mehta, Gustavo Reyes-Terán, for the HIV MexNet Group
- 955 ASSOCIATION BETWEEN VIRAL SUPPRESSION AND MOLECULAR CLUSTER GROWTH, UNITED STATES**
Nivedha Panneer, Alexandra M. Oster, Cheryl B. Ocfemia, Sheryl Lyss, Joel O. Wertheim, Anne Marie France
- 956 HIGH VIRAL LOAD ACROSS STAGE OF INFECTION ASSOCIATED WITH CLUSTERING IN US NETWORK**
Joel O. Wertheim, Alexandra M. Oster, Nivedha Panneer, Chenhua Zhang, Neeraja Saduvala, Ellsworth Campbell, Jeffrey A. Johnson, William M. Switzer, Walid Heneine
- 957 HIV TRANSMISSION CLUSTER DYNAMICS THAT INFORM PUBLIC HEALTH INTERVENTION IN ILLINOIS**
 Manon Ragonnet-Cronin, Joel O. Wertheim, Christina S. Hayford, Richard D'Aquila, Fangchao Ma, Cheryl Ward, **Nanette Benbow**
- 958 A NEW B/CRF02 CIRCULATING RECOMBINANT SPREADING QUICKLY IN PARIS AREA, FRANCE**
 Marc Wirden, Alexandre Storto, Magali Bouvier-Alias, Karine Grenet, Marie-Laure Chaix Baudier, Philippe Simon, Eric Froguel, Thuy T. Nguyen, Cathia Soulie, Vincent Calvez, Diane Descamps, Anne-Geneviève Marcellin, **Benoit Visseaux**
- 959 PREDICTIVE MODEL FOR HIV TRANSMISSION CLUSTER GROWTH IN NORTH CAROLINA**
Rachael Billock, Kimberly A. Powers, Erika Samoff, Victoria L. Mobley, William C. Miller, Joseph J. Eron, Ann M. Dennis
- 960 AGE DISPARITIES IN EUROPEAN HIV TRANSMISSION PAIRS UNCOVERED WITH VIRAL SEQUENCE DATA**
Matthew D. Hall, Chris Wymant, Oliver Ratmann, Jan Albert, Norbert Bannert, Anne-Marte Bakken Kren, Marion Cornelissen, Kate Grabowski, Huldrych F. Günthard, Laurence Meyer, Kholoud Porter, Matti Ristola, Guido Vanham, Christophe Fraser, for the BEEHIVE Collaboration

Poster P-S3 EARLY INFECTION AND RECENCY ASSAYS**Poster Hall B****2:30 PM – 4:00 PM**

- 998 HOW LOW CAN YOU GO? DIAGNOSIS OF ACUTE HIV INFECTION AT VERY LOW HIV RNA LEVELS**

Donn Colby, Siriwat Akapirat, Supanit Pattanachaiwit, Rapee Trichaviroj, Suteeraporn Pinyakorn, Sasiwimol Ubolyam, Eugène Kroon, Carlo Sacdalan, Nitiya Chomchey, Nittaya Phanuphak, Merlin L. Robb, Praphan Phanunphak, Jintanat Ananworanich, Mark de Souza, for the RV254/SEARCH010 Study Team

- 999 VALIDATION OF THE AMSTERDAM RISK SCORE FOR RECENT HIV INFECTION AMONG MSM**

Timothy Lin, Maartje Dijkstra, Godelieve J. de Bree, Maarten F. Schim van der Looff, Martin Hoenigl

- 1000 DEVELOPMENT AND VALIDATION OF THE SAN DIEGO SYMPTOM SCORE FOR ACUTE HIV INFECTION**

Timothy Lin, Tara Tenenbaum, Sara Gianella, Susan J. Little, Martin Hoenigl

- 1001 CAN THE LAG-AVIDITY ASSAY MEASURE AN INCIDENCE DIFFERENCE IN EAST AFRICA?**

Oliver Laeyendecker, Ronald H. Gray, Kate Grabowski, Steven J. Reynolds, Anthony Ndyanabo, Joseph Ssekasanvu, Reinaldo Fernandez, Maria Wawer, David Serwadda, Thomas C. Quinn

- 1002 PERFORMANCE VALIDATION OF THE SEDIA LAG ASSAY IN SOUTH AFRICAN BLOOD DONORS**

Eduard Grebe, Marion Vermeulen, Tinus Brits, Ronel Swanevelder, Genevieve Jacobs, Michael P. Busch, Alex Welte

- 1003 INNATE DYNAMIC RANGE OF ABBOT PRISM HIV O PLUS IS ADEQUATE FOR RECENCY STAGING**

Eduard Grebe, Marion Vermeulen, Tinus Brits, Ronel Swanevelder, Genevieve Jacobs, Michael P. Busch, Alex Welte

- 1004 MEASUREMENT OF ANTIBODY EPITOPE SIGNATURES TO DETERMINE RECENCY OF HIV INFECTION**

Kathryn E. Stephenson, Lisa M. Howe, Dan Barouch, Steven G. Deeks, Sheila M. Keating, Christopher D. Pilcher, Timothy J. Henrich

Poster P-T06 ORAL PrEP IN WOMEN**Poster Hall B****2:30 PM – 4:00 PM**

- 1043 PATTERNS OF ORAL PrEP ADHERENCE AND HIV RISK AMONG EASTERN AFRICAN WOMEN**

Maria Pyra, Elizabeth Brown, Jessica E. Haberer, Renee Heffron, Elizabeth A. Bukusi, Stephen Asiimwe, Connie L. Celum, Elly T. Katabira, Nelly R. Mugo, Jared Baeten, for the Partners Demonstration Project Team

- 1044 CHARACTERIZING THE HIV CONTINUUM OF CARE FOR TRANSGENDER WOMEN IN NORTH AMERICA**

Tonia Poteat, David B. Hanna, Peter F. Rebeiro, Marina Klein, Michael J. Silverberg, Joseph J. Eron, Michael A. Horberg, Mari Kitahata, W. C. Mathews, Kristin Mattocks, Angel Mayor, Ashleigh Rich, Richard D. Moore, Keri N. Althoff, for the North American AIDS Cohort Collaboration On Research and Design (NA-ACCORD) of IeDEA

1045 PREDICTORS OF WILLINGNESS TO TAKE PrEP AMONG BLACK AND LATINA TRANSGENDER WOMEN

Tonia Poteat, Erin Cooney, Mannat Malik, Thespina Yamanis, Maren Lujan, Andrea L. Wirtz

1046 PrEP AND EARLY ART FOR FEMALE SEX WORKERS IN SOUTH AFRICA: THE TAPS PROJECT

Robyn Eakle, Gabriela Gomez, Niven Naicker, Rutendo Bothma, Judie Mbogua, Maria A. Cabrera Escobar, Elaine Saayman, Michelle A. Moorhouse, **Willem D. Venter**, Helen Rees

1047 HIGH PrEP UPTAKE AMONG KENYAN PREGNANT WOMEN OFFERED PrEP DURING ANTENATAL CARE

John Kinuthia, Jillian Pintye, Kenneth K. Mugwanya, Marline Serede, Joseph Sila, Felix Abuna, Harrison Lagat, Julia Dettinger, Tina Schuh, Jared Baeten, Grace John-Stewart

1048 PREDICTORS OF PrEP ELIGIBILITY AMONG AT-RISK WOMEN IN THE SOUTHERN UNITED STATES

Anar S. Patel, Lakshmi Goparaju, Jessica M. Sales, Cyra Christina Mehta, Oni J. Blackstock, Dominika Seidman, Igbo Ofotokun, Mirjam-Colette Kempf, Margaret Fischl, Elizabeth T. Golub, Adaora Adimora, Audrey French, Gina Wingood, Seble Kassaye, Anandi N. Sheth

1049 RISK BEHAVIOR, PERCEPTION, AND REASONS FOR PrEP AMONG YOUNG AFRICAN WOMEN IN HPTN 082

Connie L. Celum, Sinead Delany-Moretlwe, Sybil Hosek, Bonnie J. Dye, Linda-Gail Bekker, Nyaradzo Mgodi, Wonderful Mabuza, Goodness Zoh Mvuyane, Shorai Mukaka, Deborah J. Donnell, Subash Pathak, Heather Noble, Denni Lennon, Jessica M. Fogel, Peter L. Anderson

1050 HIV BIOMEDICAL PREVENTION AMONG US WOMEN: KNOWLEDGE, BELIEFS, AND PRACTICES

Seble Kassaye, Lakshmi Goparaju, Amanda D. Castel, Lari Warren-Jeanpiere, Anandi N. Sheth, Adaora Adimora, Margaret Fischl, Elizabeth T. Golub, Kathleen M. Weber, Jennifer Cohen, Oluwakemi Sosanya, Anna Rubtsova, Deborah Konkle-Parker, Tracey Wilson, Chenglong Liu

1051 DEPRESSION AND PrEP ADHERENCE AMONG HIGH-RISK HIV-UNINFECTED WOMEN IN EAST AFRICA

Jennifer Velloza, Jared Baeten, Jessica E. Haberer, Kenneth Ngure, Elizabeth M. Irungu, Nelly R. Mugo, Connie L. Celum, Renee Heffron, for the Partners Demonstration Project Team

Poster P-T07 PrEP IN SERODISCORDANT COUPLES

Poster Hall B

2:30 PM – 4:00 PM

1052 REPORTED PrEP USE AMONG HIV-NEGATIVE PARTNERS OF US MSM RECEIVING HIV MEDICAL CARE

Linda Beer, R. L. Shouse, **Dawn K. Smith**, Amy R. Baugher, Jennifer Fagan, for the Medical Monitoring Project

1053 RAPID SCALE-UP OF PrEP FOR HIV SERODISCORDANT COUPLES IN HIV CARE CLINICS IN KENYA

Elizabeth M. Irungu, Kenneth K. Mugwanya, Nelly R. Mugo, Elizabeth A. Bukusi, Kenneth Ngure, Josephine Odoyo, Elizabeth Wamoni, Sarah Masyuko, Jennifer F. Morton, Lara Kidoguchi, Gena Barnabee, Gabrielle O'Malley, Jared Baeten, for the Partners Scale-Up Team

1054 NO RISK COMPENSATION BUT HIV EXPOSURE PERSISTS IN HETEROSEXUAL COUPLES USING PrEP

Kenneth K. Mugwanya, Renee Heffron, Nelly R. Mugo, Elizabeth A. Bukusi, Elly T. Katabira, Stephen Asiimwe, Kenneth Ngure, Connie L. Celum, Jared Baeten, for the Partners Demonstration Project Team

Poster P-T09 PHASE I STUDIES OF MONOCLONAL ANTIBODIES IN NON-INFECTED ADULTS**Poster Hall B****2:30 PM – 4:00 PM****1061 A PHASE I DOSE-ESCALATION STUDY OF MONOCLONAL ANTIBODY VRC07-523LS IN HEALTHY ADULTS**

Martin R. Gaudinski, Katherine V. Houser, Grace Chen, Ro Shauna Rothwell, Pamela Costner, Lasonji Holman, Ingelise Gordon, Robert Bailor, Margarita G. Lorenzo, Richard A. Koup, Edmund V. Capparelli, Barney S. Graham, John R. Mascola, Julie Ledgerwood, for the VRC 605 Study Team

1062 A PHASE 1 TRIAL OF THE COMBINATION OF 3BNC117 AND 10-1074 IN HIV-UNINFECTED ADULTS

Yehuda Z. Cohen, Allison Butler, Rebeka Levin, Katrina Millard, Maggi Pack, Shiraz A. Belblidia, Juan P. Dizon, Irina Shimeliovich, Kelly Seaton, Nicole L. Yates, Georgia Tomaras, Marshall Zingg, Michael S. Seaman, Michel Nussenzweig, Marina Caskey

1063 PHASE 1 TRIAL TO ASSESS SAFETY AND ANTIVIRAL ACTIVITY OF MB66 VAGINAL FILM

Susan Cu-Uvin, Kenneth H. Mayer, Thomas Moench, Karen T. Tashima, Jai G. Marathe, Joseph A. Politch, Tara J. Nyhuis, Larry Zeitlin, Hans M. Spiegel, Kevin Whaley, Deborah Anderson

Poster P-T10 SAFETY AND ACCEPTABILITY OF MALE CIRCUMCISION**Poster Hall B****2:30 PM – 4:00 PM****1064 ACCEPTABILITY OF TETANUS TOXOID VACCINE PRIOR TO SAFE MALE CIRCUMCISION**

Anna Lawino, Richard A. Mangwi, Christopher G. Orach

1065 PERCEPTIONS OF AND MOTIVATIONS FOR VMMC AMONG ADOLESCENTS: A MULTICOUNTRY STUDY

Eshan U. Patel, Michelle R. Kaufman, Kim H. Dam, Lynn M. Van Lith, Karin Hatzold, Arik V. Marcell, Webster Mavhu, Catherine Kahabuka, Lusanda Mahlasela, Emmanuel Njeuhmeli, Kim S. Ahanda, Getrude Ncube, Gissenge J. Lija, Collen Bonnecwe, Aaron Tobian

1066 NOTIFIABLE ADVERSE EVENTS ASSOCIATED WITH MEDICAL MALE CIRCUMCISION IN KENYA

Elijah Odoyo-June, Kawango Agot, Nandi Owuor, Cristine Kisia, Boaz Otieno-Nyunya, Paul K. Musingila, Vincent Ojiambo, Norah Talam, Hellen Mutta, Kennedy Serrem, Martin Sirengo

1067 SAFETY AND ACCEPTABILITY OF PREPEX CIRCUMCISION AMONG ADOLESCENTS IN KISUMU, KENYA

Kawango Agot, **Julie Ambia**, Risper Bosire, David Muhuaya, Joshua Juma, Abraham Bitok, Spala Ohaga, Benard Ayieko, Maurice Onyango

Poster P-U1 CLOSING THE GAP: INTEGRATION OF FAMILY PLANNING IN HIV PREVENTION AND CARE**Poster Hall B****2:30 PM – 4:00 PM****1068 INTEGRATION OF FAMILY PLANNING INTO HIV CARE AND TREATMENT PROGRAM IN KENYA**

Wangui Muthigani, Emily R. Begnel, **Dunstan Achwoka**, Tai Ho Chen, John Kinuthia, Christine J. McGrath, Alison L. Drake, for the FP Working Group

1069 MISSED OPPORTUNITY FOR FAMILY PLANNING IN HIV-INFECTED WOMEN ON ART IN TOGO

Shino Arikawa, Cécile Cazes, Anne Thomas, Thierry Tiendrebeogo, Benjamin G. Kariyiare, Vincent Pitche, Didier K. Ekouevi, Renaud Becquet

1070 CONTRACEPTION AND PREP IN SOUTH AFRICAN HAIR SALONS: OWNER, STYLIST, AND CLIENT VIEWS

Ingrid V. Bassett, Ai Xu, Sabina Govere, Hilary Thulare, Simone C. Frank, Christina Psaros, Robert A. Parker

1071 PREGNANCY INTENTION AND CONTRACEPTIVE USE IN MALAWI'S PMTCT PROGRAM

Deus Thindwa, Megan Landes, Monique van Lettow, Annie Kanyemba, Ernest Nkhoma, Thokozani Kalua, Happy Phiri, Joep J. van Oosterhout, for the NEMAPP consortium

Poster P-V1 LINKAGE, ENGAGEMENT, AND RETENTION**Poster Hall B****2:30 PM – 4:00 PM****1076 IDENTIFYING OPERATIONAL CHALLENGES IN ZAMBIAN ART CLINICS: A TIME AND MOTION STUDY**

Radhika Tampi, **Tanya Tembo**, Arianna L. Zanolini, Anjali Sharma, David Dowdy, Charles B. Holmes, Mpande Mukumbwa-Mwenechanya, Carolyn Bolton Moore, Izukanji Sikazwe, Austin Tucker, Hojoon Sohn

1077 EFFECT OF UNDISCLOSED HIV+ STATUS ON LINKAGE TO AND RETENTION IN CARE

Neena M. Philip, Yingfeng Wu, Margaret McNairy, Averie B. Gachuhi, Matthew R. Lamb, **Harriet Nuwagaba-Biribonwoha**, Veli M. Madau, Sean Burke, Zandile Mnisi, Wafaa M. El-Sadr

1078 INTEGRATED COCAINE & MENTAL HEALTH TREATMENT WITH NAVIGATION RCT FOR HIV+ OUTPATIENTS

Lisa Metsch, Daniel Feaster, Lauren Gooden, Christin Root, Pedro C. Castellon, Jonathan Colasanti, Eugene W. Farber, Gabriel Cardenas, Terri Liguori, Wendy S. Armstrong, Allan Rodriguez, Carlos del Rio

1079 SINGLE-PILL ART AND RETENTION IN CARE: A REGRESSION DISCONTINUITY STUDY IN S. AFRICA

Sheryl Kluberg, Matthew P. Fox, Michael LaValley, Denise Evans, Kamban Hirasen, Mhairi Maskew, Lawrence Long, Jacob Bor

1080 HIV CARE DELIVERY BY ID PHYSICIANS, OTHER PHYSICIANS, AND ADVANCED PRACTICE PROVIDERS

John Weiser, Guangnan Chen, Wendy S. Armstrong, Linda Beer

1081 BETTER RETENTION AMONG PATIENTS ON ART ARGUES FOR UNIVERSAL TREATMENT IN KENYA

Irene Mukui, Maureen Kimani, Samuel M. Mwalili, Agnes Natukunda, Evelyne Ngugi, Abraham Katana, Lucy Ng'ang'a, Peter W. Young, George Rutherford

- 1082 IS DIFFERENTIATED CARE IMPLEMENTED? ANALYSIS OF SEVEN AFRICAN TREATMENT PROGRAMS**
Andreas D. Haas, Leigh F. Johnson, Izukanji Sikazwe, Nathan Ford, Matthew P. Fox, Hans Prozesky, Cleophas Chimbetete, Jonathan Euvrard, Matthias Egger, for the leDEA Southern African collaboration
- 1083 LINKAGE, TREATMENT AND SUPPRESSION IN THE BOTSWANA COMBINATION PREVENTION PROJECT**
Pamela J. Bachanas, Refeletswe Lebelonyane, Mary Grace Alwano, William Abrams, Baraedi W. Sento, Lisa Block, **Tendani Gaolathe**, Shahin Lockman, Shenaaz El Halabi, Janet Moore
- 1084 DISTRIBUTION OF ADVANCED HIV IN 3 HIGH HIV PREVALENCE COUNTRIES IN AFRICA**
Menard L. Chihana, Helena Huerga, Gilles van Cutsem, Stephen Wanjala, Charles Masiku, Elisabeth Szumilin, Jean F. Etard, Mary-Ann Davies, David Maman
- 1085 CASCADE OF CARE AMONG SERODISCORDANT COUPLES IN 4 HIGH PREVALENCE SETTINGS IN AFRICA**
Menard L. Chihana, Nolwenn Conan, Erica Simons, Cyrus Paye, Daniela B. Garone, Reinaldo Ortuno, Helena Huerga, Gilles van Cutsem, Stephen Wanjala, Charles Masiku, Elisabeth Szumilin, Jean F. Etard, Mary-Ann Davies, David Maman
- 1086 MULTI-MONTH SCRIPTING (MMS) AND RETENTION ON HIV ANTIRETROVIRAL THERAPY IN HAITI**
Nancy Puttkammer, Tricia Rodriguez, Ermane Robin, Gracia Desforges, Canada Parrish, Jean Gabriel Balan, Jean Guy Honore, Joelle Deas Van Onacker, Scott Barnhart, Jane M. Simoni, Kesner Francois
- 1087 ROUTINE RETENTION IN CARE AT HOWARD BROWN, 2012-2017: ARE QUARTERLY VISITS TOO MUCH?**
Laura Rusie, Carlos Orengo, Diane Burrell, Magda Houlberg, Arthi Ramachandran, Kristin Keglovitz-Baker, David Munar, John A. Schneider
- 1088 POSTPARTUM MOBILITY AND TRANSFER OF CARE AMONG HIV+ WOMEN ON ART IN SOUTH AFRICA**
Tamsin K. Phillips, Kate Clouse, Allison Zerbe, Catherine Orrell, Elaine J. Abrams, Landon Myer
- 1089 LINKAGE TO CARE AFTER HIV TESTING IN THE COMMUNITY IN A HIGH HIV PREVALENCE SETTING**
Sarah Jane Steele, Bernadette Geronne, Liesbet Ohler, Ellie Ford-Kamara, Gilles van Cutsem, Amir Shroufi
- 1090 PHONE CALL FROM CLINICAL OFFICER AT HIV TESTING/RE-CONTACT IMPROVES LINKAGE TO CARE**
James Ayieko, Erick Wafula, Wilson Opudo, Craig R. Cohen, Elizabeth A. Bukusi, Tamara D. Clark, Laura B. Balzer, Moses R. Kamya, Edwin D. Charlebois, Maya L. Petersen, Diane V. Havlir
- 1091 UNDERSTANDING PATIENT MOBILITY IN HIV +VE ADULTS ACROSS MULTIPLE CLINICS IN ZAMBIA**
Kombatende Sikombe, Sandra Simbeza, Jillian L. Kadota, Ingrid Eshun-Wilson, Laura Beres, Carolyn Bolton Moore, Njekwa Mukamba, Charles B. Holmes, Izukanji Sikazwe, Elvin Geng
- 1092 RISK FOR ATTRITION IN HIV-INFECTED CLIENTS ON TREATMENT IN URBAN HIV CLINICS IN KENYA**
Emily C. Koech, **Sylvia Ojoo**, Caroline Ngunu

- 1093 TIME TO ART INITIATION IN KENYA, 2003-2013**
Kenneth Masamaro, Jacques Muthusi, Maureen Kimani, Irene Mukui, Evelyn Ngugi, George Mgomella, Tai Ho Chen
- 1094 YOUTH-FOCUSED CARE IN AN ADULT CLINIC IMPROVES RETENTION FOR YOUNG ADULTS WITH HIV**
David C. Griffith, Shanna Dell, Jeremy Snyder, Samantha Greenblatt, Jeanne C. Keruly, Allison Agwu
- 1095 CAN FOOD HELP RETENTION IN HIV CARE: A COHORT STUDY OF ADULTS INITIATING ART IN HAITI**
Julie Reiff, Stanislas Galbaud, Akanksha Dua, Jean Edouard Mathon, Patrice Joseph, Adias Marcellin, Pierrot Julma, Serena Koenig, Pierre Cremieux, Jean W. Pape, Margaret McNairy
- 1096 HIV CASCADE OF CARE IN GREECE: USEFUL INSIGHTS FROM ADDITIONAL STAGES**
Giota Touloumi, Georgia Vourli, Vasileios Paparizos, Athanassios Skoutelis, Simeon Metallidis, Panagiotis Gargalianos, Antonios Papadopoulos, Maria Chini, Nikolaos Sipsas, Mina Psychogiou, Georgios Chrysos, Helen Sambatakou, Charalambos Gogos, Dimitra Paraskeva, Georgios Nikolopoulos
- 1097 IMPACT OF SYSTEMS NAVIGATION AND COUNSELING ON ART, SUT AND DEATH IN PWID: HPTN 074**
William C. Miller, Irving Hoffman, Brett Hanscom, Tran V. Ha, Kostyantyn Dumchev, Zubairi Djoerban, Scott M. Rose, Kathryn E. Lancaster, Vivian Go, Sarah Reifeis, Estelle Piwowar-Manning, Carl A. Latkin, David Metzger, David Burns, for the HPTN 074 Protocol Team
- 1098 TRENDS IN UNSUPPRESSED HIV RNA AFTER LINKAGE TO CARE AMONG KEY POPULATIONS**
Fidel A. Desir, Catherine R. Lesko, Richard D. Moore, Michael A. Horberg, Peter F. Rebeiro, Michael John Gill, Mari Kitahata, Michael J. Silverberg, Julie H. Levison, Marina Klein, Angel Mayor, Amy C. Justice, Keri N. Althoff, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA
- 1099 OUTCOMES OF PATIENTS LOST TO FOLLOW-UP IN AFRICAN ART PROGRAMS: MULTI-COHORT STUDY**
Frédérique Chammartin, Kathrin Zürcher, Hannock Tweya, Paula Braitstein, Ralf Weigel, Kathryn Chu, Elvin Geng, Agnes Kiragga, Charles Kouanfack, Cristina Ardura-Garcia, Takuma Kato, Hilary Gunguwo, James R. Hargreaves, Matthias Egger, for the HIV Measurement and Surveillance Consortium (MeSH)
- 1100 IMPROVEMENT IN HIV CARE INDICATORS AMONG THE HOMELESS IN SAN FRANCISCO**
Susan Scheer, Ling Hsu, Darpan Sachdev, Oliver Bacon, Stephanie E. Cohen, Albert Y. Liu, Jennie C. Chin, Susan P. Buchbinder
- 1101LB IMPACT OF SERVICE INTEGRATION ON HIV TESTING UPTAKE AMONG KEY POPULATIONS IN INDIA**
Sunil S. Solomon, Suniti Solomon, Allison M. McFall, Aylur K. Srikrishnan, Santhanam Anand, Pachamuthu Balakrishnan, Elizabeth Ogburn, Lawrence Moulton, Muniratnam S. Kumar, David D. Celentano, Gregory M. Lucas, Shruti H. Mehta
- 1102 SHORT-TERM EFFECTS OF ALTERNATIVE MEDICATION REFILL STRATEGIES IN SOUTH AFRICA**
Matthew P. Fox, Sophie Pascoe, Amy Huber, Joshua Murphy, Mokgadi Phokojoe, Mareline Gorgens, Sydney Rosen, David Wilson, Yogan Pillay, Nicole Fraser

Poster P-V2 EARLY ANTIRETROVIRAL THERAPY INITIATIVE
Poster Hall B 2:30 PM – 4:00 PM

- 1103 EFFECT OF FAST TRACK INITIATION COUNSELLING ON ART INITIATION IN SOUTH AFRICA**
 Sophie Pascoe, Matthew P. Fox, Amy Huber, Joshua Murphy, Mokgadi Phokojoe, Marelize Gorgens, **Sydney Rosen**, David Wilson, Yogan Pillay, Nicole Fraser
- 1104 ART ELIGIBILITY EXPANSION AND TIMELY ART INITIATION: 22-COUNTRY META-ANALYSIS**
 Olga Tymejczyk, Ellen Brazier, Constantin T. Yiannoutsos, Kara K. Wools-Kaloustian, Keri N. Althoff, Brenda Crabtree-Ramírez, Kinh V. Nguyen, Elizabeth Zaniewski, François Dabis, Jean d'Amour Sinayobye, Nanina Anderegg, Nathan Ford, Radhika Wikramanayake, **Denis Nash**, for the leDEA Collaboration
- 1105 A STREAMLINED ART INITIATION ALGORITHM OF CARE REDUCES TIME TO ART**
 Izukanji Sikazwe, Samuel Bosomprah, Jake Pry, Mpande Mukumbwa-Mwenechanya, Anjali Sharma, Paul Somwe, Nancy Padian, Monika Roy, Carolyn Bolton Moore, Charles B. Holmes, Elvin Geng
- 1106 SAME-DAY ART INITIATION IN THE SLATE TRIAL IN SOUTH AFRICA: PRELIMINARY RESULTS**
 Mhairi Maskew, **Alana T. Brennan**, Matthew P. Fox, Willem D. Venter, Lungisile Vezi, Bruce Larson, Isaac Tsikhutsu, Margaret Bii, Sydney Rosen
- 1107 STARTING ART IN HIV+ DRUG USERS WHILE HOSPITALIZED PREDICTS HIV TREATMENT ENGAGEMENT**
 Petra Jacobs, Daniel Feaster, Yue Pan, Lauren Gooden, Carlos del Rio, Eric Daar, Gregory M. Lucas, Mamta K. Jain, Eliza Marsh, Lisa Metsch
- 1108 GETTING A JUMP ON HIV: EXPEDITED ARV TREATMENT AT NYC SEXUAL HEALTH CLINICS, 2017**
 Susan Blank, **Christine M. Borges**, Michael A. Castro, Kelly Jamison, John Winters, Tarek Mikati, Julie Myers, Demetre C. Daskalakis
- 1109 A RAPID ENTRY PROGRAM IN THE SOUTH: IMPROVING ACCESS TO CARE AND VIRAL SUPPRESSION**
 Jonathan Colasanti, Jeri Sumitani, Cyra Christina Mehta, Yiran Zhang, Minh Ly Nguyen, Wendy S. Armstrong, Carlos del Rio
- 1110 EARLY RETENTION DOES NOT MEDIATE/MODERATE EFFECT OF SEX/SEXUAL BEHAVIOR ON SURVIVAL**
 Lara Coelho, Peter F. Rebeiro, Jessica L. Castilho, Yanink Caro-Vega, Fernando A. Mejia, Carina Cesar, Claudia P. Cortes, Denis Padgett, Catherine McGowan, Valdilea Veloso, Timothy R. Sterling, Beatriz Grinsztejn, Bryan E. Shepherd, Paula M. Luz, for the CCASAnet
- 1111LB SAME-DAY ART INITIATION ASSOCIATED WITH POORER RETENTION BUT HIGHER VIRAL SUPPRESSION**
 Dvora Joseph Davey, Claire Serrao, Madaline Feinberg, Marljen Prins, Ernest Darkoh

WEDNESDAY, MARCH 7, 2018

Poster P-A4 HIV AND HOST DEFENSES**Poster Hall A****2:30 PM – 4:00 PM**

Poster Sessions • Wednesday

- 192 INFANT T/F HIV-1 FROM PERIPARTUM TRANSMISSION ARE RESISTANT TO MATERNAL PLASMA**
Amit Kumar, Claire E. Smith, Elena E. Giorgi, Joshua A. Eudailey, David R. Martinez, Karina Yusim, Ayooluwa O. Douglas, Lisa Stamper, Genevieve Fouda, Erin McGuire, Celia C. Lebranche, David C. Montefiori, Feng Gao, Sallie Permar
- 193 ZIKA VIRUS AND HIV-1 INTERPLAY IN HUMAN IMMUNE CELLS**
Joel Provost, Corinne Barat, Michel J. Tremblay
- 194 STRUCTURAL AND RNA BINDING MODEL OF APOBEC3G N-TERMINAL DOMAIN FOR NEW DRUG DESIGNS**
Hirofumi Fukuda, Anamaria D. Sarca, Kazuo Yamashita, Song Lin Li, Luca Sardo, Jessica Smith, Hirotaka Ebina, Kotaro Shirakawa, Kei Sato, Daron Standley, Yoshio Koyanagi, Taisuke Izumi, Akifumi Takaori-Kondo
- 195 SEMINAL CYTOKINE/CHEMOKINE NETWORK AND HIV TRANSMISSION IN MEN WHO HAVE SEX WITH MEN**
Christophe Vanpouille, Andrea Lisco, Leonid Margolis, Laura Layman, Martin Hoenigl, **Sara Gianella**
- 196 BENEFICIAL IMPACT OF EARLY TREATMENT ON RESTRICTION FACTOR EXPRESSION PROFILE**
Clarissa Van Hecke, Magdalena Sips, Eva Malatinkova, Ward De Spiegelaere, Karen Vervisch, Chris Verhofstede, Margaret Johnson, Sabine Kinloch-de Loes, Wim Trypsteen, Linos Vandekerckhove
- 197 HOST MICRORNA MIR-382-5P MAY EXERT A PROTECTIVE EFFECT ON HIV CONTROL**
Marcial García, Ricardo Ramos, María Ángeles Navarrete, Carlos Cañada, Alfonso Cabello, Juan Carlos López-Bernaldo, Francisco Javier De La Hera, Vicente Estrada, Carlos Barros, Clara Restrepo, Manuel Fernández, Miguel Górgolas, José Miguel Benito, **Norma Rallón**
- 198 NEF'S INFERIOR ABILITY TO DOWNREGULATE HLA-B CORRELATES WITH PLASMA VIRAL CONTROL**
Francis Mwimanzi, Mako Toyoda, Macdonald Mahiti, Jaclyn Mann, Jeffrey N. Martin, David R. Bangsberg, Mark Brockman, Philip J. Goulder, Frank Kirchhoff, Zabrina Brumme, Thumbi Ndungú, Takamasa Ueno
- 199 MODULATION OF HIV RESTRICTION FACTORS BY BLOCKING CCL2/CCR2 IN VITRO AND IN VIVO**
Daniela Angela Covino, Maria Clementina Galluzzo, Jing Lu, Cristina Purificato, Laura Catapano, Matteo Pellegrini, Maria Cristina Gauzzi, Stefano Vella, Eric Lefebvre, Mauro Andreotti, Laura Fantuzzi
- 200 TRIM21 –CRM-1 INTERACTION: A NOVEL MECHANISM FOR HIV RESTRICTION IN MURINE CELLS**
Roqaya Sabbah-Abudaabes, Moshe Kotler, Richard Sutton, **Hila Elinav**
- 201 NEF ANTAGONIZES TIM-MEDIATED INHIBITION OF HIV-1 RELEASE: ROLE OF SERINC5**
Minghua Li, Abdul A. Waheed, Eric O. Freed, **Shan-Lu Liu**
- 202 IMPACT OF NATURAL HIV-1 NEF POLYMORPHISMS ON SERINC5 ANTAGONISM**
Steven W. Jin, Nirmin Alsahafi, Xiao Mei T. Kuang, Philip Mwimanzi, Heinrich Gottlinger, Zabrina Brumme, Andrés Finzi, Mark Brockman

Poster P-B6 THE MICROBIOME AND HIV: TRANSLOCATION AND INTERVENTION**Poster Hall A****2:30 PM – 4:00 PM**

- 252 FECAL MICROBIOTA FROM HIV-INFECTED SUBJECTS INCREASES INNATE IMMUNE ACTIVATION**
Charles P. Neff, Owen Krueger, Sam Li, Nichole Nusbacher, Jennifer M. Schneider, Abigail Armstrong, Catherine Lozupone, Brent E. Palmer
- 253 ISOLATION OF TRANSLOCATING BACTERIA IN PROGRESSIVE SIV INFECTION OF RHESUS MACAQUES**
Jacob Flynn, Alexandra Ortiz, Jason Brenchley
- 254 CIRCULATING (1→3)-B-D-GLUCAN AS A MARKER OF MICROBIAL TRANSLOCATION IN HIV INFECTION**
Vikram Mehraj, Rayoun Ramendra, Cecilia Costiniuk, Bertrand Lebouché, Rosalie Ponte, Réjean Thomas, Jason Szabo, Pierre Coté, Roger LeBlanc, Jean-Guy Baril, Cécile Tremblay, Nicole Bernard, Don C. Sheppard, Jean-Pierre Routy, for the Montreal Primary HIV-infection Study Group
- 255 TRANSFER OF MICROBIOTA AND IMMUNOPHENOTYPES IN HIV-/+ MSM TO MICE BY FECAL TRANSPLANT**
Sam Li, Sharon Sen, Jennifer M. Schneider, Nichole Nusbacher, Nancy Moreno-Huizar, Catherine Lozupone, Brent E. Palmer
- 256 ANTIBIOTICS DISRUPT COLONIC MICROBIOTA AND MUCOSAL IMMUNE FUNTION IN RHESUS MACAQUES**
Alexander S. Zevin, Ryan Cheu, Tiffany Hensley-McBain, Jacob Modesitt, Jennifer A. Manuzak, Charlene J. Miller, Ernesto Coronado, Elise Smith, Brian Richardson, Michael Gale, Mark Cameron, Jeremy Smedley, Nichole Klatt
- 257 EFFECT OF PROBIOTICS ON GUT MICROBIOTA AND PET/MRI ACTIVITY IN HIV-INFECTED PERSONS**
Caroline Arnbjerg, Beate Vestad, Johannes Hov, Karin K. Pedersen, Sofie Jespersen, Helle H. Johannessen, Kristian Holm, Eva Fallentin, Adam E. Hansen, Theis Lange, Andreas Kjær, Marius Troseid, Barbara M. Fischer, Susanne D. Nielsen
- 258 INVESTIGATING THE EFFECT OF THERAPEUTICS ON THE MICROBIOME OF PATIENTS WITH HIV/AIDS**
Bryn C. Taylor, David M. Asmuth, Rob Knight

Poster P-B7 EFFECTS OF HIV INFECTION ON THE MICROBIOME**Poster Hall A****2:30 PM – 4:00 PM**

- 259 TLR9 AGONIST MODULATED INTESTINAL GLYCOGENE EXPRESSION IMPACTS MICROBIOME DIVERSITY**
Mohamed Abdel-Mohsen, Phillip A. Engen, Ali Keshavarzian, Stefan J. Green, Alan Landay, Satish K. Pillai, Anders K. Dige, Jørgen Agnholt, Andreas M. Petersen, Thomas Benfield, Lars Østergaard, Line K. Vibholm, Ole S. Søgaard, Martin Tolstrup, Paul W. Denton
- 260 EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION**
Muntas Rocafort, Marc Noguera-Julian, Javier Rivera, Lucia Pastor Palomo, Yolanda Guillén, Jost Langhorst, Mariona Parera, Inacio Mandomando, Jorge Carrillo, Bonaventura Clotet, Julià Blanco, Denise Naniche, Roger Paredes

- 261 HIV-ASSOCIATED CHANGES OF THE GUT MICROBIOME IN ARV-TREATED, UNTREATED, & CONTROLLERS**
Jesus M. Luevano, David B. Gootenberg, Zoe Rogers, Jeff Paer, Douglas Kwon
- 262 TIME BETWEEN HIV ACQUISITION AND ART INITIATION IMPACTS GI MICROBIOME**
Douglas Fadrosh, Susan V. Lynch, Javier R. Lama, Ricardo Alfaro, Delia Pinto-Santini, Rachel A. Bender Ignacio, Peter W. Hunt, Jessica Rios, Ann Duerr, for the MERLIN Study Group
- 263 COMPLEXITIES OF GUT MICROBIOME DYSBIOSIS IN HIV INFECTED AND HIGH RISK POPULATIONS**
Abigail Armstrong, Michael Shaffer, Nichole Nusbacher, Thomas Campbell, Brent E. Palmer, Catherine Lozupone
- 264 ELEVATED FECAL INFLAMMATORY BIOMARKERS IN HIV-/+ MSM ASSOCIATE TO GUT MICROBIOTA**
Jennifer M. Schneider, Sam Li, Charles P. Neff, Nichole Nusbacher, Nancy Moreno-Huizar, Catherine Lozupone, Brent E. Palmer
- 265 EFFECTS OF SUBSTANCE USE AND SEXUAL BEHAVIOR ON THE INTESTINAL MICROBIOME IN HIV**
Jennifer A. Fulcher, Ryan Cook, Fan Li, Shehnaz K. Hussain, Nicole Tobin, Amy Ragsdale, Steven Shoptaw, Pamina Gorbach, Grace M. Aldrovandi
- 266 LIVER BACTERIAL DYSBIOSIS PERSISTS DURING ANTIRETROVIRAL THERAPY IN SIV+ MACAQUES**
Bridget Fisher, Cole Fisher, Matthew Wood, Melanie Gasper, Elise Smith, Richard Green, Connor Driscoll, Michael Gale, Guido Silvestri, Ann Chahroudi, Nichole Klatt, Donald Sodora
- 267 PREGNANCY ASSOCIATED VAGINAL PROTEOME ALTERATIONS LINKED TO HIV ACQUISITION RISK**
Christina Farr Zuend, **Nicole Tobin**, Kenzie Birse, Laura Noël-Romas, Lani Kotyra, Trisha Vera, Sarah Mutch, Max Abou, Stuart McCorrister, Garrett Westmacott, Grace M. Aldrovandi, Adam Burgener
- 268 VAGINAL MICROBIOTA AND HIV ACQUISITION RISK AMONG AFRICAN WOMEN**
Sujatha Srinivasan, Barbra A. Richardson, Jacqueline Wallis, Tina L. Fiedler, Charlene S. Dezzutti, Z. Mike Chirenje, Edward W. Livant, David N. Fredricks, Sharon L. Hillier, Jeanne Marrazzo
- 269 THE VAGINAL MICROBIOME IN PREGNANCY DIFFERS BY HIV STATUS, ART EXPOSURE, AND CLASS**
Charlotte-Eve S. Short, Richard Brown, Rachael A. Quinlan, Robin J. Shattock, Phillip R. Bennett, Graham P. Taylor, David A. MacIntyre, for the The London HIV Pregnancy Research Group
- 270 BACTERIAL VAGINOSIS ASSOCIATED MICROBES INDUCE ALTERED INNATE IMMUNE PROFILES**
Ryan Cheu, Tiffany Hensley-McBain, Avid Mohammadi, Jennifer A. Manuzak, Alexander S. Zevin, Charlene J. Miller, Mark Yudin, Rupert Kaul, Nichole Klatt

Poster P-B8 ROLE OF THE MICROBIOME IN HIV INFECTION
Poster Hall A **2:30 PM – 4:00 PM**

- 271 MICROBIOME-ASSOCIATED EPITHELIAL DISRUPTION MODIFIES HIV ACQUISITION RISK IN WOMEN**
 Laura Noël-Romas, Michelle Perner, Alicia Berard, Ann M. Carias, Kenzie Birse, John Schellenberg, Melissa Lemke, Annelie Tjernlund, Garrett Westmacott, Douglas Lauffenburger, Kristina Brolden, Lyle McKinnon, Kelly Arnold, Thomas Hope, Adam Burgener
- 272 IMPAIRED GUT TIGHT JUNCTION BUT PRESERVED ΓΔ AND MICROBIAL TRANSLOCATION IN ACUTE HIV**
 Elvira S. Cannizzo, Giuseppe Ancona, Delfina Tosi, Federica Savi, Camilla Tincati, Antonella D'Arminio Monforte, Giulia Marchetti
- 273 MICROBIAL DYSBIOSIS DOES NOT ALTER DISEASE PROGRESSION IN SIV-INFECTED ASIAN MACAQUES**
 Alexandra Ortiz, Sarah DiNapoli, Jacob Flynn, Carly Elizabeth C. Starke, Stephen Lai, Mackenzie Long, Ornella Sortino, Carol Vinton, Joseph Mudd, Jacob D. Estes, Jason Brenchley
- 274 EFFECTS OF PROBIOTIC VISBIOME ES ON COLONIC MUCOSAL CD4 CELLS: RESULTS FROM A5352S**
 Rachel Presti, Douglas W. Kitch, Adriana Andrade, Alan Landay, Jeffrey Jacobson, Cara Wilson, Eunice Yeh, Jacob D. Estes, Claire Deleage, Karin L. Klingman, Netanya S. Utay, Edgar T. Overton, Jason Brenchley, Brett Williams, for the A5352S Clinical Trial Team
- 275 THE IMPACT OF SYNBIOTICS IN ADVANCED HIV DISEASE: A RANDOMIZED CLINICAL TRIAL**
 Sergio Serrano-Villar, Maria Lagarde, Nadia Madrid, Jose I. Bernardino, Alejandro Vallejo, Carolina Gutiérrez, Alfonso Cabello, Mariano Matarranz, Judit Villar, Alberto Díaz de Santiago, Jose-Ramón Blanco, Talía Sainz, Federico Pulido, Santiago Moreno, Vicente Estrada

Poster P-C1 KILLERS: NK AND CD8 CELLS
Poster Hall A **2:30 PM – 4:00 PM**

- 276 SIGNATURES OF PROTECTIVE SIV-SPECIFIC CD8+ T CELLS**
 Carly Elizabeth C. Starke, Jason Brenchley
- 277 TCF-1 EXPRESSION IS ASSOCIATED WITH HIV-SPECIFIC CD8+ T CELL PROLIFERATIVE CAPACITY**
 Rachel L. Rutishauser, Christian Deo T. Deguit, Rebecca Hoh, Michelle A. Hough, Melissa Krone, Rafick-Pierre Sekaly, Frederick M. Hecht, Christopher D. Pilcher, Jeffrey N. Martin, Steven G. Deeks, Joseph M. McCune, Peter W. Hunt
- 278 LONGITUDINAL T CELL RESPONSES IN HIV-EXPOSED INFANTS WITH CONGENITAL CMV INFECTION**
 Pamela M. Odorizzi, Rachel L. Rutishauser, Ruth Cortado, Margaret Feeney, Trevor Burt, Karin Nielsen-Saines, Deborah Persaud, Yvonne Bryson, Joseph M. McCune
- 279 PHOSPHORYLATED HIV-1 AS POTENTIAL CYTOTOXIC T LYMPHOCYTE (CTL) TARGETS**
 Fatema Z. Chowdhury, Shivaali Maddali, Matthew J. Szucs, Rushdy Ahmad, John Sidney, Alessandro Sette, Pratikkumar Rathod, Emmanuel J. Chang, Mathias Licherfeld, Xu G. Yu

280 EVALUATING THE LINK BETWEEN MITOCHONDRIAL STATE & HIV-SPECIFIC CD8+ T CELL EXHAUSTION

Christian Deo T. Deguit, Michelle A. Hough, Rebecca Hoh, Melissa Krone, Christopher D. Pilcher, Jeffrey N. Martin, Steven G. Deeks, Joseph M. McCune, Peter W. Hunt, Rachel L. Rutishauser

281 S100A14, NOVEL NK CROSS TALK PROTEIN FOR MONOCYTE-NK ACTIVATION IN HESN-IDU SUBJECTS

Krystal Colon-Rivera, Costin Tomescu, David Metzger, David W. Speicher, Luis Montaner

282 FUNCTIONAL MECHANISMS OF MEMORY-LIKE NK CELLS IN SIV-INFECTED MACAQUES

Spandan Shah, Cordelia Manickam, Daniel Ram, R. Keith Reeves

283 IFN-ALPHA ENHANCES NK CELL AND CD8+ T CELL MEDIATED SUPPRESSION OF HIV REPLICATION

Abena Kwaa, Joel Blankson

Poster P-C2 T AND B CELL INTERACTIONS IN LYMPH NODES**Poster Hall A**

2:30 PM – 4:00 PM

284 FREQUENCIES AND DISTRIBUTION OF ENV-SPECIFIC B CELLS IN BLOOD VERSUS LYMPH NODES

Alessandra Noto, Andrew McDavid, Phu Van, Madeleine Suffiotti, Agostino Riva, Jean-Marc Corpataux, Song Ding, Craig Fenwick, Raphael Gottardo, Giuseppe Pantaleo

285 T AND B CELL ALTERATIONS IN PERIPHERAL BLOOD AND LYMPH NODE IN ACUTE HIV INFECTION

Supranee Buranapraditkun, Hiroshi Takata, Carlo Sacdalan, Sopark Manasnayakorn, Suthat Chottanapund, Pattarawat Thantiworasit, Peeriya Prueksakaew, Khunthalee Benjapornpong, Bessara Nuntapinit, Timothy Schacker, Merlin L. Robb, Nelson L. Michael, Jintanat Ananworanich, Lydie Trautmann, for the RV254/SEARCH010

286 CYTOLYTIC CD4+ T CELLS WITH FOLLICULAR HOMING PROPERTIES IN CHRONIC HIV INFECTION

Enrico Richter, Johanna Eberhard, Marek Korencak, Bruce T. Schultz, Britta Flach, Stefan Esser, Julian Schulze zur Wiesch, Hendrik Streeck

287 TFC CELLS INTERACT WITH OTHER FOLLICULAR T CELLS TO CONTROL SIV VIREMIA

Mohammad Arif Rahman, Katherine M. McKinnon, Tatiana S. Karpova, David A. Ball, David Venzon, Wenjin Fan, Guobin Kang, Qingsheng Li, Marjorie Robert-Guroff

Poster P-D08 NOVEL INSIGHTS INTO HIV/SIV RESERVOIRS**Poster Hall A**

2:30 PM – 4:00 PM

375 SIV PROVIRAL LANDSCAPE DIFFERS FROM THAT OF HIV-1 AND SHOWS GROSS HYPERMUTATION

Alexandra J. Murray, Katherine Bruner, Mithra R. Kumar, Andrew Timmons, Po-Ting Liu, Janice E. Clements, Dan Barouch, Janet Siliciano, Robert Siliciano

376 IL-10 SIGNALING IS A KEY MECHANISM OF SIV PERSISTENCE IN ART-TREATED RHESUS MACAQUES

Justin L. Harper, **Maria Pino**, Luca Micci, Susan P. Ribeiro, Claire Deleage, Hong Wang, Colin T. King, Daniel Gorman, Jacob D. Estes, Rafick-Pierre Sekaly, Mirko Paiardini

377 NOVEL SHIVS ENCODING TRANSMITTED/FOUNDER ENVs FOR LATENCY AND CURE RESEARCH

Anya Bauer, Fang-Hua Lee, Hui Li, Ronald Veazey, Meagan Watkins, George Shaw, Katharine J. Bar

378 CLONES WITH INTACT PROVIRUSES ARE FOUND IN MULTIPLE CD4+ T CELL MATURATION SUBSETS

Andrew Musick, Eli A. Boritz, Jonathan Spindler, Michael J. Bale, Michele Sobolewski, Wei Shao, Stephen H. Hughes, John M. Coffin, John W. Mellors, Frank Maldarelli, Mary F. Kearney

379 MULTI-COMPARTMENT DISSEMINATION OF GENOME-INTACT HIV-1 RESERVOIR CLONES

Guinevere Q. Lee, Riddhima Banga, Matthias Cavassini, Jean-Marc Corpataux, Xu G. Yu, Giuseppe Pantaleo, Matthieu Perreau, Mathias Lichterfeld

380 WITHDRAWN**381 HIV INTEGRATES IN GENES REGULATING CELL CYCLE, DNA DAMAGE, & VIRAL TRANSPORT**

Sulgi Lee, Kevin G. Haworth, Cassandra Thanh, Lauren E. Schechter, Zachary K. Norgaard, Christopher D. Pilcher, Frederick M. Hecht, Jeffrey N. Martin, Timothy J. Henrich, Steven G. Deeks, Hans-Peter Kiem

382 INTEGRATION SITE-INDEPENDENT ENHANCEMENT OF LATENCY REVERSAL BY HIV-1 NEF

Xiao Mei T. Kuang, Steven W. Jin, Tristan M. Markle, Mark Brockman

Poster P-D09 MARKERS OF HIV RESERVOIRS

Poster Hall A

2:30 PM – 4:00 PM

383 HIGHER RECTAL P24 LEVELS CORRELATE WITH POOR CD4 RECOVERY IN TREATED HIV INFECTION

Bonnie J. Howell, Guoxin Wu, Shih Lin Goh, Paul Zuck, Montha Pao, Monika Deswal, Rebecca Hoh, Jeffrey N. Martin, Steven G. Deeks, Ma Somsouk, Daria Hazuda, Peter W. Hunt, for the DARE Collaboratory

384 ALTERED PD-1/PD-L1 INTERACTIONS IN GERMINAL CENTERS OF TREATED HIV-INFECTED SUBJECTS

Riddhima Banga, Caterina Rebecchini, Francesco Procopio, Stephanie D. Georget, Fabio Candotti, Matthias Cavassini, Jean-Marc Corpataux, Laurence de Leval, Giuseppe Pantaleo, Matthieu Perreau

385 CD32 EXPRESSION IS ASSOCIATED TO T CELL ACTIVATION AND UPREGULATED BY HIV

Roger Badia, Edurne García Vidal, María Pujantell, Bonaventura Clotet, Miguel Ángel Martínez, Ester Ballana, Eva Riveira-Muñoz, Jose A. Este

386 HIV-SEROREVERSION DYNAMICS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

Maria Salgado, Victoria González, Belén Rivaya, Cristina Gálvez, Mi Kwon, Jon Badiola, Alessandra Bandera, Björn Jensen, Linos Vandekerckhove, Kavita Raj, Monique Nijhuis, Jose Luis Diez, Annemarie Wensing, **Javier Martinez-Picado**, for the IciStem Consortium

- 387 IMMUNE ACTIVATION CORRELATES WITH EXPRESSION OF CD32 ON CD4+ T CELLS OF HIV PATIENTS**
Melanie Wittner, Gabor Dunay, Johanna Eberhard, Julian Schulze zur Wiesch
- 388 THE HIV RESERVOIR RESIDES MAINLY IN CD32A-/CD4+ T CELLS IN PERINATAL INFECTION**
Adit Dhummakupt, Lilly V. Siems, Dolly Singh, Ya Hui Chen, Thuy Anderson, Aleisha Collinson-Streng, Purvish Patel, Hao Zhang, Allison Agwu, Douglas Watson, Deborah Persaud
- 389 CD4+ T CELLS EXPRESSING CD32 FROM HIV-1+ PATIENTS ARE NOT ENRICHED FOR PROVIRAL DNA**
Adam M. Spivak, Racheal Nell, McKenna L. Coletti, Luis Montaner, Vicente Planelles
- 390 PRODUCTIVE HIV-1 INFECTION UPREGULATES CD32 IN VITRO AND IN VIVO**
Carla Serra Peinado, Judith Grau-Expósito, Meritxell Genescà, Laura Luque-Ballesteros, Cristina Gálvez, Josep Castellví, Rein Willekens, Luis Montaner, Vicenç Falcó, Javier Martínez-Picado, María J. Buzón
- 391 HIV-1 BURDEN IN PERIPHERAL BLOOD AND GUT CD4+ T CELLS EXPRESSING CD30 AND CD32**
Louise Hogan, Joshua Vasquez, Kristen Hobbs, Emily Hanhauser, Brandon Aguilar-Rodriguez, Cassandra Thanh, Erica Gibson, Alexander Carvidi, Louis Smith, Ma Somsouk, Daniel R. Kuritzkes, Steven G. Deeks, **Timothy J. Henrich**
- 392 HIV ANTIBODY AND T CELL RESPONSES ON ART ARE ASSOCIATED WITH HIV DNA BUT NOT RNA**
Sheila M. Keating, R. Brad Jones, Christina Lalama, Ronald Bosch, Deborah McMahon, Dylan Hampton, Evelyn Hogg, Joshua C. Cytor, Joseph J. Eron, John W. Mellors, Michael P. Busch, Rajesh T. Gandhi, for the ACTG 5321 team

Poster P-D10 QUANTIFYING HIV RESERVOIRS**Poster Hall A****2:30 PM – 4:00 PM**

Poster Sessions • Wednesday

- 393 BLINDED EVALUATION OF ULTRASENSITIVE ASSAYS OF HIV IN PLASMA**
Sheila M. Keating, Mars Stone, Xutao Deng, Sonia Bakkour, John W. Mellors, Douglas D. Richman, Rob Gorelick, Jeffrey D. Lifson, Cheryl Jennings, Martin Stengelin, Guoxin Wu, Bonnie J. Howell, Peter Bacchetti, Michael P. Busch, for the Reservoir Assay Validation and Evaluation Network (RAVEN) Study Group
- 394 QUANTIFYING THE TURNOVER OF LATENT HIV: APPLICATIONS TO ANTI-PROLIFERATIVE THERAPY**
Jeffrey Gerold, Michael J. Bale, Zheng Wang, Guinevere Q. Lee, Mathias Lichterfeld, Robert Siliciano, Mary F. Kearney, Alison L. Hill
- 395 SINGLE CELL ANALYSIS OF HIV LATENCY REVEALS DIVERSE PROVIRAL AND HOST CELL BEHAVIOR**
Edward P. Browne, Todd Bradley, Guido Ferrari, Barton F. Haynes, David M. Margolis
- 396 ULTRASENSITIVE P24 DIGITAL ELISA CAN LEAD TO AN OVERESTIMATE OF HIV RESERVOIR SIZE**
Francesco R. Simonetti, Subul A. Beg, Jun Lai, Purvish Patel, Hao Zhang, Gregory Laird, Lynn N. Bertagnolli, David Kulick, Robert Siliciano, Janet Siliciano

397 NEXT-GEN VIRAL OUTGROWTH ASSAYS AS PROXIES FOR CLASSIC QVOA TO MEASURE HIV RESERVOIR

Mars Stone, Daniel S. Rosenbloom, Peter Bacchetti, Xutao Deng, Melanie Dimapasoc, Sheila M. Keating, Douglas D. Richman, John W. Mellors, Steven G. Deeks, Janet Siliciano, Nicolas Chomont, Roger Ptak, Michael P. Busch, for the RAVEN

398 QVOA COUPLED WITH DIGITAL P24 ANALYSIS ENHANCES HIV RESERVOIR QUANTIFICATION

Elizabeth R. Wonderlich, Yury V. Kuzmichev, Carol Lackman-Smith, Marie K. Mankowski, Christine N. Raney, Hayley P. Madeira, Jiayi Wei, Rebecca M. Bernbaum, Krupa Subramanian, Rachel L. Jarrett, Ellen R. Nordgren, Mars Stone, Michael P. Busch, Roger Ptak, Deanna Kulpa

399 QUANTIFICATION OF REPLICATION COMPETENT LATENT HIV-1 IN GALT AND SEMEN

Anwesha Sanyal, Ian McGowan, Ma Somsouk, Charles Rinaldo, Nicolas Sluis-Cremer, **Phalguni Gupta**

Poster P-E5 CNS RESERVOIRS, ESCAPE, ANTIRETROVIRAL THERAPY, AND RESPONSES**Poster Hall A****2:30 PM – 4:00 PM****442 SINGLE-CELL RNA SEQUENCING TO CHARACTERIZE CSF IN VIROLOGICALLY SUPPRESSED HIV**

Shelli Farhadian, Chryssa Zografu, Sameet Mehta, Jennifer Chiarella, Kevin Robertson, Sarah Yosief, Jenna Pappalardo, David Hafler, Serena S. Spudich

443 HIV-RNA IN THE OLFACTORY MUCOSA OF HIV-POSITIVE PATIENTS

Mattia Trunfio, Tiziano Allice, Luca Bertero, Daniele Imperiale, Sebastiano Catera, Veronica Pirriatore, Giovanni Di Perri, Maria Enrica Amasio, Paola Cassoni, Valeria Ghisetti, Stefano Bonora, Andrea Calcagno

444 DISTINCT HIV POPULATIONS IN CSF AND BLOOD DURING ACTIVE CRYPTOCOCCAL MENINGITIS

Maura Manion, **Camille Lange**, Kathy Huppler Hullsieck, Brandon Keele, Helene Highbarger, David Meya, David R. Boulware, Frank Maldarelli, Irini Sereti

445 NEUROLOGIC STABILITY WITH BRIEF ANALYTIC TREATMENT INTERRUPTION AFTER EARLY ART

Joanna Hellmuth, Donn Colby, Eugène Kroon, Carlo Sacdalan, Phillip Chan, Jintana Intasan, Victor Valcour, Trevor Crowell, Linda Jagodzinski, Khunthalee Benjapornpong, Nelson L. Michael, Jintanat Ananworanich, Robert Paul, Serena S. Spudich, for the SEARCH 010/RV254 Study Group

446 SPECIFIC CSF VIRAL ESCAPE FINDINGS COMPARED TO PRE-CART HIV ENCEPHALITIS

Valentina De Zan, Francesca Ferretti, Simonetta Gerevini, Laura Passeri, Adriano Lazzarin, Cinque Paola

447 RISK AND PREDICTORS OF ASYMPTOMATIC AND SYMPTOMATIC CSF VIRAL ESCAPE IN HIV+ PATIENTS

Carmela Pinnetti, Patrizia Lorenzini, Ilaria Mastorosa, Valentina Fedele, Stefania Carta, Alessandra Vergori, Alberto Giannetti, Massimo Tempestilli, Adriana Ammassari, Susanna Grisetti, Francesco Baldini, Chiara Agrati, Maria R. Capobianchi, Carlo F. Perno, Andrea Antinori

448 CSF AND BLOOD HIV RNA RELATIONSHIP IN ACUTE HIV IS LINKED TO CD4/CD8 RATIO

Phillip Chan, Payal Patel, Joanna Hellmuth, Donn Colby, Eugène Kroon, Carlo Sacdalan, James L. Fletcher, Suteeraporn Pinyakorn, Linda Jagodzinski, Shelly J. Krebs, Nelson L. Michael, Jintanat Ananworanich, Victor Valcour, Serena S. Spudich, for the RV254/SEARCH 010 Study Team

449 PERIPHERAL AND CSF IMMUNE ACTIVATION AND INFLAMMATION IN HIV+ PATIENTS STARTING CART

Esther Merlini, Francesca Iannuzzi, Andrea Calcagno, Francesca Bai, Mattia Trunfio, Antonella D'Arminio Monforte, Stefano Bonora, Giulia Marchetti

Poster P-E6 BASIC NEUROPATHOGENES AND NEUROPATHOLOGY**Poster Hall A****2:30 PM – 4:00 PM**

Poster Sessions • Wednesday

450 NOX-4 ASSOCIATED NITROSATIVE STRESS AND INEPT REDOX ADAPTATION IN AGED HIV-1 TG RAT

William Reid, Swati Shah, Frank Denaro, Dragan Maric, Dima A. Hammoud

451 CEREBROSPINAL FLUID AND SERUM NEPRILYSIN IN PATIENTS INFECTED WITH HIV CLADES C AND B

Sergio M. de Almeida, Clea E. Ribeiro, Indianara Rotta, Mauro Piovesan, Bin Tang, Meire S. Batistela, Scott L. Letendre, Michael Potter, Florin Vaida, Ronald J. Ellis

452 REGIONAL BRAIN HEME OXYGENASE CORRELATES WITH SIV LOAD IN ACUTE/CHRONIC INFECTION

Rolando Garza, Maria Diaz Ortiz, Analise Gruenewald, Fiorella Rossi, Ferzin Sethna, Guido Silvestri, Michael R. Betts, Dennis L. Kolson

453 CSF EXTRACELLULAR VESICLES AS BIOMARKERS OF CNS INJURY IN HIV PATIENTS ON ART

Debjani Guha, Sukrutha Chettimada, Vikas Misra, David Lorenz, Dana H. Gabuzda

454 DELETERIOUS EFFECTS OF HIV-1 LATENCY-REVERSING AGENTS MEDIATED BY ASTROCYTES

Alizé Proust, Corinne Barat, Mathieu Leboeuf, Jean Drouin, Michel J. Tremblay

Poster P-F5 NOVEL FORMULATIONS FOR ANTIRETROVIRAL DRUG DELIVERY**Poster Hall D****2:30 PM – 4:00 PM****479 DESIGN & SYSTEMS PHARMACOLOGY ANALYSIS OF ORAL LONG-ACTING ANTIRETROVIRAL THERAPY**

Morgan L. Craig, Alison L. Hill, Christopher D. Bruno, Shirley S. Mo, Ameya Kirtane, Martin A. Nowak, Robert Langer, Carlo G. Traverso

480 PRECLINICAL EVALUATION OF A REDUCED DOSE DARUNAVIR/RITONAVIR NANOPARTICLE FORMULATION

Helen J. Box, Joanne Sharp, Megan Neary, Darren M. Moss, Lee M. Tatham, Hannah Kinvig, Alison C. Savage, Samantha Ashcroft, David Back, Steve Rannard, Andrew Owen

481 CHARM-03:SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ORAL AND TOPICAL MARAVIROC

Ian McGowan, Rhonda M. Brand, Jarret C. Engstrom, Aaron Siegel, Ashley Myerski, Cindy Jacobson, Mark A. Marzinke, Craig W. Hendrix, Alex Rinehart, John Steytler, Charlene S. Dezzutti, Nicola Richardson-Harman, Hans M. Spiegel, Ross Cranston, for the Charm-03 team

482 MARAVIROC SOLID DRUG NANOPARTICLES WITH IMPROVED ORAL PHARMACOKINETICS

Lee M. Tatham, Alison C. Savage, Andrew Dwyer, Marco Siccardi, Steve Rannard, Andrew Owen

483 TOWARDS A LONG-ACTING INJECTABLE (LAI) FORMULATION FOR MARAVIROC

Lee M. Tatham, Andrew Dwyer, Alison C. Savage, Marco Siccardi, Steve Rannard, Andrew Owen

484 IN VIVO PHARMACOKINETICS OF NOVEL LONG-ACTING INJECTABLE EMTRICITABINE PRODRUGS

Paul Curley, James J. Hobson, Christopher David, Amer Al-Khouja, David Meyers, Caren Freel Meyers, Charles W. Flexner, Marco Siccardi, Steve Rannard, **Andrew Owen**

485 PBPK MODELING OF MICROARRAY PATCHES FOR LONG-ACTING INTRADERMAL DRUG DELIVERY

Rajith Kumar Reddy Rajoli, Charles W. Flexner, Andrew Owen, Ryan Donnelly, Marco Siccardi

486 PHARMACOKINETICS OF TENOFOVIR ALAFENAMIDE BY SUBCUTANEOUS IMPLANT FOR HIV PREP

Greg Gatto, Natalie Girouard, Rhonda M. Brand, Leah Johnson, Mark A. Marzinke, Sudie Rowshan, Jarret C. Engstrom, Ian McGowan, Zach Demkovich, Ellen Luecke, Ariane van der Straten

487 LONG-ACTING 3 HIV-DRUGS-IN-ONE NANOPARTICLE FORMULATION INTENDED FOR ADOLESCENTS

Josefin Koehn, John C. Kraft, Lisa McConnachie, Loren Kinman, Sarah Lane, Wonsok Lee, Ann Collier, Rodney J. Ho

488 LONG-ACTING PHARMACOKINETICS OF 4 HIV DRUGS COFORMULATED IN ONE NANO-FORMULATION

Lisa McConnachie, Loren Kinman, Josefina Koehn, John C. Kraft, Sarah Lane, Wonsok Lee, Ann Collier, Rodney J. Ho, for the NIH-funded UM1 TLC-ART Program

Poster P-H4 ANTIRETROVIRAL TREATMENT EXPERIENCED STUDIES**Poster Hall D****2:30 PM – 4:00 PM****508 DTG VERSUS LPV/R IN SECOND LINE (DAWNING): OUTCOMES BY WHO-RECOMMENDED NRTI BACKBONE**

Michael Aboud, Carlos Brites, Hongzhou Lu, Khuanchai Supparatpinyo, Luis Hercilla, Jörg Sievers, Maria Claudia Nascimento, Judy Hopking, Mark Underwood, Danna Brown, Martin Gartland, Kim Smith

509 INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) EFFECTIVENESS IN ART-EXPERIENCED PATIENTS

Thibaut Davy-Mendez, Sonia Napravnik, Oksana Zakharova, David Wohl, Claire E. Farel, Joseph J. Eron

510 VIROLOGIC RESPONSE TO 2-DRUG ART REGIMENS AMONG TREATMENT-EXPERIENCED HIV+ PATIENTS

Gerald Pierone, Cassidy Henegar, Jennifer Fusco, Vani Vannappagari, Michael Aboud, Leigh Ragone, Gregory Fusco

511 TREATING MULTICLASS-RESISTANT HIV+PATIENTS IN RWANDA USING A PUBLIC HEALTH APPROACH

Sabin Nsanzimana, Muhayimpundu Ribakare, Remera Eric, Amitabh B. Suthar, Riedel J. David, Edward J. Mills, Heiner C. Bucher

Poster P-H5 ANTIRETROVIRAL ADHERENCE

Poster Hall D

2:30 PM – 4:00 PM

512 ADHERENCE IN EARLY VERSUS LATE ART INITIATION IN SUB-SAHARAN AFRICA

Jessica E. Haberer, Bosco M. Bwana, Catherine Orrell, Stephen Asiimwe, Gideon Amanyire, Nicholas Musinguzi, Mark J. Siedner, Kathleen Bell, Annet Kembabazi, Stephen Mugisha, Victoria Kibirige, Anna Cross, Nicola Kelly, David R. Bangsberg, for the META team

513 ADHERENCE TO COMBINATION ANTIRETROVIRAL THERAPY (ART) IN SUB-SAHARAN AFRICA

Judith J. Lok, Elisavet Syriopoulou, Dustin J. Rabideau, Beverly Musick, Jeffrey N. Martin, Kara K. Wools-Kaloustian, Ronald Bosch, Ann Mwangi, Constantin T. Yiannoutsos

514 USING INPATIENT DOT TO IDENTIFY TRUE ART FAILURE AND IMPROVE TREATMENT OUTCOMES

Nicole E. Winchester, Safia S. Kuriakose, Frank Maldarelli, Michael Proschan, Yolanda Mejia, Holly Ann Baus, Megan Anderson, Robin L. Dewar, H. Clifford Lane, Alice K. Pau

515 PATTERNS OF WISEPILL DEVICE USE IN AFRICAN ADULTS TAKING ANTIRETROVIRAL THERAPY (ART)

Catherine Orrell, Nicholas Musinguzi, Norma C. Ware, Anna Cross, Bosco M. Bwana, Stephen Asiimwe, Gideon Amanyire, David R. Bangsberg, Jessica E. Haberer

Poster P-H6 VIRAL LOAD MONITORING AND SUPPRESSION

Poster Hall D

2:30 PM – 4:00 PM

516 ROUTINE VS TARGETED VIRAL LOAD STRATEGY AMONG PATIENTS STARTING ART IN HANOI, VIETNAM

Todd Pollack, Duong T. Hao, Thuy T. Pham, Thang D. Nguyen, Howard Libman, Long Ngo, Julian Elliot, Cuong D. Do Duy, Donn Colby

517 CLINICAL AND VIROLOGICAL IMPACT OF LOW-LEVEL VIREMIA IN TREATED HIV INFECTED PATIENTS

Enrique Bernal, Inma Jarrin, Alfredo Cano, Antonia Alcaraz, Angeles Muñoz, Pascual Balsalobre, Jorge Romero, Jose-Ramón Blanco, Federico García, Miguel Górgolas, Félix Gutiérrez, for the CoRIS

518 VL SUPPRESSION AT ULTRASENSITIVE LEVELS IS ASSOCIATED WITH INSTI-INITIATION ART

Sidonie Lambert, Anders Boyd, Djeneba Bocar Fofana, Nadia Valin, Jean-Luc Meynard, Rachid Agher, Vincent Calvez, Christine Katlama, Pierre-Marie Girard, Anne-Geneviève Marcellin, Laurence Morand-Joubert

519 STIMULANT USERS RECEIVING ART DISPLAY INCREASING RATES OF HIV SUPPRESSION

Adam W. Carrico, Elise D. Riley, Torsten B. Neilands, Samantha E. Dilworth, Jeffrey N. Martin, Steven G. Deeks, Peter W. Hunt

Poster P-H7 IMMUNE RECOVERY AND HIV CONTROL**Poster Hall D****2:30 PM – 4:00 PM****520 FUNCTION OF CD4 RECOVERY AND DECREASING IMMUNE ACTIVATION OF A CHINESE HERB: TWHF**

Wei Lu, Yuchao Liu, Yang Han, Zhifeng Qin, Xiaojing Song, Taisheng Li

521 METABOLIC SHUT DOWN OF CD4 T CELL ACTIVITY AND FUNCTION INDUCED BY HAART

Marek Korencak, Enrico Richter, Eva Eilers, Bruce T. Schultz, Patrick Juszczak, Stefan Esser, **Hendrik Streeck**

522 NATURAL CONTROL OF HIV INFECTION IN A COHORT OF YOUNG WOMEN IN SOUTH AFRICA: HPTN 068

Mariya V. Sivay, Yinfeng Zhang, Jing Wang, Jessica M. Fogel, Estelle Piwowar-Manning, William Clarke, Erica Hamilton, Kathleen Kahn, Amanda Selin, Xavier Gomez-Olive, Catherine MacPhail, James P. Hughes, Audrey Pettifor, Susan H. Eshleman, for the HPTN 068 Study Team

Poster P-I5 PREVALENCE OF ANTIRETROVIRAL THERAPY RESISTANCE: THE POPULATION MATTERS**Poster Hall D****2:30 PM – 4:00 PM****550 ARV DRUG USE AND HIV DRUG RESISTANCE AMONG MSM IN SUB-SAHARAN AFRICA (HPTN 075)**

Yinfeng Zhang, Jessica M. Fogel, Xu Guo, William Clarke, Autumn Bread, Vanessa Cummings, Erica Hamilton, Arthur Ogendo, Noel Kayange, Ravindre Panchia, Karen Dominguez, Ying Q. Chen, Theodorus Sandfort, Susan H. Eshleman, for the HPTN 075 Study Team

551 ARV DRUG USE AND HIV DRUG RESISTANCE AMONG YOUNG WOMEN IN SOUTH AFRICA (HPTN 068)

Yinfeng Zhang, Mariya V. Sivay, Sarah E. Hudelson, Jing Wang, Yaw Agyei, William Clarke, Autumn Bread, Erica Hamilton, Kathleen Kahn, Xavier Gomez-Olive, Catherine MacPhail, James P. Hughes, Audrey Pettifor, Susan H. Eshleman, for the HPTN 068 Study Team

552 PREVALENCE OF NRTI, NNRTI AND PI MUTATIONS ACROSS BOTSWANA IN 2013 – 2015

Sikhulile Moyo, Simani Gaseitsiwe, Melissa Zahralban-Steele, Dorcas Maruapula, Baitshepi Mokaleng, Terence Mohammed, Erik van Widenfelt, Madisa Mine, Elliot G. Raizes, Etienne Kadima, Tendani Gaolathe, Joseph Makhema, Shahin Lockman, Max Essex, Vlad Novitsky

553 ARV RESISTANCE AND CO-RECEPTOR TROPISM IN HIV+ DECEASED ORGAN DONORS IN THE US

Gilad Bismut, Christine Durand, Diane M. Brown, Brianna Doby, Shanti Seaman, Michael Seisa, Christos Petropoulos, Reinaldo Fernandez, Dorry Segev, Aaron Tobian, Andrew D. Redd

554 IMPROVED CARE OF SOCIALLY DISADVANTAGED PATIENTS IS NEEDED TO REDUCE DRUG RESISTANCE

Irene A. Abela, **Alexandra Scherrer**, Jürg Böni, Sabine Yerly, Thomas Klimkait, Matthieu Perreau, Manuel Battegay, Hansjakob Furrer, Alexandra Calmy, Patrick Schmid, Matthias Cavassini, Enos Bernasconi, Huldrych F. Günthard, for the Swiss HIV Cohort Study

Poster P-16 NEW INSIGHTS INTO ANTIRETROVIRAL SUSCEPTIBILITY AND RESISTANCE
Poster Hall D**2:30 PM – 4:00 PM**

Poster Sessions • Wednesday

555 PASEQ: ONE-CLICK, CLOUD-BASED WEB SERVICE FOR NGS-BASED HIV GENOTYPING DATA ANALYSIS

Jordi Herms, Cristina Rodriguez, Maria Casadella, Teresa Puig, Bonaventura Clotet, Roger Paredes, **Marc Noguera-Julian**

556 SMRT SEQUENCING OF FULL-LENGTH POL AMPLICONS TO INVESTIGATE HIV-1 DRUG RESISTANCE

Sergio Ita, Caroline Ignacio, Sanjay Mohan, Venkatesh Kumar, Benjamin Murrell, Douglas D. Richman, Davey M. Smith, Gabriel A. Wagner

557 POINT-OF-CARE HIV-1 GENOTYPIC RESISTANCE TESTING USING MELT-CURVE ANALYSIS

Dana S. Clutter, Gelareh Mazarei, Justen Manasa, Sara Bolouki, Ruma Sinha, Peter Kuimelis, Robert Kuimelis, Benjamin Pinsky, Gary Schoolnik, Arjang Hassibi, Robert Shafer

558 PROTEASE, GAG AND GP41 MUTATIONS ASSOCIATED WITH VIROLOGICAL RESPONSE TO PI REGIMEN

Marine Perrier, Louise Castain, Eve Todesco, Roland Landman, Benoit Visseaux, Yazdan Yazdanpanah, Leslie Regad, Veronique Joly, Vincent Calvez, Anne-Geneviève Marcellin, Diane Descamps, **Charlotte Charpentier**

559 HIV-1 GAG REDUCES PI-SUSCEPTIBILITY IN THE ABSENCE OF PROTEASE RESISTANCE MUTATIONS

Oscar Blanch-Lombarte, José Ramón Santos, Ruth Penya, Alba Ruiz, Esther Jimenez-Moyano, Roger Paredes, Bonaventura Clotet, Julia G Prado, for the VIRIEVAC

560 ACTIVITY OF TENOFOVIR ALAFENAMIDE IN HIV-1 WITH THYMIDINE ANALOG MUTATIONS AND M184V

Nicolas A. Margot, Renee R. Ram, Michael E. Abram, Richard Haubrich, Michael D. Miller, Christian Callebaut

561 IBALIZUMAB SUSCEPTIBILITY IN PATIENT HIV ISOLATES RESISTANT TO ANTIRETROVIRALS

Steven Weinheimer, Zvi Cohen, Christian Marsolais, Stanley Lewis

562 RPV LA DOES NOT INHIBIT RESISTANT HIV TRANSMISSION OR SELECT SIGNIFICANT RESISTANCE

Zandrea Ambrose, Kevin Melody, Chris Kline, Mackenzie L. Cottrell, Brandon Keele, Angela Kashuba, Moses Bility

Poster P-K07 NON-B, NON-C HEPATITIS
Poster Hall D**2:30 PM – 4:00 PM**
625 HAV EPIDEMICS AMONG MSM : HIGH PREVALENCE OF HIV INFECTED PATIENTS

Veronique Lemee, Anne-Marie Roque-Afonso, Elodie Alessandri-Gradet, Lina Mouna, Laure Izquierdo, Odile Goria, Hélène Montialoux, Valerie Delbos, **Thomas Mourez**, Jeremie Leporrier, Jean-Christophe Plantier, Ghassan Riachi

626 ACUTE HEPATITIS A AMONG HIV-INFECTED THAI MSM IS LINKED TO MSM IN EUROPE AND TAIWAN

Donn Colby, Nawarat Posuwan, Carlo Sacdalan, Jintana Intasan, Eugène Kroon, Tanyaporn Wansom, Nittaya Phanuphak, Jintanat Ananworanich, Merlin L. Robb, Praphan Phanunphak, Yong Poovorawan, for the RV254/SEARCH010 Study Team

627 SEROPREVALENCE AND RISK FACTORS OF HEPATITIS E AMONG PLHIV IN SOUTH WESTERN FRANCE

Marc Vareil, Florence Abravanel, Heidi Wille, Anne-Christine Jaouen, David Leyssene, Jacques Izopet

628 HEPATITIS C VIRUS AND HUMAN PEGIVIRUS 2 SURVEILLANCE IN A LARGE CAMEROONIAN COHORT

Mary Rodgers, Vera Holzmayer, Ana Vallari, Ana Olivo, Kenn Forberg, Jill Fuhrman, Kelly Coller, Bih Awazi, Jules Bertrand Kenmegne Sidje, Matthew Frankel, Michael Berg, Dora Mbanya, Nicaise Ndembí, Gavin Cloherty

629 PREVALENCE AND CORRELATES OF HPGV INFECTION AMONG PWID WITH HIV INFECTION IN INDIA

Nandagopal Paneerselvam, Thongadi R. Dinesha, Shanmugam Saravanan, Allison M. McFall, Pachamuthu Balakrishnan, Aylur K. Srikrishnan, Sunil S. Solomon, Shruti H. Mehta

Poster P-K08 HEPATITIS BEYOND THE LIVER**Poster Hall D****2:30 PM – 4:00 PM****630 HEPATITIS C VIRUS AND INCIDENT TYPE 1 AND TYPE 2 MYOCARDIAL INFARCTION IN HIV**

Jessica Williams-Nguyen, Robin M. Nance, Sara Lindström, Susan Heckbert, Inga Peter, Matthew Budoff, W. C. Mathews, Joseph J. Eron, Peter W. Hunt, Richard D. Moore, Michael J. Mugavero, Mari Kitahata, Michael Saag, Heidi M. Crane, Joseph Delaney

631 ERADICATION OF HCV: EFFECTS ON CARDIOVASCULAR RISK AND PRECLINICAL ATHEROSCLEROSIS

Ana Carrero, **Juan Berenguer**, Victor Hontanon, Jordi Navarro, José Hernández-Quero, María J. Galindo, Carmen Quereda, Ignacio Santos, María J. Téllez, Enrique Ortega, José Sanz, Javier Bermejo, José M. Bellón, Juan González-García, for the GeSIDA 3603b Study Group

632 RISK OF DIABETES IN HCV-HIV PATIENTS IS ASSOCIATED WITH CIRRHOsis, NOT WITH HCV

Aurélien Provoost, Moustapha Drame, **Laurent Cotte**, Lise Cuzin, Rodolphe Garraffo, David Rey, François Raffi, Isabelle Poizot-Martin, Pascal Puglièse, Firouze Bani-Sadr

633 HCV AND LIVER DISEASE INCREASE RISK OF NEUROCOGNITIVE IMPAIRMENT IN HIV+ INDIVIDUALS

Ilaria Mastorosa, Carmela Pinnelli, Patrizia Lorenzini, Alessandra Vergori, Gabriele Fabbri, Pietro Balestra, Maria Maddalena Plazzi, Martina Ricottini, Rita Bellagamba, Stefania Ciccalini, Rita Maddaluno, Mauro Zaccarelli, Adriana Ammassari, Andrea Antinori

634 PORPHYRIA CUTANEA Tarda EVOLUTION IN HCV+/HIV+/- PATIENTS POST TREATMENT WITH HCV DAA

Lucio Jesus Garcia-Fraile, Pablo Rodríguez, Luisa Consuelo García Buey, Concepción Alonso Cerezo, Ignacio d. Santos Gil

- 635 INFLAMMATION AND IMMUNE ACTIVATION MARKERS IN HEPATITIS C INFECTION AND CLEARANCE**
Ruixin Wang, Chloe Thio, Otoniel Martínez-Maza, Steven Wolinsky, Yue Chen, Eric C. Seaberg
- 636 IMPACT OF OCCULT HCV INFECTION (OCI) ON SYSTEMIC IMMUNE ACTIVATION AFTER DAA THERAPY**
David M. Asmuth, Annie Y. Chen, Netanya S. Utay, Natalie Torok, Patricia L. Poole, Joy Vongspanich, Kathleen R. Haight, Anoma D. Sumasunderam, Enkhmaa Byambaa, Xiao-Dong Li, Stuart T. Cohen, Lars Berglund, Mark Holodniy, Tomasz I. Michalak

Poster P-K09 MICRO-RNA: A LOT OF INFORMATION IN A LITTLE BIT OF RNA

Poster Hall D **2:30 PM – 4:00 PM**

- 637 POTENTIAL FOR SERUM MICRO-RNAs TO PREDICT FIBROSIS REGRESSION DURING HBV TREATMENT**
Cody Orr, Rob Myers, David Gong, Biao Li, Zhaoshi Jiang, John Flaherty, Anuj Gaggar, G. Mani Subramanian, Eric G. Meissner
- 638 HEPATIC EXPRESSION OF HSA-MIR-125A-5P AND FIBROSIS IN OVERT AND OCCULT HBV INFECTION**
Lorenzo Onorato, Aniello Russo, Giorgio de Stefano, Carmine Minichini, Mario Starace, Pietro Filippini, Loredana Alessio, Nunzia Farella, Nicoletta Potenza, Evangelista Sagnelli, Nicola Coppola
- 639 CIRCULATING MICRORNAs IN HIV PATIENTS REVEAL SPECIFIC SIGNATURES FOR LIVER DAMAGE**
Miguel Angel Martinez, Sandra Franco, Daniela Buccione, Beatriz Mothe, Lidia Ruiz, Maria Nevot, Ana Jordan-Paiz, Raquel Pluvinet, Susanna Aussó, Rosa M. Morillas, Lauro Sumoy, Cristina Tural
- 640 MIRNA PROFILE OF HCV SPONTANEOUS CLEARANCE INDIVIDUALS SHOW PREVIOUS HCV INFECTION**
Óscar Brochado Kith, Alicia Gómez Sanz, Luis M. Real, Javier Crespo, Pablo Ryan, Juan Macías, Joaquín Cabezas, Juan A. Pineda, María T. Arias-Loste, Isabel Cuesta, Sara Monzón-Fernández, Luz M. Medrano, María Á. Jiménez-Sousa, Salvador Resino, Amanda Fernández-Rodríguez

Poster P-L3 HIV-RELATED LYMPHOMA AND LIVER CANCER

Poster Hall D **2:30 PM – 4:00 PM**

- 667 ANAPLASTIC LARGE CELL LYMPHOMA IN HIV-INFECTED INDIVIDUALS**
Parag Mahale, Dennis D. Weisenburger, Amy R. Kahn, Lou Gonsalves, Karen Pawlish, Lori Koch, Mirabel Tirado-Gomez, Christina A. Clarke, Glenn Copeland, Georgetta Alverson, Meredith S. Shiels, Eric A. Engels
- 668 CNS-IPI AS RISK MODEL FOR CNS RELAPSE IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA**
Alessandra Bandera, Davide Dalu, Ilaria De Benedetto, Elisa Colella, Gaia Bombonati, Elisa Doni, Fulvio Crippa, Omar Giglio, Maurizio Mena, Elisa Suardi, Paola Vitiello, Carlo Gambacorti Passerini, Andrea Gori, Luisa Verga, for the Musthal Study Group
- 669 PRESENTATION AND OUTCOME OF BIOPSY-PROVEN HEPATOCELLULAR CARCINOMA BY HIV STATUS**
Jessie Torgersen, Lesley Park, Tamar Taddei, Dena M. Carbonari, Michael J. Kallan, Kisha Mitchell-Richards, Xuchen Zhang, Kathryn D'Addeo, Rajni Mehta, Farah Kidwai-Khan, Amy C. Justice, Vincent Lo Re

Poster P-M1 ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR DISEASE**Poster Hall D****2:30 PM – 4:00 PM****670 ANTIRETROVIRAL DRUGS ASSOCIATED WITH SUBCLINICAL CORONARY ARTERY DISEASE**

Helen Kovari, Alexandra Calmy, Thanh Doco-Lecompte, René Nkoulou, Alex Marzel, Rainer Weber, Philipp A. Kaufmann, Ronny R. Buechel, Bruno Ledergerber, Philip E. Tarr

671 CAROTID IMT PROGRESSION IS MOST STRIKING IN FIRST 48 WEEKS OF ANTIRETROVIRAL THERAPY

Corrilynn O. Hileman, Grace A. McComsey

672 EFFECTS OF ANTIRETROVIRAL THERAPY ON ALLELE-ASSOCIATED LIPOPROTEIN(A) LEVEL IN HIV

Enkhmaa Byambaa, Anuurad Erdembileg, Chin-Shang Li, Robert C. Kaplan, Jason Lazar, Daniel Merenstein, Roksana Karim, Bradley E. Aouizerat, Mardge H. Cohen, Kenneth R. Butler, Savita Pahwa, Igbo Ofotokun, Adaora Adimora, Elizabeth T. Golub, Lars Berglund

673 COMPARATIVE IMPACT OF ANTIRETROVIRALS ON HUMAN PLATELET ACTIVATION

Kirk A. Taylor, Francesca Rauzi, Erica Smyth, Mark Nelson, Brian Gazzard, Michael Emerson

674 LEUKOCYTES ARE KEY TO THE PRO-THROMBOTIC EFFECTS OF ABACAVIR

Victor Collado-Diaz, Ainhoa Sanchez-Lopez, Samuel Orden, Maria Amparo Blanch-Ruiz, Maria Angeles Martinez-Cuesta, Isabel Andujar, **Angeles Alvarez**, Juan V. Esplugues

675 EXPLORING CHANGES IN HDL AND MONOCYTE CHOLESTEROL METABOLISM WITH ART INITIATION

Robert T. Maughan, Jane A. O'Halloran, Alejandro A. Garcia, Theodoros Kelesidis, Luke O'Brien, John Lambert, Gerard Sheehan, Patrick W. Mallon

676 FUNCTIONAL STATUS ASSOCIATED WITH CARDIOVASCULAR DISEASE AND DIABETES IN HIV+ ADULTS

Sean G. Kelly, Kunling Wu, Katherine Tassiopoulos, Kristine M. Erlandson, Susan L. Koletar, Frank J. Palella

677LB CHANGE IN SOLUBLE GLYCOPROTEIN VI (SGPVI) WHEN SWITCHING FROM ABC/3TC TO TAF/FTC

Patrick W. Mallon, Robert T. Maughan, Alejandro A. Garcia, Willard Tinago, Aoife Lacey, Andrew Lovell, Eimear Dunne, Elena Alvarez-Barco, Alan Winston, Frank Post, Dermot Kenny, Mingjin Yan, Moupali Das, Martin Rhee, for the GS-US-311-1717 Platelet Sub Study Team

Poster P-M2 IMMUNOLOGIC FACTORS AND PATHOGENESIS OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE**Poster Hall D****2:30 PM – 4:00 PM****678 ELEVATED MICROPARTICLE TISSUE FACTOR ACTIVITY AND CAROTID ARTERY PLAQUE IN HIV+ WOMEN**

Juan Lin, Xiaonan Xue, Kathryn Anastos, Mardge H. Cohen, Stephen J. Gange, Jason Lazar, Chenglong Liu, Wendy Mack, Phyllis Tien, Cathy Tilley, Howard Hodis, Alan Landay, Russell Tracy, Robert C. Kaplan, David B. Hanna

- 679 INFLAMMATION ASSOCIATES WITH IMPAIRED ARTERIAL ELASTICITY IN EARLY HIV DISEASE**
Tess Peterson, Kathy Huppler Hullsieck, Nicole Wyman Engen, Nagalingeswaran Kumarasamy, Pamela Schreiner, Jason V. Baker, for the INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group
- 680 PERIVASCULAR ADIPOSE INFLAMMATION AND MICROVASCULAR ENDOTHELIAL DYSFUNCTION IN HIV**
Cheng Wang, Tian Li, Philena Sun, Cuiwei Wang, Seble Kassaye, Princy Kumar, Jennifer Verbesey, Mary Young, Christopher Wilcox, **Dan Wang**
- 681 PCSK9 LEVELS IN RELATION TO IMMUNE ACTIVATION AND SUBCLINICAL CORONARY PLAQUE IN HIV**
Markella V. Zanni, **Lauren Stone**, Mabel Toribio, Dodie Rimmelin, Jake A. Robinson, Tricia H. Burdo, Kenneth C. Williams, Kathleen V. Fitch, Janet Lo, Steven K. Grinspoon
- 682 AN IMMUNOLOGICAL SIGNATURE FOR SUBCLINICAL ATHEROSCLEROSIS IN HIV-1 INFECTION**
Tomas Raul Wiche Salinas, Yuwei Zhang, Annie Gosselin, Mohamed El-Far, Inna Bacearnicova, Carl Chartrand-Lefebvre, Madeleine Durand, Cécile Tremblay, Petronela Ancuta
- 683 CARDIAC MORBIDITY IN HIV IS ASSOCIATED WITH CHECKPOINT INHIBITOR LAG3**
Suresh Pallikkuth, Bagavathi Kausalya, **Rajendra Pahwa**, Shanmugam Saravanan, Li Pan, R Vignesh, Syed Iqbal, Sunil S. Solomon, Kailapuri G. Murugavel, Selvamuthu Poongulali, Nagalingeswaran Kumarasamy, Savita Pahwa
- 684LB IMPACT OF METHOTREXATE ON ARTERIAL INFLAMMATION IN PERSONS WITH TREATED HIV**
Ahmed Tawakol, Heather Ribaudo, Amorina E. Ishai, Ashley McKhann, Daniel H. Solomon, Zahi A. Fayad, Steven G. Deeks, Michael M. Lederman, Steven K. Grinspoon, James H. Stein, Paul M. Ridker, Judith S. Currier, Priscilla Hsue

Poster P-M3 RISK FACTORS FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ROLE OF FAT AND OTHER FACTORS

Poster Hall D

2:30 PM – 4:00 PM

- 685 LIPODYSTROPHY IS AN IMPORTANT DETERMINANT OF MARKERS OF ARTERIAL INFLAMMATION IN HIV**
Suman Srinivasa, Kathleen V. Fitch, Martin Torriani, Markella V. Zanni, Patrick Maehler, Sara E. Looby, Janet Lo, Steven K. Grinspoon
- 686 CARDIAC BNP DEFICIENCY RELATES TO EXCESS ADIPOSITY AND METABOLIC PERTURBATIONS IN HIV**
Kathleen V. Fitch, Meghan Feldpausch, Patrick Maehler, Martin Torriani, Gail K. Adler, Steven K. Grinspoon, **Suman Srinivasa**
- 687 ASSOCIATION OF SUBCLINICAL CMV DNA AND IMMUNOLOGIC MARKERS OF CARDIOVASCULAR DISEASE**
Ankita Garg, Sara Gianella, Masato Nakazawa, **Stephen A. Spector**
- 688 CYSTATIN C AND ATHEROSCLEROSIS IMAGING MARKERS IN HIV INFECTED PATIENTS**
Mitchell R. McClean, Petra Buzkova, Matthew Budoff, Michelle Estrella, Matthew Freiberg, Howard Hodis, Frank J. Palella, Wendy Post, Cecilia Shikuma, Samir K. Gupta

Poster P-N03 ADIPOSE TISSUE**Poster Hall D****2:30 PM – 4:00 PM****733 CHANGE IN FAT/LEAN MASS IN HIV-POSITIVE AND -NEGATIVE SUBJECTS; DATA FROM HIV UPBEAT**

Aoife G. Cotter, Alan Macken, Willard Tinago, Eoin Kavanagh, Geraldine McCarthy, Juliet Compston, **Caroline Sabin**, Patrick W. Mallon, for the HIV UPBEAT Study Group

734 I-FABP IS ELEVATED AND IS INVERSELY RELATED TO BODY FAT IN HIV

Lediya Cheru, Elli Park, Charles Saylor, Kathleen V. Fitch, Tricia H. Burdo, Jake A. Robinson, Martin Torriani, Steven K. Grinspoon, Janet Lo

735 LOWER PRETREATMENT GUT INTEGRITY ASSOCIATED WITH FAT GAINS ON ANTIRETROVIRALS

Vanessa El Kamari, Carlee Moser, Judith S. Currier, Todd T. Brown, Liz Johnston, Corrilynn O. Hileman, Peter W. Hunt, **Grace A. McComsey**

736 TESAMORELIN IMPROVES FAT QUALITY INDEPENDENT OF CHANGES IN FAT QUANTITY

Jordan E. Lake, Kristine M. Erlandson, Stefan Adrian, Abanti Sanyal, Ann Scherzinger, Michael Dube, Takara L. Stanley, Steven K. Grinspoon, Jean-Claude Mamputu, Christian Marsolais, Todd T. Brown, Grace A. McComsey

737 FAT QUALITY IS INDEPENDENTLY ASSOCIATED WITH CARDIOMETABOLIC RISK IN HIV INFECTION

Jordan E. Lake, Carlee Moser, Liz Johnston, Clara Magyar, Scott D. Nelson, Kristine M. Erlandson, Todd T. Brown, Grace A. McComsey

738 HIV IMMUNE DYSREGULATION PREDICTS LEAN TISSUE AND FAT CHANGES DURING CHRONIC DISEASE

Louie M. Gangcuangco, Dominic Chow, Scott A. Souza, Glen M. Chew, Brooks I. Mitchell, Michelle L. D'Antoni, Jason T. Huynh, Lishomwa C. Ndhlovu, Cecilia Shikuma

Poster P-N04 DIABETES AND DIET**Poster Hall D****2:30 PM – 4:00 PM****739 DISPARITIES IN DIABETES SCREENING AND TREATMENT AMONG PATIENTS RECEIVING HIV CARE**

Kassem Bourgi, Peter F. Rebeiro, John R. Koethe, Stephen P. Raffanti, Megan M. Turner, Sally S. Bebawy, Timothy R. Sterling

740 GESTATIONAL DIABETES IN WOMEN ON DOLUTEGRAVIR- OR EFAVIRENZ-BASED ART IN BOTSWANA

Keolebogile N. Mmasa, Kathleen M. Powis, Joseph Makhema, Sikhulile Moyo, Mariana Gerschenson, Terence Mohammed, Erik VanWidenfelt, Justine Legbedze, Elaine J. Abrams, Emilia Bagiella, Irwin J. Kurland, Mitchell Geffner, Jennifer Jao

741 RECOMMENDED ANTIRETROVIRAL REGIMENS AND DIABETES MELLITUS IN THAI HIV-INFECTED ADULTS

Ninutcha Paengsai, Gonzague Jourdain, Jean-Yves Mary, Nicolas Salvadori, Tim R. Cressey, Apichat Tantraworasin, Romanee Chaiwarith, Chureeratana Bowonwatanuwong, Sorakij Bhakeecheep, Natapong Kosachunhanun

- 742 GLP-1 AND C-PEPTIDE ARE ASSOCIATED WITH INSULIN RESISTANCE AMONG PLWH IN INDIA**
Ivan Marbaniang, Shashikala Sangle, Dileep Kadam, Vandana Kulkarni, Dhananjay Shere, Nikhil Gupte, Amita Gupta, Vidya Mave
- 743 T CELL SUBSETS ASSOCIATED WITH INCIDENT DIABETES RISK IN HIV+ AND HIV– VETERANS**
Wyatt J. McDonnell, Kathleen McGinnis, Kaku So-Armah, Melissa Wellons, Glory Koerbel, Jeffrey Blume, Margaret F. Doyle, Nels C. Olson, Russell Tracy, Amy C. Justice, Simon Mallal, Matthew Freiberg, John R. Koethe
- 744 FOOD INSECURITY IS ASSOCIATED WITH INCREASED INFLAMMATION AMONG HIV-POSITIVE WOMEN**
Anna Leddy, Annelys Roque, Lila A. Sheira, Edward A. Frongillo, Alan Landay, Mardge H. Cohen, Phyllis Tien, Janet M. Turan, Bulent Turan, Sheri Weiser

Poster P-N08 AGING: BIOLOGIC MECHANISMS**Poster Hall D****2:30 PM – 4:00 PM**

- 757 REVERSING ACCELERATED AGING IN HIV PATIENTS: METABOLIC AND MITOCHONDRIAL MECHANISMS**
Rajagopal V. Sekhar, Jean W. Hsu, James Suliburk, Ruya Liu, Charles G. Minard, Vijay K. Yechoor, Farook Jahoor, Chun Liu
- 758 BLOOD TELOMERE LENGTH CHANGES AFTER DRV/R + EITHER RAL OR TDF/FTC AS FIRST LINE ART**
Natalia Stella-Ascariz, Rocio Montejano, Javier Rodriguez-Centeno, Belen Alejos, Christine Schwimmer, Jose I. Bernardino, Berta Rodes, Clotilde Allavena, Christian Hoffmann, Magnus Gisslén, Rosa de Miguel, Cédrick Wallet, François Raffi, Jose R. Arribas, for the ANRS 143/NEAT 001 Study Group
- 759 THYMUS IS THE BAROMETER OF AGING IN HIV PATIENTS, ASSOCIATED WITH FRAILTY AND QOL**
Giovanni Guaraldi, Giulia Besutti, Andrea Malagoli, Iacopo Franconi, Nicoletta Riva, Alessandro Raimondi, Riccardo Scaglioni, Guido Ligabue, Marianna Menozzi, Antonella Santoro, Federica Carli, Stefano Zona, Vanni Borghi, Andrea Cossarizza, Cristina Mussini
- 760 METHAMPHETAMINE USE INDEPENDENTLY PREDICTS PREMATURE AGING IN HIV+ INDIVIDUALS**
Sanjay R. Mehta, Jennifer Iudicello, Ronald J. Ellis, Jue Lin, Erin Morgan, Debralee Cookson, Robert K. Heaton, Igor Grant, Scott L. Letendre

Poster P-N09 HOSPITALIZATION AND OUTCOMES**Poster Hall D****2:30 PM – 4:00 PM**

- 761 SHORT-TERM OUTCOMES FOR MAJOR NON-CARDIAC SURGERY IN HIV INFECTION**
Keith M. Sigel, Lesley Park, Michael Leapman, Amy C. Justice, Sheldon T. Brown, Joseph T. King, for the VACS Project Team
- 762 HOSPITALIZATION RATES AND OUTCOMES IN A SOUTHEASTERN US CLINICAL COHORT, 1996-2016**
Thibaut Davy-Mendez, Sonia Napravnik, Oksana Zakharova, David Wohl, Claire E. Farel, Joseph J. Eron

Poster P-05 HIV-ASSOCIATED SYPHILIS**Poster Hall D****2:30 PM – 4:00 PM****796 NATURAL EXPERIMENT OF SYPHILIS TREATMENT WITH DOXYCYCLINE IN HIV-INFECTED PATIENTS****Marilia B. Antonio**, Ricardo d. Vasconcelos, Gabriel Trova, Vivian I. Avelino-Silva**797 INTRAOCCULAR TREPONEMA AND TOXOPLASMA INFECTIONS ASSOCIATED WITH BLINDING CATARACTS**Juliet Otiti-Sengeri, Colebunders Robert, Lois Bayigga, Rose Nabatanzi, Samuel Kyobe, **Damalie Nakanjako****798 PRIOR SYPHILIS PROTECTS AGAINST *T. PALLIDUM* DISSEMINATION IN REPEAT INFECTION****Christina Marra**, Clare Maxwell, Sharon Sahi, Lauren Tantalo, Shelia Dunaway, Sheila Lukehart**Poster P-06 RATES AND RISKS OF OTHER OIs****Poster Hall D****2:30 PM – 4:00 PM****799 HIV REPLICATION AS RISK FACTOR FOR 3 OPPORTUNISTIC INFECTIONS****Hansjakob Furrer**, for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord**800 HERPES ZOSTER AND ZOSTER VACCINE RATES AMONG HIV-INFECTED AND UNINFECTED IN THE VACS****Kellie L. Hawkins**, Kirsha S. Gordon, Myron Levin, Adriana Weinberg, Catherine Battaglia, Maria Rodriguez-Barradas, Sheldon T. Brown, David Rimland, Amy C. Justice, Janet Tate, Kristine M. Erlandson**801 CMV VIREMIA AND DISEASE IN PATIENTS WITH ADVANCED HIV INFECTION: A PROSPECTIVE STUDY**Adaia Albasanz, Juliana Esperalba, Ariadna Torrella, Bibiana Planas, Candela Fernández, Antonio Segura, Adrià Curran, Jordi Navarro, Esteban Ribera, Joaquin Burgos, Rein Willekens, Mario Martin, **Vicenç Falcó****802 BLASTOCYSTIS INFECTIONS IN HIV POSITIVE AND NEGATIVE ADULTS IN GHANA**Veronica Di Cristanziano, Federica Berrilli, Rossella D'Alfonso, Fred S. Sarfo, Lavinia Fabeni, Elena Knops, Eva Heger, Albert Dompreh, Rolf Kaiser, Torsten Feldt, **Kirsten Eberhardt****Poster P-P4 HIV, ANTIRETROVIRAL THERAPY, AND PREGNANCY OUTCOMES****Poster Hall D****2:30 PM – 4:00 PM****829 BIRTH DEFECTS AMONG OFFSPRING OF HIV-INFECTED & UNINFECTED WOMEN IN KAMPALA, UGANDA****Philippa Musoke**, Daniel M. Mumpe, Ayoub Kakande, Jolly Nankunda, Diana Valencia, Joyce Namale, Evelyn Nabunya, Josaphat Byagumisha, Doreen Birabwa-Male, Monica Nolan, Dhelia Williamson, Linda Barlow-Mosha**830 PRECONCEPTIONAL ART AND SPONTANEOUS PRETERM BIRTH IN AN URBAN ZAMBIAN COHORT****Joan T. Price**, Bellington Vwalika, Jennifer Winston, Margaret P. Kasaro, Humphrey Mwape, Benjamin H. Chi, Elizabeth M. Stringer, Bethany Freeman, Courtney Gravett, Katelyn J. Rittenhouse, Lungowe Njobvu, Julie A. Nelson, Angela Kashuba, Jeffrey S. Stringer

- 831 PRENATAL ANTIRETROVIRAL EXPOSURE AND RISK OF LOW BIRTH WEIGHT IN LUSAKA, ZAMBIA**
Jennifer Winston, Margaret P. Kasaro, Marie Stoner, Lloyd Mulenga, Joan T. Price, Elizabeth M. Stringer, Benjamin H. Chi, Bellington Vwalika, Jeffrey S. Stringer
- 832 PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY)**
Sufia Dadabhai, Luis Gadama, Rachel Chamanga, Rachel Kawalazira, Chaplain Katumbi, Dingase E. Dula, Isaac Singini, Leslie Degnan, Melvin C. Kamanga, Taha E. Taha
- 833 HIGH RATES OF ADVERSE BIRTH OUTCOMES IN SYPHILIS & HIV COINFECTED WOMEN IN BOTSWANA**
Emily Shava, Sikhulile Moyo, Modiegi Diseko, Rebecca Zash, Eldah N. Dintwa, Lucy Mupfumi, Judith Mabuta, Gloria Mayondi, Jennifer Y. Chen, Shahin Lockman, Mompati O. Mmalane, Joseph Makhema, Roger L. Shapiro
- 834 PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV-INFECTED WOMEN**
Rebecca Zash, Morgan Jengela, Drucilla Roberts, Sajini Souda, Modiegi Diseko, Shally Morgan, Gloria Mayondi, Mukendi Kayembe, Lisa Bebell, Mompati O. Mmalane, Max Essex, Shahin Lockman, Joseph Makhema, Roger L. Shapiro
- 835 INFLAMMATION IN HIV-INFECTED PREGNANT WOMEN IS ASSOCIATED WITH PRETERM BIRTH**
Rupak Shivakoti, Nikhil Gupte, Nathella P. Kumar, Vandana Kulkarni, Usha Balasubramanian, Ramesh Bhosale, Pradeep Sambarey, Aarti Kinikar, Renu Bharadwaj, Sandesh Patil, Sadaf Inamdar, Nishi Suryavanshi, Subash Babu, Robert Bollinger, Amita Gupta
- 836 MARKERS OF PRETERM DELIVERY IN HIV+ WOMEN; ROLE OF PROTEASE INHIBITORS AND VITAMIN D**
Adriana Weinberg, Yanling Huo, Deborah Kacanek, Kunjal Patel, Heather Watts, Diane Wara, Jelena Klawitter, Uwe Christians, for the IMPAACT Team P1025

Poster P-Q6 HEALTH OUTCOMES FOR HIV-EXPOSED UNINFECTED INFANTS, CHILDREN, AND ADOLESCENTS

Poster Hall D

2:30 PM – 4:00 PM

- 869 DECREASED DIARRHEAL AND RESPIRATORY DISEASE IN HEUS FOLLOWING RV AND PCV VACCINATION**
Gbolahan Ajibola, Kara Bennett, Kathleen M. Powis, Michael D. Hughes, Jean Leidner, Samuel W. Kgole, Kerapetse Botebele, Oganne Batlang, Chipo Petlo, Mompati O. Mmalane, Joseph Makhema, Shahin Lockman, Roger L. Shapiro
- 870 PERSISTENT B CELL DEFICIENCY IN HIV-EXPOSED UNINFECTED INFANTS FOLLOWING IMMUNIZATION**
Liane S. Sadder, Li Yin, Kai-Fen Chang, Bernard Fischer, Maureen Goodenow, John W. Sleasman
- 871 INFANT HIV VACCINATION: RELATIONSHIP TO CHILDHOOD VACCINES AND MATERNAL ANTIBODIES**
Hannah Itell, Erin McGuire, Meng Chen, Petronella Muresan, Sallie Permar, Genevieve Fouada

- 872 GROWTH AND BONE MINERAL ACCRETION IN UGANDAN INFANTS EXPOSED TO MATERNAL HIV AND ART**
Florence Nabwire, Ann Prentice, Matthew M. Hamill, Adeodata Kekitiinwa, Josaphat Byamugisha, Mary G. Fowler, Gail R. Goldberg
- 873 INFLAMMATION, CMV AND THE GROWTH HORMONE AXIS IN HIV-EXPOSED UNINFECTED INFANTS**
Ceri Evans, Bernard Chasekwa, Sandra Rukobo, Margaret Ghova, Kuda Mutasa, Robert Ntozini, Jean Humphrey, Andrew Prendergast
- 874 METABOLIC OUTCOMES IN OBESE HIV-EXPOSED UNINFECTED CHILDREN: COMPARISON WITH NHANES**
Jennifer Jao, Denise Jacobson, Wendy Yu, Matthew McKenna, William Borkowsky, Mitchell Geffner, Rohan Hazra, Brad Karalius, Elizabeth J. McFarland, Kunjal Patel, Paige L. Williams, Tracie Miller, for the Pediatric HIV/AIDS Cohort Study (PHACS)
- 875 HIV VIRAEMIA IN PREGNANCY AND NEURODEVELOPMENT OF HIV-EXPOSED UNINFECTED CHILDREN**
Stanzi M. le Roux, Elaine J. Abrams, Kirsty Donald, Kirsty Brittain, Tamsin K. Phillips, Allison Zerbe, Max Kroon, **Landon Myer**
- 876 DEVELOPMENTAL OUTCOMES AND ARV EXPOSURE IN HIV-EXPOSED UNINFECTED CHILDREN**
Micah Piske, Matthew A. Budd, Annie Q. Qiu, Evelyn J. Maan, Laura J. Sauve, John C. Forbes, Ariane Alimenti, Patricia Janssen, Helene C. Cote, for the CIHR Team Grant on Cellular Aging and HIV Comorbidities in Women and Children (CARMA)
- 877 MENTAL HEALTH DIAGNOSES, SYMPTOMS, AND SERVICE UPTAKE IN US YOUTH WITH PHIV EXPOSURE**
Renee Smith, Yanling Huo, Katherine Tassiopoulos, Richard Rutstein, Suad Kapetanovic, Claude A. Mellins, Deborah Kacanek, Kathleen Malee, for the Pediatric HIV/AIDS Cohort Study (PHACS)

Poster P-Q7 HIV-EXPOSED INFANTS: HOW ARE THEY DIFFERENT?
Poster Hall D **2:30 PM – 4:00 PM**

- 878 LOPINAVIR/RITONAVIR INDUCES MITOCHONDRIAL TOXICITY IN HIV-EXPOSED UNINFECTED CHILDREN**
Audrey Monnin, Nicolas Nagot, Marianne Periès, Roselyne Vallo, Nicolas Meda, Mandisa Singata, James Tumwine, Pascal Reynier, Thorkild Tylleskär, Philippe Van de Perre, Jean-Pierre Molès, for the PROMISE PEP consortium ANRS 12174
- 879 HEU BLOOD MTDNA CONTENT REMAINS ELEVATED FROM BIRTH INTO EARLY LIFE (0-3 YEARS)**
Abhinav Ajaykumar, Mayanne Zhu, Hugo Soudeyns, Fatima Kakkar, Jason Brophy, Ari Bitnun, Ariane Alimenti, Deborah M. Money, Helene C. Cote, for the CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children (CARMA)
- 880 INCREASED INFLAMMATION AND MONOCYTE ACTIVATION IN HIV-EXPOSED UNINFECTED INFANTS**
Marisa M. Mussi-Pinhata, Adriana Weinberg, Qilu Yu, Rachel A. Cohen, Sahera Dirajjal-Fargo, Nicholas Funderburg, Emily Bowman, Nahida Chakhtoura, Grace A. McComsey

881 INNATE IMMUNE ACTIVATION AMONG HIV-1 EXPOSED UNINFECTED INFANTS FROM BOTSWANA

Pilar Garcia Broncano, Samuel W. Kgole, Gosego Masasa, Terence Mohammed, Sikhulile Moyo, Joseph Makhema, Xu G. Yu, Jennifer Jao, Roger L. Shapiro, Mathias Lichterfeld, Kathleen M. Powis

882 MICROBIAL TRANSLOCATION, IMMUNE ACTIVATION, AND GUT DYSBIOSIS IN HIV-EXPOSED INFANTS

Charles D. Mitchell, Sady Dominguez, Varghese George, Eddy Perez-Then, Carlos V. Castillo, Juan L. Santana-Guerrero, Jeannette Baez, Margaret Roach, William Walters, Qiaojuan Shi, Shao-Pei Chou, Ruth Ley, Savita Pahwa

Poster P-Q8 INFANT TESTING AND STRATEGIES

Poster Hall D

2:30 PM – 4:00 PM

883 WILL TARGETED COMMUNITY OUTREACH IMPROVE HIV TESTING UPTAKE AMONG CHILDREN IN KENYA?

Samuel Ndolo, Nicollate A. Okoko, Mary A. Guzé, George Nyanaro, Lenah Nyabiage, Elizabeth A. Bukusi, Craig R. Cohen, Jeremy Penner, Jayne L. Kulzer

884 ENGAGEMENT IN CARE AND INFANT HIV TESTING AMONG LOST TO FOLLOW-UP OPTION B+ PATIENTS

William J. Reidy, Harriet Nuwagaba-Biribonwoha, Siphesihle Shongwe, Ruben Sahabo, Kieran Hartsough, Simangele Mhetwa, Elaine J. Abrams

885LB OPTIMIZING EID: A CLUSTER-RANDOMIZED TRIAL OF THE HIV INFANT TRACKING SYSTEM IN KENYA

Sarah Finocchario Kessler, Catherine Wexler, An-Lin Cheng, Niaman Nazir, Brad Gautney, May Maloba, Kathy Goggin, Melinda Brown, Elizabeth Muchoki, Shadrack Babu, Eric Muriithi, Martin Ochieng, Samoel Khamadi, Matthew Sandbulte, Raphael Lwembe

Poster P-R4 HIV AND DRUG USE

Poster Hall B

2:30 PM – 4:00 PM

961 RESTART OF THE HIV EPIDEMIC AMONG PWID IN OCCUPIED CRIMEA AND IN THE EAST OF UKRAINE

Marina Kornilova, Yana Sazonova

962 HIV TESTING AND PREVENTION SERVICES AMONG PERSONS WHO INJECT DRUGS—INDIANA, 2016

Mary Tanner, Sharoda Dasgupta, Monita Patel, Julie O'Donnell, Brandon Halleck, Joseph Amlung, Caitlin Conrad, Cameron McAlister, Erika Chapman, Ayriane Bailey, Michael Spiller, Dita Broz, Philip J. Peters, Paul J. Weidle, Joan Duwve

963 AN OUTBREAK OF HIV ASSOCIATED WITH SHARING OPIATE INJECTION PREPARATION EQUIPMENT

Sharon Koivu, L Ball, K Gupta, C Venner, R Tirona, Eric Arts, B Hallam, Ryan Wong, Klajdi Puka, M Speechley, G Hovhannisyan, **Michael Silverman**

964 IDENTIFYING UNDIAGNOSED HIV-INFECTED PWID IN INDIA USING RESPONDENT-DRIVEN SAMPLING

Allison M. McFall, Shruti H. Mehta, Aylur K. Srikrishnan, Santhanam Anand, Canjeevaram K. Vasudevan, Gregory M. Lucas, Sunil S. Solomon

- 965 HIV TRANSMISSION RISKS AMONG HIV-POSITIVE ADULTS IN MEDICAL CARE WHO MISUSE OPIOIDS**
Ansley Lemons, Nicholas DeGroote, Alejandro Pérez, Jason Craw, Margaret Nyaku, Dita Broz, Christine Mattson, Linda Beer, for the Medical Monitoring Project
- 966 INDICATORS OF INJECTION DRUG USE—INDIAN HEALTH SERVICE, 2010–2014**
Mary Evans, Marissa Person, Brigg Reilley, Jessica Leston, Richard Haverkate, Michelle Van Handel, Michele Bohm, Danae Bixler, Dita Broz, Andrew J. Mitsch, Dana Haberling, Eyasu Teshale, Paul J. Weidle, Philip J. Peters, Kate Buchacz
- 967 REPORTED DRUG INJECTION BEHAVIORS BEFORE AND AFTER AN HIV OUTBREAK—INDIANA, 2016**
Sharoda Dasgupta, Mary Tanner, Monita Patel, Julie O'Donnell, Brandon Halleck, Joseph Amlung, Cameron McAlister, Erika Chapman, Ayriane Bailey, Caitlin Conrad, Michael Spiller, Dita Broz, Philip J. Peters, Paul J. Weidle, Joan Duwve
- 968 JOINT TRAJECTORIES OF METHAMPHETAMINE USE AND HIV VIRAL LOAD**
Chelsea L. Shover, Heather A. Pines, Steven Shoptaw, Marjan Javanbakht, Robert Bolan, Pamina Gorbach
- 969 TRANSACTIONAL SEX AMONG MEN WHO HAVE SEX WITH MEN: WHAT'S DRUGS GOT TO DO WITH IT?**
Marjan Javanbakht, Amy Ragsdale, Steven Shoptaw, **Pamina Gorbach**
- 970 HIV DIAGNOSES AMONG PEOPLE WHO INJECT DRUGS — UNITED STATES, 2010–2015**
Sheryl Lyss, Tianchi Zhang, Alexandra M. Oster
- 971 CHARACTERISTICS OF HIV INCIDENT INFECTIONS AMONG PERSONS WHO INJECT DRUGS IN THE US**
Johanna Chapin-Bardales, Silvina Masciotra, Amanda Smith, Brooke Hoots, William M. Switzer, Wei Luo, S. Michele Owen, Gabriela Paz-Bailey
- 972 DISTRIBUTIVE SYRINGE SHARING AND USE OF SYRINGE SERVICES PROGRAMS AMONG PWID**
Monica Adams, Qian An, Dita Broz, **Janet C. Burnett**, Cyprian Wejnert, Gabriela Paz-Bailey
- 973 NEW DIAGNOSES OF HIV AMONG INJECTING DRUG USERS, NEW YORK CITY 2006–2016**
Lucia V. Torian, Jasmine Abdelnabi, Lisa A. Forgione, Joel O. Wertheim
- 974 DRUG OVERDOSE DEATHS AMONG PERSONS WITH HIV IN NEW YORK CITY, 2007–2015**
Sarah L. Braunstein, Rebekkah S. Robbins, Demetre C. Daskalakis
- 975 3-YEAR OUTCOMES OF PATIENT NAVIGATION+FINANCIAL INCENTIVES FOR HIV+ SUBSTANCE USERS**
Daniel Feaster, Carlos del Rio, Abigail Matthews, Lauren Gooden, Tim Matheson, Maxine Stitzer, Mamta K. Jain, Allan Rodriguez, Wendy S. Armstrong, Gregory M. Lucas, Mari-Lynn Drainoni, Carmen L. Masson, David C. Perlman, Petra Jacobs, Lisa Metsch
- 976LB HIV TRANSMISSION POTENTIAL DUE TO INJECTION DRUG USE IN RURAL WEST VIRGINIA, US, 2017**
Vicki Hogan, Brooke Hoots, **Christine Agnew-Brune**, Dawn Broussard, Kate Buchacz, Bridget Rose, Scott Cope, Erica Dawson, William Hoffman, Shacara Johnson, Sheryl Lyss, Laura Quilter, Paul J. Weidle, Brunilis White, Heather Bradley

Poster P-R5 STIs AND HIV**Poster Hall B****2:30 PM – 4:00 PM**

- 977 EVALUATING THE USE OF SYPHILIS PARTNER SERVICES FOR HIV CASE FINDING IN MISSISSIPPI**
Tigran Avoundjian, James Stewart, David Peyton, Christie Lewis, Kendra Johnson, Sara N. Glick, Matthew R. Golden, Christine M. Khosropour
- 978 ESTIMATED PRIMARY & SECONDARY SYPHILIS RATES IN MSM BY HIV STATUS – 34 STATES, 2014**
Jeremy A. Grey, Elizabeth A. Torrone, Sarah E. Kidd, Kyle T. Bernstein, Hillard S. Weinstock
- 979 HIGHER RISK AND VULNERABILITY BUT LOWER HIV/SYPHILIS COINFECTION IN THAI TG THAN MSM**
Akarin Hiransuthikul, Nanthika Prawepray, Supab Pengpum, Ratchadej Reankhomfu, Phubet Panpet, Nopparat Mahachokchai, Saman Sumalu, Pornpichit Brutrat, Thantip Sungsing, Jureeporn Jantarapakde, Deondara Trachunthong, Sutinee Charoenying, Praphan Phanuphak, Ravipa Vannakit, Nittaya Phanuphak
- 980 GAPS IN STI PREVENTION AMONG NIGERIAN MSM ADHERENT TO ART**
Rebecca G. Nowak, Trevor Crowell, Andrew Mitchell, Teclaire Ndomb, Babajide Keshinro Keshinro, Sheila A. Peel, Charlotte A. Gaydos, Julie Ake, William Blattner, Stefan Baral, Man Charurat, for the TRUST/RV368 Study Group
- 981 HIGH HIV-1 INCIDENCE RATE AMONG ADULTS ATTENDING STI CLINICS IN SOUTHERN MALAWI**
Fatima G. Zulu, Isaac Singini, Dean Soko, Treaser Thomas, Johnstone Kumwenda, Newton I. Kumwenda
- 982 GAPS ALONG THE PREP CONTINUUM AMONG STD CLINIC ATTENDING MSM WITH HIGH RISK BEHAVIORS**
Farah Mouhanna, Amanda D. Castel, Kerri Dorsey, Meredith Haddix, Anya Agopian, Hannah Yellin, Hibo Abdi, Michael Kharfen, Irene Kuo

Poster P-S1 IMPROVING COMMUNITY- AND CLINIC-BASED TESTING**Poster Hall B****2:30 PM – 4:00 PM**

Poster Sessions • Wednesday

- 983 COMMUNITY-BASED SERVICES REACH LARGE VOLUMES OF HIGH RISK MEN IN TANZANIA**
Caterina Casalini, Dorica Boyee, Amasha Mwanamsangu, Magnus Ndolichimpa, Yeronimo Mlawa, Peris Urasa, Neema Makyao, Erick Mlanga, Nelson Rutabanzibwa, Benjamin Myovela, Anike Akridge, Albert Komba, Jason Reed, Kelly Curran
- 984 MALE AND ADOLESCENT FIRST-TIME HIV TESTERS REACHED BY COMMUNITY HEALTH INITIATIVE**
Hong-Ha M. Truong, Dancun O. Obunge, Mary A. Guzé, Esther Wandera, Placide Ntawali, Eliud Akama, Frankline Otieno, Elizabeth A. Bukusi, Patrick Oyaro, Craig R. Cohen
- 985 DOOR-TO-DOOR HIV TESTING TO INCREASE ANTIRETROVIRAL THERAPY UPTAKE, WESTERN KENYA**
Fredrick Miruka, Kawango Agot, Spala Ohaga, Rose Oyoo, Rachael Joseph, Jonathan Mwangi, Jesee N. Nakhumwa, Isaac Ngere, Paul K. Musingila, Hellen Muttaii

986 BARRIERS TO HIV TESTING IN SWAZILAND: EFFECT OF FAMILY SUPPORT AND TRAVEL TIME

Harriet Nuwagaba-Biribonwoha, Yingfeng Wu, Averie B. Gachuhu, Margaret McNairy, Matthew R. Lamb, Sikhathelle Mazibuko, Zandile Mnisi, Veli M. Madau, Sean Burke, Neena M. Philip, Wafaa M. El-Sadr

987 HIV TESTING IN PRIMARY CARE CLINICS IN SOUTH AFRICA: A MISSED OPPORTUNITY

Bhakti Hansoti, Tonderai Mabuto, Griffiths Kubeka, Salome Charalambous, Deanne Kerrigan, Chris Hoffmann

988 HIGH PERCENTAGE OF UNDIAGNOSED HIV CASES IN A HYPER-ENDEMIC SOUTH AFRICAN POPULATION

Alain Vandormael, Tului de Oliveira, Frank Tanser, Till Bärnighausen, Joshua T. Herbeck

989 REDUCING TIME FOR HIV VIRAL LOAD RESULT DELIVERY TO ART FACILITIES IN MALAWI

Natasha Gous, Frank Chirwa, **Jeff Takle**, Alan Schooley

990 IMPACT OF TESTING DELAY ON LOW-LEVEL VIRAEMIA IN SOUTH AFRICA: A PROGRAMME-WIDE VIEW

Nei-Yuan M. Hsiao, Elton Mukonda, Maia Lesosky, Jean Maritz, Wolfgang Preiser, Landon Myer

991 RAPID VS. STANDARD TESTING FOR HIV AND HCV AT A DRUG DETOX: A RANDOMIZED TRIAL

Sabrina A. Assoumou, Samantha M. Paniagua, Benjamin Linas, Jianing Wang, Jeffrey H. Samet, Jonathan Hall, Curt G. Beckwith

Poster P-S2 ME, MYSELF, AND I: SELF-TESTING FOR HIV DIAGNOSIS**Poster Hall B****2:30 PM – 4:00 PM****992 HIV SELF-TESTING INCREASES TESTING IN YOUNG SOUTH AFRICAN WOMEN: RESULTS OF AN RCT**

Audrey Pettifor, Kathleen Kahn, Linda Kimaru, Zola Mayakayaka, Amanda Selin, Noah A. Haber, Ryan Wagner, Xavier Gomez-Olive, Hailey Gilmore, Memory Mhembere, Daniel Westreich, Rhian Twine, Sheri A. Lippman

993 FEMALE SEX WORKERS' INTERPRETATIONS OF HIV SELF-TEST RESULTS: A PERFORMANCE STUDY

Katrina F. Ortblad, Daniel K. Musoke, Thomson Ngabirano, Aidah Nakitende, Jessica E. Haberer, Margaret McConnell, Till Bärnighausen, Catherine E. Oldenburg

994 HIV SELF-TESTING AMONG MEN WHO HAVE SEX WITH MEN AND TRANSGENDER WOMEN IN MYANMAR

Andrea L. Wirtz, Soe Naing, Emily Clouse, Hsu Hnin Mon, Aung Zayar Paing, Stefan Baral, Chris Beyrer

995 EVALUATION OF TARGETED HIV SELF-TEST KIT DISTRIBUTION VIA A DIGITAL VENDING MACHINE

Alex Pollard, Gillian Dean, Suneeta Soni, Carrie Llewellyn, Carlos Peralta, Liliana Rodriguez, Jaime Vera-Rojas

996 COST ANALYSIS OF DIFFERENTIATED HIV SELF-TESTING KITS DISTRIBUTION IN ZAMBIA

Nurilign Ahmed, Lawrence Mwenge, Linda Sande, Collin Mangenah, Sarah Kanema, Mutinta Nalubamba, Sepiso Libamba, Euphemia Sibanda, Hendramoorthy Maheswaran, Cheryl Johnson, Karin Hatzold, Elizabeth L. Corbett, Helen Ayles, Fern Terris-Prestholt

997 COMPARING SELF-REPORTED VIRAL LOAD WITH HOME-COLLECTED HIV-RNA AMONG HIGH-RISK MSM

Richard A. Teran, Martin J. Downing, Mary Ann Chiasson, Hong Van Tieu, Laura Dize, Charlotte A. Gaydos, Sabina Hirshfield

Poster P-T02 PrEP AND STIs: THE EMERGING STORY**Poster Hall B****2:30 PM – 4:00 PM****1023 EFFECT OF ON DEMAND ORAL PREP WITH TDF/FTC ON HSV-1/2 INCIDENCE AMONG MSM**

Marie-Laure Chaix Baudier, Isabelle Charreau, Constance Delaugerre, Nadia Mahjoub, Martin Siguier, Catherine Capitant, Cécile Tremblay, François Raffi, Eric Cua, Gilles Pialoux, Laurent Cotte, Armelle Pasquet, Laurence Meyer, Jean-Michel Molina, for the ANRS IPERGAY Study Group

1024 INTEGRATING PREP REFERRALS INTO STD PARTNER SERVICES INCREASES PREP USE AMONG MSM

David A. Katz, Michael Barry, Julia C. Dombrowski, Teal Bell, Matthew R. Golden

1025 PARTNERS, NOT CONDOM USE, DRIVE STI RATES AMONG PREP USERS IN COMMUNITY HEALTH CENTER

Sarit A. Golub, Stephanie Pena, Rachel A. Fiksln, Matthew Goldberg, **Asa Radix**

1026 INCIDENT HIV, HEPATITIS C AND OTHER STI IN DAILY AND EVENT-DRIVEN PREP USERS

Elske Hoornenborg, Liza N. Coyer, Roel C. Achterbergh, Amy Matser, Udi Davidovich, Maarten F. Schim van der Loeff, Henry J. de Vries, Maria Prins, for the Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Initiative

1027 SEXUALLY TRANSMITTED INFECTIONS AND ADHERENCE TO PREP

Claire Bristow, David J. Moore, Michael Dube, Katya Calvo, Eric Ellorin, Jill Blumenthal, **Sheldon Morris**

1028 FACTORS IMPACTING APPROPRIATE HIV/STI SCREENING AND PrEP PERSISTENCE IN PRIMARY CARE

Matthew A. Spinelli, Hyman Scott, Eric Vltinghoff, Albert Y. Liu, Alicia Morehead-Gee, Rafael Gonzalez, Monica Gandhi, Susan P. Buchbinder

Poster P-T03 THE INTERSECTION OF DRUG USE AND PrEP**Poster Hall B****2:30 PM – 4:00 PM****1029 CHEMSEX DRUGS USE BY HAIR ANALYSIS AMONG MSM IN THE ANRS IPERGAY TRIAL.**

Julie Chas, Gilles Peytavin, Diane Carette, Nicolas Fabresse, Isabelle Charreau, Catherine Capitant, Perrine Roux, Eric Cua, Laurent Cotte, Armelle Pasquet, François Raffi, Laurence Meyer, Gilles Pialoux, Jean-Michel Molina, **Jean-Claude Alvarez**

1030 ASSESSING PrEP NEEDS AMONG HETEROSEXUALS AND PEOPLE WHO INJECT DRUGS, WASHINGTON, DC

Irene Kuo, Anya Agopian, Jenevieve Opoku, Anthony Rawls, Rudy Patrick, Manya Magnus, Michael Kharfen, Alan Greenberg

1031 STIMULANT USE AND CONDOMLESS SEX WITH MULTIPLE PARTNERS: EFFECT ON PrEP ADHERENCE

David Goodman-Meza, Matthew R. Beymer, Ryan M. Kofron, K. Rivet Amico, Christina Psaros, Lane R. Bushman, Peter L. Anderson, Robert Bolan, Wilbert C. Jordan, James F. Rooney, Amy R. Wohl, Raphael J. Landovitz

Poster P-T04 PEP AND ON-DEMAND PrEP**Poster Hall B****2:30 PM – 4:00 PM****1032 USE OF HIV PEP BY US COMMERCIALLY INSURED PERSONS INCREASED WITH AVAILABILITY OF PrEP**

Ya-Lin A. Huang, Kenneth L. Dominguez, Anne Patala, Karen W. Hoover

1033 HIV INCIDENCE AMONG MSM GIVEN PEP STARTER PACKS IN NYC SEXUAL HEALTH CLINICS, 2014-16

Christine M. Borges, Addie Crawley, Michael A. Castro, Susan Blank, Sarah L. Braunstein, Preeti Pathela

1034 COVERAGE OF SEX EVENTS WITH ON DEMAND PrEP: A MEMS SUB-STUDY OF THE IPERGAY TRIAL

Rebecca Bauer, Emmanuelle Netzer, Claire Pintado, Catherine Capitant, Eric Cua, Nicolas Etien, Gilles Pialoux, Christian Chidiac, Cedric Etienne, François Raffi, Armelle Pasquet, Veronique Dore, Laurence Meyer, Jean-Michel Molina, for the ANRS Ipergay Study Group

1035 FEASIBILITY OF SHORT-TERM PrEP UPTAKE FOR MSM WITH EPISODIC HIGH-RISK FOR HIV

James E. Egan, Ken Ho, Ronald Dean Stall, Morgan T. Drucker, Ryan Tappin, Craig W. Hendrix, Mark A. Marzinke, William Clarke, Kenneth H. Mayer

Poster P-T05 PrEP AND HIV INCIDENCE**Poster Hall B****2:30 PM – 4:00 PM****1036 PrEP USE HISTORY OF PERSONS NEWLY DIAGNOSED WITH HIV: NEW YORK CITY, 2015-2017**

Kavita Misra, Jamie Huang, Chi-Chi Udeagu

1037 DECREASES IN HIV INCIDENCE IN A MONTREAL CLINIC COINCIDE WITH EXPANDING PrEP USE

Marieve Beauchemin, Zoe Greenwald, Jason Szabo, Louise Charest, Judith Fafard, Danièle Longpré, Stéphane Lavoie, Réjean Thomas

1038 HIGH SEROCONVERSION RATES FOLLOWING PrEP DISCONTINUANCE IN A MONTREAL CLINIC

Zoe Greenwald, Marieve Beauchemin, Khadija Benomar, Gabrielle Landry, Michel Boissonnault, Louise Charest, Danièle Longpré, Stéphane Lavoie, Réjean Thomas

1039 USING HIV INCIDENCE ESTIMATES TO INFORM GUIDELINES FOR THE PrEP IMPACT TRIAL

Martina Furegato, Paula Blomquist, Sarika Desai, Hamish Mohammed, Holly Mitchell, Monica Desai, Owen N. Gill, John Saunders

1040 PrEP INTEREST AND HIV-1 INCIDENCE AMONG MSM AND TRANSGENDER WOMEN IN COASTAL KENYA

Makobu Kimani, Elisabeth M. van der Elst, Oscar Chirro, Clifford Oduor, Elizabeth Wahome, Winston Kazungu, Mahmoud Shally, Don Operario, Susan M. Graham, Eduard Sanders

1041 SEROCONVERSION ON PrEP: A PROTOCOL FOR UNTANGLING ADHERENCE VS RESISTANCE FAILURE

Joshua T. Thaden, Monica Gandhi, Karen Kuncze, Alexander Louie, Hideaki Okochi, Christopher B. Hurt, Mehri McKellar

1042 A PUBLIC HEALTH APPROACH TO VIREMIC INDIVIDUALS WITH PrEP-RESISTANT VIRUS

Susan E. Buskin, Richard Lechtenberg, Matthew R. Golden, Mark J. Fleming, Julia C. Dombrowski

Poster P-V3 TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND COMPLICATIONS**Poster Hall B****2:30 PM – 4:00 PM****1112 HIGH HIV-RELATED TUBERCULOSIS RISK IN COUNTIES WITH LOW HIV PREVALENCE—KENYA, 2015**

Herman O. Weyenga, Abraham Katana, Thomas Achia, Brian Baker, Lucy Ng'ang'a, Evelyne Ngugi, Tai Ho Chen, Maureen Kamene, Emily C. Zielinski-Gutierrez, Enos Masini, **Dunstan Achwoka**, George K. Kadondi, Christine Wambugu, Kenneth Masamaro, Kevin M. De Cock

1113 BURSTING MYTHS: PROGRAMMATIC SCALEUP OF ISONIAZID PREVENTIVE THERAPY, KENYA 2014-2016

Evelyn M. Karanja, Herman O. Weyenga, Abraham Katana, Martin Sirengo, Enos Masini, Lucy Ng'ang'a, Evelyne Ngugi, Shobha Vakil, Caroline Olwande, Agnes Langat, Christine Wambugu, Brian Baker, **Kevin M. De Cock**

1114 THE EFFECTS OF HIV TREATMENT ON UPTAKE OF TB AND NCD TREATMENT BY HOUSEHOLD MEMBERS

Suzue Saito, Andrea Howard, Magdalena Cerdá, Frank Tanser, Deenan Pillay, Wafaa M. El-Sadr, Till Bärnighausen

1115 HYPERTENSION SCREENING AND MANAGEMENT IN TWO PEPFAR-FUNDED CLINICS IN MALAWI

Sam Phiri, Hannock Tweya, Alice Maida, Sundeep Gupta, Colin Speight, Denise Giles, Oliver J. Gadabu, Fleetwood Loustalot, **Pragna Patel**

1116 HISTORICAL & CURRENT ANAL CYTOLOGY, HRHPV-DNA AND -mRNA-E6/E7 TESTS PREDICT ANAL HSIL

Dorothy J. Wiley, Hilary K. Hsu, Martha Ganser, Jenny Brook, David Elashoff, Matthew G. Moran, David H. Morris, Ronald T. Mitsuyasu, Stephen Young, Nancy Joste, Teresa Darragh, Hilary Robbins, Gypsyamber D'Souza, Otoniel Martínez-Maza, Roger Detels

1117LB COST-EFFECTIVENESS OF URINE TB SCREENING FOR HOSPITALIZED PEOPLE WITH HIV IN AFRICA

Krishna P. Reddy, Ankur Gupta-Wright, Katherine Fielding, Sydney Costantini, Amy Zheng, Elizabeth L. Corbett, Liyang Yu, Joep J. van Oosterhout, Stephen C. Resch, Doug K. Wilson, C. Robert Horsburgh, Robin Wood, Kenneth Freedberg, Stephen D. Lawn, Rochelle P. Walensky

Poster P-V4 ADHERENCE AND TREATMENT OUTCOMES**Poster Hall B****2:30 PM – 4:00 PM****1118 HIGH RATES OF VIRAL RESUPPRESSION ON FIRST-LINE ART AFTER INITIAL VIROLOGICAL FAILURE**

Lucas E. Hermans, Hugo Tempelman, Sergio Carmona, Monique Nijhuis, Diederick Grobbee, Douglas D. Richman, Michelle A. Moorhouse, Willem D. Venter, Annemarie Wensing

1119 IS CLINICAL STABILITY STABLE? MULTI-STATE SURVIVAL ANALYSIS OF HIV PATIENTS IN ZAMBIA

Monika Roy, Charles B. Holmes, Izukanji Sikazwe, Theodora Savory, Mwanza wa Mwanza, Carolyn Bolton Moore, Nancy Czaicki, David Glidden, Nancy Padian, Elvin Geng

- 1120 COMPARING TIME TO VIRAL SUPPRESSION AMONG ACUTE AND NON-ACUTE HIV IN NORTH CAROLINA**
Nicole Dzialowy Adams, Anna Cope, Brad Wheeler, Victoria L. Mobley, John Barnhart, Joann D. Kuruc, Cynthia L. Gay, Lindsey M. Filiatreau, Rhonda Ashby, Erika Samoff
- 1121 CD4 COUNT AND HIV VIRAL SUPPRESSION IMPROVE AFTER HOUSING PROGRAM ENROLLMENT, 2013-16**
Yaoyu Zhong, Ellen Wiewel, Christopher Beattie, Xiomara Farquhar, Jesse Thomas, Sarah L. Braunstein, John Rojas
- 1122 IMPROVED VIROLOGICAL OUTCOMES IN A CO-PAY MODEL SUPPORTING DIFFERENTIATED CARE**
Rosalind M. Parkes-Ratanshi, Samuel Lewis, Maria S. Nabaggala, Adelline Twimukye, Tom Kakaire, Noela Owarwo, Barbara Castelnovo, Agnes Kiragga, Walter Schlech, Mohammed Lamorde
- 1123 CLINIC-LEVEL FACTORS ASSOCIATED WITH TIME TO VIRAL SUPPRESSION IN WASHINGTON DC**
Anne K. Monroe, Nabil Rayeed, Maria Jaurretche, Lindsey Powers Happ, Kevin Trac, Arpi Terzian, Alan Greenberg, Amanda D. Castel, for the DC Cohort Executive Committee
- 1124 PREDICTORS OF PERSISTENT LOW LEVEL VIREMIA AND TRANSIENT VIRAL BLIPS**
Allahna L. Esber, Christina Polyak, Jonah Jonah Maswai, John Owuoth, Lucas Maganga, Akindiran Akintunde, Hannah Kibuuka, Julie Ake, Trevor Crowell
- 1125 IMPROVED OUTCOMES WITH MAXIMUM ASSISTANCE, LOW-THRESHOLD HIV CARE (THE “MAX CLINIC”)**
Julia C. Dombrowski, Sean Galagan, Meena Ramchandani, Shireesha Dhanireddy, Robert D. Harrington, Matthew R. Golden
- 1126 CLINICAL OUTCOMES OF US YOUNG BLACK MEN WITH HIV RECEIVING MEDICAL CARE, 2009–2014**
Pranesh P. Chowdury, Linda Beer, R. L. Shouse, Heather Bradley
- 1127 BEYOND VIRAL SUPPRESSION: BROADENING QUALITY MEASURES (QM) FOR TOTAL HIV PATIENT CARE**
Michael A. Horberg, Jackie Blank, Kevin Rubenstein, Leo Hurley, Peter Kadlecik, Daniel B. Klein, Michael J. Silverberg
- 1128 HIV STIGMA IS ASSOCIATED WITH RETENTION AND VIRAL LOAD AMONG US PATIENTS IN CARE**
Katerina A. Christopoulos, Torsten B. Neilands, Wendy Hartogensis, Michael J. Mugavero, Heidi M. Crane, Rob Fredericksen, Elvin Geng, W. C. Mathews, Geetanjali Chander, Joseph J. Eron, Kenneth H. Mayer, John Saucedo, Kimberly Koester, Troy Wood, Mallory Johnson
- 1129 HIGH VIREMIA AMONG ‘STABLE’ PATIENTS RECEIVING ANTIRETROVIRAL THERAPY IN ZAMBIA**
Mpande Mukumbwa-Mwenechanya, Emilie Efronson, Paul Somwe, Jillian L. Kadota, Monika Roy, Samuel Bosomprah, Kelvin Kaputula, Jake Pry, Nancy Padian, Elvin Geng, Charles B. Holmes, Izukanji Sikazwe, Anjali Sharma, Carolyn Bolton Moore
- 1130 COMPLIANCE TO GUIDELINES FOR ROUTINE VIRAL LOAD TESTING IN RESOURCE LIMITED SETTINGS**
Barbara Castelnovo, Frank Mubiru, Mark Nsumba, Isaac Lwanga, Ivan Lumu, Agnes Kiragga, Steven J. Reynolds

1131 HEALTHCARE PROVIDER TRUST LINKED TO LONG-TERM HIV VIRAL SUPPRESSION

Kate G. Michel, Cuiwei Wang, Tracey Wilson, Kathryn Anastos, Mardge H. Cohen, Ruth Greenblatt, Margaret Fischl, Igho Ofotokun, Mirjam-Colette Kempf, Adaora Adimora, Joel Milam, Joanne Michelle F. Ocampo, Stephen J. Gange, Michael Plankey, Seble Kassaye

1132 CHARACTERIZING HIV CARE TRAJECTORIES AND DIFFERENCES IN PATIENT OUTCOMES

Eva A. Enns, Cavan Reilly, Karen Baker, Keith Henry

1133 FROM PRISON'S GATE TO DEATH'S DOOR: SURVIVAL ANALYSIS OF RELEASED PRISONERS WITH HIV

Kelsey B. Loeliger, Jaimie P. Meyer, Maria M. Ciarleglio, Mayur M. Desai, Colleen Gallagher, Frederick Altice

1134 DISCRIMINATION IN HEALTHCARE SETTINGS AMONG PATIENTS WITH RECENT HIV DIAGNOSES

Amy R. Baugher, Linda Beer, Jennifer Fagan, Christine Mattson, R. L. Shouse, for the Medical Monitoring Project

1135 LONGITUDINAL DIFFERENCES IN POOR ADHERENCE AMONG YOUTH AND ADULTS LIVING WITH HIV

Kalysha Closson, Alexis Palmer, Cathy Puskas, Kate Salters, Surita Parashar, Karyn Gabler, Lateefa Tiamiyu, Wendy Zhang, Angela Kaida, Robert S. Hogg

1136 VIRAL SUPPRESSION AFTER INTERMITTENT VIREMIA: WOMEN'S INTERAGENCY HIV STUDY 1994-2015

Amanda B. Spence, Cuiwei Wang, Tracey Wilson, Kathryn Anastos, Mardge H. Cohen, Ruth Greenblatt, Margaret Fischl, Igho Ofotokun, Mirjam-Colette Kempf, Adaora Adimora, Joel Milam, Joanne Michelle F. Ocampo, Kate G. Michel, Seble Kassaye

1137 EVALUATING CARE OUTCOMES FOR ACUTE HIV INFECTION IN PHILADELPHIA, 2014-2016

Melissa Miller, Tanner Nassau, Coleman Terrell, Kathleen Brady

1138 HIV CARE TRAJECTORIES IN THE ERA OF UNIVERSAL TEST-AND-TREAT IN RURAL SOUTH AFRICA

Delphine Perriat, Hassimiou Diallo, François Dabis, Deenan Pillay, Joanna Orne-Gliemann, Joseph Larmarange, for the ANRS 12249 TasP Study Group

1139 THE IMPACT OF "TREATMENT FOR ALL" ON EARLY GAPS IN ART-A MULTISITE COHORT STUDY

Ingrid Katz, Nicholas Musinguzi, Kathleen Bell, Anna Cross, Bosco M. Bwana, Gideon Amanyire, Stephen Asiimwe, Catherine Orrell, David R. Bangsberg, Jessica E. Haberer, for the META Research Group

1140 VIRAL SUPPRESSION EFFECTS OF INTERVENTIONS FOR UNSTABLE ART PATIENTS IN SOUTH AFRICA

Matthew P. Fox, Sophie Pascoe, Amy Huber, Joshua Murphy, Mokgadi Phokojoe, Marelize Gorgens, **Sydney Rosen**, David Wilson, Yogan Pillay, Nicole Fraser

1141 SUSTAINABLE VIRAL LOAD MONITORING SCALE-UP: GEOSPATIAL OPTIMIZATION MODEL FOR ZAMBIA

Brooke E. Nichols, Sarah Girdwood, Thomas Crompton, Lynsey E. Stewart-Isherwood, Leigh Berrie, Dorman Chimhamhiwa, Crispin Moyo, John Kuehnle, **Sydney Rosen**, for the EQUIP Health team

1142 EXPANDING VIRAL LOAD TESTING ACCESS THROUGH EVALUATION OF THE GENEXPERT IN BOTSWANA

Rachel S. Beard, Anikie Mathoma, Mackenzie Hurlston, Naledi Nyepetsi, Christopher Serumola, Joyce Basotli, Ritah Moatlhodi, Unami Mathebula, Otsile Meswele, Charity Ralegoreng, Tefera Agizew, Rosanna Boyd, Madisa Mine, Ishmael Kasvosve

1143 THE ECONOMIES OF SCALE OF TEST AND TREAT: A LONGITUDINAL COSTING STUDY IN SWAZILAND

Shaukat Khan, Cebele Wong, Pascal Geldsetzer, Gerda Asmus, Thomas How, Charlotte Lejeune, Velephi Okello, Till Bärnighausen

1144 DECREASED ALCOHOL USE (EVEN WITHOUT ABSTINENCE) IS ASSOCIATED WITH BETTER VIRAL LOAD

Heidi M. Crane, Robin M. Nance, Andrew Hahn, Judith I. Tsui, Michael J. Mugavero, Bryan Lau, Geetanjali Chander, Sonia Napravnik, Karen Cropsey, Katerina A. Christopoulos, Rob Fredericksen, Dennis Donovan, Jane M. Simoni, Mari Kitahata, Joseph Delaney

1145 DURABILITY OF FINANCIAL INCENTIVES EFFECT ON VIRAL SUPPRESSION AND CONTINUITY IN CARE

Wafaa M. El-Sadr, Geetha Beauchamp, Irene Hall, Lucia V. Torian, Barry S. Zingman, Garret Lum, Richard A. Elion, Kate Buchacz, David Burns, Allison Zerbe, Theresa Gamble, Deborah J. Donnell

Poster P-W1 MODELING HIV TESTING AND PREVENTION STRATEGIES
Poster Hall B **2:30 PM – 4:00 PM**

1146 COST-EFFECTIVENESS OF REGULAR HIV SCREENING FOR YOUNG MEN WHO HAVE SEX WITH MEN

Anne M. Neilan, Alexander Bulteel, Kenneth Freedberg, Sybil Hosek, Raphael J. Landovitz, Rochelle P. Walensky, Craig M. Wilson, Andrea L. Ciaranello

1147 REPEAT HIV TESTING DURING PREGNANCY IN KENYA: AN ECONOMIC EVALUATION

Anna Joy Rogers, **Janet M. Turan**, Ellen F. Eaton, Stephen T. Mennemeyer

1148 PREFERENCES AND WILLINGNESS-TO-PAY FOR BLOOD AND ORAL-FLUID HIV SELF-TESTS IN KENYA

Kristen Little, Nicholas L. Wilson, Patrick Alyward, Hildah Essendi

1149 THE PrEP CARE CONTINUUM AND HIV RACIAL DISPARITIES AMONG MEN WHO HAVE SEX WITH MEN

Samuel Jenness, Kevin Maloney, Dawn K. Smith, Karen W. Hoover, Steven M. Goodreau, Kevin Weiss, Eli Rosenberg, Patrick S. Sullivan

1150 IMPROVING STATEWIDE PRE-EXPOSURE PROPHYLAXIS IMPLEMENTATION AMONG MSM

Jason Gantenberg, Maximilian King, Madeline C. Montgomery, Omar Galarraga, Mattia Prosperi, Brandon D. Marshall, Philip A. Chan

1151 POTENTIAL EFFECTIVENESS OF LONG-ACTING INJECTABLE PrEP IN MSM: A MODELING STUDY

Brandon D. Marshall, William C. Goedel, Maximilian King, David P. Durham, **Philip A. Chan**, Jeffrey P. Townsend, Alison P. Galvani

1152 QUANTIFYING INDIRECT BENEFITS OF PrEP: MODELING ANALYSIS OF ORAL PrEP IN ZIMBABWE

Zindoga Mukandavire, Daniel J. Klein, Graham F. Medley, Anna Bershteyn, Katharine Kripke, Delivette Castor, Definata Nhamo, Joseph Murungu, Taurai Bhatasara, Lawrence Nyazema, Kudakwashe Takarinda, Kristine Torjesen

1153 DESIGNING HIV VACCINE DELIVERY STRATEGIES IN SOUTH AFRICA: A POLICY ANALYSIS

Blythe J. Adamson, Simon de Montigny, Benoît R. Mâsse, Louis Garrison, James G. Kublin, Peter Gilbert, Dobromir Dimitrov

1154 FINE TUNING SPATIAL RESOLUTION OF HIV EPIDEMIOLOGIC DATA WHILE PROTECTING PRIVACY

Marta M. Jankowska, Tommi O. Gaines, Susan J. Little, Sanjay R. Mehta, **Antoine Chaillon**

POSTER SESSIONS, BY CATEGORY

All poster sessions will be held from 2:30 PM to 4:00 PM on the scheduled day (listed in parenthesis below). Poster locations are as follows:

Poster Hall A – Basic Science (categories A to E), posters 167 to 454

Poster Hall B – Epidemiology/Public Health (categories R to W), posters 886 to 1158

Poster Hall D – Clinical (categories F to Q), posters 455 to 885LB

A. VIROLOGY

- P-A1 MOLECULAR VIROLOGY (Monday)
- P-A2 HOST CELL PATHWAYS AND VIRAL REPLICATION (Tuesday)
- P-A3 EARLY EVENTS: METHODS AND MECHANISM (Tuesday)
- P-A4 HIV AND HOST DEFENSES (Wednesday)

B. PATHOGENESIS: HUMAN STUDIES AND ANIMAL MODELS

- P-B1 HIV TRANSMISSION AND DISEASE PROGRESSION (Monday)
- P-B2 IMMUNE ACTIVATION AND SUPPRESSION IN HIV INFECTION (Tuesday)
- P-B3 NATURAL AND UNNATURAL CONTROL OF HIV INFECTION (Tuesday)
- P-B4 CELL AND TISSUE DISREGULATION IN HIV INFECTION (Tuesday)
- P-B5 COMPARTMENTS FOR HIV REPLICATION (Tuesday)
- P-B6 THE MICROBIOME AND HIV: TRANSLOCATION AND INTERVENTION (Wednesday)
- P-B7 EFFECT OF HIV INFECTION ON THE MICROBIOME (Wednesday)
- P-B8 ROLE OF THE MICROBIOME IN HIV INFECTION (Wednesday)

C. HOST IMMUNE RESPONSES TO INFECTION, VACCINES, AND IMMUNOTHERAPY

- P-C1 KILLERS: NK AND CD8 CELLS (Wednesday)
- P-C2 T AND B CELL INTERACTIONS IN LYMPH NODES (Wednesday)
- P-C3 NEUTRALIZING ANTIBODIES (Monday)
- P-C4 NON-NEUTRALIZING ANTIBODIES (Monday)
- P-C5 VACCINE DESIGN AND TESTING (Tuesday)
- P-C6 NOVEL INTERVENTIONAL STRATEGIES (Tuesday)

D. HIV RESERVOIRS, LATENCY, AND ALL CURATIVE STRATEGIES INCLUDING THERAPEUTIC VACCINES AND GENE THERAPY

- P-D01 MECHANISMS OF HIV LATENCY AND ITS REVERSAL (Monday)
- P-D02 INSIGHTS FROM HIV REBOUND (Monday)
- P-D03 HIV RESERVOIRS IN ACUTE INFECTION (Monday)
- P-D04 IMPACT OF ANTIRETROVIRAL THERAPY ON HIV/SIV RESERVOIRS (Monday)
- P-D05 INTERVENTIONS IN SIV MODELS OF PERSISTENCE (Tuesday)
- P-D06 NOVEL INTERVENTIONS TO TARGET HIV RESERVOIRS (Tuesday)
- P-D07 CHARACTERIZING HIV RESERVOIRS (Tuesday)
- P-D08 NOVEL INSIGHTS INTO HIV/SIV RESERVOIRS (Wednesday)
- P-D09 MARKERS OF HIV RESERVOIRS (Wednesday)
- P-D10 QUANTIFYING HIV RESERVOIRS (Wednesday)

E. NEUROPATHOGENESIS AND CNS HIV COMPLICATIONS

- P-E1 NEUROCOGNITIVE CORRELATES, INCLUDING ANTIRETROVIRAL THERAPY AND VASCULAR DISEASE (Monday)
- P-E2 NEUROPSYCHOLOGIC COMPLICATIONS OF HIV INFECTION (Monday)
- P-E3 NEUROCOGNITIVE CORRELATES: TREATMENT STRATEGIES AND ADJUNCTIVE TREATMENT (Monday)
- P-E4 NEUROIMAGING AND ASSOCIATED BIOMARKERS (Tuesday)
- P-E5 CNS RESERVOIRS, ESCAPE, ANTIRETROVIRAL THERAPY, AND RESPONSES (Wednesday)
- P-E6 BASIC NEUROPATHOGENES AND NEUROPATHOLOGY (Wednesday)

F. CLINICAL PHARMACOLOGY

- P-F1 ANTIRETROVIRAL, ANTITUBERCULAR, AND ANTIMALARIAL PHARMACOKINETICS (Monday)
- P-F2 PHARMACOLOGIC ASSESSMENT OF ADHERENCE (Monday)
- P-F3 ANTIRETROVIRAL PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTIONS (Tuesday)
- P-F4 ANTIRETROVIRAL PHARMACOLOGY IN COMPARTMENTS AND RESERVOIRS (Tuesday)
- P-F5 NOVEL FORMULATIONS FOR ANTIRETROVIRAL DRUG DELIVERY (Wednesday)

G. ANTIRETROVIRAL THERAPY: PRE-CLINICAL AND RANDOMIZED TRIALS AND**H. ANTIRETROVIRAL THERAPY: EFFICACY AND EFFECTIVENESS STUDIES**

- P-H1 ANTIRETROVIRAL TREATMENT-NAIVE STUDIES (Monday)
- P-H2 INTEGRASE STRAND-TRANSFER INHIBITORS: SAFETY, EFFICACY, AND IRIS (Monday)
- P-H3 ANTIRETROVIRAL SWITCH STUDIES (Monday)
- P-H4 ANTIRETROVIRAL TREATMENT-EXPERIENCED STUDIES (Wednesday)
- P-H5 ANTIRETROVIRAL ADHERENCE (Wednesday)
- P-H6 VIRAL LOAD MONITORING AND SUPPRESSION (Wednesday)
- P-H7 IMMUNE RECOVERY AND HIV CONTROL (Wednesday)

I. HIV DRUG RESISTANCE

- P-I1 TRANSMITTED DRUG RESISTANCE: A GLOBAL CONCERN (Tuesday)
- P-I2 ANTIRETROVIRAL RESISTANCE AND RESPONSE TO INITIAL THERAPY (Tuesday)
- P-I3 RESISTANCE ON ANTIRETROVIRAL THERAPY: THE PROBLEM PERSISTS! (Tuesday)
- P-I4 ARE INTEGRASE STRAND-TRANSFER INHIBITORS RESISTANCE PROOF? (Tuesday)
- P-I5 PREVALENCE OF ANTIRETROVIRAL THERAPY RESISTANCE: THE POPULATION MATTERS (Wednesday)
- P-I6 NEW INSIGHTS INTO ANTIRETROVIRAL SUSCEPTIBILITY AND RESISTANCE (Wednesday)

J. HIV DIAGNOSTICS

- P-J1 HIV DIAGNOSTICS (Tuesday)

K. HEPATITIS VIRUSES AND LIVER COMPLICATIONS

- P-K01 HCV DIAGNOSIS AND TESTING (Monday)
- P-K02 MOLECULAR EPIDEMIOLOGY OF HCV NETWORKS (Monday)
- P-K03 NEW HCV INFECTIONS (Monday)
- P-K04 HCV CASCADE (Tuesday)
- P-K05 HCV CASCADE: TREATMENT AND BEYOND (Tuesday)
- P-K06 HEPATITIS B AND DELTA (Tuesday)
- P-K07 NON-B, NON-C HEPATITIS (Wednesday)
- P-K08 HEPATITIS BEYOND THE LIVER (Wednesday)
- P-K09 MICRO-RNA: A LOT OF INFORMATION IN A LITTLE BIT OF RNA (Wednesday)
- P-K10 STEATOSIS AND CIRRHOsis (Tuesday)

L. MALIGNANCIES

- P-L1 HIV-ASSOCIATED CANCER: EPIDEMIOLOGY AND OUTCOMES (Monday)
- P-L2 CERVICAL AND ANAL CANCER AND HPV (Tuesday)
- P-L3 HIV-RELATED LYMPHOMA AND LIVER CANCER (Wednesday)

M. CARDIOVASCULAR COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY

- P-M1 ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR DISEASE (Wednesday)
- P-M2 IMMUNOLOGIC FACTORS AND PATHOGENESIS OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (Wednesday)
- P-M3 RISK FACTORS FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ROLE OF FAT AND OTHER FACTORS (Wednesday)
- P-M4 PREDICTING CARDIOVASCULAR DISEASE RISK AND STATIN USE (Tuesday)
- P-M5 REDUCING CARDIOVASCULAR DISEASE RISK (Tuesday)
- P-M6 HEART FAILURE, VENTRICULAR FUNCTION, AND PERIPHERAL ARTERY DISEASE (Tuesday)
- P-M7 DISLIPIDEMIA: MECHANISMS AND INTERVENTIONS (Monday)
- P-M8 CARDIAC AND PULMONARY COMPLICATIONS IN LOW- AND MIDDLE-INCOME SETTINGS (Monday)

N. OTHER COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY

- P-N01 BONE DISEASE (Monday)
- P-N02 RENAL DISEASE (Tuesday)
- P-N03 ADIPOSE TISSUE (Wednesday)
- P-N04 DIABETES AND DIET (Wednesday)
- P-N05 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Tuesday)
- P-N06 DEPRESSION (Tuesday)
- P-N07 FRAILTY AND FUNCTIONAL STATUS (Monday)
- P-N08 AGING: BIOLOGIC MECHANISMS (Wednesday)
- P-N09 HOSPITALIZATION AND OUTCOMES (Wednesday)
- P-N10 BIOMARKER PREDICTORS OF NON-AIDS EVENTS (Tuesday)

O. TUBERCULOSIS AND OTHER OPPORTUNISTIC INFECTIONS

- P-01 TUBERCULOSIS INCIDENCE, SCREENING, AND DIAGNOSIS (Monday)
- P-02 TUBERCULOSIS BIOMARKERS AND INFLAMMATION (Monday)
- P-03 TUBERCULOSIS TRANSMISSION DYNAMICS, DRUG RESISTANCE, AND TREATMENT ISSUES (Monday)
- P-04 CRYPTOCAL MENINGITIS AND OTHER FUNGAL INFECTIONS (Tuesday)
- P-05 HIV-ASSOCIATED SYPHILIS (Wednesday)
- P-06 RATES AND RISKS OF OTHER OIs (Wednesday)

P. MATERNAL/FETAL HIV

- P-P1 ANTIRETROVIRAL PHARMACOKINETICS, SAFETY, AND STRATEGIES DURING PREGNANCY (Monday)
- P-P2 ADHERENCE, VIRAL SUPPRESSION, AND RETENTION IN PREGNANT AND POSTPARTUM WOMEN (Monday)
- P-P3 INFANT HIV INFECTION AND DIAGNOSIS IN THE ERA OF OPTION B+ (Tuesday)
- P-P4 HIV, ANTIRETROVIRAL THERAPY, AND PREGNANCY OUTCOMES (Wednesday)

Q. PEDIATRICS AND ADOLESCENTS

- P-Q1 PHARMACOKINETICS, SAFETY, AND UPTAKE OF HIV CO-TREATMENTS IN CHILDREN (Monday)
- P-Q2 SOMETHING OLD, SOMETHING NEW: PHARMACOKINETICS AND SAFETY OF ARVs FOR INFANTS, CHILDREN, AND ADOLESCENTS (Monday)
- P-Q3 AGING UP WITH HIV INFECTION: HEALTH OUTCOMES OF ADOLESCENTS AND YOUNG ADULTS (Monday)
- P-Q4 HIV AND ANTIRETROVIRAL THERAPY OUTCOMES IN CHILDREN AND ADOLESCENTS (Tuesday)
- P-Q5 RESPONSE TO EARLY INFANT ANTIRETROVIRAL THERAPY (Tuesday)
- P-Q6 HEALTH OUTCOMES FOR HIV-EXPOSED UNINFECTED INFANTS, CHILDREN, AND ADOLESCENTS (Wednesday)
- P-Q7 HIV-EXPOSED INFANTS: HOW ARE THEY DIFFERENT? (Wednesday)
- P-Q8 INFANT TESTING AND STRATEGIES (Wednesday)

R. EPIDEMIOLOGY

- P-R1 LATE PRESENTATION AND MORTALITY (Monday)
- P-R2 EPIDEMIOLOGY AND RISK FACTORS (Monday)
- P-R3 PHYLOGENETICS IN EPIDEMIOLOGY (Tuesday)
- P-R4 HIV AND DRUG USE (Wednesday)
- P-R5 STIs AND HIV (Wednesday)

S. TESTING

- P-S1 IMPROVING COMMUNITY- AND CLINIC-BASED TESTING (Wednesday)
- P-S2 ME, MYSELF, AND I: SELF-TESTING FOR HIV DIAGNOSIS (Wednesday)
- P-S3 EARLY INFECTION AND RECENTY ASSAYS (Tuesday)

T. PREVENTION INTERVENTIONS

- P-T01 BARRIERS AND FACILITATORS OF PrEP (Monday)
- P-T02 PrEP AND STIs: THE EMERGING STORY (Wednesday)
- P-T03 THE INTERSECTION OF DRUG USE AND PrEP (Wednesday)
- P-T04 PEP AND ON-DEMAND PrEP (Wednesday)
- P-T05 PrEP AND HIV INCIDENCE (Wednesday)
- P-T06 ORAL PrEP IN WOMEN (Tuesday)
- P-T07 PrEP IN SERODISCORDANT COUPLES (Tuesday)
- P-T08 MUCOSAL SAFETY STUDIES OF VAGINAL, RECTAL RING, AND ORAL PrEP (Monday)
- P-T09 PHASE I STUDIES OF MONOCLONAL ANTIBODIES IN NON-INFECTED ADULTS (Tuesday)
- P-T10 SAFETY AND ACCEPTABILITY OF MALE CIRCUMCISION (Tuesday)

U. CONTRACEPTIVE AND REPRODUCTIVE HEALTH IN WOMEN

- P-U1 CLOSING THE GAP: INTEGRATION OF FAMILY PLANNING IN HIV PREVENTION AND CARE (Tuesday)
- P-U2 CARING FOR WOMEN LIVING WITH HIV: MENOPAUSE AND CONTRACEPTION (Monday)

V. IMPLEMENTATION AND SCALE-UP OF TREATMENT AND CARE

- P-V1 LINKAGE, ENGAGEMENT, AND RETENTION (Tuesday)
- P-V2 EARLY ANTIRETROVIRAL THERAPY INITIATIVE (Tuesday)
- P-V3 TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND COMPLICATIONS (Wednesday)
- P-V4 ADHERENCE AND TREATMENT OUTCOMES (Wednesday)

W. POPULATION AND COST MODELING

- P-W1 MODELING HIV TESTING AND PREVENTION STRATEGIES (Wednesday)
- P-W2 MODELING ANTIRETROVIRAL THERAPY INTERVENTIONS AND OUTCOMES (Monday)

INDEX OF STUDIES RELATED TO WOMEN

The following index lists abstracts that the authors have noted women or women's issues as the focus of the study. This index was developed for attendees with an interest in these issues. We encourage you to refer to the full program for other presentations that may address this subject.

MONDAY, MARCH 5, 2018

- 30LB RESULTS OF ACTG A5288: A STRATEGY STUDY IN RLS FOR 3RD-LINE ART CANDIDATES** (Oral Abstract Session O-02)
- 45 FEMALE HIV ACQUISITION PER SEX ACT IS ELEVATED IN LATE PREGNANCY AND POSTPARTUM** (Oral Abstract Session O-04)
- 207 CELL RECRUITMENT EVENTS DURING THE MENSTRUAL CYCLE ASSOCIATE WITH SHIV SUSCEPTIBILITY** (Poster Session P-B1)
- 288 CHARACTERIZATION OF THE NEUTRALIZING ANTIBODY RESPONSE IN A LINKED HIV SUPERINFECTION** (Poster Session P-C3)
- 297 THE CODEVELOPMENT OF ANTIBODY GLYCOSYLATION AND FUNCTIONALITY IN HIV INFECTION** (Poster Session P-C4)
- 337 HIV-1 VIRAL REBOUND AND SAFETY OUTCOMES OF POSTPARTUM TREATMENT INTERRUPTION IN WOMEN** (Poster Session P-D02)
- 339 HIV RESERVOIR ESTABLISHMENT DURING HYPERACUTE CLADE C INFECTION** (Poster Session P-D03)
- 341 HIV RNA PERSISTS LONG-TERM IN LYMPH NODES OF INDIVIDUALS INITIATED ON ART IN FIEBIG I** (Poster Session P-D03)
- 401 USE OF NON-ANTIRETROVIRAL MEDICATIONS THAT MAY IMPACT NEUROCOGNITION** (Poster Session P-E1)
- 412 CARDIOVASCULAR RISK FACTORS ASSOCIATED WITH NEUROCOGNITIVE IMPAIRMENT DIFFER BY SEX** (Poster Session P-E1)
- 420 LOW DOSE HYDROCORTISONE ENCHANCES COGNITIVE FUNCTIONING IN HIV-INFECTED WOMEN** (Poster Session P-E2)
- 423 DEPRESSION SYMPTOM CHANGES OF HIV-POSITIVE INDIVIDUALS IN THE RAKAI COHORT** (Poster Session P-E3)
- 461 PERSISTENT LOW-LEVEL VIREMIA IS ASSOCIATED WITH LOW PROTEASE INHIBITOR LEVELS IN HAIR** (Poster Session P-F2)
- 462 EFAVIRENZ LEVEL IN HAIR PREDICTS VIROLOGIC RESPONSE BETTER THAN LEVEL IN BLOOD** (Poster Session P-F2)
- 500 SWITCHING TO BICTEGRAVIR/EMTRACITABINE/TENOFOVIR ALAFENIMIDE (B/F/TAF) IN WOMEN** (Poster Session P-H3)
- 586 ESTIMATING HIV, HCV AND HSV-2 INCIDENCE FROM EMERGENCY DEPARTMENT SEROSURVEYS** (Poster Session P-K03)
- 658LEEP TREATMENT OF EXTENSIVE CERVICAL INTRAEPITHELIAL NEOPLASIA IN HIV-INFECTED WOMEN** (Themed Discussion TD-03)
- 659 GENE PROFILE INFORMS HPV GRADE BUT NOT RELAPSE AFTER LEEP IN ART-SUPPRESSED HIV+HPV+** (Themed Discussion TD-03)
- 719 ARV-NAIVE HIV-INFECTED ADULTS HAD LOWER BONE FORMATION MARKERS THAN HIV-UNINFECTED** (Poster Session P-N01)

- 720 TDF PROPHYLAXIS FOR PMTCT OF HBV: EFFECT ON MATERNAL AND INFANT BONE MINERAL DENSITY (Poster Session P-N01)**
- 721 OPTION B-PLUS ART, PREGNANCY, LACTATION AND BONE HEALTH IN UGANDAN WOMEN (Poster Session P-N01)**
- 727 HYPERKYPHOSIS AND AGING IN THE WOMEN'S INTERAGENCY HIV STUDY (Poster Session P-N01)**
- 803 INCREASED RISK OF HYPERTENSION IN PREGNANCY AMONG WOMEN ON NEVIRAPINE-BASED REGIMENS (Poster Session P-P1)**
- 804 DOES CHANGING ART IN EARLY PREGNANCY FOR FETAL RISKS DESTABILIZE VIRAL SUPPRESSION? (Poster Session P-P1)**
- 805 COMPARISON OF FOUR CLASSICAL PI- AND Raltegravir-BASED REGIMENS DURING PREGNANCY (Poster Session P-P1)**
- 806 Raltegravir in PREGNANCY: PATTERNS OF USE AND BIRTH OUTCOMES IN THE UK AND IRELAND (Poster Session P-P1)**
- 807 DoIPHIN-1: Dolutegravir VS Efavirenz WHEN INITIATING TREATMENT IN LATE PREGNANCY (Poster Session P-P1)**
- 808 DIPSTICKS PROTEINURIA TO PREDICT RENAL DYSFUNCTION IN HIV-INFECTED PREGNANT WOMEN (Poster Session P-P1)**
- 809 CONCENTRATIONS OF TVF-DP DURING PREGNANCY AMONG WOMEN USING PrEP (Poster Session P-P1)**
- 810 EX VIVO COTYLEDON PERfusion FAIRLY PREDICTS IN VIVO ARV HUMAN PLACENTAL TRANSFER (Poster Session P-P1)**
- 811 CABERGOLINE FOR LACTATION SUPPRESSION AMONG HIV+ AND HIV-WOMEN (Poster Session P-P2)**
- 812 PREDICTORS OF VIROLOGIC FAILURE IN POSTPARTUM WOMEN ON ART IN PROMISE 1077HS (Poster Session P-P2)**
- 813 DISPARITIES IN ANTEnatal VIROLOGIC FAILURE AMONG WOMEN RECEIVING OPTION B+ IN KENYA (Poster Session P-P2)**
- 814 ART ADHERENCE AMONG PREGNANT AND NON-PREGNANT WOMEN IN SOUTH AFRICA AND UGANDA (Poster Session P-P2)**
- 815 EARLY CLINICAL EVENTS AFTER ART INITIATION IN PREGNANCY INFLUENCE VIRAL LOAD OUTCOMES (Poster Session P-P2)**
- 817 QUANTIFYING VISIT ADHERENCE IN PREGNANT WOMEN INITIATING ART IN SWAZILAND (Poster Session P-P2)**
- 818 TEXT MESSAGING FOR RETENTION IN PMTCT: A STEPPED-WEDGE CLUSTER-RANDOMIZED TRIAL (Poster Session P-P2)**
- 819 DOES QI IMPROVE PMTCT PROCESSES IN RURAL SOUTH AFRICA? A STEPPED-WEDGE CLUSTER RCT (Poster Session P-P2)**
- 820 IMPROVED POSTPARTUM HIV OUTCOMES AFTER CARE COORDINATION TEAM INTERVENTION (Poster Session P-P2)**
- 903 LIFE EXPECTANCY IN KEY POPULATIONS OF ADULTS WITH HIV IN THE US AND CANADA (Poster Session P-R1)**
- 911 HIV TRANSMISSION BETWEEN MEN WHO HAVE SEX WITH MEN AND HETEROSEXUAL WOMEN (Poster Session P-R2)**
- 917 HIV DIAGNOSES AMONG WOMEN IN RURAL VS NON-RURAL AREAS, UNITED STATES, 2010-2016 (Poster Session P-R2)**

- 920 HIV PREVALENCE AMONG WOMEN WHO EXCHANGE SEX RECRUITED IN 4 US CITIES, 2016 (Poster Session P-R2)**
- 921 TRANSACTIONAL SEX MEASUREMENT AND ASSOCIATION WITH HIV INCIDENCE AMONG WOMEN (Poster Session P-R2)**
- 922 VIOLENCE AND HIV RISK FACTORS AMONG WOMEN WHO EXCHANGE SEX FOR MONEY OR DRUGS (Poster Session P-R2)**
- 924 AN AGE-STRATIFIED RISK SCORE TO PREDICT HIV ACQUISITION IN YOUNG SOUTH AFRICAN WOMEN (Poster Session P-R2)**
- 933 NO CHANGE IN THE FREQUENCY OF AGE DISPARATE RELATIONSHIPS OR IMPACT ON HIV STATUS (Poster Session P-R2)**
- 942 CONCOMITANTLY SUPPRESSED SYSTEMIC AND IMBALANCED MUCOSAL IMMUNITY INCREASE HIV RISK (Poster Session P-R2)**
- 1059LB EARLY TERMINATION OF A PHASE 1 TRIAL OF TENOFOVIR DISOPROXIL FUMARATE VAGINAL RING (Poster Session P-T08)**
- 1072 HIV-1 RESERVOIR DYNAMICS IN MENOPAUSAL WOMEN DURING HORMONE THERAPY (Poster Session P-U2)**
- 1073 ASSOCIATION OF HIV STATUS WITH SEXUAL FUNCTION IN WOMEN AGED 45-60 (Poster Session P-U2)**
- 1074 MENOPAUSAL SYMPTOMS ARE ASSOCIATED WITH PSYCHOLOGICAL DISTRESS IN HIV+ WOMEN (Poster Session P-U2)**
- 1075 REPRODUCTIVE TRACT INFECTION RISK-BASED SCREENING FOR IUD INSERTION IN HIV+ WOMEN (Poster Session P-U2)**

TUESDAY, MARCH 6, 2018

- 67 CD8+ T CELL RESPONSES IN TREATED HYPERACUTE HIV INFECTION LIMIT HIV RESERVOIR SIZE (Oral Abstract Session O-05)**
- 246 INNATE LYMPHOID CELLS IN ENDOCERVICAL MUCOSA OF HIV INFECTED WOMEN (Poster Session P-B5)**
- 249 NEUTROPHIL EXTRACELLULAR TRAPS PREVENT HIV INFECTION IN THE GENITAL TRACT (Poster Session P-B5)**
- 271 MICROBIOME-ASSOCIATED EPITHELIAL DISRUPTION MODIFIES HIV ACQUISITION RISK IN WOMEN (Themed Discussion TD-06)**
- 361 SEX-BASED DIFFERENCES IN TRANSCRIPTOMIC PROFILES AND HIV RESERVOIR CORRELATES (Poster Session P-D07)**
- 464 HIGHER NRTI METABOLITE:ENDOGENOUS NUCLEOTIDE RATIOS IN OLDER HIV+ WOMEN ON TDF/FTC (Poster Session P-F3)**
- 466 CYP2B6 VARIANTS ALTER ETONOGESTREL PHARMACOKINETICS WHEN COMBINED WITH EFAVIRENZ (Poster Session P-F3)**
- 469 PHARMACOKINETICS (PK) OF ETHINYLESTRADIOL/LEVONORGESTREL WITH ATAZANAVIR/COBICISTAT (Poster Session P-F3)**
- 568 INCREASING POSITIVITY FOR NON-PLASMA SAMPLES USING THE ABBOTT REALTIME HIV-1 ASSAY (Poster Session P-J1)**
- 648 MR ELASTOGRAPHY DETECTS HIGHER LIVER FIBROSIS IN UNCONTROLLED HIV INFECTION (Poster Session P-K10)**

- 657 SUPPRESSIVE ART ASSOCIATED WITH EFFECTIVE TREATMENT OF CERVICAL PRECANCER (Poster Session P-L2)**
- 658LEEP TREATMENT OF EXTENSIVE CERVICAL INTRAEPITHELIAL NEOPLASIA IN HIV-INFECTED WOMEN (Poster Session P-L2)**
- 659 GENE PROFILE INFORMS HPV GRADE BUT NOT RELAPSE AFTER LEEP IN ART-SUPPRESSED HIV+HPV+ (Poster Session P-L2)**
- 660 IMPACT OF SINGLE-DOSE NANOVALENT VACCINE FOR HIV-HPV COINFECTION IN SOUTH AFRICA (Poster Session P-L2)**
- 661 COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING IN WOMEN WITH HIV IN SOUTH AFRICA (Poster Session P-L2)**
- 694 MYOCARDIAL STEATOSIS IN RELATION TO CARDIAC DYSFUNCTION AMONG WOMEN LIVING WITH HIV (Poster Session P-M6)**
- 695 SUB-CLINICAL CARDIAC SYSTOLIC DYSFUNCTION AMONG WOMEN LIVING WITH HIV (Poster Session P-M6)**
- 701 CONTRIBUTION OF HIV, HCV, AND VASCULAR RISK FACTORS TO PERIPHERAL ARTERIAL DISEASE (Poster Session P-M6)**
- 720 TDF PROPHYLAXIS FOR PMTCT OF HBV: EFFECT ON MATERNAL AND INFANT BONE MINERAL DENSITY (Themed Discussion TD-09)**
- 721 OPTION B-PLUS ART, PREGNANCY, LACTATION AND BONE HEALTH IN UGANDAN WOMEN (Themed Discussion TD-09)**
- 821 MATERNAL VIRAL LOAD SUPPRESSION AND VERTICAL TRANSMISSION IN MALAWI'S PMTCT PROGRAM (Poster Session P-P3)**
- 822 INFANT HIV-FREE SURVIVAL IN THE ERA OF "OPTION B+" SERVICES IN RURAL ZAMBIA (Poster Session P-P3)**
- 827 MATERNAL ANTI-HIV-1 NAB RESPONSE ASSOCIATES WITH TRANSMISSION AND INFANT MORBIDITY (Poster Session P-P3)**
- 903 LIFE EXPECTANCY IN KEY POPULATIONS OF ADULTS WITH HIV IN THE US AND CANADA (Themed Discussion TD-11)**
- 1043 PATTERNS OF ORAL PrEP ADHERENCE AND HIV RISK AMONG EASTERN AFRICAN WOMEN (Poster Session P-T06)**
- 1043 PATTERNS OF ORAL PrEP ADHERENCE AND HIV RISK AMONG EASTERN AFRICAN WOMEN (Themed Discussion TD-10)**
- 1046 PrEP AND EARLY ART FOR FEMALE SEX WORKERS IN SOUTH AFRICA: THE TAPS PROJECT (Themed Discussion TD-10)**
- 1046 PrEP AND EARLY ART FOR FEMALE SEX WORKERS IN SOUTH AFRICA: THE TAPS PROJECT (Poster Session P-T06)**
- 1047 HIGH PrEP UPTAKE AMONG KENYAN PREGNANT WOMEN OFFERED PrEP DURING ANTENATAL CARE (Poster Session P-T06)**
- 1047 HIGH PrEP UPTAKE AMONG KENYAN PREGNANT WOMEN OFFERED PrEP DURING ANTENATAL CARE (Themed Discussion TD-10)**
- 1048 PREDICTORS OF PrEP ELIGIBILITY AMONG AT-RISK WOMEN IN THE SOUTHERN UNITED STATES (Themed Discussion TD-10)**
- 1048 PREDICTORS OF PrEP ELIGIBILITY AMONG AT-RISK WOMEN IN THE SOUTHERN UNITED STATES (Poster Session P-T06)**
- 1049 RISK BEHAVIOR, PERCEPTION, AND REASONS FOR PrEP AMONG YOUNG AFRICAN WOMEN IN HPTN 082 (Themed Discussion TD-10)**
- 1049 RISK BEHAVIOR, PERCEPTION, AND REASONS FOR PrEP AMONG YOUNG AFRICAN WOMEN IN HPTN 082 (Poster Session P-T06)**

- 1050 HIV BIOMEDICAL PREVENTION AMONG US WOMEN: KNOWLEDGE, BELIEFS, AND PRACTICES (Poster Session P-T06)**
- 1051 DEPRESSION AND PrEP ADHERENCE AMONG HIGH-RISK HIV-UNINFECTED WOMEN IN EAST AFRICA (Poster Session P-T06)**
- 1063 PHASE 1 TRIAL TO ASSESS SAFETY AND ANTIVIRAL ACTIVITY OF MB66 VAGINAL FILM (Poster Session P-T09)**
- 1068 INTEGRATION OF FAMILY PLANNING INTO HIV CARE AND TREATMENT PROGRAM IN KENYA (Poster Session P-U1)**
- 1069 MISSED OPPORTUNITY FOR FAMILY PLANNING IN HIV-INFECTED WOMEN ON ART IN TOGO (Poster Session P-U1)**
- 1070 CONTRACEPTION AND PrEP IN SOUTH AFRICAN HAIR SALONS: OWNER, STYLIST, AND CLIENT VIEWS (Poster Session P-U1)**
- 1071 PREGNANCY INTENTION AND CONTRACEPTIVE USE IN MALAWI'S PMTCT PROGRAM (Poster Session P-U1)**
- 1088 POSTPARTUM MOBILITY AND TRANSFER OF CARE AMONG HIV+ WOMEN ON ART IN SOUTH AFRICA (Poster Session P-V1)**
- 1098 TRENDS IN UNSUPPRESSED HIV RNA AFTER LINKAGE TO CARE AMONG KEY POPULATIONS (Poster Session P-V1)**
- 1111LB SAME-DAY ART INITIATION ASSOCIATED WITH POORER RETENTION BUT HIGHER VIRAL SUPPRESSION (Poster Session P-V2)**

WEDNESDAY, MARCH 7, 2018

- 131 ITAP TRIAL: MATERNAL AND INFANT EFFICACY AND SAFETY RESULTS 12 MONTHS AFTER DELIVERY (Oral Abstract Session O-11)**
- 134 ACTG 5282: HPV TEST&TREAT VS CYTOLOGY-BASED CERVICAL CANCER PREVENTION IN HIV+ WOMEN (Oral Abstract Session O-11)**
- 138 SIMILAR CLINICAL OUTCOMES BETWEEN FORMULA AND BREASTFEEDING WOMEN IN PROMISE (Oral Abstract Session O-12)**
- 139 PROMISE TRIAL: RESULTS OF CONTINUED VS DISCONTINUED ART AFTER END OF BREASTFEEDING (Oral Abstract Session O-12)**
- 140 ART DETECTION AND RESISTANCE DURING VIRAEMIC EPISODES IN PREGNANCY AND BREASTFEEDING (Oral Abstract Session O-12)**
- 141 VAGINAL CONTRACEPTIVE HORMONE EXPOSURE PROFOUNDLY ALTERED BY EFV- AND ATV/R-BASED ART (Oral Abstract Session O-12)**
- 142LB RANDOMIZED TRIAL OF SAFETY OF ISONIAZID PREVENTIVE THERAPY DURING OR AFTER PREGNANCY (Oral Abstract Session O-12)**
- 143LB HIGH UPTAKE AND REDUCED HIV-1 INCIDENCE IN AN OPEN-LABEL TRIAL OF THE DAPIVIRINE RING (Oral Abstract Session O-13)**
- 144LB HIV INCIDENCE AND ADHERENCE IN DREAM: AN OPEN-LABEL TRIAL OF DAPIVIRINE VAGINAL RING (Oral Abstract Session O-13)**
- 148 EFFECT OF HIV SELF-TESTING ON SEXUAL PARTNER NUMBERS FOR ZAMBIAN FEMALE SEX WORKERS (Oral Abstract Session O-13)**
- 192 INFANT T/F HIV-1 FROM PERIPARTUM TRANSMISSION ARE RESISTANT TO MATERNAL PLASMA (Poster Session P-A4)**
- 267 PREGNANCY ASSOCIATED VAGINAL PROTEOME ALTERATIONS LINKED TO HIV ACQUISITION RISK (Poster Session P-B7)**

- 268 VAGINAL MICROBIOTA AND HIV ACQUISITION RISK AMONG AFRICAN WOMEN (Poster Session P-B7)
- 269 THE VAGINAL MICROBIOME IN PREGNANCY DIFFERS BY HIV STATUS, ART EXPOSURE, AND CLASS (Poster Session P-B7)
- 270 BACTERIAL VAGINOSIS ASSOCIATED MICROBES INDUCE ALTERED INNATE IMMUNE PROFILES (Poster Session P-B7)
- 271 MICROBIOME-ASSOCIATED EPITHELIAL DISRUPTION MODIFIES HIV ACQUISITION RISK IN WOMEN (Poster Session P-B8)
- 512 ADHERENCE IN EARLY VERSUS LATE ART INITIATION IN SUB-SAHARAN AFRICA (Poster Session P-H5)
- 522 NATURAL CONTROL OF HIV INFECTION IN A COHORT OF YOUNG WOMEN IN SOUTH AFRICA: HPTN 068 (Poster Session P-H7)
- 551 ARV DRUG USE AND HIV DRUG RESISTANCE AMONG YOUNG WOMEN IN SOUTH AFRICA (HPTN 068) (Poster Session P-I5)
- 672 EFFECTS OF ANTIRETROVIRAL THERAPY ON ALLELE-ASSOCIATED LIPOPROTEIN(A) LEVEL IN HIV (Poster Session P-M1)
- 678 ELEVATED MICROPARTICLE TISSUE FACTOR ACTIVITY AND CAROTID ARTERY PLAQUE IN HIV+ WOMEN (Poster Session P-M2)
- 680 PERIVASCULAR ADIPOSE INFLAMMATION AND MICROVASCULAR ENDOTHELIAL DYSFUNCTION IN HIV (Poster Session P-M2)
- 740 GESTATIONAL DIABETES IN WOMEN ON DOLUTEGRAVIR- OR EFAVIRENZ-BASED ART IN BOTSWANA (Poster Session P-N04)
- 744 FOOD INSECURITY IS ASSOCIATED WITH INCREASED INFLAMMATION AMONG HIV-POSITIVE WOMEN (Poster Session P-N04)
- 829 BIRTH DEFECTS AMONG OFFSPRING OF HIV-INFECTED & UNINFECTED WOMEN IN KAMPALA, UGANDA (Poster Session P-P4)
- 830 PRECONCEPTIONAL ART AND SPONTANEOUS PRETERM BIRTH IN AN URBAN ZAMBIAN COHORT (Poster Session P-P4)
- 831 PRENATAL ANTIRETROVIRAL EXPOSURE AND RISK OF LOW BIRTH WEIGHT IN LUSAKA, ZAMBIA (Poster Session P-P4)
- 832 PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY) (Poster Session P-P4)
- 833 HIGH RATES OF ADVERSE BIRTH OUTCOMES IN SYPHILIS & HIV COINFECTED WOMEN IN BOTSWANA (Poster Session P-P4)
- 834 PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV-INFECTED WOMEN (Poster Session P-P4)
- 835 INFLAMMATION IN HIV-INFECTED PREGNANT WOMEN IS ASSOCIATED WITH PRETERM BIRTH (Poster Session P-P4)
- 836 MARKERS OF PRETERM DELIVERY IN HIV+ WOMEN; ROLE OF PROTEASE INHIBITORS AND VITAMIN D (Poster Session P-P4)
- 884 ENGAGEMENT IN CARE AND INFANT HIV TESTING AMONG LOST TO FOLLOW-UP OPTION B+ PATIENTS (Poster Session P-Q8)
- 885LB OPTIMIZING EID: A CLUSTER-RANDOMIZED TRIAL OF THE HIV INFANT TRACKING SYSTEM IN KENYA (Poster Session P-Q8)
- 993 FEMALE SEX WORKERS' INTERPRETATIONS OF HIV SELF-TEST RESULTS: A PERFORMANCE STUDY (Poster Session P-S2)

- 1068 INTEGRATION OF FAMILY PLANNING INTO HIV CARE AND TREATMENT PROGRAM IN KENYA** (Themed Discussion TD-16)
- 1069 MISSED OPPORTUNITY FOR FAMILY PLANNING IN HIV-INFECTED WOMEN ON ART IN TOGO** (Themed Discussion TD-16)
- 1070 CONTRACEPTION AND PrEP IN SOUTH AFRICAN HAIR SALONS: OWNER, STYLIST, AND CLIENT VIEWS** (Themed Discussion TD-16)
- 1071 PREGNANCY INTENTION AND CONTRACEPTIVE USE IN MALAWI'S PMTCT PROGRAM** (Themed Discussion TD-16)
- 1131 HEALTHCARE PROVIDER TRUST LINKED TO LONG-TERM HIV VIRAL SUPPRESSION** (Poster Session P-V4)
- 1136 VIRAL SUPPRESSION AFTER INTERMITTENT VIREMIA: WOMEN'S INTERAGENCY HIV STUDY 1994-2015** (Poster Session P-V4)
- 1147 REPEAT HIV TESTING DURING PREGNANCY IN KENYA: AN ECONOMIC EVALUATION** (Poster Session P-W1)
- 1152 QUANTIFYING INDIRECT BENEFITS OF PREP: MODELING ANALYSIS OF ORAL PrEP IN ZIMBABWE** (Poster Session P-W1)

INDEX OF PRESENTING AUTHORS

The following index list presenting authors as of February 8, 2018. Changes to presenting authors after that date are not reflected. A complete list of all abstract authors can be found in the Abstract eBook.

-A-

- Aamer, Hadega 370
 Abdel-Mohsen, Mohamed 158, 259
 Abgrall, Sophie 728
 Aboud, Michael 508
 Abrams, Elaine J. 846
 Achwoka, Dunstan 1068, 1112
 Adamson, Blythe J. 1153
 Adu-Gyamfi, Clement G. 773
 Aepfelbacher, Julia A. 641
 Agnew-Brune, Christine 922
 Aguirre, Alfredo 461
 Ajaykumar, Abhinav 879
 Ajibola, Gbolahan 869
 Akapirat, Siriwat 306
 Akiyama, Hisashi 216
 Aldovini, Anna 20
 Aldrete, Sol 209
 Althoff, Keri N. 103, 903, 904
 Alvarez, Angeles 674
 Alvarez, Jean-Claude 1029
 Alvi, Raza M. 696, 697
 Ambia, Julie 1067
 Ambrose, Zandrea 562
 Amelio, Patrizia 774
 Anderson, Elizabeth M. 365
 Anderson, Motswedi 615, 616
 Andreatta, Kristen 506, 546
 Andrieux-Meyer, Isabelle 842
 Antonio, Marilia B. 796
 Apondi, Edith 852
 Arikawa, Shino 1069
 Arinaminpathy, Nimalan 56
 Armstrong, Abigail 263
 Arpadi, Stephen M. 854
 Arthos, James 50
 Asmuth, David M. 636
 Assoumou, Sabrina A. 991
 Atindaana, Edmond A. 154LB
 Atwine, Daniel W. 456
 Audsley, Jennifer 619
 Auld, Andrew F. 31
 Avihingsanon, Anchalee 718, 719
 Avila-Rios, Santiago 523, 954
 Avino, Mariano 540
 Avoundjian, Tigran 977
 Awadalla, Magid 695
 Ayieko, James 1090

-B-

- Bachmann, Nadine 41, 69LB
 Bacon, Oliver 93
 Badaro, Roberto 767
 Badia, Roger 385
 Baeten, Jared 143LB
 Baiyegunhi, Omolara 341

Baker, Jason V. 74, 104

- Balogun, Kayode 428
 Bandera, Alessandra 668
 Bandi, Kiran 749
 Banga, Riddhima 384
 Bar, Katharine J. 338
 Barouch, Dan 73LB
 Barrenas, Fredrik 233LB
 Bassett, Ingrid Valerie. 769, 1070
 Batista, Cynthia Julia B. 494
 Bauer, Anya 377
 Bauer, Rebecca 1034
 Baugher, Amy R. 1134
 Baum, Marianna K. 648
 Baxter, John D. 527
 Beard, Rachel S. 1142
 Becker, James T. 435
 Bedimo, Roger 132
 Bekker, Adrie 841
 Bekker, Linda-Gail 107
 Benbow, Nanette 957
 Benson, Eve-Marie A. 624
 Berenguer, Juan 607, 631, 646
 Bernal, Enrique 517
 Bertagnolli, Lynn N. 156
 Billings, Erik 168
 Billock, Rachael 959
 Bismut, Gilad 553
 Bjorkman, Pamela J. 4
 Blanc, François-Xavier 29LB
 Blanch-Lombarte, Oscar 559
 Blumenthal, Jill 1021
 Boerekamps, Anne 128
 Boescke, Christoph 129, 612, 9
 Boettiger, David C. 840
 Bohn, Jennifer 191LB
 Boltz, Valerie F. 536

Boon, Denali 587

- Borges, Christine M. 1033, 1108
 Boritz, Eli A. 5
 Boucau, Julie 331
 Boudreau, Carolyn 305
 Bourgi, Kassem 739
 Box, Helen Joan. 480
 Braun, Dominique L. 81LB
 Braunstein, Sarah L. 974
 Brennan, Alana T. 1106
 Brenner, Bluma G. 549, 946
 Breton, Yann 177
 Bridge, Sarah 783
 Brocca-Cofano, Egidio 235
 Brown, Todd T. 724
 Browne, Edward P. 395
 Browne, Sara H. 782
 Bruner, Katherine 151
 Buchbinder, Susan P. 87
 Bukusi, Elizabeth A. 11
 Bullo, Manuela 940

Buranapraditkun, Supranee 285

- Burgener, Adam 271
 Burgunder, Erin M. 476
 Burnett, Janet Chuyun. 44, 972
 Busch, Michael P. 575
 Buskin, Susan E. 1042
 Byambaa, Enkhmaa 672

-C-

- Cachay, Edward R. 609
 Cahn, Pedro 489
 Cai, Haotian 918
 Cai, Yanhui 327
 Calkins, Keri 652
 Callebaut, Christian 574
 Cameron, Mark 868
 Campbell, Thomas 133
 Campos, Nicole G. 661
 Cannizzo, Elvira S. 272
 Carlander, Christina 657
 Carney, Brandon W. 943
 Caro-Vega, Yanink 895
 Carr, Andrew 722, 723
 Carrico, Adam W. 519
 Castel, Amanda D. 892
 Castelnuovo, Barbara 1130
 Castillo-Mancilla, Jose R. 25
 Cavallari, Eugenio Nelson 698
 Cedarbaum, Emily 701
 Celani, Luigi 419
 Celum, Connie L. 1049
 Cerrone, Maddalena 28LB, 457
 Chaillon, Antoine 342, 1154
 Chaisson, Richard E. 1, 37LB
 Chaix Baudier, Marie-Laure 529, 1023
 Chakalisa, Unoda A. 926
 Chakrabarti, Lisa A. 225
 Chamie, Gabriel 778
 Chan, Man 137, 864
 Chan, Philip A. 1151
 Chan, Phillip 122, 448
 Chang, Ming 568
 Chapin-Bardales, Johanna 971
 Charpentier, Charlotte 547, 558
 Chaudhury, Chloe S. 643
 Chaudron, Sandra E. 947
 Chen, Bonnie 241
 Chen, Janet 843
 Cheng, Adam Z. 182LB
 Cheng, Liang 355
 Chernoff, Miriam 855
 Cheru, Lediya 734
 Chettimada, Sukrutha 218
 Cheu, Ryan 270
 Chi, Benjamin H. 822
 Chiasson, Mary Ann 909

- Chihana, Menard L. 1084,
1085
- Childs, Kathryn 647
- Chow, Dominic 707
- Chow, Felicia C. 412
- Chowdhury, Fatema Z. 279
- Chowdury, Pranesh P. 1126
- Christ, Frauke 187
- Christensen-Quick, Aaron
211
- Christopoulos, Katerina
A. 1128
- Clarridge, Katherine 334
- Clayton, Kiera L. 224LB
- Clemenzi-Allen, Angelo
A. 908
- Closson, Kalysha 894, 915,
1135
- Clutter, Dana S. 557
- Coelho, Lara 1110
- Cohen, Yehuda Z. 1062
- Cohn, Lillian B. 152LB
- Colasanti, Jonathan 1109
- Colby, Donn 626, 998
- Collins, Intira J. 853
- Colombo, Massimo G. 165
- Colon-Rivera, Krystal 281
- Coltart, Cordelia 47LB
- Copelyn, Julie 847
- Corbett, Elizabeth L. 770,
996
- Corey, Kathleen E. 9
- Corleis, Bjorn 242
- Cortés-Rubio, César N. 323
- Costagliola, Dominique 495
- Costiniuk, Cecilia 750
- Cotte, Laureen 590, 591, 632
- Council, Olivia 250
- Coutinho, Roel 106
- Covino, Daniela Angela 199
- Craig, Morgan L. 479
- Crane, Heidi M. 1144
- Crawford, Sue 172
- Cressey, Tim R. 471
- Cu-Uvin, Susan 1063
- Cuadros, Diego F. 43
- Custodio, Joseph M. 34
- Cuypers, Lize 582
- Cysique, Lucette A. 121
- D-**
- D'Souza, Gypsyamber 665
- Dadabhai, Sufia 832
- Dai, Weiwei 116
- Darling, Katharine 416
- Das, Jishnu 228
- Dasgupta, Sharoda 967
- Davis, Zachary 356
- Davy-Mendez, Thibaut
509, 762
- de Almeida, Sergio M. 451
- de Armas, Lesley R. 326
- De Cock, Kevin M. 935, 1113
- De Francesco, Davide 404
- de Montigny, Simon 1155
- De Zan, Valentina 446
- Deguit, Christian Deo T. 280
- Del Amo, Julia 931
- Del Prete, Gregory Q. 349
- del Rio, Carlos 60
- Delagreverie, Heloise M. 776
- Deleage, Claire 19
- Delelis, Olivier 544
- Derby, Nina 84
- Desir, Fidel A. 939, 1098
- Desrosiers, Vincent 178
- Dhumkupt, Adit 388
- Di Mascio, Michele 212
- Diez Fuertes, Francisco 214
- Dillon, Stephanie 239
- Dixon Diallo, Dázón 2
- Dobard, Charles 83
- Doblecki-Lewis, Susanne
1013
- Dombrowski, Julia C. 63,
1125
- Domínguez-Domínguez,
Lourdes 608
- Dooley, Kelly 33
- Döring, Matthias 295
- Doshi, Rupali K. 889
- Drain, Paul K. 715, 786
- Dryden-Peterson, Scott 649
- Dumchev, Kostyantyn 929
- Dumond, Julie B. 464
- Durand, Christine 166
- Dzialowy Adams, Nicole
1120
- E-**
- Eberhardt, Kirsten 802
- Ebrahimi, Diako 114
- Eckard, Allison R. 859
- Egan, James E. 1035
- Egger, Matthias 1099
- El-Far, Mohamed 709
- El-Sadr, Wafaa M. 1145, 1
- Elinav, Hila 200
- Eller, Michael A. 226
- Elliot, Emilie R. 467, 468,
469
- Emery, Ann 115
- Enns, Eva Andrea. 1132
- Erlandson, Kristine M. 755
- Eron, Joseph J. 502, 732
- Esber, Allahna L. 1124
- Esser, Stefan 691
- Evans, Ceri 873
- Evans, Emily 790
- Evans, Mary 966
- F-**
- Fabrizio, Claudia 184
- Fadrosh, Douglas 262
- Fairlie, Lee 851
- Falade-Nwulia, Oluwaseun
581
- Falcó, Vicenç 801
- Fanjul, Francisco 745
- Farhadian, Shelli 442
- Feaster, Daniel 975
- Feld, Jordan J. 164
- Fernández-Rodríguez,
Amanda 640
- Fichorova, Raina 942
- Finocchario Kessler, Sarah
885LB
- Fiorillo, Suzanne P. 655
- Fischinger, Stephanie 300
- Fishbein, Dawn 606
- Fisher, Bridget 266
- Flash, Moses J.E. 1157
- Fletcher, Courtney V. 27
- Flynn, Jacob 253
- Flynn, JoAnne L. 13
- Flynn, Patricia M. 109
- Fogel, Jessica M. 912
- Folkvord, Joy M. 236
- Force, Gilles 415
- Fourman, Lindsay T. 217
- France, Anne Marie 40, 937
- Franco, Ricardo A. 594
- Freeman, Michael L. 222
- Freiberg, Matthew 693
- Fujitnirun, Chris 781
- Fukuda, Hirofumi 194
- Fulcher, Jennifer A. 265
- Furrer, Hansjakob 799
- G-**
- Gabuzda, Dana H. 747
- Gaeta, Giovanni B. 622
- Gagliardini, Roberta 498
- Gaiha, Gaurav D. 232LB
- Gale, Michael 117
- Gandhi, Monica 24, 2
- Gandhi, Neel R. 57
- Ganesan, Anuradha 313
- Gangcuangco, Louie Mar
A. 738
- Gantenberg, Jason 1150
- Gantner, Pierre 346, 617
- Gaolathe, Tendani 97, 162,
1083
- Garber, David A. 82
- García, Federico 528
- Garcia Broncano, Pilar
340, 881
- García-Álvarez, Mónica 571
- Garcia-Fraile Fraile, Lucio
Jesus 634
- Garza, Rolando 452
- Gaseitsiwe, Simani 542
- Gatto, Greg 486
- Gaudinski, Martin R. 1061
- Gaur, Aditya 844
- Gelpi, Marco 706
- Genberg, Becky L. 888
- Generoso, Matthew 860
- Gerold, Jeffrey 309, 394
- Gessain, Antoine 53
- Ghulam-Smith, Melissa 827
- Gianella, Sara 195
- Gianotti, Nicola 493
- Gibb, Diana 23
- Gill, Alexander J. 126
- Girardi, Enrico 768
- Godinho-Santos, Ana 248
- Goga, Ameena 54
- Golden, Matthew R. 1019
- González Domenech,
Carmen M. 938
- Goodman-Meza, David 1031
- Gopalan, Bindu P. 535
- Gorbach, Pamina 969
- Gorman, Daniel 316
- Gornalusse, German G. 181
- Goswami, Ria 317
- Govender, Nelesh P. 788, 789
- Grabowski, Mary K. 921
- Graham, Susan M. 414
- Grant, Alison 8

- Gras, Julien 585
 Grebe, Eduard 1002, 1003
 Greenblatt, Ruth 462
 Greene, Justin 118
 Greene, Sharon A. 658
 Grey, Jeremy A. 978
 Griffith, David C. 1094
 Grinsztejn, Beatriz 30LB
 Gross, Robert 756
 Grulich, Andrew 88
 Guaraldi, Giovanni 759
 Guha, Debjani 453
 Günthard, Huldrych F. 1
 Gupta, Amita 142LB
 Gupta, Phalguni 399
 Gupta-Wright, Ankur 38LB, 777
- H-**
- Haas, Andreas D. 1082
 Haas, David 402
 Haberer, Jessica E. 512
 Haeri Mazanderani, Ahmad 826
 Haim, Hillel 294
 Halkett, Megan 243
 Hall, Matthew D. 960
 Hammoud, Dima A. 440, 441LB
 Hamzah, Lisa 731
 Han, Xiaoxu 945
 Handanagic, Senad 920
 Handoko, Ryan C. 208
 Hanna, David B. 78
 Hansoti, Bhakti 934, 987
 Hany, Laurent 179
 Harris, Tiffany G. 823
 Hataye, Jason M. 336
 Hawkins, Kellie L. 800
 Heffron, Renee 45
 Hellmuth, Joanna 445
 Henrich, Timothy J. 391
 Hensley-McBain, Tiffany 18, 256
 Hermans, Lucas E. 1118
 Higgins, Dana 593
 Hileman, Corrilynn O. 671
 Hill, Christopher P. 101
 Hiransuthikul, Akarin 979
 Hitti, Jane 811
 Ho, Ya-Chi 153
 Hodder, Sally L. 163
 Hoenigl, Martin 763
 Hoffman, Risa M. 138, 812
 Hoffmann, Chris 902
 Hoffmann, Christian 424
 Hogan, Vicki 976LB
 Holland, David P. 1010
 Holmes, Charles B. 808
 Hoornenborg, Elske 1026
 Hoots, Brooke 910
 Horberg, Michael A. 1127
 Horsburgh, Bethany A. 366
 Howard, Andrea 899
 Howell, Bonnie J. 383
 Hsiao, Nei-Yuan M. 990
 Hsieh, Yu-Hsiang 578
 Hsue, Priscilla 79, 692
 Hua, Stephane 358
 Huang, Ya-Lin A. 1032
 Hudson, Parker 537
- Huhn, Gregory D. 499
 Huppeler Hullsiek, Kathy 791
- I-**
- Imaz, Arkaitz 478
 Innes, Steve 857
 Inzaule, Seth C. 534
 Irungu, Elizabeth M. 1053
 Irvin, Risha 605
 Ita, Sergio 556
 Itell, Hannah 871
 Iwasa, Janet 1
 Iyun, Victoria 861
- J-**
- Jacobs, Petra 1107
 Jacobson, Karen R. 779
 Jaffe, Harold W. 12
 Jagodzinski, Linda 573
 Jain, Mamta K. 576, 621, 753
 Jao, Jennifer 874
 Jarvis, Joseph N. 887
 Jenness, Samuel 1149
 Jennewein, Madeleine 297
 Jesson, Julie 849
 Jewell, Britta 1005
 Jhaveri, Ravi 9
 Jin, Steven W. 202
 Johnson, Leigh F. 147
 Jones, Bradley R. 372
 Jordan, Michael R. 541
 Jordan-Paiz, Ana 180
 Joseph, Rachael 146, 985
 Joseph Davey, Dvora 1111LB
 Jourdain, Gonzague 131, 720
 Justice, Amy C. 92
 Justman, Jessica E. 7
- K-**
- Kadelka, Claus 291
 Kadima, Etienne 927
 Kagaayi, Joseph 90
 Kann, Gerrit 795
 Kant, Sanket 227
 Kaplan, Alyson 642
 Karsten, Christina B. 301
 Kassaye, Seble 1050
 Katlama, Christine 310
 Kattakuzhy, Sarah 589
 Katz, David A. 1024
 Katz, Ingrid 1139
 Kaur, Jasmine 321
 Kearney, Mary F. 70
 Keating, Sheila M. 392, 393
 Keiser, Olivia 579
 Keller, Marla J. 1059LB
 Kelley, Colleen F. 1055
 Kelley, Mark D. 434
 Kelly, Sean G. 676
 Kerani, Roxanne P. 932
 Kessler, Peter A. 828
 Khan, Shaukat 1143
 Khoo, Saye 807
 Kim, H. Nina 610
 Kim, Hae-Young 925
 Kimani, Makobu 1040
 Kinuthia, John 813, 1047
 Kirchhoff, Frank 1
 Kiser, Jennifer J. 465
 Kityo, Cissy 500, 531
- Clatt, Nichole 64
 Klevens, Monina 577
 Klingler, Jérôme 230
 Kluberg, Sheryl 1079
 Knudsen, Andreas D. 76
 Koay, Wei Li A. 867
 Koehn, Josefina 487
 Koenig, Serena 59
 Kohlmeier, Alison S. 207, 477
 Kok, Yik Lim 332
 Kornilova, Marina 961
 Kostman, Jay 600
 Kovari, Helen 670
 Krakower, Douglas 1018
 Krogstad, Paul 845
 Kroon, Eugène 51
 Kuang, Xiao Mei T. 382
 Kumar, Amit 192
 Kumwenda, Newton I. 981
 Kuo, Hsiao-Hsuan 368
 Kuo, Irene 1030
 Kuriakose, Safia S. 543
 Kuritzkes, Daniel R. 160
 Kusejko, Katharina 169
 Kwaa, Abena 283
 Kwara, Awewura 837
 Kwarisiima, Dalsone 145
 Kwiek, Jesse 176
 Kwong, Peter D. 98
- L-**
- Labhardt, Niklaus D. 94
 Lacombe, Karine 602
 Laeyendecker, Oliver 586, 1001
 Lai, Stephen 17
 Lake, Jordan E. 736, 737
 Lam, Jennifer O. 601
 Lambert, Sidonie 518
 LaMere, Sarah 333
 Landes, Megan 821
 Lange, Camille 444
 Langwenya, Nontokozo 817, 1075
 Lapadula, Giuseppe 418
 Larson, Derek T. 705
 Latini, Alessandra 663
 Laumaea, Annemarie 183
 Lawino, Anna 1064
 Le, Catherine N. 337
 Leal, Lorna 311
 Leddy, Anna 744
 Lee, Guinevere Q. 339, 379
 Lee, Sulgi 381
 Leigh Brown, Andrew 951
 Lemons, Ansley 965
 Levy, Matthew E. 690
 Levy, Yves 308
 Li, Jonathan Z. 229
 Li, Linghua 794
 Li, Sam 255
 Lin, Juan 678
 Lin, Nina 219, 427
 Lin, Timothy 999, 1000
 Lippman, Sheri A. 149
 Little, Kristen 1148
 Little, Susan J. 6
 Liu, Qingbo 296LB
 Liu, Shan-Lu 201
 Lo Re, Vincent 620

- Loeliger, Kelsey B. 1133
 Lofano, Giuseppe 312
 Lok, Judith J. 513
 Lu, Wei 520
 Luban, Jeremy 220
 Luczkowiak, Joanna 188
 Luevano, Jesus M. 261
 Lyss, Sheryl 970
- M-**
 Ma, Qing 473
 Macatangay, Bernard J. 363
 MacDonald, David 746
 Machado, Viviane 373
 Mahale, Parag 667
 Mallard, Jaclyn 421
 Mallon, Patrick W.G. 677LB, 80
 Mancarella, Antonio 171
 Manickam, Cordelia 221
 Mankowski, Joseph 124
 Manne-Goehler, Jennifer 712, 754
 Manzardo, Christian 496
 Marbaniang, Ivan 742
 Marcus, Julia L. 1011
 Margot, Nicolas A. 560
 Markowitz, Martin 89LB
 Marks, Kristen M. 604
 Marquez, Carina 766
 Marra, Christina 798
 Martin, Alyssa R. 205
 Martin, Malcolm 49
 Martin-Gayo, Enrique 15
 Martinelli, Elena 319LB
 Martinez, Miguel Angel 639
 Martinez-Picado, Javier 386
 Martinson, Neil A. 58
 Masamaro, Kenneth 1093
 Masciotra, Silvina 569, 570
 Massanella, Marta 135, 347
 Massud, Ivana 85
 Mastorrosa, Ilaria 413, 633
 Matsushita, Shuzo 289
 Matthews, Lynn T. 814
 Matthews, Randolph P. 26
 Matus-Nicodemos, Rodrigo 186
 Maughan, Robert T. 675
 Mayer, Kenneth H. 1014
 Mayer, Stockton 497
 McCauley, Sean 21
 McClean, Mitchell R. 688
 McCluskey, Suzanne 530
 McComsey, Grace A. 735
 McConnachie, Lisa 488
 McDonnell, Wyatt J. 743
 McFall, Allison M. 964
 McGowan, Ian 481
 McKellar, Mehri 1041
 McLaren, Paul J. 14
 McLaughlin, Angela 953
 McMahon, Deborah 72
 McVea, David 952
 Meffert, Susan M. 752
 Mehraj, Vikram 254
 Mehta, Nickita 302
 Mehta, Sanjay R. 760
 Meissner, Eric G. 637
 Mellgren, Åsa 422
 Meloni, Seema T. 538
- Merchante, Nicolás 644
 Merlini, Esther 449
 Metsch, Lisa 1078
 Michel, Kate Gisella. 1131
 Mikati, Tarek 592, 613
 Milanini, Benedetta 410
 Miller, Melissa 1137
 Miller, William C. 1097
 Mills, Anthony 504, 730
 Misra, Kavita 1036
 Mitchell, Brooks I. 238
 Mitchell, Charles D. 882
 Mitchell, Julie 863
 Mitsch, Andrew John. 930
 Mmalane, Mompati Oganne. 936
 Mmasa, Keolebogile N. 740
 Mody, Aaloke 900
 Mohr, Erika K. 780
 Molina, Jean-Michel 22
 Molsberry, Samantha A. 408
 Monnin, Audrey 878
 Monroe, Anne K. 1123
 Montoya, Jessica L. 411
 Morgan, Ethan 1012
 Moron-Lopez, Sara 501
 Morris, Sheldon 1027
 Morroccchi, Elena 866
 Mosepele, Mosepele 711
 Mouhanna, Farah 982
 Mourez, Thomas 625
 Moyo, Sikhulile 552, 941
 Mudd, Joseph 215
 Mugavero, Michael J. 62
 Mugo, Nelly R. 108
 Mugwanya, Kenneth K. 1054
 Muiru, Anthony 729
 Mukandavire, Zindoga 1152
 Mukerji, Shibani S. 123
 Mukui, Irene 1081
 Mukumbwa-Mwenechanya, Mpande 1129
 Mulka, Larissa V. 944
 Murray, Alexandra J. 375
 Murray, Daniel D. 318
 Musick, Andrew 378
 Musoke, Philippa 829
 Mussi-Pinhata, Marisa M. 880
 Mustanski, Brian 906
 Mutch, Sarah 1056
 Mwimanzi, Francis 198
 Mwinnyaa, George 933
 Myer, Landon 140, 702, 875
- N-**
 Nabeta, Henry 1058
 Nabwire, Florence 721, 872
 Nakanjako, Damalie 797
 Nakasujja, Noeline 423
 Nakiyingi, Lydia 771
 Namazi, Golnaz 231
 Nash, Denis 1104
 Nayrac, Manon 240
 Ndhlovu, Zaza 67
 Ndolo, Samuel 883
 Neary, Megan 466
 Neff, Charles P. 252
 Neilan, Anne M. 1146
 Nel, Annalene 144LB
- Ngugi, Evelyne 848
 Nguyen, Huyen 948
 Nguyen, Nadia 923
 Nguyen, Thuy Thi T. 545
 Nicol, Melanie 474
 Niembro-Ortega, Maria D. 793
 Niessl, Julia 234
 Nijhawan, Ank E. 598
 Nijmeijer, Bernadien 588
 Nir, Talia M. 432
 Nodder, Sarah B. 190
 Noël-Romas, Laura 1057
 Noguera-Julian, Marc 555
 North, Crystal 748
 Noto, Alessandra 155, 284
 Novitsky, Vlad 950
 Nowak, Rebecca G. 980
 Nsanzimana, Sabin 511
 Nuwagaba-Biribonwoha, Harriet 986, 1077
 Nwangwu-Ike, Ndidi 917
- O-**
 O'Connor, Erin 431
 O'Meara, Tess 417
 Odayar, Jasantha 815
 Odeny, Thomas A. 818
 Odorizzi, Pamela M. 278
 Odoyo-June, Elijah 1066
 Ojoo, Sylvia 1092
 Okoye, Afam 350
 Oldenburg, Catherine E. 148
 Onorato, Lorenzo 638
 Opoku, Jenevieve 913
 Orkin, Chloe 159, 491
 Orrell, Catherine 515
 Ortblad, Katrina F. 993
 Ortiz, Alexandra 273
 Osei-Kuffour, Edmund 189
 Osetinsky, Brianna 717
 Oster, Alexandra M. 911
 Overbaugh, Julie 10
 Owen, Andrew 484
- P-**
 Paengsai, Ninutcha 741
 Pahwa, Rajendra 683
 Pahwa, Savita 213
 Palella, Frank J. 901
 Palmer, Sarah 362
 Palumbo, Philip J. 533
 Paneerselvam, Nandagopal 293, 629
 Panneer, Nivedha 955
 Papasavvas, Emmanouil 659
 Parczewski, Milosz 583
 Parkes-Ratanshi, Rosalind M. 1122
 Patel, Anar S. 1048
 Patel, Eshan Uday. 1065
 Patel, Rupa Rajesh. 1008
 Patel, Viraj V. 1016
 Pathela, Preeti 1007
 Pavlakis, George N. 353LB
 Pegu, Amarendra 113LB
 Pérez-Valero, Ignacio 425
 Perriat, Delphine 1138
 Peterson, Tess 679
 Pett, Sarah 784
 Pettifor, Audrey 992

- Peytavin, Gilles 810
 Pham, Hanh T. 548
 Pham, Phuong 173
 Phillips, Tamsin Kate. 1088
 Phuphuakrat, Angsana 689
 Pierone, Gerald 510
 Pierre, Samuel 713
 Pinnetti, Carmela 447
 Pino, Maria 348, 376
 Piselli, Pierluca 651
 Piske, Micah 876
 Podany, Anthony 455
 Pohlmeyer, Christopher 244
 Pollack, Todd 516
 Pollard, Alex 995
 Ponte, Rosalie 371
 Poschman, Karalee 526
 Post, Frank 490
 Post, Wendy 77
 Poteat, Tonia 1044, 1045, 2
 Poveda, Eva 170
 Prendergast, Andrew 52
 Presti, Rachel 274
 Price, Joan T. 830
 Proust, Alizé 454
 Provost, Joel 193
 Purdy, Julia 700
 Puttkammer, Nancy 1086
 Pyra, Maria 809, 1043
- R-**
 Rabie, Helena 161, 838
 Rabkin, Miriam 710
 Radix, Asa 1025
 Radtke, Kendra K. 401
 Radwan, Daniel 597
 Ragonnet-Cronin, Manon 42, 949
 Rahman, Mohammad Arif 287
 Rajasingham, Radha 785
 Rajoli, Rajith Kumar Reddy 458, 485
 Rallón, Norma 197
 Ram, Daniel 245
 Ramos Muniz, Cláudia Priscila 174
 Rappocciolo, Giovanna 704
 Rashbaum, Bruce 492
 Rasmussen, Thomas Aagaard. 71
 Ravimohan, Shruthi 775
 Ready, Erin 897
 Redd, Andrew D. 288
 Reddy, Krishna P. 1117LB
 Registre, Ludy 292
 Reid, William 450
 Reidy, William J. 884
 Reiff, Julie 1095
 Remien, Robert H. 65
 Restar, Arjee J. 1017
 Revollo, Boris 666
 Reynolds, Helen 470
 Rhein, Joshua 36
 Richter, Enrico 286
 Risher, Kathryn Amanda. 886
 Ritchie, Anne M. 727
 Rivero-Juárez, Antonio 603
 Robertson, Kevin 403LB
 Rocafort, Muntas 260
- Rockstroh, Jürgen K. 618
 Rodgers, Mary 628
 Rodriguez-Garcia, Marta 249
 Rojas, Sarah 599
 Ronit, Andreas 765
 Rosales Del Real, Ofelia M. 662
 Rosen, Elias 475
 Rosen, Sydney 1102, 1103, 1140, 1141
 Rosenbloom, Daniel S. 344
 Roy, Monika 1119
 Rubin, Leah H. 420
 Rubio Garrido, Marina 566
 Rusie, Laura 1087
 Rutishauser, Rachel L. 277
 Ryan, Pablo 9
 Ryom, Lene 75
- S-**
 Sabin, Caroline 102, 733
 Sacha, Jonah 48
 Sachathep, Karampreet 614
 Sacktor, Ned 405, 406, 407, 438
 Sadanand, Saheli 299
 Sadder, Liane S. 870
 Saeed, Sahar 611
 Sailasuta, Napapon 437
 Saito, Suzue 1114
 Salahuddin, Syim 367
 Salazar-Austin, Nicole 32
 Salazar-Vizcaya, Luisa 130
 Salpini, Romina 623
 Samaneka, Wadzanai 35
 Samboju, Vishal 430
 Samri, Assia 369
 Sanford, Ryan 120
 Sanmartí, Montserrat 409
 Saravanan, Shanmugam 580
 Sarca, Anamaria D. 185
 Saroli Palumbo, Chiara 645
 Saunders, John 1039
 Scarsi, Kimberly K. 141
 Schacker, Timothy 66
 Scheer, Susan 1100
 Scherret, Alexandra 554
 Schillinger, Julia A. 105
 Schleimann, Mariane H. 315
 Schneider, Jennifer M. 264
 Schreiber-Stainthorp, William T. 429
 Schuetz, Alexandra 307
 Schuster, Christopher 699
 Sconza, Rebecca 806
 Scott, Hyman 61, 1015
 Scully, Eileen P. 361
 Seaberg, Eric C. 764
 Sekhar, Rajagopal V. 757
 Sengayi, Mazvita 650
 Serra Peinado, Carla 390
 Serrano-Villar, Sergio 275
 Sette, Paola 210
 Shah, Spandan 282
 Shah, Swati 426
 Shan, Liang 322
 Shan, Zhilei 708
 Shapiro, Adrienne E. 772
 Shapiro, Roger L. 136
- Sharaf, Radwa 364
 Sharp, Alana 1158
 Sharp, Katie 1156
 Shava, Emily 833
 Shen, Jing 858
 Sheth, Anandi N. 820
 Shiau, Stephanie 862
 Shivakoti, Rupak 835
 Short, Charlotte-Eve S. 269
 Shover, Chelsea L. 968, 1009
 Sibanda, Euphemia 150LB
 Sibiude, Jeanne 804, 805
 Siegler, Aaron J. 1022LB
 Sigel, Keith M. 664, 761
 Siika, Abraham 896
 Sikazwe, Izukanji 1105
 Sikombe, Kombatende 1091
 Silverman, Michael 963
 Simonetti, Francesco R. 396
 Sinharay, Sanhita 345
 Sivay, Mariya V. 522
 Slyker, Jennifer 865
 Smith, Bryan 433
 Smith, Dawn K. 86, 1052
 Smith, James M. 203
 Smith, Renee 877
 Smith, Shayla 825
 Solomon, Sunil S. 1101LB
 Soriano-Sarabia, Natalia 354
 Sousa, Ana E. 237
 Spector, Stephen A. 687
 Spence, Amanda B. 1136
 Spinelli, Matthew A. 1028
 Spivak, Adam M. 324, 389
 Springer, Sandra 96
 Spudich, Serena S. 119
 Srinivas, Nithya 472
 Srinivasa, Suman 685, 686
 Srinivasan, Sujatha 268
 Ssebambulidde, Kenneth 787
 Stafylis, Chrysovalantis 563
 Starke, Carly Elizabeth C. 276
 Stecher, Melanie 524
 Steele, Sarah Jane 1089
 Stekler, Joanne 565
 Stella-Ascariz, Natalia 758
 Stephenson, Kathryn E. 1004
 Stone, Lauren 681
 Stone, Mars 397, 567
 Stradling, Clare 703
 Strain, Jeremy 439
 Strbo, Natasa 246
 Streeck, Hendrik 521
 Strongin, Zachary 335
 Stumpf, Megan M. 298
 Sudjaritruk, Tavittha 850, 856
 Sun, Jing 890, 891
 Svedhem-Johansson, Veronica 893
 Swanstrom, Adrienne E. 167
- T-**
 Tadesse, Birkneh T. 539
 Taha, Taha E. 139
 Takle, Jeff 989
 Tan, Nicholas 660
 Tang, Xiaoli 325


- Tanner, Mary 962
 Tariq, Shema 1073, 1074
 Tatham, Lee M. 482, 483
 Tawakol, Ahmed 684LB
 Taylor, Bryn C. 258
 Taylor, Ian A. 100
 Taylor, Kirk A. 673
 Teasdale, Chloe A. 839, 898
 Telwatte, Sushama 320
 Tembo, Taniya 1076
 Teran, Richard A. 997
 Thao, Vu Phuong. 525
 Thiébaut, Rodolphe 507
 Thielman, Nathan 503
 Thienemann, Friedrich 714
 Thin, Kyaw 91
 Thindwa, Deus 1071
 Thirumurthy, Harsha 95
 Thomas, Réjean 1037, 1038
 Thrift, Aaron P. 653, 654
 Thudium, Rebekka F. 751
 Tiraboschi, Juan M. 726
 Tobin, Nicole 267
 Tolstrup, Martin 359
 Tomezko, Phillip 330
 Torgersen, Jessie 669
 Torian, Lucia V. 973
 Toribio, Mabel 694
 Torres, Berta 314
 Torres, Thiago S. 1020
 Touloumi, Giota 1096
 Trichavaroj, Rapee 343
 Trkola, Alexandra 1
 Trunfio, Mattia 443
 Truong, Hong-Ha M. 984
 Trypsteen, Wim 329
 Tsibris, Athé 1072
 Tully, Damien C. 584
 Turan, Janet M. 1147
- U-**
- Uldrick, Thomas S. 656LB
 Underwood, Jonathan 125, 436
 Urasa, Peris 983
- V-**
- van Bilsen, Ward P.H. 905
 Van Duyne, Rachel 111
 Van Hecke, Clarissa 196
 Vandormael, Alain 46, 988
 Vareil, Marc 627
 Vargas, Benni S. 328
 Vasan, Sandhya 204
 Velásquez, Gustavo E. 39LB
 Velloza, Jennifer 463, 1051
 Venter, Willem Daniel Francois. 1046
 Vestad, Beate 257
 Viani Puglisi, Elisabetta 99
 Vibholm, Line K. 357
- Villinge, Francois 1060LB
 Visseaux, Benoit 958
 Vo, Quynh 595
 Vos, Alinda 716
 Votteler, Joerg 3
 Vućicević, Katarina 460
- W-**
- Wagner, Thor A. 351
 Waitt, Catriona 55
 Walimbwa, Stephen Ian. 459
 Walker-Sperling, Victoria Elizabeth K. 206
 Wang, Dan 680
 Wang, Qi 247
 Wang, Ruibin 635
 Wang, Zheng 68
 Wang, Zheng 400
 Watson, Meg 907
 Webb, Nicholas E. 290
 Weinberg, Adriana 836
 Weinheimer, Steven 561
 Weiser, John 1080
 Weiss, Helen A. 110
 Weiss, Kevin 1006
 Wertheim, Joel O. 956
 Wesolowski, Laura 572
 White, Kirsten Lofgren. 532
 White, Lisa Diane 2
 Whitney, James 157
 Wiche Salinas, Tomas Raul 682
 Wijting, Ingeborg 505, 725
 Wiley, Dorothy Joann. 1116
 Wilkin, Timothy 134
 Williams, Darlisha A. 792
 Williams-Nguyen, Jessica 630
 Winchester, Nicole Eve. 514
 Winston, Jennifer 831
 Wirtz, Andrea L. 994
 Withers, Keenan 564
 Wittner, Melanie 387
 Wonderlich, Elizabeth R. 398
 Wu, Helen 352
 Wyles, David L. 127
- Y-**
- Yapa, H. Manisha Namalee. 819
 Yende-Zuma, Nonhlanhla 924
 Youn, Christine 223
 Yu, Wen-Han 303, 304
- Z-**
- Zaikos, Thomas D. 374LB
 Zangerle, Robert 596
 Zarwell, Meagan 914
 Zash, Rebecca 803, 834
 Zhang, Peng 16LB
 Zhang, Yinfeng 550, 551
 Zhao, Connie Ann. 112
 Zhong, Yaoyu 1121
 Zhou, Shuntai 175LB
 Zielinski-Gutierrez, Emily C. 928

Conference Schedule

	Sunday, March 4, 2018	Monday, March 5, 2018	Tuesday, March 6, 2018	Wednesday, March 7, 2018
8:30 AM		PLENARY SESSION Auditorium/Hall C/Balcony 8:30 AM THE EARLY DAYS OF AIDS: LOOKING BACK AND THINKING AHEAD 9:00 AM PATHOGENESIS OF TUBERCULOSIS AND VACCINE PREVENTION	PLENARY SESSION Auditorium/Hall C/Balcony 8:30 AM THE VAGINAL MICROBIOME AND ACQUISITION OF HIV INFECTION 9:00 AM ADDRESSING MENTAL HEALTH: A CRUCIAL COMPONENT TO ENDING THE HIV EPIDEMIC	PLENARY SESSION Auditorium/Hall C/Balcony 8:30 AM GROWING UP WITH HIV 9:00 AM ARE WE ON TRACK TO "BEND AND END" THE HIV EPIDEMICS?
9:00 AM	PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES 9:00 AM–12:15 PM Ballroom BC			
9:30 AM		NETWORKING BREAK 9:30 AM–10:00 AM	NETWORKING BREAK 9:30 AM–10:00 AM	NETWORKING BREAK 9:30 AM–10:00 AM
10:00 AM	LUNCH & MARTIN DELANEY PRESENTATION WOMEN IN RESEARCH: SCIENCE IS BETTER WHEN WOMEN ARE REPRESENTED 12:30 PM–1:30 PM Ballroom BC	CONCURRENT ORAL ABSTRACT SESSIONS 10:00 AM–12:00 PM 0-1 VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS <i>Ballroom A</i> 0-2 ART: NEW DATA AND NEW INSIGHTS <i>Auditorium</i> 0-3 ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION <i>Ballroom C</i> 0-4 SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES <i>Ballroom B</i>	CONCURRENT ORAL ABSTRACT SESSIONS 10:00 AM–12:00 PM 0-5 THE HIV RESERVOIR AND VIRAL REPLICATION <i>Auditorium</i> 0-6 NON-AIDS COMPLICATIONS <i>Ballroom A</i> 0-7 OF MICE, MONKEYS, AND MEN: PrEP FROM PRECLINICAL TO POPULATION LEVEL IMPACT <i>Ballroom B</i> 0-8 90:90:90: PROGRESS, CHALLENGES, AND NEW TOOLS <i>Ballroom C</i>	CONCURRENT ORAL ABSTRACT SESSIONS 10:00 AM–12:00 PM 0-9 HIV REPLICATION, INHIBITION, AND RESTRICTION <i>Ballrm. A</i> 0-10 THE CNS RESERVOIR(S), REBOUND, AND BRAIN INJURY <i>Ballroom B</i> 0-11 HEPATITIS C VIRUS/HIV-ASSOCIATED MALIGNANCIES <i>Room 304-306</i> 0-12 CRITICAL ISSUES IN WOMEN'S HEALTH AND EARLY TREATMENT OF PEDIATRIC HIV INFECTION <i>Ballroom C</i> 0-13 IMPROVING USE OF THE TOOLS WE HAVE: HIV TESTING AND VAGINAL RINGS <i>Auditorium</i>
11:00 AM		LUNCH 12:00 PM–1:30 PM	LUNCH 12:00 PM–1:30 PM	LUNCH 12:00 PM–1:30 PM
12:00 PM				
1:30 PM		CONCURRENT THEMED DISCUSSIONS 1:30 PM–2:30 PM TD-1 EARLY EVENTS: METHODS AND MECHANISMS <i>Ballroom A</i> TD-2 CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION <i>Room 304-306</i> TD-3 THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA <i>Auditorium</i> TD-4 HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY? <i>Ballroom C</i> TD-5 HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE <i>Ballroom B</i>	CONCURRENT THEMED DISCUSSIONS 1:30 PM–2:30 PM TD-6 ROLE OF THE MICROBIOME IN HIV INFECTION (AND VICE-VERSA) <i>Room 304-306</i> TD-7 AGING BRAIN AND HIV: BEFORE AND AFTER <i>Room 302</i> TD-8 ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF? <i>Ballroom C</i> TD-9 BONES OF CONTENTION <i>Auditorium</i> TD-10 EXPANDING PrEP IN WOMEN <i>Ballroom A</i> TD-11 THE PERSISTENT CHALLENGE OF LATE PRESENTATION AND MORTALITY <i>Ballroom B</i>	CONCURRENT THEMED DISCUSSIONS 1:30 PM–2:30 PM TD-12 T AND B CELL INTERACTIONS IN LYMPH NODES <i>Ballroom A</i> TD-13 BIG APPLICATIONS OF LITTLE RNAs <i>Ballroom C</i> TD-14 OUTCOMES OF PREVENTION STRATEGIES FOR CRYPTOCOCCAL MENINGITIS <i>Ballroom B</i> TD-15 PHYLOGENETICS FOR PUBLIC HEALTH INTERVENTION <i>Rm. 302</i> TD-16 CLOSING THE GAP: INTEGRATION OF FAMILY PLANNING INTO HIV PREVENTION AND CARE <i>Room 304-306</i>
2:00 PM	CONCURRENT WORKSHOPS 2:00 PM–4:00 PM CLINICAL TRIAL DESIGN AND ANALYSIS <i>Ballroom A</i> FRONTIERS IN LABORATORY SCIENCE <i>Rm 304-306</i> INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS C Ballroom BC			
2:30 PM		POSTER SESSIONS 2:30 PM–4:00 PM Basic Science (Posters 167-454) <i>Poster Hall A</i> Clinical (Posters 455-885LB) <i>Poster Hall D</i> Epidemiology/Public Health (Posters 886-1158) <i>Poster Hall B</i>	POSTER SESSIONS 2:30 PM–4:00 PM Basic Science (Posters 167-454) <i>Poster Hall A</i> Clinical (Posters 455-885LB) <i>Poster Hall D</i> Epidemiology/Public Health (Posters 886-1158) <i>Poster Hall B</i>	POSTER SESSIONS 2:30 PM–4:00 PM Basic Science (Posters 167-454) <i>Poster Hall A</i> Clinical (Posters 455-885LB) <i>Poster Hall D</i> Epidemiology/Public Health (Posters 886-1158) <i>Poster Hall B</i>
3:00 PM				
4:00 PM		CONCURRENT SYMPOSIA 4:00 PM–6:00 PM S-1 STOP IT NOW: TARGETING EARLY INFECTION EVENTS <i>Ballrm. A</i> S-2 BREAST IS BEST, BUT IT'S A VIRAL MILKSHAKE! <i>Room 304-306</i> S-3 OBSTACLES TO THE GLOBAL CONTROL OF TUBERCULOSIS <i>Ballrm. C</i> S-4 STRATEGIES FOR IMPROVING THE US CARE CASCADE: CONFRONTING A FRAGMENTED HEALTH SYSTEM <i>Ballroom B</i>	CONCURRENT SYMPOSIA 4:00 PM–6:00 PM S-5 MOLECULAR MACHINES <i>Ballroom A</i> S-6 LIFE EXPECTANCY AT 25 <i>Ballroom C</i> S-7 PrEP WORKS, NOW WHAT? <i>Ballroom B</i>	CONCURRENT SYMPOSIA AND ORAL ABSTRACT SESSION 4:00 PM–6:00 PM S-8 ART: THE NEXT 25 YEARS <i>Ballroom B</i> S-9 EMERGING PRIORITIES IN LIVER DISEASE <i>Ballroom C</i> O-14 DEFINING THE HIV RESERVOIR <i>Ballroom A</i>
5:00 PM	OPENING SESSION 5:00 PM–7:00 PM <i>Auditorium/Hall C/Balcony</i> Bernard Fields Lecture N'Galy-Mann Lecture Performance by You Shall LHiV 2: ZERO			
6:00 PM				
7:00 PM	WELCOME RECEPTION 7:00 PM–9:00 PM			

KEY

-  First Aid
 -  Fire Exit
 -  Food/Beverage
 -  Restrooms



2nd Floor

— Sheraton Entrance

This architectural floor plan illustrates the layout of the fourth floor of the Mugar Memorial Library. The space is divided into several distinct areas:

- Auditorium:** A large room on the left side.
- Hall C:** A room located above the Prefunction Auditorium.
- Poster Hall D:** A room located above the Prefunction Hall C.
- Prefunction Auditorium:** A room with tiered seating, labeled "Up" and "Down".
- Prefunction Hall C:** A long room with a series of small doors along its top edge.
- Prefunction Hall D:** A room located to the right of Prefunction Hall C.
- Boylston Hallway:** A corridor running horizontally across the bottom of the floor plan.
- Rooms 200 through 210:** Various rooms numbered 200, 201, 202, 203, 204, 205, 206, 207, 208, and 209, some featuring green or purple walls.
- Staircases:** Labeled "E" and "W" indicating East and West stairs.
- Restrooms:** Labeled "Bath Off" and "W".

Plaza Level

This architectural floor plan illustrates the layout of the Lower Level. The plan includes several rooms and hallways:

- Drop-Off (Lower Level)**: Located at the top center.
- Emergency Exit**: Located on the left side.
- Poster Hall A**: A large room on the left side.
- Poster Hall B**: A large room on the right side.
- Prefunction Hall A**: A room located below Poster Hall A.
- Prefunction Hall B**: A room located below Poster Hall B.
- Boylston Hallway**: A hallway at the bottom.
- Sidewalk (Lower Level)**: An outdoor area at the bottom.

Rooms and their labels include:

- W M M M W (top green room)
- E (middle green room)
- H (pink room)
- 102, 103, 104, 105, 110, 111 (blue rooms)
- M (green room)
- W (green room)
- E (bottom green room)

Restroom symbols are present in several locations: top center, middle green room, pink room, blue rooms, and bottom green room.

3rd Floor

This architectural floor plan illustrates the layout of the Grand Hall area. The Auditorium (Below) is a large blue room at the top. Below it is the South Lobby, a purple room with a central entrance. To the right of the Auditorium is the Ballroom Pre-function area, which includes a pink room and a black room. At the bottom is the Ballroom Foyer, a green room with a circular entrance. A purple room at the very bottom is labeled 'Drop-Off (Lower Level)'. Various other rooms and hallways are shown in different colors, including yellow, white, and grey. Stairs and elevators are indicated by symbols throughout the plan.

This architectural floor plan illustrates a section of a building with several distinct areas:

- Ballroom C**: A large room located at the top left.
- Ballroom B**: A large room located below Ballroom C.
- Ballroom A**: A large room located below Ballroom B.
- Service Corridor**: A narrow corridor connecting the ballrooms to other parts of the building.
- Poster Hall D (Below)**: A large room located at the top right, with "Below" indicating it is located beneath the main floor level.
- Boylston Hallway**: A hallway located at the bottom center, featuring a double door entrance.
- Rooms 301 through 313**: A series of rooms arranged along the bottom floor, with room numbers 301, 302, 303, 305, 306, 307, 309, W, M, and 312 labeled.
- Washroom E**: A small room located near the bottom right, indicated by a person icon.

The plan also includes various symbols such as a key, a chair, and a bed, which are typically used in architectural drawings to represent specific fixtures or features.

PLAZA LEVEL

Poster Sessions.....
Registration, Bag and Coat Check, Cafeteria

... Poster Hall A, B


2ND FLOOR

Opening Session, Plenaries	Auditorium/Hall C
Poster Sessions	Poster Hall D
Speaker Ready Room	200
IAS-IUSA Office	203

3RD FLOOR

Opening Session, Plenaries	Auditorium Balcony
Oral Sessions, Themed Discussions, Workshops, and Symposia Rooms	Ballroom A, B, C, 302, 304/306
New Mother's Room.....	307
Personal Considerations Room	308
Overflow Rooms	Rooms 202, 211, 212

Networking Areas: 303, 305, 309, 310, Cafeteria, Poster Halls A, B, D



25th CROI